Urine Biomarkers for Prediction of Recovery After Acute Kidney Injury: Proteomics

ABSTRACT

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient&#39;s having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal recovery and/or renal non-recovery.

STATEMENT OF GOVERNMENT SUPPORT

This invention was made with government support under grant #DK 070910 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, prediction of renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, differential expression platforms can be used to identify biomarker proteins in order to establish the risk of renal recovery versus renal non-recovery in patient's having suffered an acute kidney injury.

BACKGROUND

Acute Kidney Injury (AKI) has an estimated incidence rate of approximately 2000 per million population and this rate is increasing. Ali et al. “Incidence and outcomes in acute kidney injury: a comprehensive population-based study” J Am Soc Nephrol 18:1292-1298 (2007). Approximately 5% of all people admitted to intensive care units around the world develop severe AKI requiring dialysis. Uchino et al., “Acute renal failure in critically ill patients: a multinational, multicenter study” JAMA 294:813-818 (2005). A recent, multi-center study found that fewer than only about 60% patients surviving severe AKI recovered renal function by two months. Palevsky et al., “Intensity of renal support in critically ill patients with acute kidney injury” N Engl J Med 359:7-20 (2008). Thus, a large number of patients with AKI go on to have end-stage renal disease (ESRD).

However, since only a fraction of patients with AKI fail to recover renal function, interventions aimed at improving recovery or providing renal support (e.g. early dialysis) cannot be targeted appropriately without some means of determining which patients will recover and which will not. Unfortunately, clinical risk prediction for recovery after AKI is extremely limited. Research efforts to treat AKI and prevent ESRD could be tailored according to long-term-prognosis. In other words, with an accurate prediction of which patients will not recover kidney function, medical efforts could focus the development and application of aggressive treatment interventions on just these patients. Conversely, patients with a favorable prognosis would be spared from more aggressive interventions and their potential adverse effects.

Thus, development of a biomarker or biomarker panel that allows early prediction of recovery of kidney function would be an extremely valuable clinical tool. What is needed in the art are a panel of biomarkers to predict renal recovery after AKI.

SUMMARY

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, prediction of renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, differential expression platforms can be used to identify biomarker proteins in order to establish the risk of renal recovery versus renal non-recovery in patient's having suffered an acute kidney injury.

In one embodiment, the present invention contemplates a composition comprising an renal injury biomarker, wherein said biomarker comprises at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotien, carbonic anhydrase, and uromodulin precursor. In one embodiment, the composition further comprises a urine sample. In one embodiment, the urine sample is collected between 1 day and 14 days after a kidney injury. In one embodiment, the urine sample is a human urine sample. In one embodiment, the biomarker is at least 2.5 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 2.0 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.5 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.25 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 2.5 fold lower as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 2.0 fold lower as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.5 fold lower as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.25 fold lower as compared to an expected level in a renal recovery group.

In one embodiment, the present invention contemplates a method, comprising: a) providing; i) a patient exhibiting at least one symptom of an acute renal injury; and ii) a biological fluid sample obtained from said patient, wherein said sample comprises a renal injury biomarker; b) measuring a renal recovery biomarker value; c) comparing said renal biomarker value to an expected value from a renal recovery group; and d) predicting a probability of renal recovery for said patient based upon said comparison. In one embodiment, the probability of renal recovery is greater than 90%. In one embodiment, the probability of renal recovery is greater than 75%. In one embodiment, the probability of renal recovery is greater than 50%. In one embodiment, the probability of renal recovery is less than 50%. In one embodiment, the probability of renal recovery is less than 25%. In one embodiment, the probability of renal recovery is less than 10%. In one embodiment, the biomarker comprises at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotien, carbonic anhydrase, and uromodulin precursor.

In one embodiment, the present invention contemplates a kit, comprising; a) a first container comprising an antibody specifically directed to an renal injury biomarker, wherein said biomarker comprises at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotien, carbonic anhydrase, and uromodulin precursor; b) instructions for determining whether said biomarker is overexpressed as compared to an expected value from a renal recovery group; c) instructions for determining whether said biomarker is underexpressed as compared to an expected value from a renal recovery group; and d) instructions for determining the probability of renal recovery. In one embodiment, the antibody is a monoclonal antibody. In one embodiment, the monoclonal antibody is specifically directed to said biomarker protein fragment.

In one embodiment, the present invention contemplates a signature expression profile comprising a urinary protein biomarker panel, wherein said profile predicts renal recovery. In one embodiment, the biomarker panel comprises a plurality of overexpressed urinary proteins. In one embodiment, the biomarker panel comprises a plurality of underexpressed urinary proteins. In one embodiment, the plurality of overexpressed urinary proteins are selected from the group consisting of beta globin, catalase, alpha globin, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, and annexin A2. In one embodiment, the plurality of underexpressed urinary proteins are selected from the group consisting of myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, and uromodulin precursor.

In one embodiment, the present invention contemplates a signature expression profile comprising a urinary protein biomarker panel, wherein said profile predicts renal non-recovery. In one embodiment, the biomarker panel comprises a plurality of overexpressed urinary proteins. In one embodiment, the biomarker panel comprises a plurality of underexpressed urinary proteins. In one embodiment, the plurality of overexpressed urinary proteins are selected from the group consisting of beta globin, catalase, alpha globin, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, and annexin A2. In one embodiment, the plurality of underexpressed urinary proteins are selected from the group consisting of myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, and uromodulin precursor.

In one embodiment, the present invention contemplates a method, comprising: a) providing; i) a patient exhibiting at least one symptom of an acute renal injury; and ii) a biological fluid sample obtained from said patient, wherein said sample comprises a plurality of renal biomarker nucleic acids; b) expressing said plurality of renal biomarker nucleic acids, thereby creating a signature expression profile; and c) predicting a probability of renal recovery for said patient based upon said signature expression profile. In one embodiment, the signature expression profile predicts a probability of renal recovery of greater than 90%. In one embodiment, the signature expression profile predicts a probability of renal recovery of greater than 75%. In one embodiment, the signature expression profile predicts a probability of renal recovery of greater than 50%. In one embodiment, the signature expression profile predicts a probability of renal recovery of less than 50%. In one embodiment, the signature expression profile predicts a probability of renal recovery of less than 25%. In one embodiment, the signature expression profile predicts a probability of renal recovery of less than 10%. In one embodiment, the signature expression profile comprises a plurality of overexpressed urinary proteins. In one embodiment, the signature expression profile comprises a plurality of underexpressed urinary proteins. In one embodiment, the plurality of overexpressed urinary proteins are selected from the group consisting of beta globin, catalase, alpha globin, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, and annexin A2. In one embodiment, the plurality of underexpressed urinary proteins are selected from the group consisting of myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, and uromodulin precursor.

In one embodiment, the present invention contemplates a kit, comprising; a) a first container comprising reagents for creating a signature expression profile using a biological sample, wherein said signature expression profile comprises a plurality of renal biomarker nucleic acids; b) a second container comprising monoclonal antibodies specific for said renal biomarker nucleic acids; c) a set of instructions for creating said signature expression profile; d) a set of instructions for determining overexpressed renal biomarker nucleic acids; e) a set of instructions for determining underexpressed renal biomarker nucleic acids; f) a set of instructions for predicting the probability of renal recovery; and g) a set of instructions for predicting the probability of renal non-recovery.

Definitions

As used herein, an “injury to renal function” is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) measurable reduction in a measure of renal function. Such an injury to renal function may be identified, for example, by a decrease in glomerular filtration rate (GFR) or estimated GFR (eGFR), a reduction in urine output, an increase in serum creatinine, an increase in serum cystatin C, a requirement for renal replacement therapy (i.e., for example, dialysis), etc.

As used herein, an “improvement in renal function” is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) measurable increase in a measure of renal function. Preferred methods for measuring and/or estimating GFR are described hereinafter.

As used herein, “reduced renal function” is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.1 mg/dL (≧8.8 μmol/L), a percentage increase in serum creatinine of greater than or equal to 20% (1.2-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour).

As used herein, “acute renal failure” or “ARF” is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.3 mg/dl (≧26.4 μmol/l), a percentage increase in serum creatinine of greater than or equal to 50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour for at least 6 hours). This term is synonymous with “acute kidney injury” or “AKI.”

As used herein, the term “relating a signal to the presence or amount” of an analyte refers to assay measurements using a standard curve calculated with known concentrations of the analyte of interest. The skilled artisan will understand that the signals obtained from an assay are often a direct result of complexes formed between, for example, one or more antibodies and a target biomolecule (i.e., for example, an analyte) and/or polypeptides containing an epitope(s) to which, for example, antibodies bind. While such assays may detect a full length biomarker and the assay result may be expressed as a concentration of a biomarker of interest, the signal from the assay is actually a result of all such “immunoreactive” polypeptides present in the sample.

As the term is used herein, an assay is “configured to detect” an analyte if an assay can generate a detectable signal indicative of the presence or amount of a physiologically relevant concentration of the analyte. For example, an antibody epitope is usually on the order of 8 amino acids, such that an immunoassay can be configured to detect a marker of interest that will also detect polypeptides related to the marker sequence, so long as those polypeptides contain the epitope(s) necessary to bind to the antibody or antibodies used in the assay.

The term “related marker” or “biomarker” as used herein with regard to a physiological substance such as one of the proteins as described herein. A related marker may also refer to one or more fragments, variants, etc., of a particular protein and/or peptide or its biosynthetic parent that may be detected as a surrogate for the marker itself or as independent biomarkers. The term also refers to one or more polypeptides present in a biological sample that are derived from the biomarker precursor complexed to additional species, such as binding proteins, receptors, heparin, lipids, sugars, etc.

The term “subject” or “patient” as used herein, refers to a human or non-human organism. Thus, the methods and compositions described herein are equally applicable to both human and veterinary disease. Further, while a subject or patient is preferably a living organism, the invention described herein may be used in post-mortem analysis as well. Preferred subjects or patients are humans, which as used herein refer to living humans that are receiving medical care for a disease or condition.

The term “analyte” as used herein, refers to any measured compound or molecule. Preferably, an analyte is measured in a sample (i.e., for example, a body fluid sample). Such a sample may be obtained from a subject or patient, or may be obtained from biological materials intended to be provided to the subject or patient. For example, a sample may be obtained from a kidney being evaluated for possible transplantation into a subject, such that an analyte measurement may be used to evaluate the kidney for preexisting damage.

The term “body fluid sample” as used herein, refers to any sample of bodily fluid obtained for the purpose of diagnosis, prognosis, classification or evaluation of a subject of interest, such as a patient or transplant donor. In certain embodiments, such a sample may be obtained for the purpose of determining the outcome of an ongoing medical condition or the effect of a treatment regimen on a medical condition. Preferred body fluid samples include but are not limited to, blood, serum, plasma, cerebrospinal fluid, urine, saliva, sputum, or pleural effusions. In addition, certain body fluid samples may be more readily analyzed following a fractionation or purification procedure, for example, separation of whole blood into serum or plasma components.

The term “diagnosis” as used herein, refers to methods by which trained medical personnel can estimate and/or determine the probability (i.e., for example, a likelihood) of whether or not a patient is suffering from a given disease or condition. In the case of the present invention, “diagnosis” includes correlating the results of an assay (i.e., for example, an immunoassay) for a renal biomarker of the present invention, optionally together with other clinical indicia, to determine the occurrence or nonoccurrence of an acute renal injury or acute renal failure for a subject or patient from which a sample was obtained and assayed. That such a diagnosis is “determined” is not meant to imply that the diagnosis is 100% accurate. Thus, for example, a measured biomarker level below a predetermined diagnostic threshold may indicate a greater likelihood of the occurrence of a disease in the subject relative to a measured biomarker level above the predetermined diagnostic threshold may indicate a lesser likelihood of the occurrence of the same disease.

The term “prognosis” as used herein, refers to a probability (i.e., for example, a likelihood) that a specific clinical outcome will occur. For example, a level or a change in level of a prognostic indicator, which in turn is associated with an increased probability of morbidity (e.g., worsening renal function, future ARF, or death) is referred to as being “indicative of an increased likelihood” of an adverse outcome in a patient.

The term “RIFLE” criteria, as used herein, refers to any quantitative clinical evaluation of renal status used to establish renal classifications of Risk, Injury, Failure, Loss, & End Stage Renal Disease based upon a uniform definition of acute kidney injury (AKI). Kellum, Crit. Care Med. 36: S141-45 (2008); and Ricci et al., Kidney Int. 73, 538-546 (2008), each hereby incorporated by reference in its entirety.

The term, “modified RIFLE criteria”, as used herein, provide alternative classifications for stratifying AKI patients, and may include, Stage I, Stage II, and/or Stage III. Mehta et al., Crit. Care 11:R31 (2007), hereby incorporated by reference in its entirety.

The term, “Stage I”, as used herein, refers to a risk stratification comprising a RIFLE Risk category, characterized by an increase in serum creatinine of more than or equal to 0.3 mg/dL (≧26.4 μmol/L) and/or an increase to more than or equal to 150% (1.5-fold) from baseline. Alternatively, the category may be defined by a urine output less than 0.5 mL/kg per hour for more than 6 hours.

The term, “Stage II”, as used herein, refers a risk stratification comprising a RIFLE Injury category, characterized by an increase in serum creatinine to more than 200% (>2-fold) from baseline. Alternatively, the category may be defined by a urine output less than 0.5 mL/kg per hour for more than 12 hours.

The term, “Stage III”, as used herein, refers to a risk stratification comprising a RIFLE Failure category, characterized by an increase in serum creatinine to more than 300% (>3-fold) from baseline and/or serum creatinine ≧354 μmol/L accompanied by an acute increase of at least 44 μmol/L. Alternatively, the category may be defined by a urine output less than 0.3 mL/kg per hour for 24 hours or anuria for 12 hours.

The term “Risk category”, as used herein, refers to a RIFLE classification wherein, in terms of serum creatinine, means any increase of at least 1.5 fold from baseline, or urine production of <0.5 ml/kg body weight/hr for approximately 6 hours.

The term “Injury category” as used herein includes, refers to a RIFLE classification wherein, in terms of serum creatinine, means any increase of at least 2.0 fold from baseline or urine production <0.5 ml/kg/hr for 12 h.

The term “Failure category” as used herein includes, refers to a RIFLE classification wherein, in terms of serum creatinine means any increase of at least 3.0 fold from baseline or a urine creatinine >355 μmol/l (with a rise of >44) or urine output below 0.3 ml/kg/hr for 24 h, or anuria for at least 12 hours.

The term “Loss category” as used herein, refers to a clinical outcome risk and/or a RIFLE classification wherein the clinical outcome risk is characterized by a persistent need for renal replacement therapy for more than four weeks.

The term “End Stage Renal Disease category” or “ESRD category” as used herein, refers to a clinical outcome risk and/or a RIFLE classification characterized by a need for dialysis for more than 3 months.

The term “clinical outcome risk” as used herein, refers to a medical prognosis directed towards either renal recovery or renal non-recovery.

The term “renal biomarker” as used herein, refers to any biological compound related to the progressive development of chronic kidney disease. In particular, a renal biomarker may be a kidney injury marker. For example, a renal biomarker may comprise a urinary protein, or any metabolite and/or derivative thereof, wherein the renal biomarker is either overexpressed or underexpressed as a result of an AKI.

The term “positive going biomarker” as that term is used herein, refers to any biomarker that is determined to be elevated in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.

The term “negative going biomarker” as that term is used herein, refer to any biomarker that is determined to be reduced in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.

The term “positive going renal biomarker value” as used herein, refers to any increased likelihood (i.e., for example, increased probability) of suffering a future injury to renal function assigned to a subject when the measured biomarker concentration is above a specified threshold value, relative to a likelihood assigned when the measured biomarker concentration is below the specified threshold value. Alternatively, when the measured biomarker concentration is below a specified threshold value, an increased likelihood of a non-occurrence of an injury to renal function may be assigned to the subject relative to the likelihood assigned when the measured biomarker concentration is above the specified threshold value. Alternatively, when the measured biomarker concentration is below the threshold value, an improvement of renal function may be assigned to the subject. A positive going kidney injury marker may include, but not be limited to, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc.

The term “negative going renal biomarker value” as used herein, refers to any increased likelihood (i.e., for example, an increased probability) of suffering a future injury to renal function assigned to the subject when the measured biomarker concentration is below a specified threshold value, relative to a likelihood assigned when the measured biomarker concentration is above the threshold value. Alternatively, when the measured biomarker concentration is above the threshold value, an increased likelihood of a non-occurrence of an injury to renal function may be assigned to the subject relative to the likelihood assigned when the measured biomarker concentration is below the threshold value. Alternatively, when the measured biomarker concentration is above the threshold value, an improvement of renal function may be assigned to the subject. A negative going kidney injury marker may include, but not be limited to, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc.

The term “pre-existing” and “pre-existence” as used herein, means any risk factor (i.e., for example, a renal biomarker) existing at the time a body fluid sample is obtained from the subject.

The term “predicting” as used herein, refers to a method of forming a prognosis and/or a stratification risk assignment, wherein a medically trained person analyzes biomarker information, and optionally with relevant clinical indicia and/or demographic information.

The term “acute renal disease/failure/injury” as used herein, refers to any progressive worsening of renal function over hours to Days, resulting in the retention of nitrogenous wastes (such as urea nitrogen) and creatinine in the blood. Retention of these substances may also be referred to as, azotemia. In: Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, herein incorporated by reference in their entirety.

The term “chronic renal disease/failure/injury” as used herein, refers to a medical condition wherein exemplary symptoms may include, but are not limited to, hyperphosphatemia (i.e., for example, >4.6 mg/dl) or low glomerular filtration rates (i.e., for example, <90 ml/minute per 1.73 m2 of body surface). However, many CKD patients may have normal serum phosphate levels in conjunction with a sustained reduction in glomerular filtration rate for 3 or more months, or a normal GFR in conjunction with sustained evidence of a structural abnormality of the kidney. In some cases, patients diagnosed with chronic kidney disease are placed on hemodialysis to maintain normal blood homeostasis (i.e., for example, urea or phosphate levels). Alternatively, “chronic kidney disease” refers to a medical condition wherein a patients has either i) a sustained reduction in GFR<60 mi/min per 1.73 m2 of body surface for 3 or more months; or ii) a structural or functional abnormality of renal function for 3 or more months even in the absence of a reduced GFR. Structural or anatomical abnormalities of the kidney could be defined as, but not limited to, persistent microalbuminuria or proteinuria or hematuria or presence of renal cysts. Chronic renal failure (chronic kidney disease) may also result from an abnormal loss of renal function over months to years. In: Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, herein incorporated by reference in their entirety.

The term “about” as used herein in the context of any of any assay measurements refers to +/−5% of a given measurement.

The term “asymptomatic” as used herein, refers to a patient and/or subject that does not have a renal disease and/or injury, wherein a renal disease and/or injury symptom may include, but is not limited to, having a reduced glomerular filtration rate (i.e., for example, between approximately 70-89 ml/min per 1.73 m2 of body surface) for less than three months.

The term “glomerular filtration rate” as used herein, refers to any measurement capable of determining kidney function. In general, a normal glomerular filtration rate ranges between approximately 120-90 ml/minute per 1.73 m2 of body surface. Compromised kidney function is assumed when glomerular filtration rates are less than 90 ml/minute per 1.73 m2 of body surface. Kidney failure is probable when glomerular filtration rates fall below approximately 30 ml/minute per 1.73 m2 of body surface. Dialysis is frequently initiated when glomerular filtration rates fall below approximately 15 ml/minute per 1.73 m2 of body surface.

The term “renal failure” as used herein, refers to any acute, sudden, and/or chronic loss of the ability of the kidneys to remove waste and concentrate urine without losing electrolytes.

The term “biological sample” as used herein, refers to any substance derived from a living organism. For example, a sample may be derived from blood as a urine sample, serum sample, a plasma sample, and or a whole blood sample. Alternatively, a sample may be derived from a tissue collected, for example, by a biopsy. Such a tissue sample may comprise, for example, kidney tissue, vascular tissue and/or heart tissue. A biological sample may also comprise body fluids including, but not limited to, urine, saliva, or perspiration.

The term “reagent” as used herein, refers to any substance employed to produce a chemical reaction so as to detect, measure, produce, etc., other substances. The term “antibody” as used herein refers to any peptide or polypeptide derived from, modeled after, or substantially encoded by, an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an antigen or epitope. See, e.g. In: Fundamental Immunology, 3rd Edition, W. E. Paul, ed., Raven Press, N.Y. (1993); Wilson et al., J. Immunol. Methods 175:267-273 (1994); and Yarmush et al., J. Biochem. Biophys. Methods 25:85-97 (1992). The term antibody includes, but is not limited to, antigen-binding portions, i.e., “antigen binding sites” exemplified by fragments, subsequences, and/or complementarity determining regions (CDRs)) that retain capacity to bind antigen, including, but not limited to: (i) a Fab fragment, a monovalent fragment comprising VL, VH, CL or CHI domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment comprising VH and CHI domains; (iv) a Fv fragment comprising VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., Nature 341:544-546 (1989)), which comprises a VH domain; or (vi) an isolated complementarity determining region (CDR). Single chain antibodies are also included by reference in the term “antibody.”

The term “epitope” as used herein, refers to any antigenic determinant capable of specific binding to an antibody. Epitopes usually display chemically active surface molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes may be distinguished in that the binding to the former but not the latter can be lost in the presence of denaturing solvents.

The term “correlating” as used herein, in reference to the use of biomarkers, refers to comparing the presence and/or amount of any biomarker(s) in a patient to its presence and/or amount in persons known to suffer from, or known to be at risk of, a given condition; or in persons known to be free of a given condition. Often, this takes the form of comparing an assay result in the form of a biomarker concentration to a predetermined threshold selected to be indicative of the occurrence or nonoccurrence of a disease or the likelihood of some future outcome.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 presents exemplary subject information relevant to the Biological Markers of Recovery for the Kidney (BioMaRK) study cohort used as the basis for some of the data analysis presented herein.

FIG. 2: Representative protein biomarker familes identified by a proteomics platform.

FIG. 3 Representative single biomarker peptides Identified by a proteomics platform.

DETAILED DESCRIPTION

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, prediction of renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, differential expression platforms can be used to identify biomarker proteins in order to establish the risk of renal recovery versus renal non-recovery in patient's having suffered an acute kidney injury.

Despite significant advances in the epidemiology of acute kidney injury (AKI), prognostication remains a major clinical challenge. Unfortunately, there is no reliable method to predict renal recovery. The discovery of biomarkers to aid in clinical risk prediction for recovery after AKI would represent a significant advance over current practice.

I. Kidney Injury and/or Disease

The kidney is responsible for water and solute excretion from the body. Its functions include maintenance of acid-base balance, regulation of electrolyte concentrations, control of blood volume, and regulation of blood pressure. As such, loss of kidney function through injury and/or disease results in substantial morbidity and mortality. A detailed discussion of renal injuries is provided in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, which are hereby incorporated by reference in their entirety. The kidneys are located in the flank (back of the upper abdomen at either side of the spinal column). They are deep within the abdomen and are protected by the spine, lower rib cage, and the strong muscles of the back. This location protects the kidneys from many external forces. They are well-padded for a reason—kidneys are highly vascular organs, which means that they have a large blood supply. If injury occurs, severe bleeding may result.

Kidneys may be injured by damage to the blood vessels that supply or drain them. This may be in the form of aneurysm, arteriovenous fistula, arterial blockage, or renal vein thrombosis. The extent of bleeding depends on the location and the degree of injury. Kidneys may also bleed profusely if they are damaged centrally (on the inside)—this is a life-threatening injury. Fortunately, most kidney injuries caused by blunt trauma occur peripherally, only causing bruising of the kidney (usually a self-limiting process).

People with undiagnosed kidney conditions—such as angiomyolipoma (benign tumor), ureteropelvic junction obstruction (congenital or acquired UPJ Obstruction), and other disorders—are more susceptible to kidney injuries and more likely to have serious complications if they occur. Other causes of kidney injury and bleeding are medical procedures. Kidney biopsies, nephrostomy tube placements, or other surgeries can cause an abnormal connection between an artery and vein (arteriovenous fistula). This is usually a self-limiting problem, but close observation is usually needed. Injury to the kidney can also disrupt the urinary tract, causing leakage of the urine from the kidney.

Each kidney filters about 1700 liters of blood per Day and concentrates fluid and waste products into about 1 liter of urine per Day. Because of this, the kidneys receive more exposure to toxic substances in the body than almost any other organ. Therefore, they are highly susceptible to injury from toxic substances. Analgesic nephropathy is one of the most common types of toxic damage to the kidney. Exposure to lead, cleaning products, solvents, fuels, or other nephrotoxic chemicals (those which can be toxic to the kidney) can damage kidneys. Excessive buildup of body waste products, such as uric acid (that can occur with gout or with treatment of bone marrow, lymph node, or other disorders) can also damage the kidneys.

Inflammation (irritation with swelling and presence of extra immune cells) caused by immune responses to medications, infection, or other disorders may also injure the structures of the kidney, usually causing various types of glomerulonephritis or acute tubular necrosis (tissue death). Autoimmune disorders may also damage the kidneys. Injury to the kidney may result in short-term damage with minimal or no symptoms. Alternately, it can be life-threatening because of bleeding and associated shock, or it may result in acute renal failure or chronic renal failure.

Ureteral injuries (injuries to the tubes which carry urine from the kidneys to the bladder) can also be caused by trauma (blunt or penetrating), complications from medical procedures, and other diseases in the retroperitoneum such as retroperitoneal fibrosis (RPF), retroperitoneal sarcomas, or metastatic lymph node positive cancers. Medical therapies (such as OB/GYN surgeries, prior radiation or chemotherapy, and previous abdominopelvic surgeries) increase the risk for ureteral injuries.

A. Acute Kidney Failure

Acute (sudden) kidney failure is the sudden loss of the ability of the kidneys to remove waste and concentrate urine without losing electrolytes. There are many possible causes of kidney damage including, but are not limited to, decreased blood flow, which may occur with extremely low blood pressure caused by trauma, surgery, serious illnesses, septic shock, hemorrhage, burns, or dehydration, acute tubular necrosis (ATN), infections that directly injury the kidney such as acute pyelonephritis or septicemia, urinary tract obstruction (obstructive uropathy), autoimmune kidney disease such as interstitial nephritis or acute nephritic syndrome, disorders that cause clotting within the thin blood vessels of the kidney, idiopathic thrombocytopenic thrombotic purpura (ITTP), transfusion reaction, malignant hypertension, scleroderma, hemolytic-uremic syndrome, disorders of childbirth, such as bleeding placenta abruptio or placenta previa

Symptoms of acute kidney failure may include, but are not limited to, decrease in amount of urine (oliguria), urination stops (anuria), excessive urination at night, ankle, feet, and leg swelling, generalized swelling, fluid retention, decreased sensation, especially in the hands or feet, decreased appetite, metallic taste in mouth, persistent hiccups, changes in mental status or mood, agitation, drowsiness, lethargy, delirium or confusion, coma, mood changes, trouble paying attention, hallucinations, slow, sluggish, movements, seizures, hand tremor (shaking), nausea or vomiting, may last for Days, bruising easily, prolonged bleeding, nosebleeds, bloody stools, flank pain (between the ribs and hips), fatigue, breath odor, or high blood pressure.

Acute renal failure (ARF) may also be referred to as acute kidney injury (AKI) and may be characterized by an abrupt (i.e., for example, typically detected within about 48 hours to 1 week) reduction in glomerular filtration rate (GFR). This loss of filtration capacity results in retention of nitrogenous (urea and creatinine) and non-nitrogenous waste products that are normally excreted by the kidney, a reduction in urine output, or both. It is reported that ARF complicates about 5% of hospital admissions, 4-15% of cardiopulmonary bypass surgeries, and up to 30% of intensive care admissions. ARF may be categorized as prerenal, intrinsic renal, or postrenal in causation. Intrinsic renal disease can be further divided into glomerular, tubular, interstitial, and vascular abnormalities. Major causes of ARF are described in association with their respective risk factors are summarized below. See, Table 4; In: Merck Manual, 17th ed., Chapter 222, and which is hereby incorporated by reference in their entirety.

TABLE 4 Representative Acute Renal Failure Risk Factors Type of Renal Failure Risk Factors Prerenal ECF volume Excessive diuresis, hemorrhage, GI losses, loss of depletion intravascular fluid into the extravascular space (due to ascites, peritonitis, pancreatitis, or burns), loss of skin and mucus membranes, renal salt- and water-wasting states Low cardiac Cardiomyopathy, MI, cardiac tamponade, pulmonary output embolism, pulmonary hypertension, positive-pressure mechanical ventilation Low systemic Septic shock, liver failure, antihypertensive drugs vascular resistance Increased renal NSAIDs, cyclosporines, tacrolimus, hypercalcemia, vascular anaphylaxis, anesthetics, renal artery obstruction, renal resistance vein thrombosis, sepsis, hepatorenal syndrome Decreased ACE inhibitors or angiotensin II receptor blockers efferent arteriolar tone (leading to decreased GFR from reduced glomerular transcapillary pressure, especially in patients with bilateral renal artery stenosis) Intrinsic Renal Acute tubular Ischemia (prolonged or severe prerenal state): surgery, injury hemorrhage, arterial or venous obstruction; Toxins: NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, streptozotocin Acute ANCA-associated: Crescentic glomerulonephritis, glomerul- polyarteritis nodosa, Wegener's granulomatosis; Anti- onephritis GBM glomerulonephritis: Goodpasture's syndrome; Immune-complex: Lupus glomerulonephritis, postinfectious glomerulonephritis, cryoglobulinemic glomerulonephritis Acute Drug reaction (eg, β-lactams, NSAIDs, sulfonamides, tubulointerstitial ciprofloxacin, thiazide diuretics, furosemide, phenytoin, nephritis allopurinol, pyelonephritis, papillary necrosis Acute vascular Vasculitis, malignant hypertension, thrombotic nephropathy microangiopathies, scleroderma, atheroembolism Infiltrative Lymphoma, sarcoidosis, leukemia diseases Postrenal Tubular Uric acid (tumor lysis), sulfonamides, triamterene, precipitation acyclovir, indinavir, methotrexate, ethylene glycol ingestion, myeloma protein, myoglobin Ureteral Intrinsic: Calculi, clots, sloughed renal tissue, fungus obstruction ball, edema, malignancy, congenital defects; Extrinsic: Malignancy, retroperitoneal fibrosis, ureteral trauma during surgery or high impact injury Bladder Mechanical: Benign prostatic hyperplasia, prostate obstruction cancer, bladder cancer, urethral strictures, phimosis, paraphimosis, urethral valves, obstructed indwelling urinary catheter; Neurogenic: Anticholinergic drugs, upper or lower motor neuron lesion

In the case of ischemic ARF, the course of the disease may be divided into four phases. During an initiation phase, which lasts hours to Days, reduced perfusion of the kidney is evolving into injury. Glomerular ultrafiltration reduces, the flow of filtrate is reduced due to debris within the tubules, and back leakage of filtrate through injured epithelium occurs. Renal injury can be mediated during this phase by reperfusion of the kidney. Initiation is followed by an extension phase which is characterized by continued ischemic injury and inflammation and may involve endothelial damage and vascular congestion. During the maintenance phase, lasting from 1 to 2 weeks, renal cell injury occurs, and glomerular filtration and urine output reaches a minimum. A recovery phase can follow in which the renal epithelium is repaired and GFR gradually recovers. Despite this, the survival rate of subjects with ARF may be as low as about 60%.

Acute kidney injury caused by radiocontrast agents (also called contrast media) and other nephrotoxins such as cyclosporine, antibiotics including aminoglycosides and anticancer drugs such as cisplatin manifests over a period of Days to about a week. Contrast induced nephropathy (CIN, which is AKI caused by radiocontrast agents) is thought to be caused by intrarenal vasoconstriction (leading to ischemic injury) and from the generation of reactive oxygen species that are directly toxic to renal tubular epithelial cells. CIN classically presents as an acute (onset within 24-48 h) but reversible (peak 3-5 Days, resolution within 1 week) rise in blood urea nitrogen and serum creatinine.

A commonly reported criteria for defining and detecting AKI is an abrupt (typically within about 2-7 Days or within a period of hospitalization) elevation of serum creatinine. Although the use of serum creatinine elevation to define and detect AKI is well established, the magnitude of the serum creatinine elevation and the time over which it is measured to define AKI varies considerably among publications. Traditionally, relatively large increases in serum creatinine such as 100%, 200%, an increase of at least 100% to a value over 2 mg/dL and other definitions were used to define AKI. However, the recent trend has been towards using smaller serum creatinine rises to define AKI.

For example, relationships between elevated serum creatinine and AKI has been reported to be associated with health risks. Praught et al., Curr Opin Nephrol Hypertens 14:265-270 (2005); and Chertow et al., J Am Soc Nephrol 16:3365-3370 (2005) (both references are herein incorporated by reference in their entirety). As described in these publications, acute worsening renal function (AKI) and increased risk of death and other detrimental outcomes are now known to be associated with very small increases in serum creatinine. These creatinine increases may be determined as a relative (percent) value or a nominal value. Relative increases in serum creatinine as small as 20% from the pre-injury value have been reported to indicate acutely worsening renal function (AKI) and increased health risk, but the more commonly reported value to define AKI and increased health risk is a relative increase of at least 25%. Nominal increases as small as 0.3 mg/dL, 0.2 mg/dL or even 0.1 mg/dL have been reported to indicate worsening renal function and increased risk of death. Various time periods for the serum creatinine to rise to these threshold values have been used to define AKI, for example, ranging from 2 Days, 3 Days, 7 Days, or a variable period defined as the time the patient is in the hospital or intensive care unit. These studies indicate there is not a particular threshold serum creatinine rise (or time period for the rise) for worsening renal function or AKI, but rather a continuous increase in risk with increasing magnitude of serum creatinine rise.

Another study correlated serum creatinine levels with post-surgical mortality rates. Following heart surgery, patients with a mild fall in serum creatinine (i.e., for example, between approximately −0.1 to −0.3 mg/dL) had the lowest mortality rate, wherein patients had a larger mortality rate associated with either large falls in serum creatinine (i.e., for example, more than or equal to −0.4 mg/dL), or an increase in serum creatinine. Lassnigg et al., J Am Soc Nephrol 15:1597-1605 (2004), herein incorporated by reference in its entirety. These findings suggested that even very subtle changes in renal function, as detected by small creatinine changes within 48 hours of surgery, can be predictive of a patient's outcome.

A unified classification system using serum creatinine to define AKI in clinical trials and in clinical practice was proposed to stratify AKI patients. Bellomo et al., Crit Care 8(4):R204-212 (2004), which is herein incorporated by reference in its entirety. For example, a serum creatinine rise of 25% may define contrast-induced nephropathy. McCollough et al, Rev Cardiovasc Med. 7(4): 177-197 (2006), herein incorporated by reference in its entirety. Although various groups propose slightly different criteria for using serum creatinine to detect AKI, the consensus is that small changes in serum creatinine, such as 0.3 mg/dL (i.e., for example, approximately 25%) are sufficient to detect AKI that characterizes a worsening renal function and that the magnitude of the serum creatinine change may be an indicator of the severity of the AKI and mortality risk.

Although serial measurement of serum creatinine over a period of Days is an accepted method of detecting and diagnosing AKI patients, serum creatinine is generally regarded to have several limitations in the diagnosis, assessment and monitoring of AKI patients. The time period for serum creatinine to rise to approximately 0.3 mg/dL (25%) is considered diagnostic for AKI can be 48 hours or longer depending on the definition used.

Since cellular injury in AKI can occur over a period of hours, serum creatinine elevations detected at 48 hours or longer can be a late indicator of injury, and relying on serum creatinine can thus delay diagnosis of AKI. Furthermore, serum creatinine is not a good indicator of the exact kidney status and treatment needs during the most acute phases of AKI when kidney function is changing rapidly. Until defined by some embodiments of the present invention, there were no methods to determine whether some patients with AKI would recover fully, or whether some would need dialysis (either short term or long term), or whether some would have other detrimental outcomes including, but not limited to, death, major adverse cardiac events or chronic kidney disease. Because serum creatinine is a marker of filtration rate, it does not differentiate between the causes of AKI (pre-renal, intrinsic renal, post-renal obstruction, atheroembolic, etc) or the category or location of injury in intrinsic renal disease (for example, tubular, glomerular or interstitial in origin). Urine output is similarly limited.

These limitations underscore the need for better methods to detect and assess AKI, particularly in the early and subclinical stages, but also in later stages when recovery and repair of the kidney can occur. Furthermore, there is a need to better identify patients who are at risk of having an AKI.

B. Chronic Kidney Failure

Unlike acute renal failure, chronic renal failure slowly gets worse. It most often results from any disease that causes gradual loss of kidney function. It can range from mild dysfunction to severe kidney failure. Chronic renal failure may lead to end-stage renal disease (ESRD).

Chronic renal failure usually occurs over a number of years as the internal structures of the kidney are slowly damaged. In the early stages, there may be no symptoms. In fact, progression may be so slow that symptoms do not occur until kidney function is less than one-tenth of normal.

Chronic renal failure and ESRD affect more than 2 out of 1,000 people in the United States. Diabetes and high blood pressure are the two most common causes and account for most cases. Other major causes include, but are not limited to, Alport syndrome, analgesic nephropathy, glomerulonephritis of any type (one of the most common causes), kidney stones and infection, obstructive uropathy, polycystic kidney disease, or reflux nephropathy. Chronic renal failure results in an accumulation of fluid and waste products in the body, leading to a build up of nitrogen waste products in the blood (azotemia) and general ill health. Most body systems are affected by chronic renal failure.

Initial symptoms may include, but are not limited to, fatigue, frequent hiccups, general ill feeling, generalized itching (pruritus), headache, nausea, vomiting, or unintentional weight loss. Further, later symptoms may include, but are not limited to, blood in the vomit or in stools,

decreased alertness, including drowsiness, confusion, delirium, orcoma, decreased sensation in the hands, feet, or other areas, easy bruising or bleeding, increased or decreased urine output, muscle twitching or cramps, seizures, or white crystals in and on the skin (uremic frost).

Circulating levels of cytokines and other inflammation markers are markedly elevated in patients with chronic renal failure. This could be caused by increased generation, decreased removal, or both. However, it is not well established to what extent renal function per se contributes to the uremic proinflammatory milieu. Relationships between inflammation and glomerular filtration rate (GFR) were reported in 176 patients (age, 52+/−1 years; GFR, 6.5+/−0.1 mL/min) close to the initiation of renal replacement therapy. Pecoits-Filho et al., “Associations between circulating inflammatory markers and residual renal function in CRF patients” Am J Kidney Dis. 41(6):1212-1218 (2003). For example, circulating levels of high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), hyaluronan, and neopterin were measured after an overnight fast. Patients subsequently were subdivided into two groups according to median GFR (6.5 mL/min). Despite the narrow range of GFR (1.8 to 16.5 mL/min), hsCRP, hyaluronan, and neopterin levels were significantly greater in the subgroup with lower GFRs, and significant negative correlations were noted between GFR and IL-6 (rho=−0.18; P<0.05), hyaluronan (rho=−0.25; P<0.001), and neopterin (rho=−0.32; P<0.0005). In a multivariate analysis, age and GFR were associated with inflammation but cardiovascular disease and diabetes mellitus were not. These results show that a low GFR per se is associated with an inflammatory state, suggesting impaired renal elimination of proinflammatory cytokines, increased generation of cytokines in uremia, or an adverse effect of inflammation on renal function.

C. Dialysis

Dialysis (i.e., for example, renal replacement therapy) is a method of removing toxic substances (impurities or wastes) from the blood when the kidneys are unable to do so and can be performed using several different methods. For example, peritoneal dialysis may filter waste by using the peritoneal membrane inside the abdomen. The abdomen is filled with special solutions that help remove toxins. The solutions remain in the abdomen for a time and then are drained out. This form of dialysis can be performed at home, but must be done every Day. Alternatively, hemodialysis may be performed by circulating the blood through special filters outside the body. The blood flows across a filter, along with solutions that help remove toxins.

Dialysis uses special ways of accessing the blood in the blood vessels. The access can be temporary or permanent. Temporary access takes the form of dialysis catheters—hollow tubes placed in large veins that can support acceptable blood flows. Most catheters are used in emergency situations for short periods of time. However, catheters called tunneled catheters can be used for prolonged periods of time, often weeks to months. Permanent access is created by surgically joining an artery to a vein. This allows the vein to receive blood at high pressure, leading to a thickening of the vein's wall. This vein can handle repeated puncture and also provides excellent blood flow rates. The connection between an artery and a vein can be made using blood vessels (an arteriovenous fistula, or AVF) or a synthetic bridge (arteriovenous graft, or AVG). Blood is diverted from the access point in the body to a dialysis machine. Here, the blood flows counter-current to a special solution called the dialysate. The chemical imbalances and impurities of the blood are corrected and the blood is then returned to the body. Typically, most patients undergo hemodialysis for three sessions every week. Each session lasts 3-4 hours.

The purpose of dialysis is to assist kidney functions including, filters for the blood, removing waste products, regulating body water, maintaining electrolyte balance, or maintaining blood pH remains between 7.35 and 7.45. Further, dialysis may replace some of the functions for kidneys that aren't working properly that would otherwise result in the death of a patient.

Dialysis is most often used for patients who have kidney failure, but it can also quickly remove drugs or poisons in acute situations. This technique can be life saving in people with acute or chronic kidney failure.

II. Urinary Renal Biomarkers

Currently, no effective treatments exist to improve renal recovery, or to improve short and long-term renal outcome, after AKI. Furthermore, methods to predict recovery are also lacking. The emerging role of biomarkers for early detection of renal disease and/or renal injury may help identify new prognostic tools to predict renal clinical outcomes. Potential candidates for biomarkers of renal recovery include, but are not limited to, molecules expressed in pathways leading to regeneration and proliferation as well as markers of fibrosis and apoptosis. In addition, renal injury biomarkers may also serve to distinguish early resolution, and hence increased odds of recovery.

Acute kidney injury (AKI) has an estimated incidence rate of approximately 2000 per million population and this rate is increasing. Ali et al., “Incidence and outcomes in acute kidney injury: a comprehensive population-based study” J Am Soc Nephrol 18:1292-1298 (2007). Approximately 5% of all people admitted to intensive care units around the world develop severe AKI requiring dialysis. Uchino et al., “Acute renal failure in critically ill patients: a multinational, multicenter study” JAMA 294:813-818 (2005). A recent, United States multi-center study found that fewer than only about 60% patients surviving severe AKI recovered renal function by two months. Palevsky et al., “Intensity of renal support in critically ill patients with acute kidney injury” N Engl J Med 359:7-20 (2008). Thus, a large number of patients with AKI progress into end-stage renal disease (ESRD).

However, since only a fraction of patients with AKI fail to recover renal function, interventions aimed at improving recovery or at providing renal support (e.g. early dialysis) cannot be selectively targeted appropriately without some means of determining which patients will recover and which will not recover (i.e., for example, the availability of non-invasive biomarkers). Currently, clinical risk prediction for recovery after AKI is extremely limited. Thus, development of a non-invasive biomarker that allows early prediction of recovery of kidney function is a long felt need in the art of renal disease management.

The identification of such non-invasive biomarkers (i.e., for example, a urinary biomarker) would greatly improve long-term prognosis thereby tailoring research efforts to treat AKI and prevent ESRD. In other words, having the ability to predict which patients will not recover kidney function allows a clinician to focus limited resources on the development and application of aggressive treatment interventions on these predicted at-risk patients. Conversely, patients with a favorable prognosis would be spared from more aggressive interventions and their potential adverse effects, thereby releasing medical resources to those in need and reducing overall medical costs.

In one embodiment, the present invention contemplates methods and compositions for evaluating renal function in a subject. As described herein, measurement of various kidney injury markers described herein can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and a determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure (also called acute kidney injury).

Renal biomarkers as described herein may be used individually, or in panels, comprising a plurality of renal biomarkers, for risk stratification. In one embodiment, risk stratification identifies subjects at risk for a future: i) injury to renal function; ii) progression to reduced renal function; iii) progression to ARF; or iv) improvement in renal function, etc. In one embodiment, risk stratification diagnoses an existing disease, comprising identifying subjects who have: i) suffered an injury to renal function; ii) progressed to reduced renal function; or iii) progressed to ARF, etc. In one embodiment, risk stratification monitors for deterioration and/or improvement of renal function. In one embodiment, risk stratification predicts a future medical outcome including, but not limited to, an improved or worsening renal function, a decreased or increased mortality risk, a decreased or increased risk that a subject will require initiation or continuation of renal replacement therapy (i.e., hemodialysis, peritoneal dialysis, hemofiltration, and/or renal transplantation, a decreased or increased risk that a subject will recover from an injury to renal function, a decreased or increased risk that a subject will recover from ARF, a decreased or increased risk that a subject will progress to end stage renal disease, a decreased or increased risk that a subject will progress to chronic renal failure, a decreased or increased risk that a subject will suffer rejection of a transplanted kidney, etc.

III. Clinical Renal Biomarker Studies

The results of a large multicenter clinical trial has recently been reported comparing two intensities of renal support for critically ill patients with acute kidney injury (AKI) in which recovery of renal function was less than 25% at 28 days and not different between the two treatment strategies. Palevsky et al., “Intensity of renal support in critically ill patients with acute kidney injury” N Engl J Med 359:7-20 (2008). These results emphasize that incomplete renal recovery is a common problem in the patients who survive severe AKI. Uchino et al., “Acute renal failure in critically ill patients: a multinational, multicenter study” JAMA, 294: 813-818 (2005). Failure to recover renal function can have tremendous negative effects on quality of life and health care costs. Manns et al., “Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery” Crit Care Med, 31:449-455 (2003). Therefore, treatments to hasten and facilitate renal recovery are eagerly being sought by both the critical care and nephrology communities. Unfortunately, there are no effective treatments to improve renal recovery. One possible barrier to progress in this area has been the inability to forecast recovery in individual patients. The ability to prognosticate in an AKI patient population would be extremely valuable both for clinical decisions as well as to guide future research on therapy to promote recovery of renal function.

One clinical study reported that patients who recovered from AKI did not appear to differ in clinical characteristics (i.e., for example, age, gender, mechanical ventilation status, or clinical severity scores) from the non-recovery group. Bhandari et al., “Survivors of acute renal failure who do not recover renal function” QJM, 89:415-421 (1996). Secondary analysis from three randomized controlled trials (RCTs) comparing efficacy of continuous renal replacement therapy (RRT) versus intermittent RRT found that: i) APACHE III scores >100; ii) cardiovascular instability; and iii) pre-existing renal impairment were all associated with renal non-recovery. Mehta et al., “A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure” Kidney Int, 60:1154-1163 (2001); Augustine et al., “A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF” Am J Kidney Dis, 44:1000-1007 (2004); and Uehlinger et al., “Comparison of continuous and intermittent renal replacement therapy for acute renal failure” Nephrol Dial Transplant, 20:1630-1637 (2005), respectively. However, these studies did not adhere to a uniform definition of, or standard timing, to assess renal recovery.

Other studies have suggested that baseline creatinine and urine output at the time of discontinuation of RRT were most predictive of recovery. Uchino et al., “Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study” Crit Care Med, 37:2576-2582 (2009). However, urine output was analyzed after RRT had ended based on a clinical decision rather than at a fixed time point (e.g. 14 Days post AKI) to predict renal recovery. Therefore, these data are compromised to suggest that urine output was predictive of renal recovery, and further, baseline creatinine might have been less valuable because patients with stage 4 and 5 CKD were excluded.

Recently, a number of urinary biomarkers have been investigated for the purpose of early diagnosis of AKI. Since these markers correlate with renal tubular cell injury or function, their patterns in the urine, either alone or in combination, could provide new prognostic information regarding renal recovery. For example, several reports have suggested possible candidate renal biomarkers relating to three aspects of the physiology of renal recovery:

i) inflammatory markers including; a) urinary neutrophil gelatinase-associated lipocalin (uNGAL), which has been extensively studied for predicting AKI (Supavekin et al., “Differential gene expression following early renal ischemia/reperfusion” Kidney Int, 63:1714-1724 (2003); Mishra et al., “Kidney NGAL is a novel early marker of acute injury following transplantation” Pediatr Nephrol, 21:856-863 (2006); Hirsch et al., “NGAL is an early predictive biomarker of contrast-induced nephropathy in children” Pediatr Nephrol, 22: 2089-2095 (2007); and Zappitelli et al., “Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study” Crit Care, 11: R84 (2007); b) matrix metalloproteinase protein-9 (MMP-9), a matrix degradation enzyme which is up-regulated after ischemic injury in animal models and links to NGAL by a disulfide bond forming urinary NGAL/MMP-9 (uNGAL/MMP-9) (Ronco et al., “Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin” Semin Nephrol, 27:352-362 (2007); and c) urinary interleukin-18 (uIL-18), an inflammatory cytokine which is found to potentiate ischemic AKI and has been tested in many clinical settings (Parikh et al., “Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit” J Am Soc Nephrol, 16:3046-3052 (2005); and Parikh et al., “Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery” Kidney Int, 70:199-203 (2006);

ii) growth factors including urinary hepatocyte growth factor (uHGF), a biomarker linked to renal tubular epithelial cell regeneration (Liu et al., “Hepatocyte growth factor: new arsenal in the fights against renal fibrosis? Kidney Int, 70:238-240 (2006); and

iii) filtration and tubular reabsorption markers, such as cystatin C, which is freely filtered and is normally completely reabsorbed by proximal tubular epithelial cells and urine creatinine. Herget-Rosenthal et al., “Measurement of urinary cystatin C by particle-enhanced nephelometric immunoassay: precision, interferences, stability and reference range” Ann Clin Biochem, 41:111-118 (2004).

Despite these reports, only a few suggest biomarkers having an ability to predict AKI severity. But no study has identified a biomarker as a predictor of renal recovery. Coca et al., “Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review” Kidney Int, 73:1008-1016 (2008). The data presented herein provide heretofore unknown renal biomarkers identified by proteomic gene expression analysis. The data was obtained from urine samples collected during a clinical study as described below.

The data presented herein was collected from 109 patients in the BioMaRK clinical study where 76 patients had complete data available including urine samples. Exactly half (38 patients) recovered renal function (alive and without requirement for dialysis) by day 60. See, FIG. 1. Baseline clinical characteristics of the study patients were taken. See, Table 1.

TABLE 1 Summary of baseline and clinical characteristics of the study patients All subjects Recovery Non-recovery Characteristics (n = 76) (n = 38) (n = 38) P value Age, mean (SD), -yr 58.4(17.0) 52.2(15.7) 64.7(16.2) <0.001 Gender: Female (%) 30(39.5) 15(39.5) 15(39.5) 1.00 Race: White (%) 64(84.2) 30(79.0) 34(89.5) 0.21 Baseline serum creatinine, mean (SD) (mg/dl) 1.1(0.4) 1.1(0.4) 1.2(0.5) 0.45 BUN at initiation of RRT, mean (SD) (mg/dl) 55.6(29.9) 51.3(28.8) 59.9(30.8) 0.23 Cause of acute kidney injury Ischemia (%) 66(86.8) 29(76.3) 37(97.4) 0.007 Nephrotoxins (%) 16(21.3) 10(26.3) 6(16.2) 0.29 Sepsis (%) 50(65.8) 23(60.5) 27(71.1) 0.33 Multifunctional causes (%) 51(68.0) 25(65.8) 26(70.3) 0.68 Length of ICU stay before randomization-days, mean (SD) 5.4(4.1) 4.2(2.8) 6.5(4.9) 0.03 Length of hospital stay before randomization-days, mean (SD) 8.5(7.1) 6.7(5.0) 10.2(8.5) 0.08 Charlson comorbidity index^(a), mean (SD) 4.1(3.3) 3.3(3.8) 4.9(2.7) 0.008 Mechanical ventilation (%) 69(90.8) 34(89.5) 35(92.1) 1.00 Sepsis^(b) (%) 47(62.7) 22(57.9) 25(67.6) 0.39 APACHE II score^(c), mean (SD) 23.4(7.2) 21.8(7.2) 25.0(6.8) 0.06 Non-renal SOFA organ-system score^(d), mean (SD) Respiratory 2.1(1.3) 2.1(1.5) 2.1(1.2) 0.98 Coagulation 1.5(1.3) 1.4(1.3) 1.5(1.3) 0.58 Liver 0.9(1.3) 1.2(1.5) 0.6(1.0) 0.08 Cardiovascular 2.2(1.7) 2.0(1.7) 2.5(1.6) 0.17 Central nervous system 2.2(1.4) 2.3(1.3) 2.1(1.5) 0.45 Total 8.9(4.0) 9.2(4.6) 8.5(3.3) 0.43 Cleveland Clinic ICU ARF Renal Failure score^(e), mean (SD) 11.9(3.0) 11.6(3.0) 12.2(3.0) 0.49 Intensive category^(f) (%) 34(44.7) 18(47.4) 16(42.1) 0.64 Abbreviations: RRT, Renal Replacement Therapy. ICU, Intensive Care Unit. APACHE II, Acute Physiology and Chronic Health Evaluation II. SOFA, Sequential Organ Failure Assessment. ARF, Acute Renal Failure. ^(a)According to the method of Charlson et al.²³ ^(b)Defined as sepsis plus acute organ dysfunction according to 2001 international consensus criteria for sever sepsis.²⁶ ^(c)According to the method of Knaus et al.²⁹ ^(d)Non renal SOFA score, excluding the renal part, assessed on the first day according to the method of Vincent et al.³⁰ ^(e)According to the method of Thakar et al.³¹ ^(f)Intensive strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided six times per week (every day except Sunday), and continuous venovenous hemodiafiltration was prescribed to provide a flow rate of the total effluent (the sum of the dialysate and ultrafiltrate) of 35 ml per kilogram of body weight per hour, based on the weight before the onset of acute illness.¹

Patients recovering from renal injury were more likely to be younger, had a shorter length of intensive care unit (ICU) stay before randomization, lower Charlson comorbidity index, and lower nonrenal SOFA score as compared to those not recovering renal function. By contrast, there were no statistical differences in gender, ethnicity, baseline serum creatinine, blood urea nitrogen (BUN) at initiation of RRT, length of hospital stay, length of ICU stay, requirement for mechanical ventilation, Cleveland Clinic ICU Acute Renal Failure (ARF) score, or intensity of RRT. The primary etiology of AKI was ischemia in both groups. However, a significantly lower percentage of ischemia (76.3%) was noted as the cause of AKI in the recovery group compared to 97.4% in non-recovery group. Of the 38 participants who recovered renal function, 26 (68.4%) had complete recovery. Among those failing to recover renal function, 25 patients (65.8%), did not survive past day 60.

IV. Proteomics Gene Expression Platforms

In one embodiment, the present invention contemplates a method for identifying urinary biomarkers using a proteomics platform. In one embodiment, the proteomics platform detects protein expression profiles. In one embodiment, the method further comprises comparing a first protein expression profile to a second protein expression profile. In one embodiment, the comparing identifies an overexpressed protein in the first protein expression profile relative to the second protein expression profile. In one embodiment, the comparing identifies an underexpressed protein in the first protein expression profile relative to the second protein expression profile.

A Introduction

In one embodiment, the present invention contemplates a method comprising a proteomics platform (i.e., for example, iTRAQ) capable of summarizing an analysis of relative protein biomarker expression. For example, the proteomics platform may use reporter ion peak area measurements (i.e., for example, supplied by ABI software) to estimate treatment-dependent peptide and protein biomarker relative expression. Such estimations may be accomplished using a Bayesian approach. The proteomics platform described herein includes a protein biomarker relative expression summary and a per-protein biomarker detailed analysis.

B Experiment and Model Description

1. Experiment Design

Proteomic platforms contemplated herein may summarize data from one or more experiments addressing a common comparison. For example, a possible experimental design for such an analysis is presented below. See, Table 5.

TABLE 5 Representative Proteomic Experimental Designs Experiment Treatment Channel Sample 1 A A 113 A1 2 A A 114 A2 3 A A 115 A3 4 A A 116 A4 5 A B 117 B1 6 A B 118 B2 7 A B 119 B4 8 A B 121 B4

2. Input Files

Data for proteomic analyses may be extracted from input files including but not limited to a tandem mass spectra (MSMS) summary file, such as:

$\frac{{Experiment}\mspace{14mu} {MSMS}\mspace{14mu} {Summary}\mspace{20mu} {File}}{A\mspace{239mu} \text{?}}$ ?indicates text missing or illegible when filed

3. Statistical Modeling Statistical models to estimate the treatment-dependent effects may including but not limited to: LogIntensity^(˜)Channel+Spectrum+Protein+Peptide+Protein:Treatment+Peptide:Treatment.

4. Data Summarization

The proteomics platform may comprise filtering the data supplied in the MSMS summary to remove unidentified proteins, contaminants, and/or peptides containing selected modifications. A representative analysis may provide a data summary as presented below. See, Table 6.

TABLE 6 Representative Data Summary A Combined Supplied Spectra 4608 4608 Unidentified Spectra 0 0 Disallowed Modifications 249 249 Spectra from Contaminants 1210 1210 Missing Data 115 115 Low Confidence Spectra 0 0 Degenerate Peptides 379 379 Remaining Spectra 2655 Unique Proteins 360 Unique Peptides 1473 Model R2 0.767

C. Protein Biomarker Summary

In one embodiment, the proteomics platform may identify each protein biomarker in one or more of the MSMS summaries, for example, in decreasing order of expression change magnitude. See, FIG. 2. The median and estimated credible interval for each protein biomarker is given to the left in the table. Similar data is shown where protein biomarkers are identified by a single peptide. See FIG. 3.

D. Protein Biomarker Details

A detailed summary of each protein biomarker is given below, wherein each protein biomarker is designated as 5.###. These sections include protein biomarker relative expression estimates in addition to protein-level estimates.

5.1 beta globin [Homo sapiens] Protein Accession gi|4504349

Mean Expression Ratio 2.31 Median Expression Ratio 2.31 Credible Interval (1.9, 2.82) Associated Peptides 7 Associated Spectra 29 Coverage 0.51

A 2.5 50 97.5 SEQ ID NO: Sequence  1 1.6 2.2 3.0 SEQ ID NO: 1 EFTPPVQAAYQK  3 1.8 2.4 3.1 SEQ ID NO: 2 FESFGDLSTPDA VMGNPK  4 1.8 2.4 3.2 SEQ ID NO: 3 FFESFGDLSTPD AVMGNPK  4 1.9 2.5 3.3 SEQ ID NO: 4 GTFATLSELHCD K 13 2.1 2.6 3.2 SEQ ID NO: 5 LLGNVLVCVLAH HFGK  3 1.6 2.2 2.9 SEQ ID NO: 6 VNVDEVGGEALG R  1 1.7 2.4 3.3 SEQ ID NO: 7 FRLLGNVLVCVL AHHFGK SEQ ID NO: 8  1 M V H L T P E E K S A V T A L W G K V N V D E V G G E A L G R L L V V Y P W T Q R F F E S F G D L S T P D A V M G N P K V K A H G K K V L G A F S D G L A H L D 81 N L K G T F A T L S E L H C D K L H V D P E N F R L L G N V L V C V L A H H F G K E F T P P V Q A A Y Q K V V A G V A N A L A H K Y H 5.2 catalase [Homo sapiens] Protein Accession gi|4557014

Mean Expression Ratio 1.97 Median Expression Ratio 1.97 Credible Interval (1.61, 2.40) Associated Peptides 13 Associated Spectra 20 Coverage 0.279

Sequence A 2.5 50 97.5 ID No. Sequence 2 1.4 1.8 2.5 SEQ ID NO: 9 AFYVNVLNEEQR 2 1.4 2.0 2.6 SEQ ID NO: 10 DPILFPSFIHSQ K 1 1.5 2   2.8 SEQ ID NO: 11 FSTVAGESGSAD TVR 4 1.7 2.2 2.9 SEQ ID NO: 12 GPLLVQDVVFTD EMAHFDR 1 1.6 2.2 3   SEQ ID NO: 13 GPRGPLLVQDVV FTDEMAHFDR 1 1.6 2.1 3.0 SEQ ID NO: 14 IRDPILFPSFIH SQK 1 1.5 2   2.7 SEQ ID NO: 15 LFAYPDTHR 1 1.4 1.9 2.6 SEQ ID NO: 16 LSQEDPDYGIR 2 1.4 2.0 2.7 SEQ ID NO: 17 LVQDVVFTDEMA HFDR 2 1.5 2.0 2.7 SEQ ID NO: 18 NFTEVHPDYGSH IQALLDK 1 1.4 2.0 2.7 SEQ ID NO: 19 FAEVEQIAFDPS NMPPGIEASPDK 1 1.4 1.9 2.7 SEQ ID NO: 20 VFEHIGK 1 1.4 2.0 2.7 SEQ ID NO: 21 FNTANDDNVTQV R SEQ ID NO: 22   1 M A D S R D P A S D Q M Q H W K E Q R A A Q K A D V L T T G A G N P V G D K L N V I T V G P R G P L L V Q D V V F T D E M A H F D R E R I P E R V V H A K G A G  81 A F G Y F E V T H D I T K Y S K A K V F E H I G K K T P I A V R F S T V A G E S G S A D T V R D P R G F A V K F Y T E D G N W D L V G N N T P I F F I R D P I L 161 F P S F I H S Q K R N P Q T H L K D P D M V W D F W S L R P E S L H Q V S F L F S D R G I P D G H R H M N G Y G S H T F K L V N A N G E A V Y C K F H Y K T D Q 241 G I K N L S V E D A A R L S Q E D P D Y G I R D L F N A I A T G K Y P S W T F Y I Q V M T F N Q A E T F P F N P F D L T K V W P H K D Y P L I P V G K L V L N R 321 N P V N Y F A E V E Q I A F D P S N M P P G I E A S P D K M L Q G R L F A Y P D T H R H R L G P N Y L H I P V N C P Y R A R V A N Y Q R D G P M C M Q D N Q G G 401 A P N Y Y P N S F G A P E Q Q P S A L E H S I Q Y S G E V R R F N T A N D D N V T Q V R A F Y V N V L N E E Q R K R L C E N I A G H L K D A Q I F I Q K K A V K 481 N F T E V H P D Y G S H I Q A L L D K Y N A E K P K N A I H T F V Q S G S H L A A R E K A N L 5.3 myoglobin [Homo sapiens]; myoglobin [Homo sapiens]; myoglobin [Homo sapiens] Protein Accession gi|4885477 gi|44955888 gi|44955885

Mean Expression Ratio 0.525 Median Expression Ratio 0.526 Credible Interval (0.373, 0.736) Associated Peptides 3 Associated Spectra 5 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.35 0.53 0.8  SEQ ID NO: 23 GLSDGEWQLVLN VWGK 2 0.36 0.53 0.77 SEQ ID NO: 24 HGATVLTALGGI LK 2 0.31 0.45 0.65 SEQ ID NO: 25 VEADIPGHGQEV LIR 5.4 alpha 1 globin [Homo sapiens]; alpha 2 globin [Homo sapiens] Protein Accession gi|4504347 gi|4504345

Mean Expression Ratio 1.86 Median Expression Ratio 1.86 Credible Interval (1.56, 2.22) Associated Peptides 12 Associated Spectra 36 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 2 1.6 2.2 2.9 SEQ ID NO: 26 AAHLPAEFTPAV HASLDK 1 1.4 1.9 2.7 SEQ ID NO: 27 ALSALSDLHAHK 1 1.4 1.9 2.6 SEQ ID NO: 28 FLSFPTTK 1 1.4 1.9 2.6 SEQ ID NO: 29 FPHFDLSHGSAQ VK 1 1.4 1.9 2.7 SEQ ID NO: 30 MFLSFPTTK 7 1.6 2.1 2.6 SEQ ID NO: 31 TYFPHFDLSHGS AQVK 3 1.4 1.8 2.4 SEQ ID NO: 32 VADALTNAVAHV DDMPNAL 2 1.3 1.7 2.3 SEQ ID NO: 33 VADALTNAVAHV DDMPNALSALSD LHAH 1 1.5 2   2.7 SEQ ID NO: 34 VDDMPNALSALS DLHAHK 9 1.2 1.5 1.9 SEQ ID NO: 35 VGAHAGEYGAEA LER 6 1.5 1.9 2.4 SEQ ID NO: 36 VADALTNAVAHV DDMPNALSALSD LHAHK 2 1.4 1.8 2.4 SEQ ID NO: 37 VDPVNFK 5.5 hemopexin [Homo sapiens] Protein Accession gi|11321561

Mean Expression Ratio 0.547 Median Expression Ratio 0.547 Credible Interval (0.444, 0.676) Associated Peptides 12 Associated Spectra 17 Coverage 0.297

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.4   0.55 0.77 SEQ ID NO: 38 DYFMPCPGR 1 0.4   0.55 0.76 SEQ ID NO: 39 EWFWDLATGTMK 1 0.40 0.56 0.79 SEQ ID NO: 40 FDPVRGEVPPR 1 0.39 0.54 0.76 SEQ ID NO: 41 FQGDREWFWDLA TGTMK 4 0.35 0.46 0.62 SEQ ID NO: 42 LLQDEFPGIPSP LDAAVECHR 1 0.4   0.56 0.77 SEQ ID NO: 43 NFPSPVDAAFR 2 0.4   0.55 0.75 SEQ ID NO: 44 RLWWLDLK 1 0.39 0.55 0.77 SEQ ID NO: 45 SGAQATWTELPW PHEK 2 0.4   0.55 0.75 SEQ ID NO: 46 VAEGETKPDPDV TER 1 0.39 0.54 0.75 SEQ ID NO: 47 YYCFQGNQFLR 1 0.39 0.54 0.77 SEQ ID NO: 48 GIILDSVDAAFI CPGSSR 1 0.37 0.52 0.73 SEQ ID NO: 49 LWWLDLK SEQ ID NO: 50   1 M A R V L G A P V A L G L W S L C W S L A I A T P L P P T S A H G N V A E G E T K P D P D V T E R C S D G W S F D A T T L D D N G T M L F F K G E F V W K S H K  81 W D R E L I S E R W K N F P S P V D A A F R Q G H N S V F L I K G D K V W V Y P P E K K E K G Y P K L L Q D E F P G I P S P L D A A V E C H R G E C Q A E G V L 161 F F Q G D R E W F W D L A T G T M K E R S W P A V G N C S S A L R W L G R Y Y C F Q G N Q F L R F D P V R G E V P P R Y P R D V R D Y F M P C P G R G H G H R N 241 G T G H G N S T H H G P E Y M R C S P H L V L S A L T S D N H G A T Y A F S G T H Y W R L D T S R D G W H S W P I A H Q W P Q G P S A V D A A F S W E E K L Y L 321 V Q G T Q V Y V F L T K G G Y T L V S G Y P K R L E K E V G T P H G I I L D S V D A A F I C P G S S R L H I M A G R R L W W L D L K S G A Q A T W T E L P W P H 401 E K V D G A L C M E K S L G P N S C S A N G P G L Y L I H G P N L Y C Y S D V E K L N A A K A L P Q P Q N V T S L L G C T H 5.6 serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens] Protein Accession gi|50363221 gi|50363219 gi|50363217 gi|189163542 gi|189163540 gi|189163538 gi|189163536

Mean Expression Ratio 0.551 Median Expression Ratio 0.551 Credible Interval (0.482, 0.627) Associated Peptides 27 Associated Spectra 68 Coverage NaN

Sequence A 2.5 50 97.5 ID No: Sequence  9 0.46 0.57 0.7  SEQ ID NO: 51 DTEEEDFH VDQVTTVK  1 0.43 0.57 0.77 SEQ ID NO: 52 DTVFALVN YIFFK  2 0.40 0.53 0.71 SEQ ID NO: 53 ELDRDTVF ALVNYIFF K  1 0.42 0.56 0.76 SEQ ID NO: 54 GTEAAGAM FLEAIPMS IPPEVK  1 0.4  0.54 0.72 SEQ ID NO: 55 ITPNLAEF AFSLYR  2 0.43 0.57 0.75 SEQ ID NO: 56 KLSSWVLL MK  2 0.44 0.58 0.77 SEQ ID NO: 57 KQINDYVE K  1 0.43 0.57 0.77 SEQ ID NO: 58 LAEFAFSL YR  4 0.4  0.52 0.67 SEQ ID NO: 59 LGMFNIQH CK 18 0.39 0.46 0.55 SEQ ID NO: 60 LQHLENEL THDIITK  5 0.42 0.53 0.68 SEQ ID NO: 61 LVDKFLED VK  2 0.42 0.56 0.74 SEQ ID NO: 62 QINDYVEK  2 0.44 0.59 0.78 SEQ ID NO: 63 SASLHLPK  1 0.4  0.54 0.73 SEQ ID NO: 64 SVLGQLGI TK  1 0.42 0.57 0.77 SEQ ID NO: 65 TLNQPDSQ LQLTTGNG LFLSEGLK  1 0.4  0.54 0.73 SEQ ID NO: 66 TVNFGDTE EAKK  3 0.41 0.53 0.69 SEQ ID NO: 67 VFSNGADL SGVTEEAP LK  2 0.39 0.52 0.69 SEQ ID NO: 68 WERPFEVK  1 0.41 0.54 0.73 SEQ ID NO: 69 LVDKFLED VKK  1 0.39 0.53 0.71 SEQ ID NO: 70 GKWERPFE VK  1 0.42 0.57 0.76 SEQ ID NO: 71 AVLTIDEK  1 0.4  0.54 0.73 SEQ ID NO: 72 FLEDVKK  1 0.41 0.56 0.75 SEQ ID NO: 73 LSITGTYD LK  2 0.42 0.56 0.73 SEQ ID NO: 74 FLEDVK  1 0.39 0.53 0.71 SEQ ID NO: 75 EEEDFHVD QVTTVK  1 0.43 0.58 0.77 SEQ ID NO: 76 GLFLSEGL K  1 0.41 0.55 0.74 SEQ ID NO: 77 FNKPFVF 5.7 mucin 1 isoform 3 precursor [Homo sapiens]; mucin 1 isoform 2 precursor [Homo sapiens]; mucin 1 isoform 1 precursor [Homo sapiens] Protein Accession gi|67189069 gi|67189007 gi|65301117

Mean Expression Ratio 1.81 Median Expression Ratio 1.81 Credible Interval (1.45, 2.27) Associated Peptides 6 Associated Spectra 22 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence  1 1.3 1.8 2.5 SEQ ID NO: 78 DISEMFLQIYK  2 1.4 1.9 2.6 SEQ ID NO: 79 HDVETQFNQYK  2 1.3 1.7 2.4 SEQ ID NO: 80 KNYGQLDIFPAR  4 1.5 1.9 2.6 SEQ ID NO: 81 NYGQLDIFPAR  1 1.3 1.8 2.4 SEQ ID NO: 82 QGGFLGLSNIK 12 1.6 2.0 2.5 SEQ ID NO: 83 EGTINVHDVETQ FNQYK 5.8 serpin peptidase inhibitor, clade A, member 3 precursor [Homo sapiens] Protein Accession gi|50659080

Mean Expression Ratio 0.563 Median Expression Ratio 0.563 Credible Interval (0.463, 0.681) Associated Peptides 15 Associated Spectra 21 Coverage 0.388

Sequence A 2.5 50 97.5 ID No. Sequence 2 0.41 0.55 0.74 SEQ ID NO: 84 AVLDVFEEGTEA SAATAVK 1 0.39 0.54 0.75 SEQ ID NO: 85 DYNLNDILLQLG IEEAFTSK 1 0.42 0.58 0.8  SEQ ID NO: 86 EIGELYLPK 2 0.37 0.51 0.68 SEQ ID NO: 87 HPNSPLDEENLT QENQDR 1 0.38 0.53 0.73 SEQ ID NO: 88 ITLLSALVETR 1 0.42 0.57 0.8  SEQ ID NO: 89 KLINDYVK 1 0.4  0.55 0.76 SEQ ID NO: 90 LYGSEAFATDFQ DSAAAK 3 0.45 0.6  0.8  SEQ ID NO: 91 MEEVEAMLLPET LK 1 0.42 0.57 0.79 SEQ ID NO: 92 MEEVEAMLLPET LKR 2 0.42 0.57 0.77 SEQ ID NO: 93 NLAVSQVVHK 2 0.42 0.56 0.76 SEQ ID NO: 94 NSPLDEENLTQE NQDR 1 0.40 0.55 0.76 SEQ ID NO: 95 SPLDEENLTQEN QDR 1 0.41 0.57 0.77 SEQ ID NO: 96 WEMPFDPQDTHQ SR 1 0.4  0.55 0.76 SEQ ID NO: 97 WRDSLEFR 1 0.41 0.57 0.78 SEQ ID NO: 98 EQLSLLDRFTED AK SEQ ID NO: 99   1 M E R M L P L L A L G L L A A G F C P A V L C H P N S P L D E E N L T Q E N Q D R G T H V D L G L A S A N V D F A F S L Y K Q L V L K A P D K N V I F S P L S I  81 S T A L A F L S L G A H N T T L T E I L K G L K F N L T E T S E A E I H Q S F Q H L L R T L N Q S S D E L Q L S M G N A M F V K E Q L S L L D R F T E D A K R L 161 Y G S E A F A T D F Q D S A A A K K L I N D Y V K N G T R G K I T D L I K D L D S Q T M M V L V N Y I F F K A K W E M P F D P Q D T H Q S R F Y L S K K K W V M 241 V P M M S L H H L T I P Y F R D E E L S C T V V E L K Y T G N A S A L F I L P D Q D K M E E V E A M L L P E T L K R W R D S L E F R E I G E L Y L P K F S I S R 321 D Y N L N D I L L Q L G I E E A F T S K A D L S G I T G A R N L A V S Q V V H K A V L D V F E E G T E A S A A T A V K I T L L S A L V E T R T I V R F N R P F L 401 M I I V P T D T Q N I F F M S K V T N P K Q A 5.9 CD14 antigen precursor [Homo sapiens]; CD14 antigen precursor [Homo sapiens] Protein Accession gi|91105159 gi|4557417

Mean Expression Ratio 0.567 Median Expression Ratio 0.567 Credible Interval (0.452, 0.707) Associated Peptides 9 Associated Spectra 16 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 4 0.4  0.53 0.71 SEQ ID NO: 100 AFPALTSL DLSDNPGL GER 1 0.41 0.58 0.81 SEQ ID NO: 101 GLMAALCP HK 1 0.42 0.58 0.8  SEQ ID NO: 102 GLMAALCP HKFPAIQN L 1 0.40 0.56 0.79 SEQ ID NO: 103 GLMAALCP HKFPAIQN LALR 2 0.43 0.58 0.8  SEQ ID NO: 104 ITGTMPPL PLEATGLA LSSLR 3 0.39 0.53 0.72 SEQ ID NO: 105 LTVGAAQV PAQLLVGA LR 1 0.4  0.56 0.78 SEQ ID NO: 106 SWLAELQQ WLKPGLK 2 0.41 0.56 0.77 SEQ ID NO: 107 TTPEPCEL DDEDFR 1 0.39 0.54 0.76 SEQ ID NO: 108 VLSIAQAH SPAFSCEQ VR 5.10 brain abundant, membrane attached signal protein 1 [Homo sapiens] Protein Accession gi|30795231

Mean Expression Ratio 1.75 Median Expression Ratio 1.75 Credible Interval (1.30, 2.35) Associated Peptides 5 Associated Spectra 7 Coverage 0.396

Sequence A 2.5 50 97.5 ID No. Sequence 1 1.2 1.8 2.7 SEQ ID NO: 109 AAEAAAAP AESAAPAA GEEPSKEE GEPK 1 1.2 1.7 2.5 SEQ ID NO: 110 AEPPKAPE QEQAAPGP AAGGEAPK 2 1.3 1.8 2.6 SEQ ID NO: 111 APEQEQAA PGPAAGGE APK 1 1.2 1.8 2.7 SEQ ID NO: 112 AQGPAASA EEPKPVEA PAANSDQT VTVK 2 1.3 1.8 2.6 SEQ ID NO: 113 EKPDQDAE GK SEQ ID NO: 114   1 M G G K L S K K K K G Y N V N D E K A K E K D K K A E G A A T E E E G T P K E S E P Q A A A E P A E A K E G K E K P D Q D A E G K A E E K E G E K D A A A A K E  81 E A P K A E P E K T E G A A E A K A E P P K A P E Q E Q A A P G P A A G G E A P K A A E A A A A P A E S A A P A A G E E P S K E E G E P K K T E A P A A P A A Q 161 E T K S D G A P A S D S K P G S S E A A P S S K E T P A A T E A P S S T P K A Q G P A A S A E E P K P V E A P A A N S D Q T V T V K E 5.11 dipeptidase 1 [Homo sapiens]; dipeptidase 1 [Homo sapiens] Protein Accession gi|4758190 gi|89458885

Mean Expression Ratio 1.72 Median Expression Ratio 1.72 Credible Interval (1.25, 2.37) Associated Peptides 5 Associated Spectra 6 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 1.2 1.7 2.6 SEQ ID NO: 115 AVGFGGDF DGVPR 1 1.2 1.8 2.6 SEQ ID NO: 116 DSPVIDGH NDLPWQLL DMFNNR 1 1.2 1.8 2.7 SEQ ID NO: 117 VPEGLEDV SKYPDLIA ELLR 1 1.2 1.8 2.7 SEQ ID NO: 118 YPDLIAEL LR 2 1.2 1.8 2.5 SEQ ID NO: 119 VASLIGVE GGHSIDSS LGVLR 5.12 fibronectin 1 isoform 5 preproprotein [Homo sapiens] Protein Accession gi|47132553

Mean Expression Ratio 0.586 Median Expression Ratio 0.585 Credible Interval (0.475, 0.724) Associated Peptides 11 Associated Spectra 17 Coverage 0.0758

Sequence A 2.5 50 97.5 ID No. Sequence 3 0.40 0.55 0.74 SEQ ID NO: 120 AVEENQES TPVVIQQE TTGTPR 2 0.43 0.58 0.79 SEQ ID NO: 121 EESPLLIG QQSTVSDV PR 2 0.41 0.57 0.77 SEQ ID NO: 122 ESVPISDT IIPAVPPP TDLR 1 0.45 0.63 0.88 SEQ ID NO: 123 LISWDAPA VTVR 1 0.42 0.58 0.81 SEQ ID NO: 124 QVDAVPAN GQTPIQR 1 0.43 0.59 0.82 SEQ ID NO: 125 SSPVVIDA STAIDAPS NLR 2 0.43 0.59 0.81 SEQ ID NO: 126 TETITGFQ VDAVPANG QTPIQR 2 0.42 0.57 0.78 SEQ ID NO: 127 VDVIPVNL PGEHGQR 1 0.43 0.6  0.84 SEQ ID NO: 128 VTWAPPPS IDLTNFLV R 1 0.43 0.6  0.83 SEQ ID NO: 129 DLEVVAAT PTSLLISW DAPAVTVR 1 0.37 0.51 0.7  SEQ ID NO: 130 IISCHPVG TDEEPLQF R SEQ ID NO: 131    1 M L R G P G P G L L L L A V Q C L G T A V P S T G A S K S K R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q I N Q Q W E R T Y L G N A L V C T C Y G   81 G S R G F N C E S K P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I G D T W R R P H E T  161 G G Y M L E C V C L G N G K G E W T C K P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  241 R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P Q P P P Y G H C V T D S G V V Y S V G M  321 Q W L K T Q G N K Q M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C V L P F T Y N G R T F Y S C T T E G R Q D G H L W C S T T S N Y E Q D Q K Y S F  401 C T D H T V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A H E E I C T T N E G V M Y R I  481 G D Q W D K Q H D M G H M M R C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C D P V D Q  561 C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F I T E T P S Q P N S H P I Q W N A P Q P S H I S K  641 Y I L R W R P K N S V G R W K E A T I P G H L N S Y T I K G L K P G V V Y E G Q L I S I Q Q Y G H Q E V T R F D F T T T S T S T P V T S N T V T G E T T P F S P  721 L V A T S E S V T E I T A S S F V V S W V S A S D T V S G F R V E Y E L S E E G D E P Q Y L D L P S T A T S V N I P D L L P G R K Y I V N V Y Q I S E D G E Q S  801 L I L S T S Q T T A P D A P P D P T V D Q V D D T S I V V R W S R P Q A P I T G Y R I V Y S P S V E G S S T E L N L P E T A N S V T L S D L Q P G V Q Y N I T I  881 Y A V E E N Q E S T P V V I Q Q E T T G T P R S D T V P S P R D L Q F V E V T D V K V T I M W T P P E S A V T G Y R V D V I P V N L P G E H G Q R L P I S R N T  961 F A E V T G L S P G V T Y Y F K V F A V S H G R E S K P L T A Q Q T T K L D A P T N L Q F V N E T D S T V L V R W T P P R A Q I T G Y R L T V G L T R R G Q P R 1041 Q Y N V G P S V S K Y P L R N L Q P A S E Y T V S L V A I K G N Q E S P K A T G V F T T L Q P G S S I P P Y N T E V T E T T I V I T W T P A P R I G F K L G V R 1121 P S Q G G E A P R E V T S D S G S I V V S G L T P G V E Y V Y T I Q V L R D G Q E R D A P I V N K V V T P L S P P T N L H L E A N P D T G V L T V S W E R S T T 1201 P D I T G Y R I T T T P T N G Q Q G N S L E E V V H A D Q S S C T F D N L S P G L E Y N V S V Y T V K D D K E S V P I S D T I I P A V P P P T D L R F T N I G P 1281 D T M R V T W A P P P S I D L T N F L V R Y S P V K N E E D V A E L S I S P S D N A V V L T N L L P G T E Y V V S V S S V Y E Q H E S T P L R G R Q K T G L D S 1361 P T G I D F S D I T A N S F T V H W I A P R A T I T G Y R I R H H P E H F S G R P R E D R V P H S R N S I T L T N L T P G T E Y V V S I V A L N G R E E S P L L 1441 I G Q Q S T V S D V P R D L E V V A A T P T S L L I S W D A P A V T V R Y Y R I T Y G E T G G N S P V Q E F T V P G S K S T A T I S G L K P G V D Y T I T V Y A 1521 V T G R G D S P A S S K P I S I N Y R T E I D K P S Q M Q V T D V Q D N S I S V K W L P S S S P V T G Y R V T T T P K N G P G P T K T K T A G P D Q T E M T I E 1601 G L Q P T V E Y V V S V Y A Q N P S G E S Q P L V Q T A V T T I P A P T D L K F T Q V T P T S L S A Q W T P P N V Q L T G Y R V R V T P K E K T G P M K E I N L 1681 A P D S S S V V V S G L M V A T K Y E V S V Y A L K D T L T S R P A Q G V V T T L E N V S P P R R A R V T D A T E T T I T I S W R T K T E T I T G F Q V D A V P 1761 A N G Q T P I Q R T I K P D V R S Y T I T G L Q P G T D Y K I Y L Y T L N D N A R S S P V V I D A S T A I D A P S N L R F L A T T P N S L L V S W Q P P R A R I 1841 T G Y I I K Y E K P G S P P R E V V P R P R P G V T E A T I T G L E P G T E Y T I Y V I A L K N N Q K S E P L I G R K K T D E L P Q L V T L P H P N L H G P E I 1921 L D V P S T V Q K T P F V T H P G Y D T G N G I Q L P G T S G Q Q P S V G Q Q M I F E E H G F R R T T P P T T A T P I R H R P R P Y P P N V G E E I Q I G H I P 2001 R E D V D Y H L Y P H G P G L N P N A S T G Q E A L S Q T T I S W A P F Q D T S E Y I I S C H P V G T D E E P L Q F R V P G T S T S A T L T G L T R G A T Y N I 2081 I V E A L K D Q Q R H K V R E E V V T V G N S V N E G L N Q P T D D S C F D P Y T V S H Y A V G D E W E R M S E S G F K L L C Q C L G F G S G H F R C D S S R W 2161 C H D N G V N Y K I G E K W D R Q G E N G Q M M S C T C L G N G K G E F K C D P H E A T C Y D D G K T Y H V G E Q W Q K E Y L G A I C S C T C F G G Q R G W R C 2241 D N C R R P G G E P S P E G T T G Q S Y N Q Y S Q R Y H Q R T N T N V N C P I E C F M P L D V Q A D R E D S R E 5.13 angiotensinogen preproprotein [Homo sapiens] Protein Accession gi|4557287

Mean Expression Ratio 0.59 Median Expression Ratio 0.59 Credible Interval (0.482, 0.718) Associated Peptides 10 Associated Spectra 25 Coverage 0.293

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.42 0.57 0.77 SEQ ID NO: 132 AAMVGMLANFLGFR 2 0.4 0.54 0.73 SEQ ID NO: 133 ADSQAQLLLSTVVGVFTAPGLHLK 1 0.44 0.6 0.83 SEQ ID NO: 134 ALQDQLVLVAAK 2 0.46 0.62 0.85 SEQ ID NO: 135 DPTFIPAPIQAK 1 0.45 0.63 0.87 SEQ ID NO: 136 FMQAVTGWK 1 0.42 0.56 0.78 SEQ ID NO: 137 QPFVQGLALYTPVVLPR 2 0.46 0.62 0.85 SEQ ID NO: 138 VGEVLNSIFFELEADER 2 0.43 0.58 0.79 SEQ ID NO: 139 VLSALQAVQGLLVAQGR 11 0.4 0.5 0.61 SEQ ID NO: 140 DRVYIHPFHL 1 0.44 0.6 0.84 SEQ ID NO: 141 LQAILGVPWK SEQ ID NO: 142   1 M R K R A P Q S E M A P A G V S L R A T I L C L L A W A G L A A G D R V Y I H P F H L V I H N E S T C E Q L A K A N A G K P K D P T F I P A P I Q A K T S P V D  81 E K A L Q D Q L V L V A A K L D T E D K L R A A M V G M L A N F L G F R I Y G M H S E L W G V V H G A T V L S P T A V F G T L A S L Y L G A L D H T A D R L Q A 161 I L G V P W K D K N C T S R L D A H K V L S A L Q A V Q G L L V A Q G R A D S Q A Q L L L S T V V G V F T A P G L H L K Q P F V Q G L A L Y T P V V L P R S L D 241 F T E L D V A A E K I D R F M Q A V T G W K T G C S L M G A S V D S T L A F N T Y V H F Q G K M K G F S L L A E P Q E F W V D N S T S V S V P M L S G M G T F Q 321 H W S D I Q D N F S V T Q V P F T E S A C L L L I Q P H Y A S D L D K V E G L T F Q Q N S L N W M K K L S P R T I H L T M P Q L V L Q G S Y D L Q D L L A Q A E 401 L P A I L H T E L N L Q K L S N D R I R V G E V L N S I F F E L E A D E R E P T E S T Q Q L N K P E V L E V T L N R P F L F A V Y D Q S A T A L H F L G R V A N 481 P L S T A 5.14 complement component 3 precursor [Homo sapiens] Protein Accession gi|115298678

Mean Expression Ratio 0.601 Median Expression Ratio 0.602 Credible Interval (0.532, 0.678) Associated Peptides 39 Associated Spectra 69 Coverage 0.301

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.46 0.61 0.82 SEQ ID NO: 143 CAEENCFIQK 1 0.45 0.6 0.8 SEQ ID NO: 144 DAPDHQELNLDVSLQLPSR 2 0.44 0.58 0.77 SEQ ID NO: 145 DFDFVPPVVR 1 0.45 0.6 0.81 SEQ ID NO: 146 DTWVEHWPEEDECQDEENQK 11 0.35 0.43 0.53 SEQ ID NO: 147 EDIPPADLSDQVPDTESETR 3 0.45 0.59 0.76 SEQ ID NO: 148 EPGQDLVVLPLSITTDFIPSFR 1 0.45 0.6 0.81 SEQ ID NO: 149 EYVLPSFEVIVEPTEK 1 0.46 0.6 0.81 SEQ ID NO: 150 FYHPEKEDGK 1 0.46 0.61 0.83 SEQ ID NO: 151 HQQTVTIPPK 1 0.46 0.61 0.82 SEQ ID NO: 152 IHWESASLLR 5 0.44 0.56 0.71 SEQ ID NO: 153 ILLQGTPVAQMTEDAVDAER 3 0.48 0.62 0.81 SEQ ID NO: 154 IPIEDGSGEVVLSR 1 0.44 0.59 0.79 SEQ ID NO: 155 IWDVVEK 2 0.46 0.61 0.8 SEQ ID NO: 156 KQELSEAEQATR 2 0.47 0.62 0.83 SEQ ID NO: 157 LESEETMVLEAHDAQGDVPVTVTVHD FPGK 1 0.46 0.61 0.82 SEQ ID NO: 158 LMNIFL K 3 0.48 0.62 0.81 SEQ ID NO: 159 QKPDGVFQEDAPVIHQEMIGGLR 1 0.47 0.63 0.85 SEQ ID NO: 160 SGQSEDRQPVPGQQMTLK 1 0.45 0.59 0.8 SEQ ID NO: 161 SITTDFIPSFR 2 0.45 0.59 0.78 SEQ ID NO: 162 SNLDEDIIAEENIVSR 1 0.44 0.59 0.79 SEQ ID NO: 163 SWDIPELVNMGQWK 1 0.45 0.61 0.81 SEQ ID NO: 164 TELRPGETLNVNF 2 0.46 0.61 0.81 SEQ ID NO: 165 TELRPGETLNVNFLLR 2 0.47 0.63 0.83 SEQ ID NO: 166 TVMVNIENPEGIPVK 1 0.46 0.61 0.81 SEQ ID NO: 167 VFVTNPDGSPAYR 1 0.45 0.61 0.82 SEQ ID NO: 168 VIFGIQDGEQR 1 0.45 0.6 0.8 SEQ ID NO: 169 VLLDGVQNPR 3 0.44 0.58 0.75 SEQ ID NO: 170 VQLSNDFDEYIMAIEQTIK 3 0.45 0.58 0.76 SEQ ID NO: 171 VTIKPAPETEK 1 0.46 0.61 0.81 SEQ ID NO: 172 AGDFLEANYMNLQR 1 0.45 0.6 0.8 SEQ ID NO: 173 GICVADPFEVTVMQDFFIDLR 1 0.46 0.61 0.81 SEQ ID NO: 174 LKGPLLNK 1 0.41 0.54 0.72 SEQ ID NO: 175 FYYIYNEK 1 0.47 0.63 0.84 SEQ ID NO: 176 QPVPGQQMTLK 1 0.46 0.62 0.83 SEQ ID NO: 177 RIPIEDGSGEVVLSR 1 0.47 0.62 0.83 SEQ ID NO: 178 VSHSEDDCLAFK 1 0.45 0.6 0.8 SEQ ID NO: 179 LSINTHPSQKPL 1 0.45 0.6 0.8 SEQ ID NO: 180 GLSSDFWGEKPNLSY 1 0.48 0.64 0.85 SEQ ID NO: 181 QIHFTK SEQ ID NO: 182    1 M G P T S G P S L L L L L L T H L P L A L G S P M Y S I I T P N I L R L E S E E T M V L E A H D A Q G D V P V T V T V H D F P G K K L V L S S E K T V L T P A T   81 N H M G N V T F T I P A N R E F K S E K G R N K F V T V Q A T F G T Q V V E K V V L V S L Q S G Y L F I Q T D K T I Y T P G S T V L Y R I F T V N H K L L P V G  161 R T V M V N I E N P E G I P V K Q D S L S S Q N Q L G V L P L S W D I P E L V N M G Q W K I R A Y Y E N S P Q Q V F S T E F E V K E Y V L P S F E V I V E P T E  241 K F Y Y I Y N E K G L E V T I T A R F L Y G K K V E G T A F V I F G I Q D G E Q R I S L P E S L K R I P I E D G S G E V V L S R K V L L D G V Q N P R A E D L V  321 G K S L Y V S A T V I L H S G S D M V Q A E R S G I P I V T S P Y Q I H F T K T P K Y F K P G M P F D L M V F V T N P D G S P A Y R V P V A V Q G E D T V Q S L  401 T Q G D G V A K L S I N T H P S Q K P L S I T V R T K K Q E L S E A E Q A T R T M Q A L P Y S T V G N S N N Y L H L S V L R T E L R P G E T L N V N F L L R M D  481 R A H E A K I R Y Y T Y L I M N K G R L L K A G R Q V R E P G Q D L V V L P L S I T T D F I P S F R L V A Y Y T L I G A S G Q R E V V A D S V W V D V K D S C V  561 G S L V V K S G Q S E D R Q P V P G Q Q M T L K I E G D H G A R V V L V A V D K G V F V L N K K N K L T Q S K I W D V V E K A D I G C T P G S G K D Y A G V F S  641 D A G L T F T S S S G Q Q T A Q R A E L Q C P Q P A A R R R R S V Q L T E K R M D K V G K Y P K E L R K C C E D G M R E N P M R F S C Q R R T R F I S L G E A C  721 K K V F L D C C N Y I T E L R R Q H A R A S H L G L A R S N L D E D I I A E E N I V S R S E F P E S W L W N V E D L K E P P K N G I S T K L M N I F L K D S I T  801 T W E I L A V S M S D K K G I C V A D P F E V T V M Q D F F I D L R L P Y S V V R N E Q V E I R A V L Y N Y R Q N Q E L K V R V E L L H N P A F C S L A T T K R  881 R H Q Q T V T I P P K S S L S V P Y V I V P L K T G L Q E V E V K A A V Y H H F I S D G V R K S L K V V P E G I R M N K T V A V R T L D P E R L G R E G V Q K E  961 D I P P A D L S D Q V P D T E S E T R I L L Q G T P V A Q M T E D A V D A E R L K H L I V T P S G C G E Q N M I G M T P T V I A V H Y L D E T E Q W E K F G L E 1041 K R Q G A L E L I K K G Y T Q Q L A F R Q P S S A F A A F V K R A P S T W L T A Y V V K V F S L A V N L I A I D S Q V L C G A V K W L I L E K Q K P D G V F Q E 1121 D A P V I H Q E M I G G L R N N N E K D M A L T A F V L I S L Q E A K D I C E E Q V N S L P G S I T K A G D F L E A N Y M N L Q R S Y T V A I A G Y A L A Q M G 1201 R L K G P L L N K F L T T A K D K N R W E D P G K Q L Y N V E A T S Y A L L A L L Q L K D F D F V P P V V R W L N E Q R Y Y G G G Y G S T Q A T F M V F Q A L A 1281 Q Y Q K D A P D H Q E L N L D V S L Q L P S R S S K I T H R I H W E S A S L L R S E E T K E N E G F T V T A E G K G Q G T L S V V T M Y H A K A K D Q L T C N K 1361 F D L K V T I K P A P E T E K R P Q D A K N T M I L E I C T R Y R G D Q D A T M S I L D I S M M T G F A P D T D D L K Q L A N G V D R Y I S K Y E L D K A F S D 1441 R N T L I T Y L D K V S H S E D D C L A F K V H Q Y F N V E L I Q P G A V K V Y A Y Y N L E E S C T R F Y H P E K E D G K L N K L C R D E L C R C A E E N C F I 1521 Q K S D D K V T L E E R L D K A C E P G V D Y V Y K T R L V K V Q L S N D F D E Y I M A I E Q T I K S G S D E V Q V G Q Q R T F I S P I K C R E A L K L E E K K 1601 H Y L M W G L S S D F W G E K P N L S Y I I G K D T W V E H W P E E D E C Q D E E N Q K Q C Q D L G A F T E S M V V F G C P N 5.15 carbonic anhydrase I [Homo sapiens]; carbonic anhydrase I [Homo sapiens]; carbonic anhydrase I [Homo sapiens]; carbonic anhydrase I [Homo sapiens] Protein Accession gi|4502517 gi|92447434 gi|92447432 gi|92447430

Mean Expression Ratio 0.602 Median Expression Ratio 0.604 Credible Interval (0.499, 0.718) Associated Peptides 13 Associated Spectra 28 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.47 0.63 0.85 SEQ ID NO: 183 ADGLAVIGVLMK 3 0.47 0.63 0.83 SEQ ID NO: 184 EIINVGHSFHVNFEDNDNR 1 0.43 0.59 0.82 SEQ ID NO: 185 ESISVSSEQLAQFR 1 0.43 0.58 0.8 SEQ ID NO: 186 HDTSLKPISVSYNPATAK 1 0.43 0.59 0.8 SEQ ID NO: 187 LFQFHF 6 0.45 0.58 0.74 SEQ ID NO: 188 LYPIANGNNQSPVDIK 2 0.45 0.6 0.81 SEQ ID NO: 189 NGPEQWSK 2 0.46 0.62 0.83 SEQ ID NO: 190 SFHVNFEDNDNR 1 0.43 0.6 0.82 SEQ ID NO: 191 SLLSNVEGDNAVPMQHN 1 0.41 0.57 0.78 SEQ ID NO: 192 VLDALQAIK 2 0.45 0.61 0.81 SEQ ID NO: 193 YSAELHVAHW 1 0.46 0.63 0.87 SEQ ID NO: 194 YSAELHVAHWNSAK 5 0.41 0.53 0.68 SEQ ID NO: 195 SLLSNVEGDNAVPMQHNNR PTQPLK 5.16 uromodulin precursor [Homo sapiens]; uromodulin precursor [Homo sapiens] Protein Accession gi|59850812 gi|56550049

Mean Expression Ratio 0.608 Median Expression Ratio 0.607 Credible Interval (0.528, 0.701) Associated Peptides 25 Associated Spectra 50 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.47 0.63 0.86 SEQ ID NO: 196 ACSYPLDMK 9 0.51 0.64 0.79 SEQ ID NO: 197 DSTIQVVENGESSQGR 3 0.46 0.6 0.8 SEQ ID NO: 198 DWVSVVTPAR 1 0.45 0.59 0.8 SEQ ID NO: 199 FSVQMFR 1 0.44 0.59 0.8 SEQ ID NO: 200 INFACSYPLDMK 4 0.47 0.6 0.78 SEQ ID NO: 201 LADEIIIR 1 0.45 0.62 0.83 SEQ ID NO: 202 LECGANDMK 1 0.46 0.61 0.83 SEQ ID NO: 203 LSPGLGCTDVDECAEP GLSHCH 2 0.46 0.61 0.8 SEQ ID NO: 204 LYVGTMLDGGDLSR 5 0.45 0.58 0.73 SEQ ID NO: 205 MAETCVPVLR 1 0.44 0.59 0.8 SEQ ID NO: 206 SCVCPEGFR 1 0.43 0.59 0.79 SEQ ID NO: 207 SNTLYLADEIIIR 3 0.46 0.6 0.79 SEQ ID NO: 208 STEYGEGYACDTDLR 1 0.45 0.6 0.8 SEQ ID NO: 209 TALQPMVSALNIR 2 0.43 0.57 0.76 SEQ ID NO: 210 TLDEYWR 1 0.44 0.6 0.81 SEQ ID NO: 211 VFMYLSDSR 1 0.45 0.61 0.82 SEQ ID NO: 212 VGTMLDGGDLSR 1 0.47 0.64 0.86 SEQ ID NO: 213 VLNLGPITR 1 0.43 0.58 0.79 SEQ ID NO: 214 WHCQCK 5 0.46 0.58 0.74 SEQ ID NO: 215 YFIIQDR 1 0.48 0.64 0.86 SEQ ID NO: 216 SLGFDKVFMYLSDSR 1 0.46 0.61 0.83 SEQ ID NO: 217 SLGFDK 1 0.46 0.62 0.83 SEQ ID NO: 218 SYPLDMK 1 0.45 0.6 0.8 SEQ ID NO: 219 CSGFNDR 1 0.46 0.61 0.82 SEQ ID NO: 220 DLNIK 5.17 heparan sulfate proteoglycan 2 [Homo sapiens] Protein Accession gi|126012571

Mean Expression Ratio 0.614 Median Expression Ratio 0.614 Credible Interval (0.488, 0.761) Associated Peptides 9 Associated Spectra 16 Coverage 0.0239

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.42 0.58 0.79 SEQ ID NO: 221 DFISLGLQDGHLVFR 2 0.43 0.6 0.82 SEQ ID NO: 222 FHDDGFLAFPGHVF 1 0.42 0.6 0.83 SEQ ID NO: 223 FHDDGFLAFPGHVFSR 1 0.45 0.63 0.9 SEQ ID NO: 224 GSIQVDGEELVSGR 2 0.47 0.64 0.88 SEQ ID NO: 225 GSVYIGGAPDVATLTGGR 2 0.42 0.59 0.8 SEQ ID NO: 226 LVSEDPINDGEWHR 2 0.44 0.61 0.83 SEQ ID NO: 227 PGAPPPQPLDLQHR 3 0.44 0.59 0.8 SEQ ID NO: 228 SLPEVPETIELEVR 1 0.44 0.63 0.87 SEQ ID NO: 229 IGGAPDVATLTGGR SEQ ID NO: 230   1 M G W R A A G A L L L A L L L H G R L L A V T H G L R A Y D G L S L P E D I E T V T A S Q M R W T H S Y L S D D E D M L A D S I S G D D L G S G D L G S G D F Q   81 M V Y F R A L V N F T R S I E Y S P Q L E D A G S R E F R E V S E A V V D T L E S E Y L K I P G D Q V V S V V F I K E L D G W V F V E L D V G S E G N A D G A Q  161 I Q E M L L R V I S S G S V A S Y V T S P Q G F Q F R R L G T V P Q F P R A C T E A E F A C H S Y N E C V A L E Y R C D R R P D C R D M S D E L N C E E P V L G  241 I S P T F S L L V E T T S L P P R P E T T I M R Q P P V T H A P Q P L L P G S V R P L P C G P Q E A A C R N G H C I P R D Y L C D G Q E D C E D G S D E L D C G  321 P P P P C E P N E F P C G N G H C A L K L W R C D G D F D C E D R T D E A N C P T K R P E E V C G P T Q F R C V S T N M C I P A S F H C D E E S D C P D R S D E  401 F G C M P P Q V V T P P R E S I Q A S R G Q T V T F T C V A I G V P T P I I N W R L N W G H I P S H P R V T V T S E G G R G T L I I R D V K E S D Q G A Y T C E  481 A M N A R G M V F G I P D G V L E L V P Q R G P C P D G H F Y L E H S A A C L P C F C F G I T S V C Q S T R R F R D Q I R L R F D Q P D D F K G V N V T M P A Q  561 P G T P P L S S T Q L Q I D P S L H E F Q L V D L S R R F L V H D S F W A L P E Q F L G N K V D S Y G G S L R Y N V R Y E L A R G M L E P V Q R P D V V L M G A  641 G Y R L L S R G H T P T Q P G A L N Q R Q V Q F S E E H W V H E S G R P V Q R A E L L Q V L Q S L E A V L I Q T V Y N T K M A S V G L S D I A M D T T V T H A T  721 S H G R A H S V E E C R C P I G Y S G L S C E S C D A H F T R V P G G P Y L G T C S G C N C N G H A S S C D P V Y G H C L N C Q H N T E G P Q C N K C K A G F F  801 G D A M K A T A T S C R P C P C P Y I D A S R R F S D T C F L D T D G Q A T C D A C A P G Y T G R R C E S C A P G Y E G N P I Q P G G K C R P V N Q E I V R C D  881 E R G S M G T S G E A C R C K N N V V G R L C N E C A D G S F H L S T R N P D G C L K C F C M G V S R H C T S S S W S R A Q L H G A S E E P G H F S L T N A A S  961 T H T T N E G I F S P T P G E L G F S S F H R L L S G P Y F W S L P S R F L G D K V T S Y G G E L R F T V T Q R S Q P G S T P L H G Q P L V V L Q G N N I I L E 1041 H H V A Q E P S P G Q P S T F I V P F R E Q A W Q R P D G Q P A T R E H L L M A L A G I D T L L I R A S Y A Q Q P A E S R V S G I S M D V A V P E E T G Q D P A 1121 L E V E Q C S C P P G Y R G P S C Q D C D T G Y T R T P S G L Y L G T C E R C S C H G H S E A C E P E T G A C Q G C Q H H T E G P R C E Q C Q P G Y Y G D A Q R 1201 G T P Q D C Q L C P C Y G D P A A G Q A A H T C F L D T D G H P T C D A C S P G H S G R H C E R C A P G Y Y G N P S Q G Q P C Q R D S Q V P G P I G C N C D P Q 1281 G S V S S Q C D A A G Q C Q C K A Q V E G L T C S H C R P H H F H L S A S N P D G C L P C F C M G I T Q Q C A S S A Y T R H L I S T H F A P G D F Q G F A L V N 1361 P Q R N S R L T G E F T V E P V P E G A Q L S F G N F A Q L G H E S F Y W Q L P E T Y Q G D K V A A Y G G K L R Y T L S Y T A G P Q G S P L S D P D V Q I T G N 1441 N I M L V A S Q P A L Q G P E R R S Y E I M F R E E F W R R P D G Q P A T R E H L L M A L A D L D E L L I R A T F S S V P L A A S I S A V S L E V A Q P G P S N 1521 R P R A L E V E E C R C P P G Y I G L S C Q D C A P G Y T R T G S G L Y L G H C E L C E C N G H S D L C H P E T G A C S Q C Q H N A A G E F C E L C A P G Y Y G 1601 D A T A G T P E D C Q P C A C P L T N P E N M F S R T C E S L G A G G Y R C T A C E P G Y T G Q Y C E Q C G P G Y V G N P S V Q G G Q C L P E T N Q A P L V V E 1681 V H P A R S I V P Q G G S H S L R C Q V S G S P P H Y F Y W S R E D G R P V P S G T Q Q R H Q G S E L H F P S V Q P S D A G V Y I C T C R N L H Q S N T S R A E 1761 L L V T E A P S K P I T V T V E E Q R S Q S V R P G A D V T F I C T A K S K S P A Y T L V W T R L H N G K L P T R A M D F N G I L T I R N V Q L S D A G T Y V C 1841 T G S N M F A M D Q G T A T L H V Q A S G T L S A P V V S I H P P Q L T V Q P G Q L A E F R C S A T G S P T P T L E W T G G P G G Q L P A K A Q I H G G I L R L 1921 P A V E P T D Q A Q Y L C R A H S S A G Q Q V A R A V L H V H G G G G P R V Q V S P E R T Q V H A G R T V R L Y C R A A G V P S A T I T W R K E G G S L P P Q A 2001 R S E R T D I A T L L I P A I T T A D A G F Y L C V A T S P A G T A Q A R I Q V V V L S A S D A S P P P V K I E S S S P S V T E G Q T L D L N C V V A G S A H A 2081 Q V T W Y R R G G S L P P H T Q V H G S R L R L P Q V S P A D S G E Y V C R V E N G S G P K E A S I T V S V L H G T H S G P S Y T P V P G S T R P I R I E P S S 2161 S H V A E G Q T L D L N C V V P G Q A H A Q V T W H K R G G S L P A R H Q T H G S L L R L H Q V T P A D S G E Y V C H V V G T S G P L E A S V L V T I E A S V I 2241 P G P I P P V R I E S S S S T V A E G Q T L D L S C V V A G Q A H A Q V T W Y K R G G S L P A R H Q V R G S R L Y I F Q A S P A D A G Q Y V C R A S N G M E A S 2321 I T V T V T G T Q G A N L A Y P A G S T Q P I R I E P S S S Q V A E G Q T L D L N C V V P G Q S H A Q V T W H K R G G S L P V R H Q T H G S L L R L Y Q A S P A 2401 D S G E Y V C R V L G S S V P L E A S V L V T I E P A G S V P A L G V T P T V R I E S S S S Q V A E G Q T L D L N C L V A G Q A H A Q V T W H K R G G S L P A R 2481 H Q V H G S R L R L L Q V T P A D S G E Y V C R V V G S S G T Q E A S V L V T I Q Q R L S G S H S Q G V A Y P V R I E S S S A S L A N G H T L D L N C L V A S Q 2561 A P H T I T W Y K R G G S L P S R H Q I V G S R L R I P Q V T P A D S G E Y V C H V S N G A G S R E T S L I V T I Q G S G S S H V P S V S P P I R I E S S S P T 2641 V V E G Q T L D L N C V V A R Q P Q A I I T W Y K R G G S L P S R H Q T H G S H L R L H Q M S V A D S G E Y V C R A N N N I D A L E A S I V I S V S P S A G S P 2721 S A P G S S M P I R I E S S S S H V A E G E T L D L N C V V P G Q A H A Q V T W H K R G G S L P S H H Q T R G S R L R L H H V S P A D S G E Y V C R V M G S S G 2801 P L E A S V L V T I E A S G S S A V H V P A P G G A P P I R I E P S S S R V A E G Q T L D L K C V V P G Q A H A Q V T W H K R G G N L P A R H Q V H G P L L R L 2881 N Q V S P A D S G E Y S C Q V T G S S G T L E A S V L V T I E P S S P G P I P A P G L A Q P I Y I E A S S S H V T E G Q T L D L N C V V P G Q A H A Q V T W Y K 2961 R G G S L P A R H Q T H G S Q L R L H L V S P A D S G E Y V C R A A S G P G P E Q E A S F T V T V P P S E G S S Y R L R S P V I S I D P P S S T V Q Q G Q D A S 3041 F K C L I H D G A A P I S L E W K T R N Q E L E D N V H I S P N G S I I T I V G T R P S N H G T Y R C V A S N A Y G V A Q S V V N L S V H G P P T V S V L P E G 3121 P V W V K V G K A V T L E C V S A G E P R S S A R W T R I S S T P A K L E Q R T Y G L M D S H A V L Q I S S A K P S D A G T Y V C L A Q N A L G T A Q K Q V E V 3201 I V D T G A M A P G A P Q V Q A E E A E L T V E A G H T A T L R C S A T G S P A P T I H W S K L R S P L P W Q H R L E G D T L I I P R V A Q Q D S G Q Y I C N A 3281 T S P A G H A E A T I I L H V E S P P Y A T T V P E H A S V Q A G E T V Q L Q C L A H G T P P L T F Q W S R V G S S L P G R A T A R N E L L H F E R A A P E D S 3361 G R Y R C R V T N K V G S A E A F A Q L L V Q G P P G S L P A T S I P A G S T P T V Q V T P Q L E T K S I G A S V E F H C A V P S D R G T Q L R W F K E G G Q L 3441 P P G H S V Q D G V L R I Q N L D Q S C Q G T Y I C Q A H G P W G K A Q A S A Q L V I Q A L P S V L I N I R T S V Q T V V V G H A V E F E C L A L G D P K P Q V 3521 T W S K V G G H L R P G I V Q S G G V V R I A H V E L A D A G Q Y R C T A T N A A G T T Q S H V L L L V Q A L P Q I S M P Q E V R V P A G S A A V F P C I A S G 3601 Y P T P D I S W S K L D G S L P P D S R L E N N M L M L P S V R P Q D A G T Y V C T A T N R Q G K V K A F A H L Q V P E R V V P Y F T Q T P Y S F L P L P T I K 3681 D A Y R K F E I K I T F R P D S A D G M L L Y N G Q K R V P G S P T N L A N R Q P D F I S F G L V G G R P E F R F D A G S G M A T I R H P T P L A L G H F H T V 3761 T L L R S L T Q G S L I V G D L A P V N G T S Q G K F Q G L D L N E E L Y L G G Y P D Y G A I P K A G L S S G F I G C V R E L R I Q G E E I V F H D L N L T A H 3841 G I S H C P T C R D R P C Q N G G Q C H D S E S S S Y V C V C P A G F T G S R C E H S Q A L H C H P E A C G P D A T C V N R P D G R G Y T C R C H L G R S G L R 3921 C E E G V T V T T P S L S G A G S Y L A L P A L T N T H H E L R L D V E F K P L A P D G V L L F S G G K S G P V E D F V S L A M V G G H L E F R Y E L G S G L A 4001 V L R S A E P L A L G R W H R V S A E R L N K D G S L R V N G G R P V L R S S P G K S Q G L N L H T L L Y L G G V E P S V P L S P A T N M S A H F R G C V G E V 4081 S V N G K R L D L T Y S F L G S Q G I G Q C Y D S S P C E R Q P C Q H G A T C M P A G E Y E F Q C L C R D G F K G D L C E H E E N P C Q L R E P C L H G G T C Q 4161 G T R C L C L P G F S G P R C Q Q G S G H G I A E S D W H L E G S G G N D A P G Q Y G A Y F H D D G F L A F P G H V F S R S L P E V P E T I E L E V R T S T A S 4241 G L L L W Q G V E V G E A G Q G K D F I S L G L Q D G H L V F R Y Q L G S G E A R L V S E D P I N D G E W H R V T A L R E G R R G S I Q V D G E E L V S G R S P 4321 G P N V A V N A K G S V Y I G G A P D V A T L T G G R F S S G I T G C V K N L V L H S A R P G A P P P Q P L D L Q H R A Q A G A N T R P C P S 5.18 clusterin isoform 1 [Homo sapiens] Protein Accession gi|42716297

Mean Expression Ratio 0.62 Median Expression Ratio 0.619 Credible Interval (0.484, 0.788) Associated Peptides 9 Associated Spectra 12 Coverage 0.194

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.42 0.59 0.82 SEQ ID NO: 231 ASSIIDELFQDR 1 0.45 0.63 0.89 SEQ ID NO: 232 ASSIIDELFQDRF 1 0.44 0.62 0.87 SEQ ID NO: 233 EILSVDCSTNNPSQAK 1 0.45 0.63 0.9 SEQ ID NO: 234 ELDESLQVAER 3 0.42 0.57 0.77 SEQ ID NO: 235 LFDSDPITVTVPVEVSR 1 0.44 0.63 0.89 SEQ ID NO: 236 MLDVMQDHF 1 0.44 0.63 0.89 SEQ ID NO: 237 PITVTVPVEVSR 1 0.44 0.62 0.88 SEQ ID NO: 238 VTTVASHTSDSDVPSGVTEVVVK 1 0.43 0.6 0.85 SEQ ID NO: 239 RPHFFFPK SEQ ID NO: 240   1 M Q V C S Q P Q R G C V R E Q S A I N T A P P S A H N A A S P G G A R G H R V P L T E A C K D S R I G G M M K T L L L F V G L L L T W E S G Q V L G D Q T V S D  81 N E L Q E M S N Q G S K Y V N K E I Q N A V N G V K Q I K T L I E K T N E E R K T L L S N L E E A K K K K E D A L N E T R E S E T K L K E L P G V C N E T M M A 161 L W E E C K P C L K Q T C M K F Y A R V C R S G S G L V G R Q L E E F L N Q S S P F Y F W M N G D R I D S L L E N D R Q Q T H M L D V M Q D H F S R A S S I I D 241 E L F Q D R F F T R E P Q D T Y H Y L P F S L P H R R P H F F F P K S R I V R S L M P F S P Y E P L N F H A M F Q P F L E M I H E A Q Q A M D I H F H S P A F Q 321 H P P T E F I R E G D D D R T V C R E I R H N S T G C L R M K D Q C D K C R E I L S V D C S T N N P S Q A K L R R E L D E S L Q V A E R L T R K Y N E L L K S Y 401 Q W K M L N T S S L L E Q L N E Q F N W V S R L A N L T Q G E D Q Y Y L R V T T V A S H T S D S D V P S G V T E V V V K L F D S D P I T V T V P V E V S R K N P 481 K F M E T V A E K A L Q E Y R K K H R E E 5.19 ezrin [Homo sapiens]; ezrin [Homo sapiens] Protein Accession gi|21614499 gi|161702986

Mean Expression Ratio 1.62 Median Expression Ratio 1.61 Credible Interval (1.23, 2.13) Associated Peptides 7 Associated Spectra 8 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 1.2 1.7 2.5 SEQ ID NO: 241 FYPEDVAEELIQDITQK 1 1.1 1.6 2.3 SEQ ID NO: 242 KEDEVEEWQHR 1 1.1 1.6 2.4 SEQ ID NO: 243 QLLTLSSELSQAR 1 1.1 1.6 2.4 SEQ ID NO: 244 QQLETEK 1 1.2 1.7 2.4 SEQ ID NO: 245 GFPTWLK 1 1.1 1.6 2.3 SEQ ID NO: 246 IAQDLEMYGINYFEIK 1 1.1 1.6 2.3 SEQ ID NO: 247 ILQLCMGNHELYMR 5.20 delta globin [Homo sapiens] Protein Accession gi|4504351

Mean Expression Ratio 1.60 Median Expression Ratio 1.60 Credible Interval (1.12, 2.29) Associated Peptides 3 Associated Spectra 4 Coverage 0.306

A 2.5 50 97.5 Sequence ID No. Sequence 2 1.2 1.7 2.6 SEQ ID NO: 248 F F E S F G D L S S P D A V M G N P K 1 1.1 1.6 2.5 SEQ ID NO: 249 V N V D A V G G E A L G R 1 1.1 1.6 2.5 SEQ ID NO: 250 G T F S Q L S E L H C D K SEQ ID NO: 251  1 M V H L T P E E K T A V N A L W G K V N V D A V G G E A L G R L L V V Y P W T Q R F F E S F G D L S S P D A V M G N P K V K A H G K K V L G A F S D G L A H L D 81 N L K G T F S Q L S E L H C D K L H V D P E N F R L L G N V L V C V L A R N F G K E F T P Q M Q A A Y Q K V V A G V A N A L A H K Y H 5.21 fibrinogen, beta chain preproprotein [Homo sapiens] Protein Accession gi|70906435

Mean Expression Ratio 0.633 Median Expression Ratio 0.633 Credible Interval (0.527, 0.76) Associated Peptides 14 Associated Spectra 27 Coverage 0.291

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.49 0.66 0.87 SEQ ID NO: 252 AHYGGFTVQNEANK 1 0.46 0.62 0.85 SEQ ID NO: 253 DNENVVNEYSSELEK 1 0.5 0.68 0.92 SEQ ID NO: 254 ETVNSNIPTNLR 1 0.47 0.64 0.88 SEQ ID NO: 255 GGETSEMYLIQPDSSVKPYR 7 0.47 0.59 0.75 SEQ ID NO: 256 HQLYIDETVNSNIPTNLR 1 0.47 0.65 0.9 SEQ ID NO: 257 IDETVNSNIPTNLR 2 0.45 0.6 0.8 SEQ ID NO: 258 LIQPDSSVKPYR 2 0.44 0.59 0.8 SEQ ID NO: 259 MGPTELLIEMEDWK 1 0.45 0.62 0.85 SEQ ID NO: 260 NYCGLPGEYWLGNDK 1 0.45 0.62 0.86 SEQ ID NO: 261 QGFGNVATNTDGK 1 0.46 0.63 0.87 SEQ ID NO: 262 YIDETVNSNIPTNLR 4 0.45 0.6 0.78 SEQ ID NO: 263 QGVNDNEEGFFSAR 1 0.47 0.65 0.9 SEQ ID NO: 264 LESDVSAQMEYCR 1 0.46 0.64 0.88 SEQ ID NO: 265 SILENLR SEQ ID NO: 266   1 M K R M V S W S F H K L K T M K H L L L L L L C V F L V K S Q G V N D N E E G F F S A R G H R P L D K K R E E A P S L R P A P P P I S G G G Y R A R P A K A A A  81 T Q K K V E R K A P D A G G C L H A D P D L G V L C P T G C Q L Q E A L L Q Q E R P I R N S V D E L N N N V E A V S Q T S S S S F Q Y M Y L L K D L W Q K R Q K 161 Q V K D N E N V V N E Y S S E L E K H Q L Y I D E T V N S N I P T N L R V L R S I L E N L R S K I Q K L E S D V S A Q M E Y C R T P C T V S C N I P V V S G K E 241 C E E I I R K G G E T S E M Y L I Q P D S S V K P Y R V Y C D M N T E N G G W T V I Q N R Q D G S V D F G R K W D P Y K Q G F G N V A T N T D G K N Y C G L P G 321 E Y W L G N D K I S Q L T R M G P T E L L I E M E D W K G D K V K A H Y G G F T V Q N E A N K Y Q I S V N K Y R G T A G N A L M D G A S Q L M G E N R T M T I H 401 N G M F F S T Y D R D N D G W L T S D P R K Q C S K E D G G G W W Y N R C H A A N P N G R Y Y W G G Q Y T W D M A K H G T D D G V V W M N W K G S W Y S M R K M 481 S M K I R P F F P Q Q 5.22 moesin [Homo sapiens] Protein Accession gi|4505257

Mean Expression Ratio 1.57 Median Expression Ratio 1.57 Credible Interval (1.18, 2.08) Associated Peptides 5 Associated Spectra 9

A 2.5 50 97.5 Sequence ID No. Sequence 4 1.3 1.8 2.4 SEQ ID NO: 267 FYPEDVSEELIQDITQR 2 1.1 1.5 2.2 SEQ ID NO: 268 GSELWLGVDALGLNIYEQNDR 1 1.1 1.6 2.3 SEQ ID NO: 269 TQEQLALEMAELTAR 1 1.1 1.6 2.3 SEQ ID NO: 270 ERQEAEEAK 1 1.1 1.6 2.3 SEQ ID NO: 271 KTQEQLALEMAELTAR SEQ ID NO: 272   1 M P K T I S V R V T T M D A E L E F A I Q P N T T G K Q L F D Q V V K T I G L R E V W F F G L Q Y Q D T K G F S T W L K L N K K V T A Q D V R K E S P L L F K F  81 R A K F Y P E D V S E E L I Q D I T Q R L F F L Q V K E G I L N D D I Y C P P E T A V L L A S Y A V Q S K Y G D F N K E V H K S G Y L A G D K L L P Q R V L E Q 161 H K L N K D Q W E E R I Q V W H E E H R G M L R E D A V L E Y L K I A Q D L E M Y G V N Y F S I K N K K G S E L W L G V D A L G L N I Y E Q N D R L T P K I G F 241 P W S E I R N I S F N D K K F V I K P I D K K A P D F V F Y A P R L R I N K R I L A L C M G N H E L Y M R R R K P D T I E V Q Q M K A Q A R E E K H Q K Q M E R 321 A M L E N E K K K R E M A E K E K E K I E R E K E E L M E R L K Q I E E Q T K K A Q Q E L E E Q T R R A L E L E Q E R K R A Q S E A E K L A K E R Q E A E E A K 401 E A L L Q A S R D Q K K T Q E Q L A L E M A E L T A R I S Q L E M A R Q K K E S E A V E W Q Q K A Q M V Q E D L E K T R A E L K T A M S T P H V A E P A E N E Q 481 D E Q D E N G A E A S A D L R A D A M A K D R S E E E R T T E A E K N E R V Q K H L K A L T S E L A N A R D E S K K T A N D M I H A E N M R L G R D K Y K T L R 561 Q I R Q G N T K Q R I D E F E S M 5.23 transferrin [Homo sapiens] Protein Accession gi|4557871

Mean Expression Ratio 0.648 Median Expression Ratio 0.648 Credible Interval (0.535, 0.786) Associated Peptides 12 Associated Spectra 22 Coverage 0.216

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.46 0.64 0.88 SEQ ID NO: 273 CSTSSLLEACTFR 1 0.46 0.63 0.88 SEQ ID NO: 274 DCHLAQVPSHTVVAR 3 0.47 0.62 0.83 SEQ ID NO: 275 EDLIWELLNQAQEHFGK 2 0.45 0.61 0.83 SEQ ID NO: 276 EGTCPEAPTDECKPVK 3 0.53 0.7 0.93 SEQ ID NO: 277 HQTVPQNTGGK 2 0.47 0.63 0.85 SEQ ID NO: 278 HSTIFENLANK 3 0.48 0.64 0.86 SEQ ID NO: 279 KPVEEYANCHLAR 1 0.47 0.64 0.9 SEQ ID NO: 280 MYLGYEYVTAIR 1 0.48 0.66 0.9 SEQ ID NO: 281 NIPIGLLYCDLPEPR 2 0.47 0.64 0.87 SEQ ID NO: 282 NLNEKDYELLCLDGTR 2 0.47 0.63 0.86 SEQ ID NO: 283 SAGWNIPIGLLYCDLPEPR 1 0.48 0.66 0.91 SEQ ID NO: 284 YLGEEYVK SEQUENCE ID NO: 285   1 M R L A V G A L L V C A V L G L C L A V P D K T V R W C A V S E H E A T K C Q S F R D H M K S V I P S D G P S V A C V K K A S Y L D C I R A I A A N E A D A V T  81 L D A G L V Y D A Y L A P N N L K P V V A E F Y G S K E D P Q T F Y Y A V A V V K K D S G F Q M N Q L R G K K S C H T G L G R S A G W N I P I G L L Y C D L P E 161 P R K P L E K A V A N F F S G S C A P C A D G T D F P Q L C Q L C P G C G C S T L N Q Y F G Y S G A F K C L K D G A G D V A F V K H S T I F E N L A N K A D R D 241 Q Y E L L C L D N T R K P V D E Y K D C H L A Q V P S H T V V A R S M G G K E D L I W E L L N Q A Q E H F G K D K S K E F Q L F S S P H G K D L L F K D S A H G 321 F L K V P P R M D A K M Y L G Y E Y V T A I R N L R E G T C P E A P T D E C K P V K W C A L S H H E R L K C D E W S V N S V G K I E C V S A E T T E D C I A K I 401 M N G E A D A M S L D G G F V Y I A G K C G L V P V L A E N Y N K S D N C E D T P E A G Y F A V A V V K K S A S D L T W D N L K G K K S C H T A V G R T A G W N G L N L C E P N N K E G Y Y G Y T G A F R C L V E K G D V A F V K H Q T V P Q N 561 T G G K N P D P W A K N L N E K D Y E L L C L D G T R K P V E E Y A N C H L A R A P N H A V V T R K D K E A C V H K I L R Q Q Q H L F G S N V T D C S G N F C L 641 F R S E T K D L L F R D D T V C L A K L H D R N T Y E K Y L G E E Y V K A V G N L R K C S T S S L L E A C T F R R P 5.24 secreted phosphoprotein 1 isoform c [Homo sapiens]; secreted phosphoprotein 1 isoform a [Homo sapiens]; secreted phosphoprotein 1 isoform b [Homo sapiens] Protein Accession gi|91598939 gi|91206462 gi|4759166

Mean Expression Ratio 1.53 Median Expression Ratio 1.52 Credible Interval (1.10, 2.13) Associated Peptides 4 Associated Spectra 5 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 1 1.5 2.1 SEQ ID NO: 286 AIPVAQDLNAPSDWDSR 1 1.1 1.7 2.5 SEQ ID NO: 287 GKDSYETSQLDDQSAETHSHK 1 1.0 1.5 2.3 SEQ ID NO: 288 KANDESNEHSDVIDSQELSK 1 1.1 1.6 2.4 SEQ ID NO: 289 SKEEDK 5.25 pancreatic amylase alpha 2A precursor [Homo sapiens] Protein Accession gi|4502085

Mean Expression Ratio 0.664 Median Expression Ratio 0.664 Credible Interval (0.527, 0.841) Associated Peptides 8 Associated Spectra 14 Coverage 0.213

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.46 0.63 0.86 SEQ ID NO: 290 ALVFVDNHDNQR 1 0.49 0.69 0.97 SEQ ID NO: 291 EVTINPDTTCGNDWVCEHR 5 0.48 0.64 0.84 SEQ ID NO: 292 IAEYMNHLIDIGVAGFR 1 0.47 0.66 0.95 SEQ ID NO: 293 LTGLLDLALEK 2 0.46 0.64 0.89 SEQ ID NO: 294 LTGLLDLALEKDYVR 1 0.48 0.68 0.95 SEQ ID NO: 295 NVVDGQPFTNWYDNGSNQVAFGR 1 0.47 0.66 0.93 SEQ ID NO: 296 NWGEGWGFVPSDR 1 0.46 0.66 0.93 SEQ ID NO: 297 WVDIALECER SEQ ID NO: 298   1 M K F F L L L F T I G F C W A Q Y S P N T Q Q G R T S I V H L F E W R W V D I A L E C E R Y L A P K G F G G V Q V S P P N E N V A I Y N P F R P W W E R Y Q P V  81 S Y K L C T R S G N E D E F R N M V T R C N N V G V R I Y V D A V I N H M C G N A V S A G T S S T C G S Y F N P G S R D F P A V P Y S G W D F N D G K C K T G S 161 G D I E N Y N D A T Q V R D C R L T G L L D L A L E K D Y V R S K I A E Y M N H L I D I G V A G F R L D A S K H M W P G D I K A I L D K L H N L N S N W F P A G 241 S K P F I Y Q E V I D L G G E P I K S S D Y F G N G R V T E F K Y G A K L G T V I R K W N G E K M S Y L K N W G E G W G F V P S D R A L V F V D N H D N Q R G H 321 G A G G A S I L T F W D A R L Y K M A V G F M L A H P Y G F T R V M S S Y R W P R Q F Q N G N D V N D W V G P P N N N G V I K E V T I N P D T T C G N D W V C E 401 H R W R Q I R N M V I F R N V V D G Q P F T N W Y D N G S N Q V A F G R G N R G F I V F N N D D W S F S L T L Q T G L P A G T Y C D V I S G D K I N G N C T G I 481 K I Y V S D D G K A H F S I S N S A E D P F I A I H A E S K L 5.26 annexin A2 isoform 1 [Homo sapiens] Protein Accession gi|50845388

Mean Expression Ratio 1.50 Median Expression Ratio 1.5 Credible Interval (1.07, 2.11) Associated Peptides 3 Associated Spectra 5 Coverage 0.129

A 2.5 50 97.5 Sequence ID No. Sequence 2 1.1  1.6  2.4 SEQ ID NO: 299 GLGTDEDSLIEIICSR 2 1.0  1.5  2.2 SEQ ID NO: 300 RAEDGSVIDYELIDQDAR 1 1.0  1.5  2.4 SEQ ID NO: 301 SYSPYDMLESIR SEQ ID NO: 302 1 MGRQLAGCGDAGKKASFKMSTVHEILCKLSLEGDHSTPPS AYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNILTN 5.27 complement component 4 binding protein, alpha chain precursor [Homo sapiens] Protein Accession gi|4502503

Mean Expression Ratio 0.673 Median Expression Ratio 0.675 Credible Interval (0.48, 0.94) Associated Peptides 5 Associated Spectra 5 Coverage 0.104

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.44  0.66  0.99 SEQ ID NO: 303 EDVYVVGTVLR 1 0.42  0.64  0.95 SEQ ID NO: 304 LSLEIEQLELQR 1 0.45  0.68  1.0 SEQ ID NO: 305 FSAICQGDGTWSPR 1 0.44  0.67  1 SEQ ID NO: 306 YTCLPGYVR 1 0.44  0.66  1 SEQ ID NO: 307 CEWETPEGCEQVLTGK SEQUENCE ID NO: 308   1 MHPPKTPSGALHRKRKMAAWPFSRLWKVSDPILFQMTLIA ALLPAVLGNCGPPPTLSFAAPMDITLTETRFKTGTTLKYT  81 CLPGYVRSHSTQTLTCNSDGEWVYNTFCIYKRCRHPGELR NGQVEIKTDLSFGSQIEFSCSEGFFLIGSTTSRCEVQDRG 161 VGWSHPLPQCEIVKCKPPPDIRNGRHSGEENFYAYGFSVT YSCDPRFSLLGHASISCTVENETIGVWRPSPPTCEKITCR 241 KPDVSHGEMVSGFGPIYNYKDTIVFKCQKGFVLRGSSVIH CDADSKWNPSPPACEPNSCINLPDIPHASWETYPRPTKED 321 VYVVGTVLRYRCHPGYKPTTDEPTTVICQKNLRWTPYQG CEALCCPEPKLNNGEITQHRKSRPANHCVYFYGDEISFSCH 401 ET5RFSAICQGDGTWSPRTPSCGDICNFPPKIAHGHYKQS SSYSFFKEEIIYECDKGYILVGQAKLSCSYSHWSAPAPQC 5.28 albumin preproprotein [Homo sapiens] Protein Accession gi|4502027

Mean Expression Ratio 0.681 Median Expression Ratio 0.681 Credible Interval (0.626, 0.74) Associated Peptides 65 Associated Spectra 259 Coverage 0.744

A 2.5 50 97.5 Sequence ID No. Sequence  1 0.49  0.64  0.86 SEQ ID NO: 309 AAFTECCQAADK  5 0.46  0.58  0.74 SEQ ID NO: 310 ADDKETCFAEEGK  1 0.49  0.64   0.85 SEQ ID NO: 311 ADDKETCFAEEGKK  3 0.55  0.7  0.9 SEQ ID NO: 312 AEFAEVSK 10 0.56  0.68  0.83 SEQ ID NO: 313 ALVLIAFAQYLQQCPFEDHVK  1 0.52  0.69  0.9 SEQ ID NO: 314 AQYLQQCPFEDHVK  9 0.51  0.63  0.77 SEQ ID NO: 315 AVMDDFAAFVEK  1 0.5  0.66  0.87 SEQ ID NO: 316 CCTESLVNR  5 0.62  0.78  0.99 SEQ ID NO: 317 CIAEVENDEMPADLPSLAADFVESK  7 0.61  0.76  0.94 SEQ ID NO: 318 CTAFHDNEETFLK  1 0.5  0.66  0.87 SEQ ID NO: 319 DDNPNLPR  2 0.52  0.69  0.9 SEQ ID NO: 320 DLGEENFK  2 0.48  0.63  0.82 SEQ ID NO: 321 ECCEKPLLEK  2 0.56  0.74  0.96 SEQ ID NO: 322 ETCFAEEGK  2 0.5  0.65  0.85 SEQ ID NO: 323 ETCFAEEGKK  1 0.51  0.68  0.89 SEQ ID NO: 324 ETYGEMADCCAK  4 0.49  0.63  0.8 SEQ ID NO: 325 FKDLGEENFK  3 0.49  0.64  0.82 SEQ ID NO: 326 FQNALLVR  1 0.52  0.69  0.9 SEQ ID NO: 327 FSALEVDETYVPK  1 0.53  0.7  0.92 SEQ ID NO: 328 FYAPELLFFAK  1 0.54  0.72  0.96 SEQ ID NO: 329 HDNEETFLK  2 0.53  0.7  0.91 SEQ ID NO: 330 HPDYSVVLLLR  1 0.55  0.72  0.95 SEQ ID NO: 331 IAEVENDEMPADLPSLAADFVESK  4 0.54  0.68  0.87 SEQ ID NO: 332 KQTALVELVK 15 0.55  0.65  0.79 SEQ ID NO: 333 KVPQVSTPTLVEVSR  2 0.5  0.65  0.85 SEQ ID NO: 334 KYLYEIAR  2 0.51  0.67  0.87 SEQ ID NO: 335 LCTVATLR  3 0.52  0.66  0.86 SEQ ID NO: 336 LDELRDEGK  1 0.48  0.64  0.85 SEQ ID NO: 337 LKECCEKPLLEK  4 0.52  0.67  0.85 SEQ ID NO: 338 LVNEVTEFAK  7 0.52  0.64  0.8 SEQ ID NO: 339 LVRPEVDVMCTAFHDNEETFLK  2 0.54  0.7  0.9 SEQ ID NO: 340 LVTDLTK  3 0.51  0.66  0.86 SEQ ID NO: 341 MPCAEDYLSVVLNQLCVLHEK  7 0.6  0.74  0.92 SEQ ID NO: 342 NECFLQHK  1 0.54  0.7  0.93 SEQ ID NO: 343 PLVEEPQNLIK  4 0.51  0.65  0.83 SEQ ID NO: 344 QEPERNECFLQHK  2 0.53  0.7  0.91 SEQ ID NO: 345 QLCVLHEK  2 0.54  0.7  0.91 SEQ ID NO: 346 QTALVELVK  4 0.49  0.63  0.8 SEQ ID NO: 347 RPCFSALEVDETYVPK  1 0.52  0.69  0.91 SEQ ID NO: 348 SALEVDETYVPK 18 0.5  0.59  0.7 SEQ ID NO: 349 SHCIAEVENDEMPADLPSLAADFVESK 23 0.64  0.75  0.88 SEQ ID NO: 350 SLHTLFGDK  1 0.52  0.69  0.9 SEQ ID NO: 351 TAFHDNEETFLK  2 0.52  0.69  0.9 SEQ ID NO: 352 TCVADESAENCDK  2 0.52  0.68  0.9 SEQ ID NO: 353 TFHADICTLSEK  1 0.53  0.7  0.93 SEQ ID NO: 354 VFDEFKPL  1 0.51  0.68  0.9 SEQ ID NO: 355 VFDEFKPLVEEPQNL 46 0.59  0.67  0.75 SEQ ID NO: 356 VFDEFKPLVEEPQNLIK  4 0.52  0.67  0.86 SEQ ID NO: 357 VHTECCHGDLLECADDR  4 0.57  0.72  0.93 SEQ ID NO: 358 VPQVSTPTLVEVSR  1 0.52  0.7  0.93 SEQ ID NO: 359 VSTPTLVEVSR  1 0.52  0.69  0.91 SEQ ID NO: 360 YLYEIAR  1 0.52  0.69  0.91 SEQ ID NO: 361 YTKKVPQVSTPTLVEVSR  9 0.62  0.76  0.94 SEQ ID NO: 362 DVFLGMFLYEYAR  2 0.51  0.67  0.87 SEQ ID NO: 363 QNCELFEQLGEYK  2 0.54  0.71  0.92 SEQ ID NO: 364 YICENQDSISSK  1 0.52  0.68  0.91 SEQ ID NO: 365 CASLQK  1 0.51  0.68  0.9 SEQ ID NO: 366 KLVAASQAALGL  1 0.51  0.67  0.89 SEQ ID NO: 367 LQQCPFEDHVK  3 0.52  0.67  0.86 SEQ ID NO: 368 FYAPELLFFAKR  1 0.52  0.7  0.92 SEQ ID NO: 369 AACLLPKLDELR  1 0.53  0.7  0.92 SEQ ID NO: 370 VFDEFK  1 0.51  0.67  0.9 SEQ ID NO: 371 RHPDYSVVLLLR  1 0.51  0.68  0.9 SEQ ID NO: 372 RHPYFYAPELLFFAK  1 0.52  0.69  0.91 SEQ ID NO: 373 AACLLPK SEQ ID NO: 374   1 MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEE NFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVAD  81 ESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQE PERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLK 161 KYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKA ACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV 241 ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECAD DRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVEND 321 EMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEY ARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFD E 401 FKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVP QVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV 481 LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDET YVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHK 561 PKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKK LVAASQAALGL 5.29 epidermal growth factor receptor pathway substrate 8 [Homo sapiens] Protein Accession gi|56682953

Mean Expression Ratio 1.46 Median Expression Ratio 1.46 Credible Interval (1.13, 1.86) Associated Peptides 9 Associated Spectra 11 Coverage 0.153

A 2.5 50 97.5 Sequence ID No. Sequence 1 1.1  1.6  2.3 SEQ ID NO: 376 APAPAPPGTVTQVDVR 1 1.1  1.5  2.1 SEQ ID NO: 377 EQFIPPYVPR 2 1.1  1.5  2.0 SEQ ID NO: 378 ISAAASDSGVESFDEGSSH 1 1.0  1.5  2.1 SEQ ID NO: 379 NILDIVRPPESGLGR 1 1.0  1.4  2.0 SEQ ID NO: 380 SQMEEVQDELIHR 1 1  1.4  2.0 SEQ ID NO: 381 VWTQDMILQVDDR 1 1  1.4  2 SEQ ID NO: 382 DDILEILDDR 2 1.0  1.4  2.0 SEQ ID NO: 383 MISNADPSIPPPPR 1 1.0  1.5  2.0 SEQ ID NO: 384 ANLISEDIESAISDSK SEQ ID NO: 385   1 MNGHISNHPSSFGMYPSQMNGYGSSPTFSQTDREHGSKTS AKALYEQRKNYARDSVSSVSDISQYRVEHLTTFVLDRKDA  81 MITVDDGIRKLKLLDAKGKVWTQDMILQVDDRAVSLIDLE SKNELENFPLNTIQHCQAVMHSCSYDSVLALVCKEPTQNK 161 PDLHLFQCDEVKANLISEDIESAISDSKGGKQKRRPDALR MISNADPSIPPPPRAPAPAPPGTVTQVDVRSRVAAWSAWA 241 ADQGDFEKPRQYHEQEETPEMMAARIDRDVQILNHILDDI EFFITKLQKAAEAFSELSKRKKNKKGKRKGPGEGVLTLRA 321 KPPPPDEFLDCFQKFKHGFNLLAKLKSHIQNPSAADLVHF LFTPLNMVVQATGGPELASSVLSPLLNKDTIDFLNYTVNG 401 DERQLWMSLGGTWMKARAEWPKEQFIPPYVPRFRNGWE PPMLNFMGATMEQDLYQLAESVANVAEHQRKQEIKRLSTEH S 481 SVSEYHPADGYAFSSNIYTRGSHLDQGEAAVAFKPTSNR HIDRNYEPLKTQPKKYAKSKYDFVARNNSELSVLKDDILEI 561 LDDRKQWWKVRNASGDSGFVPNNILDIVRPPESGLGRAD PPYTHTIQKQRMEYGPRPADTPPAPSPPPTPAPVPVPLPPS 641 TPAPVPVSKVPANITRQNSSSSDSGGSIVRDSQRHKQLPV DRRKSQMEEVQDELIHRLTIGRSAAQKKFHVPRQNVPVIN 721 ITYD5TPEDVKTWLQSKGFNPVTVNSLGVLNGAQLFSLN KDELRTVCPEGARVYSQITVQKAALEDSSGSSELQEIMRRR 801 QEKISAAASDSGVESFDEGSSH 5.30 apolipoprotein B precursor [Homo sapiens] Protein Accession gi|105990532

Mean Expression Ratio 0.688 Median Expression Ratio 0.688 Credible Interval (0.585, 0.815) Associated Peptides 27 Associated Spectra 30 Coverage 0.073

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.5  0.68  0.92 SEQ ID NO: 386 AHLDIAGSLEGHLR 1 0.48  0.65  0.88 SEQ ID NO: 387 ATFQTPDFIVPLTDLR 1 0.47  0.65  0.88 SEQ ID NO: 388 DKDQEVLLQTFLDDASPGDKR 1 0.5  0.69  0.93 SEQ ID NO: 389 ELPVLHVPR 1 0.51  0.7  0.95 SEQ ID NO: 390 FLDMLIK 1 0.52  0.7  0.96 SEQ ID NO: 391 HSITNPLAVLCEFISQSIK 2 0.5  0.68  0.9 SEQ ID NO: 392 ILGEELGFASLHDLQLLGK 1 0.5  0.69  0.94 SEQ ID NO: 393 LELELRPTGEIEQY 1 0.52  0.7  0.96 SEQ ID NO: 394 LHVAGNLK 1 0.51  0.69  0.94 SEQ ID NO: 395 LIDVISMYR 1 0.49  0.67  0.92 SEQ ID NO: 396 LVALIPEPSAQQLR 2 0.51  0.67  0.9 SEQ ID NO: 397 NMGLPDFHIPENLFLK 1 0.51  0.69  0.94 SEQ ID NO: 398 QSMTLSSEVQIPDFDVDLGTILR 1 0.5  0.68  0.93 SEQ ID NO: 399 QTIIVVLENVQR 1 0.49  0.67  0.9 SEQ ID NO: 400 SSEVQIPDFDVDLGTILR 1 0.5  0.68  0.92 SEQ ID NO: 401 TEVIPPLIENR 1 0.51  0.69  0.95 SEQ ID NO: 402 TLQGIPQMIGEVIR 1 0.52  0.7  0.96 SEQ ID NO: 403 TLSSEVQIPDFDVDLGTILR 1 0.49  0.67  0.92 SEQ ID NO: 404 TQFNNNEYSQDLDAYNTK 2 0.53  0.72  0.95 SEQ ID NO: 405 VAWHYDEEK 1 0.49  0.68  0.92 SEQ ID NO: 406 YTYNYEAESSSGVPGTADSR 1 0.51  0.7  0.95 SEQ ID NO: 407 QSFDLSVK 1 0.51  0.69  0.94 SEQ ID NO: 408 VTNMGIIIPDFAR 1 0.51  0.7  0.95 SEQ ID NO: 409 HIQNIDIQHLAGK 1 0.53  0.72  0.99 SEQ ID NO: 410 VLLDQLGTTISFER 1 0.52  0.71  0.97 SEQ ID NO: 411 LALWGEHTGQLY 1 0.51  0.68  0.94 SEQ ID NO: 412 MGIIIPDFAR SEQ ID NO: 413    1 MDPPRPALLALLALPALLLLLLAGARAEEEMLENVSLVCP KDATRFKHLRKYTYNYEAESSSGVPGTADSRSATRINCKV   81 ELEVPQLCSFILKTSQCTLKEVYGFNPEGKALLKKTKNSEE FAAAMSRYELKLAIPEGKQVFLYPEKDEPTYILNIKRGI  161 ISALLVPPETEEAKQVLFLDTVYGNCSTHFTVKTRKGNVA TEISTERDLGQCDRFKPIRTGISPLALIKGMTRPLSTLIS  241 SSQSCQYTLDAKRKHVAEAICKEQHLFLPFSYKNKYGMV AQVTQTLKLEDTPKINSRFFGEGTKKMGLAFESTKSTSPPK  321 QAEAVLKTLQELKKLTISEQNIQRANLFNKLVTELRGLSD EAVTSLLPQLIEVSSPITLQALVQCGQPQCSTHILQWLKR  401 VHANPLLIDVVTYLVALIPEPSAQQLREIFNMARDQRSRA TLYALSHAVNNYHKTNPTGTQELLDIANYLMEQIQDDCTG  481 DEDYTYLILRVIGNMGQTMEQLTPELKSSILKCVQSTKPS LMIQKAAIQALRKMEPKDKDQEVLLQTFLDDASPGDKRLA  561 AYLMLMRSPSQADINKIVQILPWEQNEQVKNFVASHIANI LNSEELDIQDLKKLVKEALKESQLPTVMDFRKFSRNYQLY  641 KSVSLPSLDPASAKIEGNLIFDPNNYLPKESMLKTTLTAF GFASADLIEIGLEGKGFEPTLEALFGKQGFFPDSVNKALY  721 WVNGQVPDGVSKVLVDHFGYTKDDKHEQDMVNGIMLSV EKLIKDLKSKEVPEARAYLRILGEELGFASLHDLQLLGKLLL  801 MGARTLQGIPQMIGEVIRKGSKNDFFLHYIFMENAFELPT GAGLQLQISSSGVIAPGAKAGVKLEVANMQAELVAKPSVS  881 VEFVTNMGIIIPDFARSGVQMNTNFFHESGLEAHVALKAG KLKFIIPSPKRPVKLLSGGNTLHLVSTTKTEVIPPLIENR  961 QSWSVCKQVFPGLNYCTSGAYSNASSTDSASYYPLTGDT RLELELRPTGEIEQYSVSATYELQREDRALVDTLKFVTQAE 1041 GAKQTEATMTFKYNRQSMTLSSEVQIPDFDVDLGTILRV NDESTEGKTSYRLTLDIQNKKITEVALMGHLSCDTKEERKI 1121 KGVISIPRLQAEARSEILAHWSPAKLLLQMDSSATAYGS TVSKRVAWHYDEEKIEFEWNTGTNVDTKKMTSNFPVDLSD Y 1201 PKSLHMYANRLLDHRVPQTDMTFRHVGSKLIVAMSSWL QKASGSLPYTQTLQDHLNSLKEFNLQNMGLPDFHIPENLFLK 1281 SDGRVKYTLNKNSLKIEIPLPFGGKSSRDLKMLETVRTP ALHFKSVGFHLPSREFQVPTFTIPKLYQLQVPLLGVLDLST 1361 NVYSNLYNWSASYSGGNTSTDHFSLRARYHMKADSVVD LLSYNVQGSGETTYDHKNTFTLSCDGSLRHKFLDSNIKFSHV 1441 EKLGNNPVSKGLLIFDASSSWGPQMSASVHLDSKKKQHL FVKEVKIDGQFRVSSFYAKGTYGLSCQRDPNTGRLNGESNL 1521 RFNSSYLQGTNQITGRYEDGTLSLTSTSDLQSGIIKNTAS LKYENYELTLKSDTNGKYKNFATSNKMDMTFSKQNALLRS 1601 EYQADYESLRFFSLLSGSLNSHGLELNADILGTDKINSGA HKATLRIGQDGISTSATTNLKCSLLVLENELNAELGLSGA 1681 SMKLTTNGRFREHNAKFSLDGKAALTELSLGSAYQAMIL GVDSKNIFNFKVSQEGLKLSNDMMGSYAEMKFDHTNSLNIA 1761 GLSLDFSSKLDNIYSSDKFYKQTVNLQLQPYSLVTTLNS DLKYNALDLTNNGKLRLEPLKLHVAGNLKGAYQNNEIKHIY 1841 AISSAALSASYKADTVAKVQGVEFSHRLNTDIAGLASAI DMSTNYNSDSLHFSNVFRSVMAPFTMTIDAHTNGNGKLALW 1921 GEHTGQLYSKFLLKAEPLAFTFSHDYKGSTSHHLVSRKS ISAALEHKVSALLTPAEQTGTWKLKTQFNNNEYSQDLDAYN 2001 TKDKIGVELTGRTLADLTLLDSPIKVPLLLSEPINIIDALE MRDAVEKPQEFTIVAFVKYDKNQDVHSINLPFFETLQEY 2081 FERNRQTIIVVLENVQRNLKHINIDQFVRKYRAALGKLP QQANDYLNSFNWERQVSHAKEKLTALTKKYRITENDIQIAL 2161 DDAKINFNEKLSQLQTYMIQFDQYIKDSYDLHDLKIAIA NIIDEIIEKLKSLDEHYHIRVNLVKTIHDLHLFIENIDFNK 2241 SGSSTASWIQNVDTKYQIRIQIQEKLQQLKRHIQNIDIQH LAGKLKQHIEAIDVRVLLDQLGTTISFERINDVLEHVKHF 2321 VINLIGDFEVAEKINAFRAKVHELIERYEVDQQIQVLMD KLVELAHQYKLKETIQKLSNVLQQVKIKDYFEKLVGFIDDA 2401 VKKLNELSFKTFIEDVNKFLDMLIKKLKSFDYHQFVDET NDKIREVTQRLNGEIQALELPQKAEALKLFLEETKATVAVY 2481 LESLQDTKITLIINWLQEALSSASLAHMKAKFRETLEDTR DRMYQMDIQQELQRYLSLVGQVYSTLVTYISDWWTLAAKN 2561 LTDFAEQYSIQDWAKRMKALVEQGFTVPEIKTILGTMPA FEVSLQALQKATFQTPDFIVPLTDLRIPSVQINFKDLKNIK 2641 IPSRFSTPEFTILNTFHIPSFTIDFVEMKVKIIRTIDQMLNS ELQWPVPDIYLRDLKVEDIPLARITLPDFRLPEIAIPE 2721 FIIPTLNLNDFQVPDLHIPEFQLPHISHTIEVPTFGKLYSIL KIQSPLFTLDANADIGNGTTSANEAGIAASITAKGESK 2801 LEVLNFDFQANAQLSNPKINPLALKESVKFSSKYLRTEH GSEMLFFGNAIEGKSNTVASLHTEKNTLELSNGVIVKINNQ 2881 LTLDSNTKYFHKLNIPKLDFSSQADLRNEIKTLLKAGHIA WTSSGKGSWKWACPRFSDEGTHESQISFTIEGPLTSFGLS 2961 NKINSKHLRVNQNLVYESGSLNFSKLEIQSQVDSQHVGH SVLTAKGMALFGEGKAEFTGRHDAHLNGKVIGTLKNSLFFS 3041 AQPFEITASTNNEGNLKVRFPLRLTGKIDFLNNYALFLSP SAQQASWQVSARFNQYKYNQNFSAGNNENIMEAHVGINGE 3121 ANLDFLNIPLTIPEMRLPYTIITTPPLKDFSLWEKTGLKEF LKTTKQSFDLSVKAQYKKNKHRHSITNPLAVLCEFISQS 3201 IKSFDRHFEKNRNNALDFVTKSYNETKIKFDKYKAEKSH DELPRTFQIPGYTVPVVNVEVSPFTIEMSAFGYVFPKAVSM 3281 PSFSILGSDVRVPSYTLILPSLELPVLHVPRNLKLSLPDFK ELCTISHIFIPAMGNITYDFSFKSSVITLNTNAELFNQS 3361 DIVAHLLSSSSSVIDALQYKLEGTTRLTRKRGLKLATALS LSNKFVEGSHNSTVSLTTKNMEVSVATTTKAQIPILRMNF 3441 KQELNGNTKSKPTVSSSMEFKYDFNSSMLYSTAKGAVD HKLSLESLTSYFSIESSTKGDVKGSVLSREYSGTIASEANTY 3521 LNSKSTRSSVKLQGTSKIDDIWNLEVKENFAGEATLQRI YSLWEHSTKNHLQLEGLFFTNGEHTSKATLELSPWQMSALV 3601 QVHASQPSSFHDFPDLGQEVALNANTKNQKIRWKNEVRI HSGSFQSQVELSNDQEKAHLDIAGSLEGHLRFLKNIILPVY 3681 DKSLWDFLKLDVTTSIGRRQHLRVSTAFVYTKNPNGYSF SIPVKVLADKFIIPGLKLNDLNSVLVMPTFHVPFTDLQVPS 3761 CKLDFREIQIYKKLRTSSFALNLPTLPEVKFPEVDVLTKY SQPEDSLIPFFEITVPESQLTVSQFTLPKSVSDGIAALDL 3841 NAVANKIADFELPTIIVPEQTIEIPSIKFSVPAGIVIPSFQA LTARFEVDSPVYNATWSASLKNKADYVETVLDSTCSST 3921 VQFLEYELNVLGTHKIEDGTLASKTKGTFAHRDFSAEYE EDGKYEGLQEWEGKAHLNIKSPAFTDLHLRYQKDKKGISTS 4001 AASPAVGTVGMDMDEDDDFSKWNFYYSPQSSPDKKLTI FKTELRVRESDEETQIKVNWEEEAASGLLTSLKDNVPKATG V 4081 LYDYVNKYHWEHTGLTLREVSSKLRRNLQNNAEWVYQ GAIRQIDDIDVRFQKAASGTTGTYQEWKDKAQNLYQELLTQ EG 4161 QASFQGLKDNVFDGLVRVTQEFHMKVKHLIDSLIDFLNF PRFQFPGKPGIYTREELCTMFIREVGTVLSQVYSKVHNGSE 4241 ILFSYFQDLVITLPFELRKHKLIDVISMYRELLKDLSKEA QEVFKAIQ SLKTTEVLRNLQDLLQFIFQLIEDNIKQLKEM 4321 KFTYLINYIQDEINTIFSDYIPYVFKLLKENLCLNLHKFN EFIQNELQEASQELQQIHQYIMALREEYFDPSIVGWTVKY 4401 YELEEKIVSLIKNLLVALKDFHSEYIVSASNFTSQLSSQV EQFLHRNIQEYLSILTDPDGKGKEKIAELSATAQEIIKSQ 4481 AIATKKIISDYHQQFRYKLQDFSDQLSDYYEKFIAESKRL IDLSIQNYHTFLIYITELLKKLQSTTVMNPYMKLAPGELT 4561 IIL 5.31 peroxiredoxin 2 isoform a [Homo sapiens] Protein Accession gi|32189392

Mean Expression Ratio 1.44 Median Expression Ratio 1.43 Credible Interval (1.03, 2.04) Associated Peptides 3 Associated Spectra 5 Coverage 0.146

A 2.5 50 97.5 Sequence ID No. Sequence 3 1.1  1.5  2.2 SEQ ID NO: 414 EGGLGPLNIPLLADVTR 1 0.99  1.5  2.2 SEQ ID NO: 415 KEGGLGPLNIPLLADVTR 1 0.96  1.5  2.2 SEQ ID NO: 416 QITVNDLPVGR SEQ ID NO: 417   1 MASGNARIGKPAPDFKATAVVDGAFKEVKLSDYKGKYVV LFFYPLDFTFVCPTEIIAFSNRAEDFRKLGCEVLGVSVDSQ  81 FTHLAWINTPRKEGGLGPLNIPLLADVTRRLSEDYGVLKT DEGIAYRGLFIIDGKGVLRQITVNDLPVGRSVDEALRLVQ 161 AFQYTDEHGEVCPAGWKPGSDTIKPNVDDSKEYFSKHN 5.32 sphingomyelin phosphodiesterase 1, acid lysosomal isoform 1 precursor [Homo sapiens] Protein Accession gi|56117840

Mean Expression Ratio 0.703 Median Expression Ratio 0.702 Credible Interval (0.479, 1.03) Associated Peptides 2 Associated Spectra 3 Coverage 0.0285

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.43  0.65  0.98 SEQ ID NO: 418 AWEPWLPAEALR 1 0.45  0.69  1.1 SEQ ID NO: 419 LCNLLK SEQ ID NO: 420   1 MPRYGASLRQSCPRSGREQGQDGTAGAPGLLWMGLVLAL ALALALALALSDSRVLWAPAEAHPLSPQGHPARLHRIVPRL  81 RDVFGWGNLTCPICKGLFTAINLGLKKEPNVARVGSVAIK LCNLLKIAPPAVCQSIVHLFEDDMVEVWRRSVLSPSEACG 161 LLLGSTCGHWDIFSSWNISLPTVPKPPPKPPSPPAPGAPVS RILFLTDLHWDHDYLEGTDPDCADPLCCRRGSGLPPASR 241 PGAGYWGEYSKCDLPLRTLESLLSGLGPAGPFDMVYWTG DIPAHDVWHQTRQDQLRALTTVTALVRKFLGPVPVYPAVGN 321 HESTPVNSFPPPFIEGNHSSRWLYEAMAKAWEPWLPAEA LRTLRIGGFYALSPYPGLRLISLNMNFCSRENFWLLINSTD 401 PAGQLQWLVGELQAAEDRGDKVHIIGHIPPGHCLKSWSW NYYRIVARYENTLAAQFFGHTHVDEFEVFYDEETLSRPLAV 481 AFLAPSATTYIGLNPGYRVYQIDGNYSGSSHVVLDHETYI LNLTQANIPGAIPHWQLLYRARETYGLPNTLPTAWHNLVY 561 RMRGDMQLFQTFWFLYHKGHPPSEPCGTPCRLATLCAQL SARADSPALCRHLMPDGSLPEAQSLWPRPLFC 5.33 proteasome beta 2 subunit [Homo sapiens] Protein Accession gi|4506195

Mean Expression Ratio 1.41 Median Expression Ratio 1.41 Credible Interval (0.987, 2.04) Associated Peptides 3 Associated Spectra 4 Coverage 0.224

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.97  1.5  2.3 SEQ ID NO: 421 FILNLPTFSVR 2 1.0  1.5  2.2 SEQ ID NO: 422 LIGIQGPDYVLVASDR 1 0.91  1.4  2.1 SEQ ID NO: 423 HVNLLLAGYDEHEGPALY SEQ ID NO: 424   1 MEYLIGIQGPDYVLVASDRVAASNIVQMKDDHDKMFKMSE KILLLCVGEAGDTVQFAEYIQKNVQLYKMRNGYELSPTAA  81 ANFTRRNLADCLRSRTPYHVNLLLAGYDEHEGPALYYMD YLAALAKAPFAAHGYGAFLTLSILDRYYTPTISRERAVELL 161 RKCLEELQKRFILNLPTFSVRIIDKNGIHDLDNISFPKQGS 5.34 complement component 4B preproprotein [Homo sapiens] Protein Accession gi|178557739

Mean Expression Ratio 0.712 Median Expression Ratio 0.711 Credible Interval (0.435, 1.15) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.39  0.65  1.1 SEQ ID NO: 425 LLSQQQADGSFQDLSPVIHR 5.35 manganese superoxide dismutase isoform A precursor [Homo sapiens]; manganese superoxide dismutase isoform A precursor [Homo sapiens] Protein Accession gi|67782307 gi|67782305

Mean Expression Ratio 1.40 Median Expression Ratio 1.40 Credible Interval (1.10, 1.77) Associated Peptides 9 Associated Spectra 13 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 1.0  1.4  1.9 SEQ ID NO: 426 AIWNVINWENVTER 2 1.1  1.5  2.1 SEQ ID NO: 427 DFGSFDKFK 1 1.0  1.4  2.0 SEQ ID NO: 428 FNGGGHINHSIFW 1 1  1.4  2 SEQ ID NO: 429 GDVTAQIALQPALK 2 1.0  1.4  2 SEQ ID NO: 430 GELLEAIKR 1 0.97  1.4  1.9 SEQ ID NO: 431 HHAAYVNNLNVTEEK 2 1  1.4  1.9 SEQ ID NO: 432 NVRPDYLK 1 1.0  1.4  2 SEQ ID NO: 433 GWLGFNK 1 0.96  1.4  1.9 SEQ ID NO: 434 YQEALAK 5.36 transthyretin [Homo sapiens] Protein Accession gi|4507725

Mean Expression Ratio 0.718 Median Expression Ratio 0.718 Credible Interval (0.572, 0.9) Associated Peptides 6 Associated Spectra 17 Coverage 0.49

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.54  0.73  1 SEQ ID NO: 435 ALGISPFHEHAEVVF 2 0.56  0.76  1.0 SEQ ID NO: 436 ALGISPFHEHAEVVFTANDSGPR 6 0.48  0.61  0.8 SEQ ID NO: 437 GSPAINVAVHVFR 2 0.5  0.7  0.95 SEQ ID NO: 438 KAADDTWEPFASGK 3 0.54  0.74  1 SEQ ID NO: 439 TSESGELHGLTTEEEFVEGIYK 1 0.51  0.72  1 SEQ ID NO: 440 AADDTWEPFASGK SEQ ID NO: 441 1 MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAV RGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTT 5.37 haptoglobin isoform 1 preproprotein [Homo sapiens]; haptoglobin isoform 2 preproprotein [Homo sapiens] Protein Accession gi|4826762 gi|186910296

Mean Expression Ratio 0.721 Median Expression Ratio 0.72 Credible Interval (0.565, 0.918) Associated Peptides 9 Associated Spectra 13 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.52  0.74  1.1 SEQ ID NO: 442 AVHDLEEDTWYATGILSFDK 1 0.51  0.73  1.0 SEQ ID NO: 443 GSFPWQAK 1 0.5  0.71  1.0 SEQ ID NO: 444 HYEGSTVPEKK 2 0.54  0.74  1.0 SEQ ID NO: 445 ILGGHLDAK 1 0.48  0.67  0.95 SEQ ID NO: 446 SPVGVQPILNEHTFCAGMSK 1 0.52  0.72  1.0 SEQ ID NO: 447 VMPICLPSKDYAEVGR 1 0.52  0.73  1.0 SEQ ID NO: 448 VTSIQDWVQK 3 0.51  0.69  0.93 SEQ ID NO: 449 YVMLPVADQDQCIR 2 0.5  0.7  0.97 SEQ ID NO: 450 FTDHLK 5.38 fibulin 1 isoform D [Homo sapiens] Protein Accession gi|34734066

Mean Expression Ratio 0.726 Median Expression Ratio 0.728 Credible Interval (0.464, 1.12) Associated Peptides 2 Associated Spectra 2 Coverage 0.0327

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.42  0.68  1.1 SEQ ID NO: 451 EFTRPEEIIFLR 1 0.45  0.73  1.2 SEQ ID NO: 452 IIFDITEGNLR SEQ ID NO: 453   1 MERAAPSRRVPLPLLLLGGLALLAAGVDADVLLEACCADG HRMATHQKDCSLPYATESKECRMVQEQCCHSQLEELHCAT  81 GISLANEQDRCATPHGDNASLEATFVKRCCHCCLLGRAAQ AQGQSCEYSLMVGYQCGQVFRACCVKSQETGDLDVGGLQE 161 TDKIIEVEEEQEDPYLNDRCRGGGPCKQQCRDTGDEVVC SCFVGYQLLSDGVSCEDVNECITGSHSCRLGESCINTVGSF 241 RCQRDSSCGTGYELTEDNSCKDIDECESGIHNCLPDFICQ NTLGSFRCRPKLQCKSGFIQDALGNCIDINECLSISAPCP 321 IGHTCINTEGSYTCQKNVPNCGRGYHLNEEGTRCVDVDE CAPPAEPCGKGHRCVNSPGSFRCECKTGYYFDGISRMCVDV 401 NECQRYPGRLCGHKCENTLGSYLCSCSVGFRLSVDGRSC EDINECSSSPCSQECANVYGSYQCYCRRGYQLSDVDGVTCE 481 DIDECALPTGGHICSYRCINIPGSFQCSCPSSGYRLAPNGR NCQDIDECVTGIHNCSINETCFNIQGGFRCLAFECPENY 561 RRSAATLQQEKTDTVRCIKSCRPNDVTCVFDPVHTISHTV ISLPTFREFTRPEEIIFLRAITPPHPASQANIIFDITEGN 641 LRDSFDIIKRYMDGMTVGVVRQVRPIVGPFHAVLKLEMN YVVGGVVSHRNVVNVHIFVSEYWF 5.39 serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1 [Homo sapiens] Protein Accession gi|4502261

Mean Expression Ratio 0.73 Median Expression Ratio 0.73 Credible Interval (0.529, 1.00) Associated Peptides 5 Associated Spectra 5 Coverage 0.194

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.48  0.72  1.1 SEQ ID NO: 454 AFLEVNEEGSEAAASTAVVIAGR 1 0.49  0.74  1.1 SEQ ID NO: 455 EVPLNTIIFMGR 1 0.48  0.72  1.1 SEQ ID NO: 456 VAEGTQVLELPFK 1 0.49  0.72  1.1 SEQ ID NO: 457 ELTPEVLQEWLDELEEMMLVVHMPR 1 0.47  0.7  1.0 SEQ ID NO: 458 ATEDEGSEQKIPEATNR SEQ ID NO: 459   1 MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICT AKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRV  81 WELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFA MTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNC 161 RLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYG AKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAIN 241 ELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCS ASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKP 321 EKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIED GFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAF 401 HKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPF LVFIREVPLNTIIFMGRVANPCVK 5.40 hypothetical protein LOC148362 [Homo sapiens] Protein Accession gi|124244088

Mean Expression Ratio 1.37 Median Expression Ratio 1.37 Credible Interval (0.994, 1.92) Associated Peptides 5 Associated Spectra 5 Coverage 0.141

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.92  1.4  2.0 SEQ ID NO: 460 LLELFTDLSCNPEMMK 1 0.94  1.4  2.1 SEQ ID NO: 461 NAADSYFSLLQGFINSLDESTQESK 1 0.93  1.4  2.1 SEQ ID NO: 462 SLLQGFINSLDESTQESK 1 0.94  1.4  2.1 SEQ ID NO: 463 YIQNFK 1 0.92  1.4  2.1 SEQ ID NO: 464 IPTEAPQLELK SEQ ID NO: 465   1 MTHWFHRNPLKATAPVSFNYYGVVTGPSASKICNDLRSSR ARLLELFTDLSCNPEMMKNAADSYFSLLQGFINSLDESTQ  81 ESKLRYIQNFKWTDTLQGQVPSAQQDAVFELISMGFNVAL WYTKYASRLAGKENITEDEAKEVHRSLKIAAGIFKHLKES 161 HLPKLITPAEKGRDLESRLIEAYVIQCQAEAQEVTIARAIE LKHAPGLIAALAYETANFYQKADHTLSSLEPAYSAKWRK 241 YLHLKMCFYTAYAYCYHGETLLASDKCGEAIRSLQEAEK LYAKAEALCKEYGETKGPGPTVKPSGHLFFRKLGNLVKNTL 321 EKCQRENGFIYFQKIPTEAPQLELKANYGLVEPIPFEFPPT SVQWTPETLAAFDLTKRPKDDSTKPKPEEEVKPVKEPDI 401 KPQKDTGCYIS 5.41 ferritin, heavy polypeptide 1 [Homo sapiens] Protein Accession gi|56682959

Mean Expression Ratio 1.36 Median Expression Ratio 1.36 Credible Interval (1.12, 1.67) Associated Peptides 9 Associated Spectra 21 Coverage 0.41

A 2.5 50 97.5 Sequence ID No. Sequence 3 1.0  1.4  1.9 SEQ ID NO: 466 ELGDHVTNLR 1 1.1  1.5  2.1 SEQ ID NO: 467 GGRIFLQDIK 2 0.9  1.2  1.6 SEQ ID NO: 468 LCDFIETHYLNEQVK 2 1.0  1.4  1.9 SEQ ID NO: 469 MGAPESGLAEYLFDK 3 1.1  1.5  1.9 SEQ ID NO: 470 NDPHLCDFIETHYLNEQVK 5 1.1  1.4  1.9 SEQ ID NO: 471 NVNQSLLELHK 1 0.97  1.3  1.8 SEQ ID NO: 472 YFLHQSHEER 1 0.96  1.3  1.8 SEQ ID NO: 473 LCDFIETHY 3 1.0  1.4  1.9 SEQ ID NO: 474 IFLQDIK SEQ ID NO: 475   1 MTTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSY YFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGR  81 IFLQDIKKPDCDDWESGLNAMECALHLEKNVNQSLLELHK LATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMG 161 APESGLAEYLFDKHTLGDSDNES 5.42 serum amyloid A1 preproprotein [Homo sapiens]; serum amyloid A1 preproprotein [Homo sapiens] Protein Accession gi|40316912 gi|40316910

Mean Expression Ratio 0.738 Median Expression Ratio 0.737 Credible Interval (0.512, 1.06) Associated Peptides 3 Associated Spectra 4 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.47  0.69  1.0 SEQ ID NO: 476 FFGHGAEDSLADQAANEWGR 1 0.48  0.73  1.1 SEQ ID NO: 477 SFFSFLGEAFDGAR 1 0.48  0.74  1.1 SEQ ID NO: 478 GPGGAWAAEVISDAR 5.43 programmed cell death 6 [Homo sapiens] Protein Accession gi|7019485

Mean Expression Ratio 1.34 Median Expression Ratio 1.34 Credible Interval (1.02, 1.77) Associated Peptides 4 Associated Spectra 10 Coverage 0.319

A 2.5 50 97.5 Sequence ID No. Sequence 4 0.99  1.3  1.8 SEQ ID NO: 479 LSDQFHDILIR 4 1.0  1.4  1.9 SEQ ID NO: 480 SGVISDTELQQALSNGTWTPFNPVTVR 1 0.99  1.4  2.1 SEQ ID NO: 481 YITDWQNVFR 1 0.93  1.3  2.0 SEQ ID NO: 482 AGVNFSEFTGVWK SEQ ID NO: 483   1 MAAYSYRPGPGAGPGPAAGAALPDQSFLWNVFQRVDKDR SGVISDTELQQALSNGTWTPFNPVTVRSIISMFDRENKAGV  81 NFSEFTGVWKYITDWQNVFRTYDRDNSGMIDKNELKQAL SGFGYRLSDQFHDILIRKFDRQGRGQIAFDDFIQGCIVLQR 161 LTDIFRRYDTDQDGWIQVSYEQYLSMVFSIV 5.44 complement component 1 inhibitor precursor [Homo sapiens]; complement component 1 inhibitor precursor [Homo sapiens] Protein Accession gi|73858570 gi|73858568

Mean Expression Ratio 0.745 Median Expression Ratio 0.744 Credible Interval (0.58, 0.953) Associated Peptides 8 Associated Spectra 12 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.5  0.69  0.93 SEQ ID NO: 484 GVTSVSQIFHSPDLAIR 2 0.55  0.77  1.1 SEQ ID NO: 485 KYPVAHFIDQTLK 1 0.52  0.74  1.0 SEQ ID NO: 486 LEDMEQALSPSVFK 1 0.52  0.75  1.0 SEQ ID NO: 487 LLDSLPSDTR 1 0.53  0.75  1.1 SEQ ID NO: 488 LVLLNAIYLSAK 1 0.52  0.74  1.1 SEQ ID NO: 489 QHQTVLELTETGVEAAAASAISVAR 2 0.53  0.73  1.0 SEQ ID NO: 490 QTVLELTETGVEAAAASAISVAR 1 0.53  0.76  1.1 SEQ ID NO: 491 DFTCVHQALK 5.45 chromatin modifying protein 5 [Homo sapiens] Protein Accession gi|189409150

Mean Expression Ratio 1.34 Median Expression Ratio 1.34 Credible Interval (0.915, 2.00) Associated Peptides 3 Associated Spectra 3 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.89  1.4  2.1 SEQ ID NO: 492 APPPSLTDCIGTVDSR 1 0.88  1.4  2.1 SEQ ID NO: 493 IDQIEDLQDQLEDMMEDANEIQEALSR 1 0.9  1.4  2.1 SEQ ID NO: 494 YKDQIK 5.46 vacuolar protein sorting factor 4B [Homo sapiens] Protein Accession gi|17865802

Mean Expression Ratio 1.33 Median Expression Ratio 1.33 Credible Interval (0.961, 1.84) Associated Peptides 4 Associated Spectra 5 Coverage 0.146

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.9  1.4  2.0 SEQ ID NO: 495 ENKPSIIFIDEIDSLCGSR 1 0.88  1.3  2.0 SEQ ID NO: 496 LLEPVVSMSDMLR 2 0.94  1.4  2.0 SEQ ID NO: 497 LQNQLQGAIVIERPNVK 1 0.9  1.3  2 SEQ ID NO: 498 SLSNTKPTVNEHDLLK SEQ ID NO: 499   1 MSSTSPNLQKAIDLASKAAQEDKAGNYEEALQLYQHAVQY FLHVVKYEAQGDKAKQSIRAKCTEYLDRAEKLKEYLKNKE  81 KKAQKPVKEGQPSPADEKGNDSDGEGESDDPEKKKLQNQ LQGAIVIERPNVKWSDVAGLEGAKEALKEAVILPIKFPHLF 161 TGKRTPWRGILLFGPPGTGKSYLAKAVATEANNSTFFSIS SSDLVSKWLGESEKLVKNLFQLARENKPSIIFIDEIDSLC 241 GSRSENESEAARRIKTEFLVQMQGVGVDNDGILVLGATNI PWVLDSAIRRRFEKRIYIPLPEPHARAAMFKLHLGTTQNS 321 LTEADFRELGRKTDGYSGADISIIVRDALMQPVRKVQSAT HFKKVRGPSRADPNHLVDDLLTPCSPGDPGAIEMTWMDVP 5.47 prominin 1 [Homo sapiens] Protein Accession gi|5174387

Mean Expression Ratio 1.32 Median Expression Ratio 1.32 Credible Interval (1.05, 1.66) Associated Peptides 9 Associated Spectra 15 Coverage 0.158

A 2.5 50 97.5 Sequence ID No. Sequence 3 1 1.  4  1.8 SEQ ID NO: 500 AFTDLNSINSVLGGGILDR 1 0.96  1.3  1.9 SEQ ID NO: 501 LLNEDWEYYLSGK 1 0.96  1.3  1.9 SEQ ID NO: 502 LTFEQVYSDCK 3 0.95  1.3  1.7 SEQ ID NO: 503 QLPPVDAELDNVNNVLR 1 0.96  1.3  1.9 SEQ ID NO: 504 SLHQQSTQLSSSLTSVK 3 1.0  1.4  1.9 SEQ ID NO: 505 TDLDGLVQQGYQSLNDIPDR 1 0.94  1.3  1.8 SEQ ID NO: 506 TLLNETPEQIK 1 0.92  1.3  1.8 SEQ ID NO: 507 VLPIEQSLSTLYQSVK 1 0.94  1.3  1.9 SEQ ID NO: 508 VNLNIFLLGAAGR SEQ ID NO: 509   1 MALVLGSLLLLGLCGNSFSGGQPSSTDAPKAWNYELPATN YETQDSHKAGPIGILFELVHIFLYVVQPRDFPEDTLRKFL   81 QKAYESKIDYDKPETVILGLKIVYYEAGIILCCVLGLLFIIL MPLVGYFFCMCRCCNKCGGEMHQRQKENGPFLRKCFAI 161 SLLVICIIISIGIFYGFVANHQVRTRIKRSRKLADSNFKDLR TLLNETPEQIKYILAQYNTTKDKAFTDLNSINSVLGGG 241 ILDRLRPNIIPVLDEIKSMATAIKETKEALENMNSTLKSLH QQSTQLSSSLTSVKTSLRSSLNDPLCLVHPSSETCNSIR 321 LSLSQLNSNPELRQLPPVDAELDNVNNVLRTDLDGLVQQ GYQSLNDIPDRVQRQTTTVVAGIKRVLNSIGSDIDNVTQRL 401 PIQDILSAFSVYVNNTESYIHRNLPTLEEYDSYWWLGGLV ICSLLTLIVIFYYLGLLCGVCGYDRHATPTTRGCVSNTGG 481 VFLMVGVGLSFLFCWILMIIVVLTFVFGANVEKLICEPYT SKELFRVLDTPYLLNEDWEYYLSGKLFNKSKMKLTFEQVY 561 SDCKKNRGTYGTLHLQNSFNISEHLNINEHTGSISSELESL KVNLNIFLLGAAGRKNLQDFAACGIDRMNYDSYLAQTGK 641 SPAGVNLLSFAYDLEAKANSLPPGNLRNSLKRDAQTIKTI HQQRVLPIEQSLSTLYQSVKILQRTGNGLLERVTRILASL 721 DFAQNFITNNTSSVIIEETKKYGRTIIGYFEHYLQWIEFSIS EKVASCKPVATALDTAVDVFLCSYIIDPLNLFWFGIGK 801 ATVFLLPALIFAVKLAKYYRRMDSEDVYDDVETIPMKNM ENGNNGYHKDHVYGIHNPVMTSPSQH 5.48 alpha 3 type VI collagen isoform 1 precursor [Homo sapiens] Protein Accession gi|55743098

Mean Expression Ratio 0.756 Median Expression Ratio 0.757 Credible Interval (0.563, 1.02) Associated Peptides 6 Associated Spectra 7 Coverage 0.0353

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.49 0.71 1.0 SEQ ID NO: 510 AAPLQGMLPGLLAPLR 1 0.51 0.75 1.1 SEQ ID NO: 511 GADQAELEEIAFDSSLVFI PAEFR 1 0.5 0.73 1.1 SEQ ID NO: 512 GAQGPAGPAGPPGLIGEQG ISGPR 1 0.51 0.75 1.1 SEQ ID NO: 513 ITEGVPQLLIVLTADR 1 0.51 0.75 1.1 SEQ ID NO: 514 LVDYLDVGFDTTR 2 0.56 0.8 1.1 SEQ ID NO: 515 MKPLDGSALYTGSALDFVR SEQ ID NO: 516    1 MRKHRHLPLVAVFCLFLSGFPTTHAQQQQADVKNGAAADIIFL      VDSSWTIGEEHFQLVREFLYDVVKSLAVGENDFHFAL   81 VQFNGNPHTEFLLNTYRTKQEVLSHISNMSYIGGTNQTGKGLE      YIMQSHLTKAAGSRAGDGVPQVIVVLTDGHSKDGLAL  161 PSAELKSADVNVFAIGVEDADEGALKEIASEPLNMHMFNLENF      TSLHDIVGNLVSCVHSSVSPERAGDTETLKDITAQDS  241 ADIIFLIDGSNNTGSVNFAVILDFLVNLLEKLPIGTQQIRVGV      VQFSDEPRTMFSLDTYSTKAQVLGAVKALGFAGGELA  321 NIGLALDFVVENHFTRAGGSRVEEGVPQVLVLISAGPSSDEIR      YGVVALKQASVFSFGLGAQAASRAELQHIATDDNLVF  401 TVPEFRSFGDLQEKLLPYIVGVAQRHIVLKPPTIVTQVIEVNK      RDIVFLVDGSSALGLANFNAIRDFIAKVIQRLEIGQD  481 LIQVAVAQYADTVRPEFYFNTHPTKREVITAVRKMKPLDGSAL      YTGSALDFVRNNLFTSSAGYRAAEGIPKLLVLITGGK  561 SLDEISQPAQELKRSSIMAFAIGNKGADQAELEEIAFDSSLVF      IPAEFRAAPLQGMLPGLLAPLRTLSGTPEVHSNKRDI  641 IFLLDGSANVGKTNFPYVRDFVMNLVNSLDIGNDNIRVGLVQF      SDTPVTEFSLNTYQTKSDILGHLRQLQLQGGSGLNTG  721 SALSYVYANHFTEAGGSRIREHVPQLLLLLTAGQSEDSYLQAA      NALTRAGILTFCVGASQANKAELEQIAFNPSLVYLMD  801 DFSSLPALPQQLIQPLTTYVSGGVEEVPLAQPESKRDILFLFD      GSANLVGQFPVVRDFLYKIIDELNVKPEGTRIAVAQY  881 SDDVKVESRFDEHQSKPEILNLVKRMKIKTGKALNLGYALDYA      QRYIFVKSAGSRIEDGVLQFLVLLVAGRSSDRVDGPA  961 SNLKQSGVVPFIFQAKNADPAELEQIVLSPAFILAAESLPKIG      DLHPQIVNLLKSVHNGAPAPVSGEKDVVFLLDGSEGV 1041 RSGFPLLKEFVQRVVESLDVGQDRVRVAVVQYSDRTRPEFYLN      SYMNKQDVVNAVRQLTLLGGPTPNTGAALEFVLRNIL 1121 VSSAGSRITEGVPQLLIVLTADRSGDDVRNPSVVVKRGGAVPI      GIGIGNADITEMQTISFIPDFAVAIPTFRQLGTVQQV 1201 ISERVTQLTREELSRLQPVLQPLPSPGVGGKRDVVFLIDGSQS      AGPEFQYVRTLIERLVDYLDVGFDTTRVAVIQFSDDP 1281 KVEFLLNAHSSKDEVQNAVQRLRPKGGRQINVGNALEYVSRNI      FKRPLGSRIEEGVPQFLVLISSGKSDDEVDDPAVELK 1361 QFGVAPFTIARNADQEELVKISLSPEYVFSVSTFRELPSLEQK      LLTPITTLTSEQIQKLLASTRYPPPAVESDAADIVFL 1441 IDSSEGVRPDGFAHIRDFVSRIVRRLNIGPSKVRVGVVQFSND      VFPEFYLKTYRSQAPVLDAIRRLRLRGGSPLNTGKAL 1521 EFVARNLFVKSAGSRIEDGVPQHLVLVLGGKSQDDVSRFAQVI      RSSGIVSLGVGDRNIDRTELQTITNDPRLVFTVREFR 1601 ELPNIEERIMNSFGPSAATPAPPGVDTPPPSRPEKKKADIVFL      LDGSINFRRDSFQEVLRFVSEIVDTVYEDGDSIQVGL 1681 VQYNSDPTDEFFLKDFSTKRQIIDAINKVVYKGGRHANTKVGL      EHLRVNHFVPEAGSRLDQRVPQIAFVITGGKSVEDAQ 1761 DVSLALTQRGVKVFAVGVRNIDSEEVGKIASNSATAFRVGNVQ      ELSELSEQVLETLHDAMHETLCPGVTDAAKACNLDVI 1841 LGFDGSRDQNVFVAQKGFESKVDAILNRISQMHRVSCSGGRSP      TVRVSVVANTPSGPVEAFDFDEYQPEMLEKFRNMRSQ 1921 HPYVLTEDTLKVYLNKFRQSSPDSVKVVIHFTDGADGDLADLH      RASENLRQEGVRALILVGLERVVNLERLMHLEFGRGF 2001 MYDRPLRLNLLDLDYELAEQLDNIAEKACCGVPCKCSGQRGDR      GPIGSIGPKGIPGEDGYRGYPGDEGGPGERGPPGVNG 2081 TQGFQGCPGQRGVKGSRGFPGEKGEVGEIGLDGLDGEDGDKGL      PGSSGEKGNPGRRGDKGPRGEKGERGDVGIRGDPGNP 2161 GQDSQERGPKGETGDLGPMGVPGRDGVPGGPGETGKNGGFGRR      GPPGAKGNKGGPGQPGFEGEQGTRGAQGPAGPAGPPG 2241 LIGEQGISGPRGSGGAAGAPGERGRTGPLGRKGEPGEPGPKGG      IGNRGPRGETGDDGRDGVGSEGRRGKKGERGFPGYPG 2321 PKGNPGEPGLNGTTGPKGIRGRRGNSGPPGIVGQKGDPGYPGP      AGPKGNRGDSIDQCALIQSIKDKCPCCYGPLECPVFP 2401 TELAFALDTSEGVNQDTFGRMRDVVLSIVNDLTIAESNCPRGA      RVAVVTYNNEVTTEIRFADSKRKSVLLDKIKNLQVAL 2481 TSKQQSLETAMSFVARNTFKRVRNGFLMRKVAVFFSNTPTRAS      PQLREAVLKLSDAGITPLFLTRQEDRQLINALQINNT 2561 AVGHALVLPAGRDLTDFLENVLTCHVCLDICNIDPSCGFGSWR      PSFRDRRAAGSDVDIDMAFILDSAETTTLFQFNEMKK 2641 YIAYLVRQLDMSPDPKASQHFARVAVVQHAPSESVDNASMPPV      KVEFSLTDYGSKEKLVDFLSRGMTQLQGTRALGSAIE 2721 YTIENVFESAPNPRDLKIVVLMLTGEVPEQQLEEAQRVILQAK      CKGYFFVVLGIGRKVNIKEVYTFASEPNDVFFKLVDK 2801 STELNEEPLMRFGRLLPSFVSSENAFYLSPDIRKQCDWFQGDQ      PTKNLVKFGHKQVNVPNNVTSSPTSNPVTTTKPVTTT 2881 KPVTTTTKPVTTTTKPVTIINQPSVKPAAAKPAPAKPVAAKPV      ATKMATVRPPVAVKPATAAKPVAAKPAAVRPPAAAAA 2961 KPVATKPEVPRPQAAKPAATKPATTKPMVKMSREVQVFEITEN      SAKLHWERAEPPGPYFYDLTVTSAHDQSLVLKQNLTV 3041 TDRVIGGLLAGQTYHVAVVCYLRSQVRATYHGSFSTKKSQPPP      PQPARSASSSTINLMVSTEPLALTETDICKLPKDEGT 3121 CRDFILKWYYDPNTKSCARFWYGGCGGNENKFGSQKECEKVCA      PVLAKPGVISVMGT 5.49 actin, gamma 1 propeptide [Homo sapiens]; beta actin [Homo sapiens] Protein Accession gi|4501887 gi|4501885

Mean Expression Ratio 1.31 Median Expression Ratio 1.31 Credible Interval (1.05, 1.67) Associated Peptides 10 Associated Spectra 13 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.9 1.3 1.8 SEQ ID NO: 517 ANTVLSGGTTMYPGIADR 1 0.95 1.4 1.9 SEQ ID NO: 518 DLYANTVLSGGTTMYPGIADR 1 1 1.4 1.9 SEQ ID NO: 519 KDLYANTVLSGGTTMYPGIAD R 2 0.97 1.3 1.8 SEQ ID NO: 520 LCYVALDFEQEMATAASSSSL EK 2 0.92 1.3 1.8 SEQ ID NO: 521 TTGIVMDSGDGVTHTVPIYEG Y 1 0.95 1.3 1.9 SEQ ID NO: 522 TTGIVMDSGDGVTHTVPIYEG YALPHAILR 1 0.93 1.3 1.8 SEQ ID NO: 523 TVLSGGTTMYPGIADR 1 0.91 1.3 1.8 SEQ ID NO: 524 VALDFEQEMATAASSSSLEK 1 0.98 1.4 2.0 SEQ ID NO: 525 VAPEEHPVLLTEAPLNPK 2 0.97 1.3 1.8 SEQ ID NO: 526 YPIEHGIVTNWDDMEK 5.50 solute carrier family 5 (sodium/glucose cotransporter), member 12 [Homo sapiens] Protein Accession gi|157671931

Mean Expression Ratio 0.762 Median Expression Ratio 0.764 Credible Interval (0.515, 1.12) Associated Peptides 2 Associated Spectra 3 Coverage 0.0388

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.44 0.68 1 SEQ ID NO: 527 LHIFDFDVDPLR 1 0.52 0.8 1.2 SEQ ID NO: 528 QGAESVLQNGLR SEQ ID NO: 529   1 MEVKNFAVWDYVVFAALFFISSGIGVFFAIKERKKATSREF     LVGGRQMSFGPVGLSLTASFMSAVTVLGTPSEVYRFGAS  81 FLVFFIAYLFVILLTSELFLPVFYRSGITSTYEYLQLRFNK     PVRYAATVIYIVQTILYTGVVVYAPALALNQVTGFDLWG 161 SVFATGIVCTFYCTLGGLKAVVWTDAFQMVVMIVGFLTVLI     QGSTHAGGFHNVLEQSTNGSRLHIFDFDVDPLRRHTFWT 241 ITVGGTFTWLGIYGVNQSTIQRCISCKTEKHAKLALYFNLL     GLWIILVCAVFSGLIMYSHFKDCDPWTSGIISAPDQLMP 321 YFVMEIFATMPGLPGLFVACAFSGTLSTVASSINALATVTF     EDFVKSCFPHLSDKLSTWISKGLCLLFGVMCTSMAVAAS 401 VMGGVVQASLSIHGMCGGPMLGLFSLGIVFPFVNWKGALGG     LLTGITLSFWVAIGAFIYPAPASKTWPLPLSTDQCIKSN 481 VTATGPPVLSSRPGIADTWYSISYLYYSAVGCLGCIVAGVI     ISLITGRQRGEDIQPLLIRPVCNLFCFWSKKYKTLCWCG 561 VQHDSGTEQENLENGSARKQGAESVLQNGLRRESLVHVPGY     DPKDKSYNNMAFETTHF 5.51 vacuolar protein sorting 25 [Homo sapiens] Protein Accession gi|14150155

Mean Expression Ratio 1.31 Median Expression Ratio 1.30 Credible Interval (0.845, 2.04) Associated Peptides 1 Associated Spectra 2 Coverage 0.0852

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.9 1.4 2.2 SEQ ID NO: 530 KLPVESIQIVLEELR SEQ ID NO: 531   1 MAMSFEWPWQYRFPPFFTLQPNVDTRQKQLAAWCSLVLSF     CRLHKQSSMTVMEAQESPLFNNVKLQRKLPVESIQIVLEE  81 LRKKGNLEWLDKSKSSFLIMWRRPEEWGKLIYQWVSRSGQ     NNSVFTLYELTNGEDTEDEEFHGLDEATLLRALQALQQEH 161 KAEIITVSDGRGVKFF 5.52 annexin A11 [Homo sapiens]; annexin A11 [Homo sapiens]; annexin A11 [Homo sapiens] Protein Accession gi|4557317 gi|22165433 gi|22165431

Mean Expression Ratio 1.3 Median Expression Ratio 1.30 Credible Interval (0.93, 1.82) Associated Peptides 4 Associated Spectra 5 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.88 1.3 2.0 SEQ ID NO: 532 AHLVAVFNEYQR 1 0.9 1.3 2 SEQ ID NO: 533 GFGTDEQAIIDCLGSR 1 0.9 1.3 2 SEQ ID NO: 534 GTITDAPGFDPLR 2 0.9 1.3 1.9 SEQ ID NO: 535 GVGTDEACLIEILASR 5.53 chromatin modifying protein 4B [Homo sapiens] Protein Accession gi|28827795

Mean Expression Ratio 1.3 Median Expression Ratio 1.30 Credible Interval (0.882, 1.89) Associated Peptides 3 Associated Spectra 3 Coverage 0.147

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.87 1.3 2.1 SEQ ID NO: 536 QLAQIDGTLSTIEFQR 1 0.85 1.3 2.0 SEQ ID NO: 537 KIEQELTAAK 1 0.87 1.3 2.1 SEQ ID NO: 538 KQEFLEK SEQ ID NO: 539   1 MSVFGKLFGAGGGKAGKGGPTPQEAIQRLRDTEEMLSKKQ     EFLEKKIEQELTAAKKHGTKNKRAALQALKRKKRYEKQLA  81 QIDGTLSTIEFQREALENANTNTEVLKNMGYAAKAMKAAH     DNMDIDKVDELMQDIADQQELAEEISTAISKPVGFGEEFD 161 EDELMAELEELEQEELDKNLLEISGPETVPLPNVPSIALP     SKPAKKKEEEDDDMKELENWAGSM 5.54 fatty acid binding protein 4, adipocyte [Homo sapiens] Protein Accession gi|4557579

Mean Expression Ratio 0.769 Median Expression Ratio 0.771 Credible Interval (0.526, 1.12) Associated Peptides 2 Associated Spectra 4 Coverage 0.242

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.49 0.73 1.1 SEQ ID NO: 540 NTEISFILGQEFDEVTADDR 1 0.49 0.76 1.2 SEQ ID NO: 541 LVSSENFDDYMK SEQ ID NO: 542  1 MCDAFVGTWKLVSSENFDDYMKEVGVGFATRKVAGMAKPNMIISV    NGDVITIKSESTFKNTEISFILGQEFDEVTADDRK 81 VKSTITLDGGVLVHVQKWDGKSTTIKRKREDDKLVVECVMKGVTS    TRVYERA 5.55 chloride intracellular channel 6 [Homo sapiens] Protein Accession gi|27894378

Mean Expression Ratio 1.29 Median Expression Ratio 1.29 Credible Interval (0.8, 2.07) Associated Peptides 1 Associated Spectra 1 Coverage 0.0219

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.82 1.4 2.2 SEQ ID NO: 543 VGDGPQQEPGEDEER SEQ ID NO: 544   1 MAEAAEPEGVAPGPQGPPEVPAPLAERPGEPGAAGGEAEGP     EGSEGAEEAPRGAAAVKEAGGGGPDRGPEAEARGTRGAH  81 GETEAEEGAPEGAEVPQGGEETSGAQQVEGASPGRGAQGEP     RGEAQREPEDSAAPERQEEAEQRPEVPEGSASGEAGDSV 161 DAEGPLGDNIEAEGPAGDSVEAEGRVGDSVDAEGPAGDSVD     AEGPLGDNIQAEGPAGDSVDAEGRVGDSVDAEGPAGDSV 241 DAEGRVGDSVEAGDPAGDGVEAGVPAGDSVEAEGPAGDSMD     AEGPAGRARRVSGEPQQSGDGSLSPQAEAIEVAAGESAG 321 RSPGELAWDAAEEAEVPGVKGSEEAAPGDARADAGEDRVGD     GPQQEPGEDEERRERSPEGPREEEAAGGEEESPDSSPHG 401 EASRGAAEPEAQLSNHLAEEGPAEGSGEAARVNGRREDGEA     SEPRALGQEHDITLFVKAGYDGESIGNCPFSQRLFMILW 481 LKGVIFNVTTVDLKRKPADLQNLAPGTNPPFMTFDGEVKTD     VNKIEEFLEEKLAPPRYPKLGTQHPESNSAGNDVFAKFS 561 AFIKNTKKDANEIHEKNLLKALRKLDNYLNSPLPDEIDAYS     TEDVTVSGRKFLDGDELTLADCNLLPKLHIIKIVAKKYR 641 DFEFPSEMTGIWRYLNNAYARDEFTNTCPADQEIEHAYSDV     AKRMK 5.56 proteasome alpha 3 subunit isoform 1 [Homo sapiens]; proteasome alpha 3 subunit isoform 2 [Homo sapiens] Protein Accession gi|4506183 gi|23110939

Mean Expression Ratio 1.29 Median Expression Ratio 1.29 Credible Interval (0.844, 1.97) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.85 1.4 2.2 SEQ ID NO: 545 HVGMAVAGLLADAR 1 0.82 1.3 2.1 SEQ ID NO: 546 AFELELSWVGELTNGR 5.57 gelsolin isoform a precursor [Homo sapiens]; gelsolin isoform b [Homo sapiens]; gelsolin isoform c [Homo sapiens]; gelsolin isoform c [Homo sapiens]; gelsolin isoform b [Homo sapiens]; gelsolin isoform b [Homo sapiens]; gelsolin isoform b [Homo sapiens]; gelsolin isoform b [Homo sapiens] Protein Accession gi|4504165 gi|38044288 gi|89083782 gi|89083780 gi|89083778 gi|189083776 gi|189083774

Mean Expression Ratio 0.776 Median Expression Ratio 0.777 Credible Interval (0.57, 1.05) Associated Peptides 5 Associated Spectra 6 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.56 0.8 1.2 SEQ ID NO: 547 AAQHGMDDDGTGQK 1 0.53 0.77 1.1 SEQ ID NO: 548 AQPVQVAEGSEPDGFWEALG GK 1 0.53 0.78 1.1 SEQ ID NO: 549 DSQEEEKTEALTSAK 1 0.49 0.73 1.1 SEQ ID NO: 550 NWQGAQSTQDEVAASAILTA QLDEELGGTPVQSR 1 0.52 0.77 1.1 SEQ ID NO: 551 TAQLDEELGGTPVQSR 5.58 vacuolar protein sorting 37B [Homo sapiens] Protein Accession gi|13375926

Mean Expression Ratio 1.29 Median Expression Ratio 1.28 Credible Interval (0.848, 1.94) Associated Peptides 1 Associated Spectra 3 Coverage 0.0912

A 2.5 50 97.5 Sequence ID No. Sequence 3 0. 93 1.4 2.0 SEQ ID NO: 552 LPELAPTAPLPYPAPEASG PPAVAPR SEQ ID NO: 553   1 MAGAGSEARFAGLSLVQLNELLEDEGQLTEMVQKMEETQNVQLN     KEMTLASNRSLAEGNLLYQPQLDTLKARLTQKYQEL  81 QVLFEAYQIKKTKLDRQSSSASLETLLALLQAEGAKIEEDTENM     AEKFLDGELPLDSFIDVYQSKRKLAHMRRVKIEKLQ 161 EMVLKGQRLPQALAPLPPRLPELAPTAPLPYPAPEASGPPAVAP     RRIPPPPPPVPAGRLATPFTAAMSSGQAVPYPGLQC 241 PPLPPRVGLPTQQGFSSQFVSPYPPPLPQRPPPRLPPHQPGFIL     Q 5.59 programmed cell death 6 interacting protein [Homo sapiens] Protein Accession gi|22027538

Mean Expression Ratio 1.28 Median Expression Ratio 1.28 Credible Interval (1.05, 1.57) Associated Peptides 12 Associated Spectra 20 Coverage 0.192

A 2.5 50 97.5 Sequence ID No. Sequence 2 1 1.3 1.8 SEQ ID NO: 554 EPSAPSIPTPAYQSSPAGGH APTPPTPAPR 1 0.9 1.3 1.7 SEQ ID NO: 555 FIQQTYPSGGEEQAQYCR 3 1 1.3 1.8 SEQ ID NO: 556 FLTALAQDGVINEEALSVTE LDR 2 0.97 1.3 1.8 SEQ ID NO: 557 FYNELTEILVR 1 0.92 1.3 1.7 SEQ ID NO: 558 HEGALETLLR 2 0.93 1.3 1.7 SEQ ID NO: 559 LQHAAELIK 1 0.93 1.3 1.8 SEQ ID NO: 560 NIQVSHQEFSK 3 0.98 1.3 1.7 SEQ ID NO: 561 NLATAYDNFVELVANLK 2 0.97 1.3 1.8 SEQ ID NO: 562 SVIEQGGIQTVDQLIK 1 0.88 1.2 1.7 SEQ ID NO: 563 FTDLFEK 1 0.95 1.3 1.8 SEQ ID NO: 564 KQEGLLK 1 0.91 1.3 1.7 SEQ ID NO: 565 YDEYVNVK SEQ ID NO: 566   1 MATFISVQLKKTSEVDLAKPLVKFIQQTYPSGGEEQAQYCRAA     EELSKLRRAAVGRPLDKHEGALETLLRYYDQICSIEP  81 KFPFSENQICLTFTWKDAFDKGSLFGGSVKLALASLGYEKSCV     LFNCAALASQIAAEQNLDNDEGLKIAAKHYQFASGAF 161 LHIKETVLSALSREPTVDISPDTVGTLSLIMLAQAQEVFFLKA     TRDKMKDAIIAKLANQAADYFGDAFKQCQYKDTLPKE 241 VFPVLAAKHCIMQANAEYHQSILAKQQKKFGEEIARLQHAAEL     IKTVASRYDEYVNVKDFSDKINRALAAAKKDNDFIYH 321 DRVPDLKDLDPIGKATLVKSTPVNVPISQKFTDLFEKMVPVSV     QQSLAAYNQRKADLVNRSIAQMREATTLANGVLASLN 401 LPAAIEDVSGDTVPQSILTKSRSVIEQGGIQTVDQLIKELPEL     LQRNREILDESLRLLDEEEATDNDLRAKFKERWQRTP 481 SNELYKPLRAEGTNFRTVLDKAVQADGQVKECYQSHRDTIVLL     CKPEPELNAAIPSANPAKTMQGSEVVNVLKSLLSNLD 561 EVKKEREGLENDLKSVNFDMTSKFLTALAQDGVINEEALSVTE     LDRVYGGLTTKVQESLKKQEGLLKNIQVSHQEFSKMK 641 QSNNEANLREEVLKNLATAYDNFVELVANLKEGTKFYNELTEI     LVRFQNKCSDIVFARKTERDELLKDLQQSIAREPSAP 721 SIPTPAYQSSPAGGHAPTPPTPAPRTMPPTKPQPPARPPPPVL     PANRAPSATAPSPVGAGTAAPAPSQTPGSAPPPQAQG 801 PPYPTYPGYPGYCQMPMPMGYNPYAYGQYNMPYPPVYHQSPGQ     APYPGPQQPSYPFPQPPQQSYYPQQ 5.60 prosaposin isoform a preproprotein [Homo sapiens] Protein Accession gi|11386147

Mean Expression Ratio 0.78 Median Expression Ratio 0.78 Credible Interval (0.587, 1.04) Associated Peptides 5 Associated Spectra 8 Coverage 0.0954

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.51 0.72 1.0 SEQ ID NO: 567 EIVDSYLPVILDIIK 1 0.55 0.8 1.2 SEQ ID NO: 568 GCSFLPDPYQK 1 0.55 0.79 1.1 SEQ ID NO: 569 LVGYLDR 3 0.55 0.77 1.1 SEQ ID NO: 570 QEILAALEK 1 0.54 0.78 1.1 SEQ ID NO: 571 SLPCDICK SEQ ID NO: 572   1 MYALFLLASLLGAALAGPVLGLKECTRGSAVWCQNVKTASD     CGAVKHCLQTVWNKPTVKSLPCDICKDVVTAAGDMLKDN  81 ATEEEILVYLEKTCDWLPKPNMSASCKEIVDSYLPVILDII     KGEMSRPGEVCSALNLCESLQKHLAELNHQKQLESNKIP 161 ELDMTEVVAPFMANIPLLLYPQDGPRSKPQPKDNGDVCQDC     IQMVTDIQTAVRTNSTFVQALVEHVKEECDRLGPGMADI 241 CKNYISQYSEIAIQMMMHMQPKEICALVGFCDEVKEMPMQT     LVPAKVASKNVIPALELVEPIKKHEVPAKSDVYCEVCEF 321 LVKEVTKLIDNNKTEKEILDAFDKMCSKLPKSLSEECQEVV     DTYGSSILSILLEEVSPELVCSMLHLCSGTRLPALTVHV 401 TQPKDGGFCEVCKKLVGYLDRNLEKNSTKQEILAALEKGCS     FLPDPYQKQCDQFVAEYEPVLIEILVEVMDPSFVCLKIG 481 ACPSAHKPLLGTEKCIWGPSYWCQNTETAAQCNAVEHCKRH     VWN 5.61 ferritin, light polypeptide [Homo sapiens] Protein Accession gi|20149498

Mean Expression Ratio 1.28 Median Expression Ratio 1.28 Credible Interval (1.11, 1.47) Associated Peptides 16 Associated Spectra 66 Coverage 0.634

A 2.5 50 97.5 Sequence ID No. Sequence  1 0.97 1.3 1.7 SEQ ID NO: 573 AAMALEK  5 1.0 1.3 1.7 SEQ ID NO: 574 ALFQDIK  3 0.98 1.3 1.7 SEQ ID NO: 575 DDVALEGVSHFFR  3 0.93 1.2 1.6 SEQ ID NO: 576 DLHALGSAR  1 0.96 1.3 1.7 SEQ ID NO: 577 FDRDDVALEGVSHFFR  1 0.98 1.3 1.8 SEQ ID NO: 578 KLNQALLDLHALGSAR  3 1.0 1.3 1.7 SEQ ID NO: 579 KPAEDEWGK  4 0.92 1.2 1.5 SEQ ID NO: 580 LCDFLETHFLDEEVK 12 0.93 1.1 1.4 SEQ ID NO: 581 LGGPEAGLGEYLFER  1 1.0 1.4 1.9 SEQ ID NO: 582 LGGPEAGLGEYLFERLTLK  2 1.1 1.5 2.0 SEQ ID NO: 583 LGGPEAGLGEYLFERLTLK HD 12 1 1.2 1.5 SEQ ID NO: 584 LNQALLDLHALGSAR  1 0.96 1.3 1.7 SEQ ID NO: 585 MGDHLTNLHR  1 0.85 1.1 1.5 SEQ ID NO: 586 QALLDLHALGSAR 15 1.1 1.4 1.7 SEQ ID NO: 587 TDPHLCDFLETHFLDEEVK  1 0.96 1.3 1.7 SEQ ID NO: 588 ELAEEK SEQ ID NO: 589   1 MSSQIRQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVAL     EGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQ  81 DIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSARTDPH     LCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEA 161 GLGEYLFERLTLKHD 5.62 galectin 3 binding protein [Homo sapiens] Protein Accession gi|5031863

Mean Expression Ratio 1.28 Median Expression Ratio 1.28 Credible Interval (1.11, 1.48) Associated Peptides 19 Associated Spectra 57 Coverage 0.369

A 2.5 50 97.5 Sequence ID No. Sequence  3 1.0 1.3 1.8 SEQ ID NO: 590 AAFGQGSGPIMLDEVQCTGT EASLADCK  2 0.93 1.2 1.6 SEQ ID NO: 591 ALMLCEGLFVADVTDFEGWK  3 1.0 1.3 1.7 SEQ ID NO: 592 ASHEEVEGLVEK 15 1.0 1.2 1.5 SEQ ID NO: 593 ELSEALGQIFDSQR  8 0.96 1.2 1.5 SEQ ID NO: 594 GQWGTVCDNLWDLTDASVVC R  1 0.95 1.3 1.7 SEQ ID NO: 595 IDITLSSVK  1 0.92 1.2 1.7 SEQ ID NO: 596 IYTSPTWSAFVTDSSWSAR  1 0.95 1.3 1.7 SEQ ID NO: 597 QSFQTPQHPSFL  3 1.0 1.3 1.8 SEQ ID NO: 598 QSFQTPQHPSFLFQDK  3 1 1.3 1.7 SEQ ID NO: 599 QTPQHPSFLFQDK  1 0.94 1.3 1.7 SEQ ID NO: 600 RIDITLSSVK  2 0.96 1.3 1.7 SEQ ID NO: 601 SDLAVPSELALLK  6 1.2 1.5 1.9 SEQ ID NO: 602 STSSFPCPAGHFNGFR  1 0.97 1.3 1.8 SEQ ID NO: 603 TIAYENK  1 0.97 1.3 1.7 SEQ ID NO: 604 TLQALEFHTVPF  1 0.92 1.3 1.7 SEQ ID NO: 605 VADVTDFEGWK  2 0.92 1.2 1.6 SEQ ID NO: 606 WSHEALFQK  2 0.9 1.2 1.6 SEQ ID NO: 607 YSSDYFQAPSDYR  1 0.96 1.3 1.8 SEQ ID NO: 608 VEIFYR SEQ ID NO: 609   1 MTPPRLFWVWLLVAGTQGVNDGDMRLADGGATNQGRVEIFYRGQW     GTVCDNLWDLTDASVVCRALGFENATQALGRAAFG  81 QGSGPIMLDEVQCTGTEASLADCKSLGWLKSNCRHERDAGVVCTN     ETRSTHTLDLSRELSEALGQIFDSQRGCDLSISVN 161 VQGEDALGFCGHTVILTANLEAQALWKEPGSNVTMSVDAECVPMV     RDLLRYFYSRRIDITLSSVKCFHKLASAYGARQLQ 241 GYCASLFAILLPQDPSFQMPLDLYAYAVATGDALLEKLCLQFLAW     NFEALTQAEAWPSVPTDLLQLLLPRSDLAVPSELA 321 LLKAVDTWSWGERASHEEVEGLVEKIRFPMMLPEELFELQFNLSL     YWSHEALFQKKTLQALEFHTVPFQLLARYKGLNLT 401 EDTYKPRIYTSPTWSAFVTDSSWSARKSQLVYQSRRGPLVKYSSD     YFQAPSDYRYYPYQSFQTPQHPSFLFQDKRVSWSL 481 VYLPTIQSCWNYGFSCSSDELPVLGLTKSGGSDRTIAYENKALML     CEGLFVADVTDFEGWKAAIPSALDTNSSKSTSSFP 561 CPAGHFNGFRTVIRPFYLTNSSGVD 5.63 peptidoglycan recognition protein 1 [Homo sapiens] Protein Accession gi|4827036

Mean Expression Ratio 0.784 Median Expression Ratio 0.786 Credible Interval (0.55, 1.12) Associated Peptides 3 Associated Spectra 4 Coverage 0.276

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.51 0.77 1.2 SEQ ID NO: 610 AAQGLLACGVAQGALR 2 0.52 0.76 1.1 SEQ ID NO: 611 ALASECAQHLSLPLR 1 0.51 0.77 1.2 SEQ ID NO: 612 TLGWCDVGYNFLIGEDGLVY EGR SEQ ID NO: 613   1 MSRRSMLLAWALPSLLRLGAAQETEDPACCSPIVPRNEWKALAS     ECAQHLSLPLRYVVVSHTAGSSCNTPASCQQQARNV  81 QHYHMKTLGWCDVGYNFLIGEDGLVYEGRGWNFTGAHSGHLWNP     MSIGISFMGNYMDRVPTPQAIRAAQGLLACGVAQGA 161 LRSNYVLKGHRDVQRTLSPGNQLYHLIQNWPHYRSP 5.64 ubiquitin and ribosomal protein S27a precursor [Homo sapiens]; ubiquitin and ribosomal protein S27a precursor [Homo sapiens] Protein Accession gi|4506713 gi|208022622

Mean Expression Ratio 1.27 Median Expression Ratio 1.27 Credible Interval (0.99, 1.64) Associated Peptides 5 Associated Spectra 12 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.95 1.3 1.8 SEQ ID NO: 614 ESTLHLVLR 4 1.0 1.4 1.8 SEQ ID NO: 615 TITLEVEPSDTIENVK 1 0.9 1.3 1.9 SEQ ID NO: 616 TLSDYNIQK 1 0.9 1.3 1.8 SEQ ID NO: 617 LIFAGK 3 0.89 1.2 1.7 SEQ ID NO: 618 MQIFVK 5.65 complement component 4A preproprotein [Homo sapiens] Protein Accession gi|67190748

Mean Expression Ratio 0.787 Median Expression Ratio 0.786 Credible Interval (0.511, 1.21) Associated Peptides 1 Associated Spectra 2 Coverage 0.0115

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.48 0.74 1.2 SEQ ID NO: 619 LLSQQQADGSFQDPCPVLDR SEQ ID NO: 620    1 MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQL      QDVPRGQVVKGSVFLRNPSRNNVPCSPKVDFTLSSER   81 DFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDSLSR      TTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRV  161 FALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQDDFV      IPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPN  241 FEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVR      FGLLDEDGKKTFFRGLESQTKLVNGQSHISLSKAEFQ  321 DALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSWYFV      SSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG  401 IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISE      LQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDS  481 RPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPK      RTLTSVSVFVDHHLAPSFYFVAFYYHGDHPVANSLRV  561 DVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVALGA      LDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGG  641 DSALQVFQAAGLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNF      QKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRA  721 ARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQE      EDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP  801 DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSV      RRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGG  881 GGLAQQVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPV      GDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEI  961 PGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL      LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPE 1041 TKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVL      KVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDP 1121 CPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEP      LKQRVEASISKANSFLGEKASAGLLGAHAAAITAYAL 1201 TLTKAPVDLLGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSP      TPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAE 1281 MADQASAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASHTTE      ERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQF 1361 SLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTV      KGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTP 1441 LQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGM      AIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGP 1521 HVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPE      RRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRR 1601 ALERGLQDEDGYRMKFACYYPRVEYGFQVKVLREDSRAAFRLF      ETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPG 1681 KEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQ      RAACAQLNDFLQEYGTQGCQV 5.66 hypothetical protein LOC169693 [Homo sapiens] Protein Accession gi|23397518

Mean Expression Ratio 0.788 Median Expression Ratio 0.788 Credible Interval (0.572, 1.07) Associated Peptides 3 Associated Spectra 8 Coverage 0.282

A 2.5 50 97.5 Sequence ID No. Sequence 6 0.56 0.75 1 SEQ ID NO: 621 ESIAGLVVTAISEDAQR 1 0.52 0.77 1.1 SEQ ID NO: 622 QHLAHGALPVATVDRPDF YPPAYEESLEVEK 1 0.53 0.8 1.2 SEQ ID NO: 623 QHLAHGALPVATVDRPDF SEQ ID NO: 624   1 MQNRTGLILCALALLMGFLMVCLGAFFISWGSIFDCQGSLIAA     YLLLPLGFVILLSGIFWSNYRQVTESKGVLRHMLRQH  81 LAHGALPVATVDRPDFYPPAYEESLEVEKQSCPAEREASGIPP     PLYTETGLEFQDGNDSHPEAPPSYRESIAGLVVTAIS 161 EDAQRRGQEC 5.67 nidogen 1 precursor [Homo sapiens] Protein Accession gi|115298674

Mean Expression Ratio 0.79 Median Expression Ratio 0.788 Credible Interval (0.513, 1.22) Associated Peptides 1 Associated Spectra 2 Coverage 0.0217

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.48 0.75 1.2 SEQ ID NO: 625 GPGQGDLELEDGDDFVSPALE LSGALR SEQ ID NO: 626    1 MLASSSRIRAAWTRALLLPLLLAGPVGCLSRQELFPFGPGQGDL      ELEDGDDFVSPALELSGALRFYDRSDIDAVYVTTNG   81 IIATSEPPAKESHPGLFPPTFGAVAPFLADLDTTDGLGKVYYRE      DLSPSITQRAAECVHRGFPEISFQPSSAVVVTWESV  161 APYQGPSRDPDQKGKRNTFQAVLASSDSSSYAIFLYPEDGLQFH      TTFSKKENNQVPAVVAFSQGSVGFLWKSNGAYNIFA  241 NDRESVENLAKSSNSGQQGVWVFEIGSPATTNGVVPADVILGTE      DGAEYDDEDEDYDLATTRLGLEDVGTTPFSYKALRR  321 GGADTYSVPSVLSPRRAATERPLGPPTERTRSFQLAVETFHQQH      PQVIDVDEVEETGVVFSYNTDSRQTCANNRHQCSVH  401 AECRDYATGFCCSCVAGYTGNGRQCVAEGSPQRVNGKVKGRIFV      GSSQVPIVFENTDLHSYVVMNHGRSYTAISTIPETV  481 GYSLLPLAPVGGIIGWMFAVEQDGFKNGFSITGGEFTRQAEVTF      VGHPGNLVIKQRFSGIDEHGHLTIDTELEGRVPQIP  561 FGSSVHIEPYTELYHYSTSVITSSSTREYTVTEPERDGASPSRI      YTYQWRQTITFQECVHDDSRPALPSTQQLSVDSVFV  641 LYNQEEKILRYALSNSIGPVREGSPDALQNPCYIGTHGCDTNAA      CRPGPRTQFTCECSIGFRGDGRTCYDIDECSEQPSV  721 CGSHTICNNHPGTFRCECVEGYQFSDEGTCVAVVDQRPINYCET      GLHNCDIPQRAQCIYTGGSSYTCSCLPGFSGDGQAC  801 QDVDECQPSRCHPDAFCYNTPGSFTCQCKPGYQGDGFRCVPGEV      EKTRCQHEREHILGAAGATDPQRPIPPGLFVPECDA  881 HGHYAPTQCHGSTGYCWCVDRDGREVEGTRTRPGMTPPCLSTVA      PPIHQGPAVPTAVIPLPPGTHLLFAQTGKIERLPLE  961 GNTMRKTEAKAFLHVPAKVIIGLAFDCVDKMVYWTDITEPSIGR      ASLHGGEPTTIIRQDLGSPEGIAVDHLGRNIFWTDS 1041 NLDRIEVAKLDGTQRRVLFETDLVNPRGIVTDSVRGNLYWTDWN      RDNPKIETSYMDGTNRRILVQDDLGLPNGLTFDAFS 1121 SQLCWVDAGTNRAECLNPSQPSRRKALEGLQYPFAVTSYGKNLY      FTDWKMNSVVALDLAISKETDAFQPHKQTRLYGITT 1201 ALSQCPQGHNYCSVNNGGCTHLCLATPGSRTCRCPDNTLGVDCI      EQK 5.68 CD9 antigen [Homo sapiens] Protein Accession gi|4502693

Mean Expression Ratio 1.27 Median Expression Ratio 1.27 Credible Interval (0.856, 1.88) Associated Peptides 2 Associated Spectra 3 Coverage 0.0921

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.91 1.4 2.1 SEQ ID NO: 627 EVQEFYK 1 0.8 1.2 2.0 SEQ ID NO: 628 AGGVEQFISDICPK SEQ ID NO: 629   1 MPVKGGTKCIKYLLFGFNFIFWLAGIAVLAIGLWLRFDSQT     KSIFEQETNNNNSSFYTGVYILIGAGALMMLVGFLGCCG  81 AVQESQCMLGLFFGFLLVIFAIEIAAAIWGYSHKDEVIKEV     QEFYKDTYNKLKTKDEPQRETLKAIHYALNCCGLAGGVE 161 QFISDICPKKDVLETFTVKSCPDAIKEVFDNKFHIIGAVGI     GIAVVMIFGMIFSMILCCAIRRNREMV 5.69 solute carrier family 5 (sodium/glucose cotransporter), member 10 isoform 2 [Homo sapiens] Protein Accession gi|109659836

Mean Expression Ratio 0.79 Median Expression Ratio 0.79 Credible Interval (0.519, 1.22) Associated Peptides 2 Associated Spectra 2 Coverage 0.047

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.47 0.76 1.2 SEQ ID NO: 630 ALFPDDVGCVVPSECLR 1 0.48 0.78 1.2 SEQ ID NO: 631 LVMELMPIGLR SEQ ID NO: 632   1 MAANSTSDLHTPGTQLSVADIIVITVYFALNVAVGIWSSCR     ASRNTVNGYFLAGRDMTWWPIGASLFASSEGSGLFIGLA  81 GSGAAGGLAVAGFEWNATYVLLALAWVFVPIYISSEIVTLP     EYIQKRYGGQRIRMYLSVLSLLLSVFTKISLDLYAGALF 161 VHICLGWNFYLSTILTLGITALYTIAGGLAAVIYTDALQTL     IMVVGAVILTIKAFDQIGGYGQLEAAYAQAIPSRTIANT 241 TCHLPRTDAMHMFRDPHTGDLPWTGMTFGLTIMATWYWCTD     QVIVQRSLSARDLNHAKAGSILASYLKMLPMGLIIMPGM 321 ISRALFPDDVGCVVPSECLRACGAEVGCSNIAYPKLVMELM     PIGLRGLMIAVMLAALMSSLTSIFNSSSTLFTMDIWRRL 401 RPRSGERELLLVGRLVIVALIGVSVAWIPVLQDSNSGQLFI     YMQSVTSSLAPPVTAVFVLGVFWRRANEQGAFWGLIAGL 481 VVGATRLVLEFLNPAPPCGEPDTRPAVLGSIHYLHFAVALF     ALSGAVVVAGSLLTPPPQSVQIENLTWWTLAQDVPLGTK 561 AGDGQTPQKHAFWARVCGFNAILLMCVNIFFYAYFA 5.70 sorting nexin 18 isoform a [Homo sapiens]; sorting nexin 18 isoform b 30 [Homo sapiens]

Protein Accession gi 157057545 gi 157057543 Mean Expression Ratio 1.26 Median Expression Ratio 1.26 Credible Interval (0.82, 1.91) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.86 1.4 2.2 SEQ ID NO: 633 APEPGPAGDGGPGAPAR 1 0.78 1.2 2.0 SEQ ID NO: 634 LVPTHTQVPVHR 5.71 syntenin isoform 1 [Homo sapiens]; syntenin isoform 1 [Homo sapiens] Protein Accession gi|56243522 gi|55749490

Mean Expression Ratio 1.26 Median Expression Ratio 1.26 Credible Interval (0.87, 1.83) Associated Peptides 2 Associated Spectra 4 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.94 1.4 2.0 SEQ ID NO: 635 ANVAVVSGAPLQGQLVAR 1 0.82 1.2 1.9 SEQ ID NO: 636 VAVVSGAPLQGQLVAR 5.72 glutamyl aminopeptidase (aminopeptidase A) [Homo sapiens] Protein Accession gi|132814467

Mean Expression Ratio 0.795 Median Expression Ratio 0.794 Credible Interval (0.682, 0.932) Associated Peptides 25 Associated Spectra 39 Coverage 0.268

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.6 0.8 1.1 SEQ ID NO: 637 AQLLDYK 1 0.58 0.78 1.1 SEQ ID NO: 638 ASLIDDAFALAR 2 0.62 0.81 1.1 SEQ ID NO: 639 AVHQFDSVK 1 0.63 0.84 1.1 SEQ ID NO: 640 EESVDDKWTR 1 0.6 0.8 1.1 SEQ ID NO: 641 ETNLLYDPK 1 0.61 0.83 1.1 SEQ ID NO: 642 EYGALSNMPVAK 4 0.65 0.84 1.1 SEQ ID NO: 643 IAIPDFGTGAMENWGLI TYR 6 0.6 0.76 0.98 SEQ ID NO: 644 INPDHIGFYR 1 0.59 0.8 1.1 SEQ ID NO: 645 KSFPCFDEPNKK 1 0.59 0.8 1.1 SEQ ID NO: 646 LLYGLASVK 1 0.58 0.79 1.1 SEQ ID NO: 647 LPDFVNPVHY 1 0.57 0.77 1.0 SEQ ID NO: 648 NMAWNWIQLNWDYLVNR 1 0.58 0.79 1.1 SEQ ID NO: 649 NNIEWLK 1 0.61 0.83 1.1 SEQ ID NO: 650 QMGYPVLNVNGVK 1 0.57 0.77 1.1 SEQ ID NO: 651 SFPCFDEPNKK 1 0.56 0.75 1.0 SEQ ID NO: 652 SIVATDHEPTDAR 1 0.57 0.78 1.0 SEQ ID NO: 653 SSHPIIVTVTTPDEITS VFDGISY 3 0.57 0.75 0.99 SEQ ID NO: 654 TSDFWAALEEASR 1 0.61 0.82 1.1 SEQ ID NO: 655 TSDFWAALEEASRLPVK 2 0.62 0.82 1.1 SEQ ID NO: 656 YLWLHLR 3 0.58 0.77 1.0 SEQ ID NO: 657 YPQAGAGEKPR 1 0.58 0.8 1.1 SEQ ID NO: 658 MLEDWIKPENFQK 1 0.58 0.78 1.1 SEQ ID NO: 659 IQLNWDYLVNR 1 0.57 0.77 1.0 SEQ ID NO: 660 YLDLLK 1 0.58 0.78 1.1 SEQ ID NO: 661 QMESFFAK SEQ ID NO: 662   1 MNFAEREGSKRYCIQTKHVAILCAVVVGVGLIVGLAVGLTRSCD     SSGDGGPGTAPAPSHLPSSTASPSGPPAQDQDICPA  81 SEDESGQWKNFRLPDFVNPVHYDLHVKPLLEEDTYTGTVSISIN     LSAPTRYLWLHLRETRITRLPELKRPSGDQVQVRRC 161 FEYKKQEYVVVEAEEELTPSSGDGLYLLTMEFAGWLNGSLVGFY     RTTYTENGQVKSIVATDHEPTDARKSFPCFDEPNKK 241 ATYTISITHPKEYGALSNMPVAKEESVDDKWTRTTFEKSVPMST     YLVCFAVHQFDSVKRISNSGKPLTIYVQPEQKHTAE 321 YAANITKSVFDYFEEYFAMNYSLPKLDKIAIPDFGTGAMENWGL     ITYRETNLLYDPKESASSNQQRVATVVAHELVHQWF 401 GNIVTMDWWEDLWLNEGFASFFEFLGVNHAETDWQMRDQMLLED     VLPVQEDDSLMSSHPIIVTVTTPDEITSVFDGISYS 481 KGSSILRMLEDWIKPENFQKGCQMYLEKYQFKNAKTSDFWAALE     EASRLPVKEVMDTWTRQMGYPVLNVNGVKNITQKRF 561 LLDPRANPSQPPSDLGYTWNIPVKWTEDNITSSVLFNRSEKEGI     TLNSSNPSGNAFLKINPDHIGFYRVNYEVATWDSIA 641 TALSLNHKTFSSADRASLIDDAFALARAQLLDYKVALNLTKYLK     REENFLPWQRVISAVTYIISMFEDDKELYPMIEEYF 721 QGQVKPIADSLGWNDAGDHVTKLLRSSVLGFACKMGDREALNNA     SSLFEQWLNGTVSLPVNLRLLVYRYGMQNSGNEISW 801 NYTLEQYQKTSLAQEKEKLLYGLASVKNVTLLSRYLDLLKDTNL     IKTQDVFTVIRYISYNSYGKNMAWNWIQLNWDYLVN 881 RYTLNNRNLGRIVTIAEPFNTELQLWQMESFFAKYPQAGAGEKP     REQVLETVKNNIEWLKQHRNTIREWFFNLLESG 5.73 histone cluster 2, H4b [Homo sapiens]; histone cluster 2, H4a [Homo sapiens]; histone cluster 1, H4i [Homo sapiens]; histone cluster 1, H41 [Homo sapiens]; histone cluster 1, H4e [Homo sapiens]; histone cluster 1, H4b [Homo sapiens]; histone cluster 1, H4h [Homo sapiens]; histone cluster 1, H4c [Homo sapiens]; histone cluster 1, H4k [Homo sapiens]; histone cluster 1, H4f [Homo sapiens]; histone cluster 1, H4d [Homo sapiens]; histone cluster 1, H4a [Homo sapiens]; histone cluster 4, H4 [Homo sapiens]; histone cluster 1, H4j [Homo sapiens] Protein Accession gi|77539758 gi|4504323 gi|4504321 gi|4504317 gi|4504315 gi|4504313 gi|4504311 gi|4504309

Mean Expression Ratio 0.791 Median Expression Ratio 0.794 Credible Interval (0.489, 1.26) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.45 0.75 1.3 SEQ ID NO: 663 VFLENVIR 5.74 guanine nucleotide binding protein (G protein), q polypeptide [Homo sapiens] Protein Accession gi|40254462

Mean Expression Ratio 1.25 Median Expression Ratio 1.26 Credible Interval (0.847, 1.88) Associated Peptides 2 Associated Spectra 3 Coverage 0.0947

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.86 1.3 1.9 SEQ ID NO: 664 VADPAYLPTQQDVLR 1 0.83 1.3 2 SEQ ID NO: 665 VPTTGIIEYPFDLQSVIFR SEQ ID NO: 666   1 MTLESIMACCLSEEAKEARRINDEIERQLRRDKRDARRELKL     LLLGTGESGKSTFIKQMRIIHGSGYSDEDKRGFTKLVY  81 QNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKVS     AFENPYVDAIKSLWNDPGIQECYDRRREYQLSDSTKYY 161 LNDLDRVADPAYLPTQQDVLRVRVPTTGIIEYPFDLQSVIFR     MVDVGGQRSERRKWIHCFENVTSIMFLVALSEYDQVLV 241 ESDNENRMEESKALFRTIITYPWFQNSSVILFLNKKDLLEEK     IMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDS 321 DKIIYSHFTCATDTENIRFVFAAVKDTILQLNLKEYNLV 5.75 syndecan 1 precursor [Homo sapiens]; syndecan 1 precursor [Homo sapiens] Protein Accession gi|55749480 gi|29568086

Mean Expression Ratio 0.797 Median Expression Ratio 0.795 Credible Interval (0.536, 1.19) Associated Peptides 2 Associated Spectra 3 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.49 0.74 1.1 SEQ ID NO: 667 EGEAVVLPEVEPGLTAR 1 0.52 0.8 1.3 SEQ ID NO: 668 NQSPVDQGATGASQGLLDR 5.76 copine III [Homo sapiens] Protein Accession gi|4503015

Mean Expression Ratio 1.26 Median Expression Ratio 1.26 Credible Interval (0.877, 1.80) Associated Peptides 3 Associated Spectra 4 Coverage 0.0782

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.9 1.3 1.9 SEQ ID NO: 669 DIVQFVPFR 1 0.83 1.3 1.9 SEQ ID NO: 670 LYGPTNFSPIINHVAR 1 0.82 1.3 1.9 SEQ ID NO: 671 VLLIITDGVITDLDETR SEQ ID NO: 672   1 MAAQCVTKVALNVSCANLLDKDIGSKSDPLCVLFLNTSGQQ     WYEVERTERIKNCLNPQFSKTFIIDYYFEVVQKLKFGVY  81 DIDNKTIELSDDDFLGECECTLGQIVSSKKLTRPLVMKTGR     PAGKGSITISAEEIKDNRVVLFEMEARKLDNKDLFGKSD 161 PYLEFHKQTSDGNWLMVHRTEVVKNNLNPVWRPFKISLNSL     CYGDMDKTIKVECYDYDNDGSHDLIGTFQTTMTKLKEAS 241 RSSPVEFECINEKKRQKKKSYKNSGVISVKQCEITVECTFL     DYIMGGCQLNFTVGVDFTGSNGDPRSPDSLHYISPNGVN 321 EYLTALWSVGLVIQDYDADKMFPAFGFGAQIPPQWQVSHEF     PMNFNPSNPYCNGIQGIVEAYRSCLPQIKLYGPTNFSPI 401 INHVARFAAAATQQQTASQYFVLLIITDGVITDLDETRQAI     VNASRLPMSIIIVGVGGADFSAMEFLDGDGGSLRSPLGE 481 VAIRDIVQFVPFRQFQNAPKEALAQCVLAEIPQQVVGYFNT     YKLLPPKNPATKQQKQ 5.77 annexin VII isoform 2 [Homo sapiens]; annexin VII isoform 1 [Homo sapiens] Protein Accession gi|4809279 gi|4502111

Mean Expression Ratio 1.26 Median Expression Ratio 1.26 Credible Interval (0.897, 1.79) Associated Peptides 3 Associated Spectra 5 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.9 1.3 1.8 SEQ ID NO: 673 DENQSINHQMAQEDAQR 1 0.86 1.3 2 SEQ ID NO: 674 GFGTDEQAIVDVVANR 1 0.83 1.3 1.9 SEQ ID NO: 675 VLIEILCTR 5.78 cubilin [Homo sapiens] Protein Accession gi|126091152

Mean Expression Ratio 0.798 Median Expression Ratio 0.798 Credible Interval (0.637, 1.01) Associated Peptides 10 Associated Spectra 14 Coverage 0.0461

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.56  0.79  1.1 SEQ ID NO: 676 CNFDVLEIYGGPDFHSPR 4 0.56  0.75  1 SEQ ID NO: 677 DFVEILDGGHEDAPLR 1 0.58  0.81  1.1 SEQ ID NO: 678 EQLANPIVSSGNSLFLR 1 0.57  0.8  1.1 SEQ ID NO: 679 LQVLLLTDGVGR 1 0.57  0.8  1.1 SEQ ID NO: 680 NGGSPESPIIGQYCGNSNPR 2 0.58  0.78  1.1 SEQ ID NO: 681 SPENPMQVSSTGNELAIR 1 0.57  0.8  1.1 SEQ ID NO: 682 SPFFPNVYPGER 1 0.55  0.78  1.1 SEQ ID NO: 683 VPGQSGVVESIGHPTLPYR 1 0.57  0.8  1.1 SEQ ID NO: 684 LNDEDLSECLHQIQK 1 0.59  0.82  1.2 SEQ ID NO: 685 YCGNTIPDSIDTSSNTAVVR SEQ ID NO: 686    1 M M N M S L P F L W S L L T L L I F A E V N      G E A G E L E L Q R Q K R S I N L Q Q P R M      A T E R G N L V F L T G S A Q N I E F R T G      S L G K I K L N D E D L S E   81 C L H Q I Q K N K E D I I E L K G S A I G L      P Q N I S S Q I Y Q L N S K L V D L E R K F      Q G L Q Q T V D K K V C S S N P C Q N G G T      C L N L H D S F F C I C P P  161 Q W K G P L C S A D V N E C E I Y S G T P L      S C Q N G G T C V N T M G S Y S C H C P P E      T Y G P Q C A S K Y D D C E G G S V A R C V      H G I C E D L M R E Q A G E  241 P K Y S C V C D A G W M F S P N S P A C T L      D R D E C S F Q P G P C S T L V Q C F N T Q      G S F Y C G A C P T G W Q G N G Y I C E D I      N E C E I N N G G C S V A P  321 P V E C V N T P G S S H C Q A C P P G Y Q G      D G R V C T L T D I C S V S N G G C H P D A      S C S S T L G S L P L C T C L P G Y T G N G      Y G P N G C V Q L S N I C L  401 S H P C L N G Q C I D T V S G Y F C K C D S      G W T G V N C T E N I N E C L S N P C L N G      G T C V D G V D S F S C E C T R L W T G A L      C Q V P Q Q V C G E S L S G  481 I N G S F S Y R S P D V G Y V H D V N C F W      V I K T E M G K V L R I T F T F F R L E S M      D N C P H E F L Q V Y D G D S S S A F Q L G      R F C G S S L P H E L L S S  561 D N A L Y F H L Y S E H L R N G R G F T V R      W E T Q Q P E C G G I L T G P Y G S I K S P      G Y P G N Y P P G R D C V W I V V T S P D L      L V T F T F G T L S L E H H  641 D D C N K D Y L E I R D G P L Y Q D P L L G      K F C T T F S V P P L Q T T G P F A R I H F      H S D S Q I S D Q G F H I T Y L T S P S D L      R C G G N Y T D P E G E L F  721 L P E L S G P F T H T R Q C V Y M M K Q P Q      G E Q I Q I N F T H V E L Q C Q S D S S Q N      Y I E V R D G E T L L G K V C G N G T I S H      I K S I T N S V W I R F K I  801 D A S V E K A S F R A V Y Q V A C G D E L T      G E G V I R S P F F P N V Y P G E R T C R W      T I H Q P Q S Q V I L L N F T V F E I G S S      A H C E T D Y V E I G S S S  881 I L G S P E N K K Y C G T D I P S F I T S V      Y N F L Y V T F V K S S S T E N H G F M A K      F S A E D L A C G E I L T E S T G T I Q S P      G H P N V Y P H G I N C T W  961 H I L V Q P N H L I H L M F E T F H L E F H      Y N C T N D Y L E V Y D T D S E T S L G R Y      C G K S I P P S L T S S G N S L M L V F V T      D S D L A Y E G F L I N Y E 1041 A I S A A T A C L Q D Y T D D L G T F T S P      N F P N N Y P N N W E C I Y R I T V R T G Q      L I A V H F T N F S L E E A I G N Y Y T D F      L E I R D G G Y E K S P L L 1121 G I F Y G S N L P P T I I S H S N K L W L K      F K S D Q I D T R S G F S A Y W D G S S T G      C G G N L T T S S G T F I S P N Y P M P Y Y      H S S E C Y W W L K S S H G 1201 S A F E L E F K D F H L E H H P N C T L D Y      L A V Y D G P S S N S H L L T Q L C G D E K      P P L I R S S G D S M F I K L R T D E G Q Q      G R G F K A E Y R Q T C E N 1281 V V I V N Q T Y G I L E S I G Y P N P Y S E      N Q H C N W T I R A T T G N T V N Y T F L A      F D L E H H I N C S T D Y L E L Y D G P R Q      M G R Y C G V D L P P P G S 1361 T T S S K L Q V L L L T D G V G R R E K G F      Q M Q W F V Y G C G G E L S G A T G S F S S      P G F P N R Y P P N K E C I W Y I R T D P G      S S I Q L T I H D F D V E Y 1441 H S R C N F D V L E I Y G G P D F H S P R I      A Q L C T Q R S P E N P M Q V S S T G N E L      A I R F K T D L S I N G R G F N A S W Q A V      T G G C G G I F Q A P S G E 1521 I H S P N Y P S P Y R S N T D C S W V I R V      D R N H R V L L N F T D F D L E P Q D S C I      M A Y D G L S S T M S R L A R T C G R E Q L      A N P I V S S G N S L F L R 1601 F Q S G P S R Q N R G F R A Q F R Q A C G G      H I L T S S F D T V S S P R F P A N Y P N N      Q N C S W I I Q A Q P P L N H I T L S F T H      F E L E R S T T C A R D F V 1681 E I L D G G H E D A P L R G R Y C G T D M P      H P I T S F S S A L T L R F V S D S S I S A      G G F H T T V T A S V S A C G G T F Y M A E      G I F N S P G Y P D I Y P P 1761 N V E C V W N I V S S P G N R L Q L S F I S      F Q L E D S Q D C S R D F V E I R E G N A T      G H L V G R Y C G N S F P L N Y S S I V G H      T L W V R F I S D G S G S G 1841 T G F Q A T F M K I F G N D N I V G T H G K      V A S P F W P E N Y P H N S N Y Q W T V N V      N A S H V V H G R I L E M D I E E I Q N C Y      Y D K L R I Y D G P S I H A 1921 R L I G A Y C G T Q T E S F S S T G N S L T      F H F Y S D S S I S G K G F L L E W F A V D      A P D G V L P T I A P G A C G G F L R T G D      A P V F L F S P G W P D S Y 2001 S N R V D C T W L I Q A P D S T V E L N I L      S L D I E S H R T C A Y D S L V I R D G D N      N L A Q Q L A V L C G R E I P G P I R S T G      E Y M F I R F T S D S S V T 2081 R A G F N A S F H K S C G G Y L H A D R G I      I T S P K Y P E T Y P S N L N C S W H V L V      Q S G L T I A V H F E Q P F Q I P N G D S S      C N Q G D Y L V L R N G P D 2161 I C S P P L G P P G G N G H F C G S H A S S      T L F T S D N Q M F V Q F I S D H S N E G Q      G F K I K Y E A K S L A C G G N V Y I H D A      D S A G Y V T S P N H P H N 2241 Y P P H A D C I W I L A A P P E T R I Q L Q      F E D R F D I E V T P N C T S N Y L E L R D      G V D S D A P I L S K F C G T S L P S S Q W      S S G E V M Y L R F R S D N 2321 S P T H V G F K A K Y S I A Q C G G R V P G      Q S G V V E S I G H P T L P Y R D N L F C E      W H L Q G L S G H Y L T I S F E D F N L Q N      S S G C E K D F V E I W D N 2401 H T S G N I L G R Y C G N T I P D S I D T S      S N T A V V R F V T D G S V T A S G F R L R      F E S S M E E C G G D L Q G S I G T F T S P      N Y P N P N P H G R I C E W 2481 R I T A P E G R R I T L M F N N L R L A T H      P S C N N E H V I V F N G I R S N S P Q L E      K L C S S V N V S N E I K S S G N T M K V I      F F T D G S R P Y G G F T A 2561 S Y T S S E D A V C G G S L P N T P E G N F      T S P G Y D G V R N Y S R N L N C E W T L S      N P N Q G N S S I S I H F E D F Y L E S H Q      D C Q F D V L E F R V G D A 2641 D G P L M W R L C G P S K P T L P L V I P Y      S Q V W I H F V T N E R V E H I G F H A K Y      S F T D C G G I Q I G D S G V I T S P N Y P      N A Y D S L T H C S S L L E 2721 A P Q G H T I T L T F S D F D I E P H T T C      A W D S V T V R N G G S P E S P I I G Q Y C      G N S N P R T I Q S G S N Q L V V T F N S D      H S L Q G G G F Y A T W N T 2801 Q T L G C G G I F H S D N G T I R S P H W P      Q N F P E N S R C S W T A I T H K S K H L E      I S F D N N F L I P S G D G Q C Q N S F V K      V W A G T E E V D K A L L A 2881 T G C G N V A P G P V I T P S N T F T A V F      Q S Q E A P A Q G F S A S F V S R C G S N F      T G P S G Y I I S P N Y P K Q Y D N N M N C      T Y V I E A N P L S V V L L 2961 T F V S F H L E A R S A V T G S C V N D G V      H I I R G Y S V M S T P F A T V C G D E M P      A P L T I A G P V L L N F Y S N E Q I T D F      G F K F S Y R I I S C G G V 3041 F N F S S G I I T S P A Y S Y A D Y P N D M      H C L Y T I T V S D D K V I E L K F S D F D      V V P S T S C S H D Y L A I Y D G A N T S D      P L L G K F C G S K R P P N 3121 V K S S N N S M L L V F K T D S F Q T A K G      W K M S F R Q T L G P Q Q G C G G Y L T G S      N N T F A S P D S D S N G M Y D K N L N C V      W I I I A P V N K V I H L T 3201 F N T F A L E A A S T R Q R C L Y D Y V K L      Y D G D S E N A N L A G T F C G S T V P A P      F I S S G N F L T V Q F I S D L T L E R E G      F N A T Y T I M D M P C G G 3281 T Y N A T W T P Q N I S S P N S S D P D V P      F S I C T W V I D S P P H Q Q V K I T V W A      L Q L T S Q D C T Q N Y L Q L Q D S P Q G H      G N S R F Q F C G R N A S A 3361 V P V F Y S S M S T A M V I F K S G V V N R      N S R M S F T Y Q I A D C N R D Y H K A F G      N L R S P G W P D N Y D N D K D C T V T L T      A P Q N H T I S L F F H S L 3441 G I E N S V E C R N D F L E V R N G S N S N      S P L L G K Y C G T L L P N P V F S Q N N E      L Y L R F K S D S V T S D R G Y E I I W T S      S P S G C G G T L Y G D R G 3521 S F T S P G Y P G T Y P N N T Y C E W V L V      A P A G R L V T I N F Y F I S I D D P G D C      V Q N Y L T L Y D G P N A S S P S S G P Y C      G G D T S I A P F V A S S N 3601 Q V F I K F H A D Y A R R P S A F R L T W D      S 5.79 guanine nucleotide binding protein (G protein), alpha 11 (Gq class) [Homo sapiens] Protein Accession gi|115511049

Mean Expression Ratio 1.25 Median Expression Ratio 1.25 Credible Interval (0.849, 1.85) Associated Peptides 2 Associated Spectra 3 Coverage 0.0947

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.8  1.2  1.9 SEQ ID  SHLVDYFPEFDGPQR NO: 687 2 0.88  1.3  2 SEQ ID  VPTTGIIEYPFDLENIIFR NO: 688 SEQ ID NO: 689   1 M T L E S M M A C C L S D E V K E S K R I N A     E I E K Q L R R D K R D A R R E L K L L L L G     T G E S G K S T F I K Q M R I I H G A G Y S E     E D K R G F T K L V Y  81 Q N I F T A M Q A M I R A M E T L K I L Y K Y     E Q N K A N A L L I R E V D V E K V T T F E H     Q Y V S A I K T L W E D P G I Q E C Y D R R R     E Y Q L S D S A K Y Y 161 L T D V D R I A T L G Y L P T Q Q D V L R V R     V P T T G I I E Y P F D L E N I I F R M V D V     G G Q R S E R R K W I H C F E N V T S I M F L     V A L S E Y D Q V L V 241 E S D N E N R M E E S K A L F R T I I T Y P W     F Q N S S V I L F L N K K D L L E D K I L Y S     H L V D Y F P E F D G P Q R D A Q A A R E F I     L K M F V D L N P D S 321 D K I I Y S H F T C A T D T E N I R F V F A A     V K D T I L Q L N L K E Y N L V 5.80 proteasome alpha 1 subunit isoform 2 [Homo sapiens]; proteasome alpha 1 subunit isoform 1 [Homo sapiens] Protein Accession gi|4506179 gi|23110935

Mean Expression Ratio 1.25 Median Expression Ratio 1.25 Credible Interval (0.869, 1.78) Associated Peptides 3 Associated Spectra 4 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 2 0.9  1.3  2.0 SEQ ID  DLEFTIYDDDDVSPFLEGLEER NO: 690 1 0.82  1.2  1.9 SEQ ID  ILHVDNHIGISIAGLTADAR NO: 691 1 0.84  1.3  1.9 SEQ ID  DLEFTIYDDDDVSPFLEGLEERPQR NO: 692 5.81 myeloperoxidase [Homo sapiens] Protein Accession gi|4557759

Mean Expression Ratio 0.805 Median Expression Ratio 0.805 Credible Interval (0.627, 1.04) Associated Peptides 9 Associated Spectra 11 Coverage 0.172

Sequence A 2.5 50 97.5 ID No. Sequence 2 0.55  0.78  1.1 SEQ ID  FCGLPQPETVGQLGTVLR NO: 693 1 0.56  0.8  1.1 SEQ ID  FPTDQLTPDQER NO: 694 2 0.56  0.78  1.1 SEQ ID  IGLDLPALNMQR NO: 695 1 0.56  0.8  1.1 SEQ ID  IVGAMVQIITYR NO: 696 1 0.57  0.83  1.2 SEQ ID  NIDIWMGGVSEPLK NO: 697 1 0.56  0.8  1.1 SEQ ID  NQINALTSFVDASMVYGSEEPLAR NO: 698 1 0.58  0.81  1.2 SEQ ID  QALAQISLPR NO: 699 1 0.55  0.79  1.1 SEQ ID  VVLEGGIDPILR NO: 700 1 0.57  0.81  1.2 SEQ ID  VGPLLACIIGTQFR NO: 701 SEQ ID NO: 702   1 M G V P F F S S L R C M V D L G P C W A G G L     T A E M K L L L A L A G L L A I L A T P Q P S     E G A A P A V L G E V D T S L V L S S M E E A     K Q L V D K A Y K E R  81 R E S I K Q R L R S G S A S P M E L L S Y F K     Q P V A A T R T A V R A A D Y L H V A L D L L     E R K L R S L W R R P F N V T D V L T P A Q L     N V L S K S S G C A Y 161 Q D V G V T C P E Q D K Y R T I T G M C N N R     R S P T L G A S N R A F V R W L P A E Y E D G     F S L P Y G W T P G V K R N G F P V A L A R A     V S N E I V R F P T D 241 Q L T P D Q E R S L M F M Q W G Q L L D H D L     D F T P E P A A R A S F V T G V N C E T S C V     Q Q P P C F P L K I P P N D P R I K N Q A D C     I P F F R S C P A C P 321 G S N I T I R N Q I N A L T S F V D A S M V Y     G S E E P L A R N L R N M S N Q L G L L A V N     Q R F Q D N G R A L L P F D N L H D D P C L L     T N R S A R I P C F L 401 A G D T R S S E M P E L T S M H T L L L R E H     N R L A T E L K S L N P R W D G E R L Y Q E A     R K I V G A M V Q I I T Y R D Y L P L V L G P     T A M R K Y L P T Y R 481 S Y N D S V D P R I A N V F T N A F R Y G H T     L I Q P F M F R L D N R Y Q P M E P N P R V P     L S R V F F A S W R V V L E G G I D P I L R G     L M A T P A K L N R Q 561 N Q I A V D E I R E R L F E Q V M R I G L D L     P A L N M Q R S R D H G L P G Y N A W R R F C     G L P Q P E T V G Q L G T V L R N L K L A R K     L M E Q Y G T P N N I 641 D I W M G G V S E P L K R K G R V G P L L A C     I I G T Q F R K L R D G D R F W W E N E G V F     S M Q Q R Q A L A Q I S L P R I I C D N T G I     T T V S K N N I F M S 721 N S Y P R D F V N C S T L P A L N L A S W R E     A S 5.82 solute carrier family 5 (iodide transporter), member 8 [Homo sapiens] Protein Accession gi|167466278

Mean Expression Ratio 0.808 Median Expression Ratio 0.806 Credible Interval (0.554, 1.18) Associated Peptides 2 Associated Spectra 4 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.54  0.84  1.3 SEQ ID  EDFLSNFDIFK NO: 703 3 0.51  0.74  1.1 SEQ ID  SHPVEDGGTDNPAFNHIELNSDQSGK NO: 704 5.83 ras homolog gene family, member C precursor [Homo sapiens]; ras homolog gene family, member C precursor [Homo sapiens]; ras homolog gene family, member C precursor [Homo sapiens]; ras homolog gene family, member A [Homo sapiens] Protein Accession gi|28395033 gi|11494251 gi|11494248 gi|0835049

Mean Expression Ratio 1.24 Median Expression Ratio 1.24 Credible Interval (0.815, 1.90) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.78  1.3  2 SEQ ID NO: 705 HFCPNVPIILVGNK 1 0.82  1.3  2.0 SEQ ID NO: 706 QVELALWDTAGQEDYDR 5.84 complement factor H isoform a precursor [Homo sapiens] Protein Accession gi|62739186

Mean Expression Ratio 0.806 Median Expression Ratio 0.807 Credible Interval (0.627, 1.04) Associated Peptides 8 Associated Spectra 10 Coverage 0.0812

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.56  0.8  1.1 SEQ ID NO: 707 EQVQSCGPPPELLNGNVK 2 0.55  0.76  1.0 SEQ ID NO: 708 KGEWVALNPLR 1 0.57  0.81  1.2 SEQ ID NO: 709 LIILEEHLK 1 0.55  0.78  1.1 SEQ ID NO: 710 RPYFPVAVGK 1 0.59  0.85  1.2 SEQ ID NO: 711 SCDNPYIPNGDYSPLR 2 0.57  0.79  1.1 SEQ ID NO: 712 SSNLIILEEHLK 1 0.58  0.83  1.2 SEQ ID NO: 713 TCNEGYQLLGEINYR 1 0.55  0.79  1.1 SEQ ID NO: 714 TDCLSLPSFENAIPMGEK SEQ ID NO: 715    1 M R L L A K I I C L M L W A I C V A E D C N      E L P P R R N T E I L T G S W S D Q T Y P E      G T Q A I Y K C R P G Y R S L G N V I M V C      R K G E W V A L N P L R K C   81 Q K R P C G H P G D T P F G T F T L T G G N      V F E Y G V K A V Y T C N E G Y Q L L G E I      N Y R E C D T D G W T N D I P I C E V V K C      L P V T A P E N G K I V S S  161 A M E P D R E Y H F G Q A V R F V C N S G Y      K I E G D E E M H C S D D G F W S K E K P K      C V E I S C K S P D V I N G S P I S Q K I I      Y K E N E R F Q Y K C N M G  241 Y E Y S E R G D A V C T E S G W R P L P S C      E E K S C D N P Y I P N G D Y S P L R I K H      R T G D E I T Y Q C R N G F Y P A T R G N T      A K C T S T G W I P A P R C  321 T L K P C D Y P D I K H G G L Y H E N M R R      P Y F P V A V G K Y Y S Y Y C D E H F E T P      S G S Y W D H I H C T Q D G W S P A V P C L      R K C Y F P Y L E N G Y N Q  401 N H G R K F V Q G K S I D V A C H P G Y A L      P K A Q T T V T C M E N G W S P T P R C I R      V K T C S K S S I D I E N G F I S E S Q Y T      Y A L K E K A K Y Q C K L G  481 Y V T A D G E T S G S I T C G K D G W S A Q      P T C I K S C D I P V F M N A R T K N D F T      W F K L N D T L D Y E C H D G Y E S N T G S      T T G S I V C G Y N G W S D  561 L P I C Y E R E C E L P K I D V H L V P D R      K K D Q Y K V G E V L K F S C K P G F T I V      G P N S V Q C Y H F G L S P D L P I C K E Q      V Q S C G P P P E L L N G N  641 V K E K T K E E Y G H S E V V E Y Y C N P R      F L M K G P N K I Q C V D G E W T T L P V C      I V E E S T C G D I P E L E H G W A Q L S S      P P Y Y Y G D S V E F N C S  721 E S F T M I G H R S I T C I H G V W T Q L P      Q C V A I D K L K K C K S S N L I I L E E H      L K N K K E F D H N S N I R Y R C R G K E G      W I H T V C I N G R W D P E  801 V N C S M A Q I Q L C P P P P Q I P N S H N      M T T T L N Y R D G E K V S V L C Q E N Y L      I Q E G E E I T C K D G R W Q S I P L C V E      K I P C S Q P P Q I E H G T  881 I N S S R S S Q E S Y A H G T K L S Y T C E      G G F R I S E E N E T T C Y M G K W S S P P      Q C E G L P C K S P P E I S H G V V A H M S      D S Y Q Y G E E V T Y K C F  961 E G F G I D G P A I A K C L G E K W S H P P      S C I K T D C L S L P S F E N A I P M G E K      K D V Y K A G E Q V T Y T C A T Y Y K M D G      A S N V T C I N S R W T G R 1041 P T C R D T S C V N P P T V Q N A Y I V S R      Q M S K Y P S G E R V R Y Q C R S P Y E M F      G D E E V M C L N G N W T E P P Q C K D S T      G K C G P P P P I D N G D I 1121 T S F P L S V Y A P A S S V E Y Q C Q N L Y      Q L E G N K R I T C R N G Q W S E P P K C L      H P C V I S R E I M E N Y N I A L R W T A K      Q K L Y S R T G E S V E F V 1201 C K R G Y R L S S R S H T L R T T C W D G K      L E Y P T C A K R 5.85 flotillin 1 [Homo sapiens] Protein Accession gi|5031699

Mean Expression Ratio 1.23 Median Expression Ratio 1.23 Credible Interval (0.95, 1.62) Associated Peptides 7 Associated Spectra 9 Coverage 0.234

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.88  1.2  1.8 SEQ ID NO: 716 AQQVAVQEQEIAR 1 0.88  1.3  1.8 SEQ ID NO: 717 DIHDDQDYLHSLGK 1 0.85  1.2  1.8 SEQ ID NO: 718 LPQVAEEISGPLTSANK 3 0.9  1.2  1.7 SEQ ID NO: 719 TEAEIAHIALETLEGHQR 1 0.87  1.3  1.8 SEQ ID NO: 720 VTGEVLDILTR 1 0.87  1.3  1.8 SEQ ID NO: 721 LTGVSISQVNHKPLR 1 0.83  1.2  1.7 SEQ ID NO: 722 VFVLPCIQQIQR SEQ ID NO: 723   1 M F F T C G P N E A M V V S G F C R S P P V M     V A G G R V F V L P C I Q Q I Q R I S L N T L     T L N V K S E K V Y T R H G V P I S V T G I A     Q V K I Q G Q N K E M  81 L A A A C Q M F L G K T E A E I A H I A L E T     L E G H Q R A I M A H M T V E E I Y K D R Q K     F S E Q V F K V A S S D L V N M G I S V V S Y     T L K D I H D D Q D Y 161 L H S L G K A R T A Q V Q K D A R I G E A E A     K R D A G I R E A K A K Q E K V S A Q Y L S E     I E M A K A Q R D Y E L K K A A Y D I E V N T     R R A Q A D L A Y Q L 241 Q V A K T K Q Q I E E Q R V Q V Q V V E R A Q     Q V A V Q E Q E I A R R E K E L E A R V R K P     A E A E R Y K L E R L A E A E K S Q L I M Q A     E A E A A S V R M R G 321 E A E A F A I G A R A R A E A E Q M A K K A E     A F Q L Y Q E A A Q L D M L L E K L P Q V A E     E I S G P L T S A N K I T L V S S G S G T M G     A A K V T G E V L D I 401 L T R L P E S V E R L T G V S I S Q V N H K P     L R T A 5.86 hypothetical protein LOC91894 [Homo sapiens] Protein Accession gi|131889517

Mean Expression Ratio 1.23 Median Expression Ratio 1.23 Credible Interval (0.786, 1.91) Associated Peptides 1 Associated Spectra 2 Coverage 0.122

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.83  1.3  2 SEQ ID NO: 724 TLKPQPQQLQQNLPK SEQ ID NO: 725  1 M G N R V C C G G S W S C P S T F Q K K K K T    G S Q T R R T L K P Q P Q Q L Q Q N L P K G H    E T T G H T Y E R V L Q Q Q G S Q E R S P G L    M S E D S N L H Y A D 81 I Q V C S R P H A R E V K H V H L E N A T E Y    A T L R F P Q A T P R Y D S K N G T L V 5.87 ring finger protein 152 [Homo sapiens] Protein Accession gi|27734873

Mean Expression Ratio 0.815 Median Expression Ratio 0.814 Credible Interval (0.506, 1.31) Associated Peptides 1 Associated Spectra 1 Coverage 0.143

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.46  0.77  1.3 SEQ ID  SVTVVTIPAEQQPLQGGAPQEAVEEE NO: 726 QDR SEQ ID NO: 727   1 M E T L S Q D S L L E C Q I C F N Y Y S P R R     R P K L L D C K H T C C S V C L Q Q M R T S Q     K D V R C P W C R G V T K L P P G F S V S Q L     P D D P E V L A V I A  81 I P H T S E H T P V F I K L P S N G C Y M L P     L P I S K E R A L L P G D M G C R L L P G S Q     Q K S V T V V T I P A E Q Q P L Q G G A P Q E     A V E E E Q D R R G V 161 V K S S T W S G V C T V I L V A C V L V F L L     G I V L H N M S C I S K R F T V I S C G 5.88 WIRE protein [Homo sapiens] Protein Accession gi|18959210

Mean Expression Ratio 1.22 Median Expression Ratio 1.23 Credible Interval (0.829, 1.8) Associated Peptides 2 Associated Spectra 3 Coverage 0.0841

Sequence A 2.5 50 97.5 ID No. Sequence 2 0.83  1.3  1.9 SEQ ID  QPPGVPNGPSSPTNESAPELPQR NO: 728 1 0.8  1.2  1.9 SEQ ID  TPAGPPPPPPPPLR NO: 729 SEQ ID NO: 730   1 M P I P P P P P P P P G P P P P P T F H Q A N     T E Q P K L S R D E Q R G R G A L L Q D I C K     G T K L K K V T N I N D R S A P I L E K P K G     S S G G Y G S G G A A  81 L Q P K G G L F Q G G V L K L R P V G A K D G     S E N L A G K P A L Q I P S S R A A A P R P P     V S A A S G R P Q D D T D S S R A S L P E L P     R M Q R P S L P D L S 161 R P N T T S S T G M K H S S S A P P P P P P G     R R A N A P P T P L P M H S S K A P A Y N R E     K P L P P T P G Q R L H P G R E G P P A P P P     V K P P P S P V N I R 241 T G P S G Q S L A P P P P P Y R Q P P G V P N     G P S S P T N E S A P E L P Q R H N S L H R K     T P G P V R G L A P P P P T S A S P S L L S N     R P P P P A R D P P S 321 R G A A P P P P P P V I R N G A R D A P P P P     P P Y R M H G S E P P S R G K P P P P P S R T     P A G P P P P P P P P L R N G H R D S I T T V     R S F L D D F E S K Y 401 S F H P V E D F P A P E E Y K H F Q R I Y P S     K T N R A A R G A P P L P P I L R 5.89 putative MAPK activating protein PM28 [Homo sapiens] Protein Accession gi|41281489

Mean Expression Ratio 1.22 Median Expression Ratio 1.22 Credible Interval (0.829, 1.77) Associated Peptides 3 Associated Spectra 3 Coverage 0.0833

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.79 1.2 1.9 SEQ ID NO: 731 LQSEVAELK 1 0.79 1.2 1.9 SEQ ID NO: 732 YLIEIAK 1 0.81 1.3 1.9 SEQ ID NO: 733 KEIADYLAAGKDER SEQ ID NO: 734 1 M L G S G F K A E R L R V N L R L V I N R L K L L E K K K T E L A Q K A R K E I A D Y L A A G K D E R A R I R V E H I I R E D Y L V E A M E I L E L Y C D L L L 81 A R F G L I Q S M K E L D S G L A E S V S T L I W A A P R L Q S E V A E L K I V A D Q L C A K Y S K E Y G K L C R T N Q I G T V N D R L M H K L S V E A P P K I 161 L V E R Y L I E I A K N Y N V P Y E P D S V V M A E A P P G V E T D L I D V G F T D D V K K G G P G R G G S G G F T A P V G G P D G T V P M P M P M P M P M P S 241 A N T P F S Y P L P K G P S D F N G L P M G T Y Q A F P N I H P P Q I P A T P P S Y E S M T L M L I R I S L L H R L L V L D P S Q K P L Q S F L P D L Q I T M T 321 T L S Y Q S C H L C Q T H Y Q L H L L V P A P Q H L K T L T L M I F P G G L K S 5.90 flotillin 2 [Homo sapiens] Protein Accession gi|94538362

Mean Expression Ratio 1.22 Median Expression Ratio 1.22 Credible Interval (0.969, 1.55) Associated Peptides 8 Associated Spectra 15 Coverage 0.238

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.87  1.2  1.7 SEQ ID NO: 735 ELLAVACEQFLGK 1 0.87  1.2  1.7 SEQ ID NO: 736 IGEAEAAVIEAMGK 7 1.0  1.3  1.7 SEQ ID NO: 737 NVVLQTLEGHLR 1 0.85  1.2  1.7 SEQ ID NO: 738 QIAVEAQEILR 1 0.89  1.2  1.7 SEQ ID NO: 739 SILGTLTVEQIYQDR 1 0.87  1.2  1.7 SEQ ID NO: 740 TAEAQLAYELQGAR 2 0.88  1.2  1.7 SEQ ID NO: 741 MALVLEALPQIAAK 1 0.84  1.2  1.7 SEQ ID NO: 742 RPAEAEAHR SEQ ID NO: 743   1 M G N C H T V G P N E A L V V S G G C C G S D     Y K Q Y V F G G W A W A W W C I S D T Q R I S     L E I M T L Q P R C E D V E T A E G V A L T V     T G V A Q V K I M T E  81 K E L L A V A C E Q F L G K N V Q D I K N V V     L Q T L E G H L R S I L G T L T V E Q I Y Q D     R D Q F A K L V R E V A A P D V G R M G I E I     L S F T I K D V Y D K 161 V D Y L S S L G K T Q T A V V Q R D A D I G V     A E A E R D A G I R E A E C K K E M L D V K F     M A D T K I A D S K R A F E L Q K S A F S E E     V N I K T A E A Q L A 241 Y E L Q G A R E Q Q K I R Q E E I E I E V V Q     R K K Q I A V E A Q E I L R T D K E L I A T V     R R P A E A E A H R I Q Q I A E G E K V K Q V     L L A Q A E A E K I R 321 K I G E A E A A V I E A M G K A E A E R M K L     K A E A Y Q K Y G D A A K M A L V L E A L P Q     I A A K I A A P L T K V D E I V V L S G D N S     K V T S E V N R L L A 401 E L P A S V H A L T G V D L S K I P L I K K A     T G V Q V 5.91 ephrin receptor EphA1 [Homo sapiens] Protein Accession gi|56119207

Mean Expression Ratio 0.819 Median Expression Ratio 0.821 Credible Interval (0.508, 1.33) Associated Peptides 1 Associated Spectra 1 Coverage 0.0184

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.46  0.78  1.3 SEQ ID NO: 744 APGEGPQVACTGPPSAPR SEQ ID NO: 745   1 M E R R W P L G L G L V L L L C A P L P P G A     R A K E V T L M D T S K A Q G E L G W L L D P     P K D G W S E Q Q Q I L N G T P L Y M Y Q D C     P M Q G R R D T D H W  81 L R S N W I Y R G E E A S R V H V E L Q F T V     R D C K S F P G G A G P L G C K E T F N L L Y     M E S D Q D V G I Q L R R P L F Q K V T T V A     A D Q S F T I R D L A 161 S G S V K L N V E R C S L G R L T R R G L Y L     A F H N P G A C V A L V S V R V F Y Q R C P E     T L N G L A Q F P D T L P G P A G L V E V A G     T C L P H A R A S P R 241 P S G A P R M H C S P D G E W L V P V G R C H     C E P G Y E E G G S G E A C V A C P S G S Y R     M D M D T P H C L T C P Q Q S T A E S E G A T     I C T C E S G H Y R A 321 P G E G P Q V A C T G P P S A P R N L S F S A     S G T Q L S L R W E P P A D T G G R Q D V R Y     S V R C S Q C Q G T A Q D G G P C Q P C G V G     V H F S P G A R G L T 401 T P A V H V N G L E P Y A N Y T F N V E A Q N     G V S G L G S S G H A S T S V S I S M G H A E     S L S G L S L R L V K K E P R Q L E L T W A G     S R P R S P G A N L T 481 Y E L H V L N Q D E E R Y Q M V L E P R V L L     T E L Q P D T T Y I V R V R M L T P L G P G P     F S P D H E F R T S P P V S R G L T G G E I V     A V I F G L L L G A A 561 L L L G I L V F R S R R A Q R Q R Q Q R Q R D     R A T D V D R E D K L W L K P Y V D L Q A Y E     D P A Q G A L D F T R E L D P A W L M V D T V     I G E G E F G E V Y R 641 G T L R L P S Q D C K T V A I K T L K D T S P     G G Q W W N F L R E A T I M G Q F S H P H I L     H L E G V V T K R K P I M I I T E F M E N G A     L D A F L R E R E D Q 721 L V P G Q L V A M L Q G I A S G M N Y L S N H     N Y V H R D L A A R N I L V N Q N L C C K V S     D F G L T R L L D D F D G T Y E T Q G G K I P     I R W T A P E A I A H 801 R I F T T A S D V W S F G I V M W E V L S F G     D K P Y G E M S N Q E V M K S I E D G Y R L P     P P V D C P A P L Y E L M K N C W A Y D R A R     R P H F Q K L Q A H L 881 E Q L L A N P H S L R T I A N F D P R M T L R     L P S L S G S D G I P Y R T V S E W L E S I R     M K R Y I L H F H S A G L D T M E C V L E L T     A E D L T Q M G I T L 961 P G H Q K R I L C S I Q G F K D 5.92 proteasome beta 3 subunit [Homo sapiens] Protein Accession gi|22538465

Mean Expression Ratio 1.22 Median Expression Ratio 1.22 Credible Interval (0.756, 1.98) Associated Peptides 1 Associated Spectra 1 Coverage 0.0878

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.77  1.3  2.2 SEQ ID NO: 746 LYIGLAGLATDVQTVAQR SEQ ID NO: 747   1 M S I M S Y N G G A V M A M K G K N C V A I A     A D R R F G I Q A Q M V T T D F Q K I F P M G     D R L Y I G L A G L A T D V Q T V A Q R L K F     R L N L Y E L K E G R  81 Q I K P Y T L M S M V A N L L Y E K R F G P Y     Y T E P V I A G L D P K T F K P F I C S L D L     I G C P M V T D D F V V S G T C A E Q M Y G M     C E S L W E P N M D P 161 D H L F E T I S Q A M L N A V D R D A V S G M     G V I V H I I E K D K I T T R T L K A R M D 5.93 cathepsin D preproprotein [Homo sapiens] Protein Accession gi|4503143

Mean Expression Ratio 0.826 Median Expression Ratio 0.824 Credible Interval (0.69, 0.984) Associated Peptides 15 Associated Spectra 29 Coverage 0.456

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.61  0.83  1.1 SEQ ID  AIGAVPLIQGEYMIPCEK NO: 748 1 0.61  0.83  1.1 SEQ ID  AYWQVHLDQVEVASGL NO: 749 4 0.63  0.82  1.1 SEQ ID  DPDAQPGGELMLGGTDSK NO: 750 5 0.6  0.78  1 SEQ ID  EGCEAIVDTGTSLMVGPVDEVR NO: 751 4 0.63  0.83  1.1 SEQ ID  ISVNNVLPVFDNLMQQK NO: 752 1 0.62  0.85  1.2 SEQ ID  LLDIACWIHHK NO: 753 1 0.6  0.82  1.1 SEQ ID  MVGPVDEVR NO: 754 1 0.61  0.84  1.2 SEQ ID  QVFGEATK NO: 755 2 0.65  0.87  1.2 SEQ ID  TVVFDTGSSNLWVPSIHCK NO: 756 1 0.6  0.83  1.1 SEQ ID  VSTLPAITLK NO: 757 2 0.6  0.8  1.1 SEQ ID  WILGDVFIGR NO: 758 3 0.6  0.8  1.1 SEQ ID  FDGILGMAYPR NO: 759 1 0.6  0.82  1.1 SEQ ID  AYWQVHLDQVEVASGLTLCK NO: 760 1 0.6  0.82  1.1 SEQ ID  VSQAGK NO: 761 1 0.6  0.83  1.1 SEQ ID  YSQAVPAVTEGPIPEVLK NO: 762 SEQ ID NO: 763   1 M Q P S S L L P L A L C L L A A P A S A L V R     I P L H K F T S I R R T M S E V G G S V E D L     I A K G P V S K Y S Q A V P A V T E G P I P E     V L K N Y M D A Q Y Y  81 G E I G I G T P P Q C F T V V F D T G S S N L     W V P S I H C K L L D I A C W I H H K Y N S D     K S S T Y V K N G T S F D I H Y G S G S L S G     Y L S Q D T V S V P C 161 Q S A S S A S A L G G V K V E R Q V F G E A T     K Q P G I T F I A A K F D G I L G M A Y P R I     S V N N V L P V F D N L M Q Q K L V D Q N I F     S F Y L S R D P D A Q 241 P G G E L M L G G T D S K Y Y K G S L S Y L N     V T R K A Y W Q V H L D Q V E V A S G L T L C     K E G C E A I V D T G T S L M V G P V D E V R     E L Q K A I G A V P L 321 I Q G E Y M I P C E K V S T L P A I T L K L G     G K G Y K L S P E D Y T L K V S Q A G K T L C     L S G F M G M D I P P P S G P L W I L G D V F     I G R Y Y T V F D R D 401 N N R V G F A E A A R L 5.94 hypothetical protein LOC58527 [Homo sapiens] Protein Accession gi|24308273

Mean Expression Ratio 0.824 Median Expression Ratio 0.827 Credible Interval (0.557, 1.22) Associated Peptides 2 Associated Spectra 3 Coverage 0.358

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.53  0.82  1.3 SEQ ID NO: 764 CANLFEALVGTLK 2 0.52  0.78  1.2 SEQ ID NO: 765 MNVDHEVNLLVEEIHR SEQ ID NO: 766  1 M N V D H E V N L L V E E I H R L G S K N A D G     K L S V K F G V L F R D D K C A N L F E A L V G    T L K A A K R R K I V T Y P G E L L L Q G V H D     D V D I I L L Q 81 D 5.95 annexin 5 [Homo sapiens] Protein Accession gi|4502107

Mean Expression Ratio 1.21 Median Expression Ratio 1.21 Credible Interval (0.82, 1.80) Associated Peptides 3 Associated Spectra 3 Coverage 0.141

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.78  1.2  1.8 SEQ ID  GTVTDFPGFDER NO: 767 1 0.78  1.2  1.9 SEQ ID  QEISAAFK NO: 768 1 0.83  1.3  2 SEQ ID  QVYEEEYGSSLEDDVVGDTSGYYQR NO: 769 SEQ ID NO: 770   1 M A Q V L R G T V T D F P G F D E R A D A E T     L R K A M K G L G T D E E S I L T L L T S R S     N A Q R Q E I S A A F K T L F G R D L L D D L     K S E L T G K F E K L  81 I V A L M K P S R L Y D A Y E L K H A L K G A     G T N E K V L T E I I A S R T P E E L R A I K     Q V Y E E E Y G S S L E D D V V G D T S G Y Y     Q R M L V V L L Q A N 161 R D P D A G I D E A Q V E Q D A Q A L F Q A G     E L K W G T D E E K F I T I F G T R S V S H L     R K V F D K Y M T I S G F Q I E E T I D R E T     S G N L E Q L L L A V 241 V K S I R S I P A Y L A E T L Y Y A M K G A G     T D D H T L I R V M V S R S E I D L F N I R K     E F R K N F A T S L Y S M I K G D T S G D Y K     K A L L L L C G E D D 5.96 carboxypeptidase M precursor [Homo sapiens]; carboxypeptidase M precursor [Homo sapiens]; carboxypeptidase M precursor [Homo sapiens] Protein Accession gi|6631081 gi|53832021 gi|38327526

Mean Expression Ratio 0.83 Median Expression Ratio 0.829 Credible Interval (0.535, 1.28) Associated Peptides 1 Associated Spectra 2 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 2 0.51  0.79  1.2 SEQ ID  GQVFDQNGNPLPNVIVEVQDR NO: 771 5.97 profilin 1 [Homo sapiens] Protein Accession gi|4826898

Mean Expression Ratio 0.829 Median Expression Ratio 0.83 Credible Interval (0.563, 1.23) Associated Peptides 3 Associated Spectra 3 Coverage 0.293

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.52  0.8  1.2 SEQ ID NO: 772 DSLLQDGEFSMDLR 1 0.52  0.83  1.3 SEQ ID NO: 773 EGVHGGLINKK 1 0.53  0.82  1.3 SEQ ID NO: 774 TFVNITPAEVGVLVGK SEQ ID NO: 775 1  M A G W N A Y I D N L M A D G T C Q D A A I V G    Y K D S P S V W A A V P G K T F V N I T P A E V    G V L V G K D R S S F Y V N G L T L G G Q K C S    V I R D S L L Q 81 D G E F S M D L R T K S T G G A P T F N V T V T    K T D K T L V L L M G K E G V H G G L I N K K C    Y E M A S H L R R S Q Y 5.98 cortactin isoform b [Homo sapiens]; cortactin isoform a [Homo sapiens] Protein Accession gi|20357556 gi|20357552

Mean Expression Ratio 1.2 Median Expression Ratio 1.20 Credible Interval (0.78, 1.81) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.76  1.2  1.9 SEQ ID NO: 776 GPVSGTEPEPVYSMEAADYR 1 0.77  1.2  2.0 SEQ ID NO: 777 TQTPPVSPAPQPTEER 5.99 solute carrier family 3, member 1 [Homo sapiens] Protein Accession gi|187423904

Mean Expression Ratio 0.833 Median Expression Ratio 0.832 Credible Interval (0.642, 1.09) Associated Peptides 8 Associated Spectra 10 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.56  0.8  1.1 SEQ ID  CLDWWQEGPMYQIYPR NO: 778 3 0.63  0.84  1.1 SEQ ID  EVDPIFGTMEDFENLVAAIHDK NO: 779 1 0.6  0.85  1.2 SEQ ID  FMGTEAYAESIDR NO: 780 1 0.58  0.82  1.2 SEQ ID  LIIDFIPNHTSDK NO: 781 1 0.59  0.84  1.2 SEQ ID  LYQDLSLLHANELLLNR NO: 782 1 0.57  0.81  1.2 SEQ ID  TQIPDTVTQYSELYHDFTTTQVGMHD NO: 783 IVR 1 0.58  0.82  1.2 SEQ ID  WPNWMIGGPDSSR NO: 784 1 0.59  0.84  1.2 SEQ ID  FLLEAK NO: 785 5.100 cell division cycle 42 isoform 1 [Homo sapiens]; cell division cycle 42 isoform 1 [Homo sapiens] Protein Accession gi|89903012 gi|4757952

Mean Expression Ratio 1.20 Median Expression Ratio 1.20 Credible Interval (0.894, 1.62) Associated Peptides 5 Associated Spectra 7 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.8  1.2  1.7 SEQ ID NO: 786 NVFDEAILAALEPPEPK 3 0.95  1.3  1.8 SEQ ID NO: 787 QKPITPETAEK 1 0.8  1.2  1.7 SEQ ID NO: 788 TLGLFDTAGQEDYDR 1 0.79  1.2  1.7 SEQ ID NO: 789 PYTLGLFDTAGQEDYDR 1 0.85  1.2  1.8 SEQ ID NO: 790 TPFLLVGTQIDLR 5.101 CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein 15 [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens] Protein Accession gi|42761474 gi|42716302 gi|42716299 gi|187829185 gi|187829183 gi|187829070 gi|187828910

Mean Expression Ratio 1.20 Median Expression Ratio 1.2 Credible Interval (0.832, 1.72) Associated Peptides 1 Associated Spectra 5 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 5 0.9  1.3  1.7 SEQ ID NO: 791 FEHCNFNDVTTR 5.102 amnionless protein precursor [Homo sapiens] Protein Accession gi|110611172

Mean Expression Ratio 1.2 Median Expression Ratio 1.20 Credible Interval (0.807, 1.81) Associated Peptides 1 Associated Spectra 3 Coverage 0.0353

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.85  1.3  1.8 SEQ ID NO: 792 NPVFDVTASEELPLPR SEQ ID NO: 793   1 M G V L G R V L L W L Q L C A L T Q A V S K L     W V P N T D F D V A A N W S Q N R T P C A G G     A V E F P A D K M V S V L V Q E G H A V S D M     L L P L D G E L V L A  81 S G A G F G V S D V G S H L D C G A G E P A V     F R D S D R F S W H D P H L W R S G D E A P G     L F F V D A E R V P C R H D D V F F P P S A S     F R V G L G P G A S P 161 V R V R S I S A L G R T F T R D E D L A V F L     A S R A G R L R F H G P G A L S V G P E D C A     D P S G C V C G N A E A Q P W I C A A L L Q P     L G G R C P Q A A C H 241 S A L R P Q G Q C C D L C G A V V L L T H G P     A F D L E R Y R A R I L D T F L G L P Q Y H G     L Q V A V S K V P R S S R L R E A D T E I Q V     V L V E N G P E T G G 321 A G R L A R A L L A D V A E N G E A L G V L E     A T M R E S G A H V W G S S A A G L A G G V A     A A V L L A L L V L L V A P P L L R R A G R L     R W R R H E A A A P A 401 G A P L G F R N P V F D V T A S E E L P L P R     R L S L V P K A A A D S T S H S Y F V N P L F     A G A E A E A 5.103 von Willebrand factor A domain containing 1 isoform 1 [Homo sapiens] Protein Accession gi|40068485

Mean Expression Ratio 0.834 Median Expression Ratio 0.836 Credible Interval (0.511, 1.35) Associated Peptides 1 Associated Spectra 1 Coverage 0.0404

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.48  0.8  1.3 SEQ ID NO: 794 EFVGQLVAPLPLGTGALR SEQ ID NO: 795 1   M L P W T A L G L A L S L R L A L A R S G A E     R G P P A S A P R G D L M F L L D S S A S V S     H Y E F S R V R E F V G Q L V A P L P L G T G     A L R A S L V H V G S 81  R P Y T E F P F G Q H S S G E A A Q D A V R A     S A Q R M G D T H T G L A L V Y A K E Q L F A     E A S G A R P G V P K V L V W V T D G G S S D     P V G P P M Q E L K D 161 L G V T V F I V S T G R G N F L E L S A A A S     A P A E K H L H F V D V D D L H I I V Q E L R     G S I L D A M R P Q Q L H A T E I T S S G F R     L A W P P L L T A D S 241 G Y Y V L E L V P S A Q P G A A R R Q Q L P G     N A T D W I W A G L D P D T D Y D V A L V P E     S N V R L L R P Q I L R V R T R P G E A G P G     A S G P E S G A G P A 321 P T Q L A A L P A P E E A G P E R I V I S H A     R P R S L R V S W A P A L G S A A A L G Y H V     Q F G P L R G G E A Q R V E V P A G R N C T T     L Q G L A P G T A Y L 401 V T V T A A F R S G R E S A L S A K A C T P D     G P R P R P R P V P R A P T P G T A S R E P 5.104 vacuolar protein sorting 28 isoform 1 [Homo sapiens] Protein Accession gi|7705885

Mean Expression Ratio 1.20 Median Expression Ratio 1.19 Credible Interval (0.815, 1.77) Associated Peptides 3 Associated Spectra 3 Coverage 0.249

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.79  1.2  1.9 SEQ ID  QMLFDLESAYNAFNR NO: 796 1 0.82  1.3  2.0 SEQ ID  QTVSQWLQTLSGMSASDELDDSQVR NO: 797 1 0.76  1.2  1.8 SEQ ID  QVQGSEISSIDEFCR NO: 798 SEQ ID NO: 799   1 M F H G I P A T P G I G A P G N K P E L Y E E     V K L Y K N A R E R E K Y D N M A E L F A V V     K T M Q A L E K A Y I K D C V S P S E Y T A A     C S R L L V Q Y K A A  81 F R Q V Q G S E I S S I D E F C R K F R L D C     P L A M E R I K E D R P I T I K D D K G N L N     R C I A D V V S L F I T V M D K L R L E I R A     M D E I Q P D L R E L 161 M E T M H R M S H L P P D F E G R Q T V S Q W     L Q T L S G M S A S D E L D D S Q V R Q M L F     D L E S A Y N A F N R F L H A 5.105 mannosidase, alpha, class 2B, member 1 precursor [Homo sapiens] Protein Accession gi|51873064

Mean Expression Ratio 1.19 Median Expression Ratio 1.19 Credible Interval (0.812, 1.76) Associated Peptides 3 Associated Spectra 3 Coverage 0.0415

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.79  1.2  1.9 SEQ ID NO: 800 ELVDYFLNVATAQGR 1 0.78  1.2  1.9 SEQ ID NO: 801 FQVIVYNPLGR 1 0.76  1.2  1.9 SEQ ID NO: 802 HLVLLDTAQAAAAGHR SEQ ID NO: 803   1 M G A Y A R A S G V C A R G C L D S A G P W T     M S R A L R P P L P P L C F F L L L L A A A G     A R A G G Y E T C P T V Q P N M L N V H L L P     H T H D D V G W L K T  81 V D Q Y F Y G I K N D I Q H A G V Q V I L D S     V I S A L L A D P T R R F I Y V E I A F F S R     W W H Q Q T N A T Q E V V R D L V R Q G R L E     F A N G G W V M N D E 161 A A T H Y G A I V D Q M T L G L R F L E D T F     G N D G R P R V A W H I D P F G H S R E Q A S     L F A Q M G F D G F F F G R L D Y Q D K W V R     M Q K L E M E Q V W R 241 A S T S L K P P T A D L F T G V L P N G Y N P     P R N L C W D V L C V D Q P L V E D P R S P E     Y N A K E L V D Y F L N V A T A Q G R Y Y R T     N H T V M T M G S D F 321 Q Y E N A N M W F K N L D K L I R L V N A Q Q     A K G S S V H V L Y S T P A C Y L W E L N K A     N L T W S V K H D D F F P Y A D G P H Q F W T     G Y F S S R P A L K R 401 Y E R L S Y N F L Q V C N Q L E A L V G L A A     N V G P Y G S G D S A P L N E A M A V L Q H H     D A V S G T S R Q H V A N D Y A R Q L A A G W     G P C E V L L S N A L 481 A R L R G F K D H F T F C Q Q L N I S I C P L     S Q T A A R F Q V I V Y N P L G R K V N W M V     R L P V S E G V F V V K D P N G R T V P S D V     V I F P S S D S Q A H 561 P P E L L F S A S L P A L G F S T Y S V A Q V     P R W K P Q A R A P Q P I P R R S W S P A L T     I E N E H I R A T F D P D T G L L M E I M N M     N Q Q L L L P V R Q T 641 F F W Y N A S I G D N E S D Q A S G A Y I F R     P N Q Q K P L P V S R W A Q I H L V K T P L V     Q E V H Q N F S A W C S Q V V R L Y P G Q R H     L E L E W S V G P I P 721 V G D T W G K E V I S R F D T P L E T K G R F     Y T D S N G R E I L E R R R D Y R P T W K L N     Q T E P V A G N Y Y P V N T R I Y I T D G N M     Q L T V L T D R S Q G 801 G S S L R D G S L E L M V H R R L L K D D G R     G V S E P L M E N G S G A W V R G R H L V L L     D T A Q A A A A G H R L L A E Q E V L A P Q V     V L A P G G G A A Y N 881 L G A P P R T Q F S G L R R D L P P S V H L L     T L A S W G P E M V L L R L E H Q F A V G E D     S G R N L S A P V T L N L R D L F S T F T I T     R L Q E T T L V A N Q 961 L R E A A S R L K W T T N T G P T P H Q T P Y     Q L D P A N I T L E P M E I R T F L A S V Q W     K E V D G 5.106 chloride intracellular channel 1 [Homo sapiens] Protein Accession gi|14251209

Mean Expression Ratio 1.19 Median Expression Ratio 1.19 Credible Interval (0.876, 1.62) Associated Peptides 4 Associated Spectra 7 Coverage 0.224

Se- quence A 2.5 50 97.5 ID No. Sequence 1 0.82  1.2  1.8 SEQ   LAALNPESNTAGLDIFAK ID NO:  804 2 0.83  1.2  1.7 SEQ   LHIVQVVCK ID NO:  805 1 0.8  1.2  1.7 SEQ   LTSPLPEEVDETSAEDEGVSQR ID NO:  806 3 0.9  1.3  1.8 SEQ   VLDNYLTSPLPEEVDETSAEDEGVSQ ID  R NO: 807 SEQ ID NO: 808   1 M A E E Q P Q V E L F V K A G S D G A K I G N     C P F S Q R L F M V L W L K G V T F N V T T V     D T K R R T E T V Q K L C P G G Q L P F L L Y     G T E V H T D T N K I  81 E E F L E A V L C P P R Y P K L A A L N P E S     N T A G L D I F A K F S A Y I K N S N P A L N     D N L E K G L L K A L K V L D N Y L T S P L P     E E V D E T S A E D E 161 G V S Q R K F L D G N E L T L A D C N L L P K     L H I V Q V V C K K Y R G F T I P E A F R G V     H R Y L S N A Y A R E E F A S T C P D D E E I     E L A Y E Q V A K A L 241 K 5.107 complement factor D preproprotein [Homo sapiens] Protein Accession gi|42544239

Mean Expression Ratio 0.84 Median Expression Ratio 0.84 Credible Interval (0.568, 1.24) Associated Peptides 3 Associated Spectra 3 Coverage 0.241

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.54  0.85  1.3 SEQ ID  AVPHPDSQPDTIDHDLLLLQLSEK NO: 809 1 0.53  0.83  1.3 SEQ ID  RPDSLQHVLLPVLDR NO: 810 1 0.51  0.81  1.3 SEQ ID  GDSGGPLVCGGVLEGVVTSGSR NO: 811 SEQ ID NO: 812   1 M H S W E R L A V L V L L G A A A C A A P P R     G R I L G G R E A E A H A R P Y M A S V Q L N     G A H L C G G V L V A E Q W V L S A A H C L E     D A A D G K V Q V L L  81 G A H S L S Q P E P S K R L Y D V L R A V P H     P D S Q P D T I D H D L L L L Q L S E K A T L     G P A V R P L P W Q R V D R D V A P G T L C D     V A G W G I V N H A G 161 R R P D S L Q H V L L P V L D R A T C N R R T     H H D G A I T E R L M C A E S N R R D S C K G     D S G G P L V C G G V L E G V V T S G S R V C     G N R K K P G I Y T R 241 V A S Y A A W I D S V L A 5.108 scavenger receptor class B, member 2 [Homo sapiens] Protein Accession gi|5031631

Mean Expression Ratio 0.842 Median Expression Ratio 0.841 Credible Interval (0.677, 1.04) Associated Peptides 11 Associated Spectra 17 Coverage 0.247

Sequence A 2.5 50 97.5  ID No. Sequence 1 0.64  0.89  1.2 SEQ ID  DEVLYVFPSDFCR NO: 813 1 0.59  0.83  1.2 SEQ ID  EIIEAMLK NO: 814 1 0.58  0.81  1.1 SEQ ID  FVSAIEGMHPNQEDHETFVDIN NO: 815 PLTGIILK 2 0.6  0.82  1.1 SEQ ID  ITFSDYESVQGLPAFR NO: 816 1 0.58  0.8  1.1 SEQ ID  IVEWNGK NO: 817 3 0.59  0.79  1.1 SEQ ID  KLDDFVETGDIR NO: 818 1 0.62  0.86  1.2 SEQ ID  LDDFVETGDIR NO: 819 1 0.6  0.83  1.2 SEQ ID  SDYESVQGLPAFR NO: 820 4 0.69  0.91  1.2 SEQ ID  SVYITFSDYESVQGLPAFR NO: 821 1 0.61  0.85  1.2 SEQ ID  TLNIPVLTVIEWSQVHFLR NO: 822 1 0.61  0.84  1.2 SEQ ID  TSLDWWITDK NO: 823 SEQ ID NO: 824   1 M G R C C F Y T A G T L S L L L L V T S V T L     L V A R V F Q K A V D Q S I E K K I V L R N G     T E A F D S W E K P P L P V Y T Q F Y F F N V     T N P E E I L R G E T  81 P R V E E V G P Y T Y R E L R N K A N I Q F G     D N G T T I S A V S N K A Y V F E R D Q S V G     D P K I D L I R T L N I P V L T V I E W S Q V     H F L R E I I E A M L 161 K A Y Q Q K L F V T H T V D E L L W G Y K D E     I L S L I H V F R P D I S P Y F G L F Y E K N     G T N D G D Y V F L T G E D S Y L N F T K I V     E W N G K T S L D W W 241 I T D K C N M I N G T D G D S F H P L I T K D     E V L Y V F P S D F C R S V Y I T F S D Y E S     V Q G L P A F R Y K V P A E I L A N T S D N A     G F C I P E G N C L G 321 S G V L N V S I C K N G A P I I M S F P H F Y     Q A D E R F V S A I E G M H P N Q E D H E T F     V D I N P L T G I I L K A A K R F Q I N I Y V     K K L D D F V E T G D 401 I R T M V F P V M Y L N E S V H I D K E T A S     R L K S M I N T T L I I T N I P Y I I M A L G     V F F G L V F T W L A C K G Q G S M D E G T A     D E R A P L I R T 5.109 plasminogen [Homo sapiens] Protein Accession gi|4505881

Mean Expression Ratio 0.845 Median Expression Ratio 0.844 Credible Interval (0.519, 1.39) Associated Peptides 1 Associated Spectra 1 Coverage 0.0272

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.49 0.81 1.4 SEQ ID NO: 825 VILGAHQEVNLEPHVQEIEVSR SEQ ID NO: 826 1 M E H K E V V L L L L L F L K S G Q G E P L D D Y V N T Q G A S L F S V T K K Q L G A G S I E E C A A K C E E D E E F T C R A F Q Y H S K E Q Q C V I M A E N R 81 K S S I I I R M R D V V L F E K K V Y L S E C K T G N G K N Y R G T M S K T K N G I T C Q K W S S T S P H R P R F S P A T H P S E G L E E N Y C R N P D N D P Q 161 G P W C Y T T D P E K R Y D Y C D I L E C E E E C M H C S G E N Y D G K I S K T M S G L E C Q A W D S Q S P H A H G Y I P S K F P N K N L K K N Y C R N P D R E 241 L R P W C F T T D P N K R W E L C D I P R C T T P P P S S G P T Y Q C L K G T G E N Y R G N V A V T V S G H T C Q H W S A Q T P H T H N R T P E N F P C K N L D 321 E N Y C R N P D G K R A P W C H T T N S Q V R W E Y C K I P S C D S S P V S T E Q L A P T A P P E L T P V V Q D C Y H G D G Q S Y R G T S S T T T T G K K C Q S 401 W S S M T P H R H Q K T P E N Y P N A G L T M N Y C R N P D A D K G P W C F T T D P S V R W E Y C N L K K C S G T E A S V V A P P P V V L L P D V E T P S E E D 481 C M F G N G K G Y R G K R A T T V T G T P C Q D W A A Q E P H R H S I F T P E T N P R A G L E K N Y C R N P D G D V G G P W C Y T T N P R K L Y D Y C D V P Q C 561 A A P S F D C G K P Q V E P K K C P G R V V G G C V A H P H S W P W Q V S L R T R F G M H F C G G T L I S P E W V L T A A H C L E K S P R P S S Y K V I L G A H 641 Q E V N L E P H V Q E I E V S R L F L E P T R K D I A L L K L S S P A V I T D K V I P A C L P S P N Y V V A D R T E C F I T G W G E T Q G T F G A G L L K E A Q 721 L P V I E N K V C N R Y E F L N G R V Q S T E L C A G H L A G G T D S C Q G D S G G P L V C F E K D K Y I L Q G V T S W G L G C A R P N K P G V Y V R V S R F V 801 T W I E G V M R N N 5.110 ficolin 2 isoform a precursor [Homo sapiens] Protein Accession gi|61744445

Mean Expression Ratio 0.842 Median Expression Ratio 0.844 Credible Interval (0.539, 1.31) Associated Peptides 1 Associated Spectra 2 Coverage 0.0671

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.52 0.81 1.2 SEQ ID NO: 827 AGPPGPNGAPGEPQPCLTGPR SEQ ID NO: 828 1 M E L D R A V G V L G A A T L L L S F L G M A W A L Q A A D T C P E V K M V G L E G S D K L T I L R G C P G L P G A P G P K G E A G T N G K R G E R G P P G P P 81 G K A G P P G P N G A P G E P Q P C L T G P R T C K D L L D R G H F L S G W H T I Y L P D C R P L T V L C D M D T D G G G W T V F Q R R V D G S V D F Y R D W A 161 T Y K Q G F G S R L G E F W L G N D N I H A L T A Q G T S E L R V D L V D F E D N Y Q F A K Y R S F K V A D E A E K Y N L V L G A F V E G S A G D S L T F H N N 241 Q S F S T K D Q D N D L N T G N C A V M F Q G A W W Y K N C H V S N L N G R Y L R G T H G S F A N G I N W K S G K G Y N Y S Y K V S E M K V R P A 5.111 glycophorin C isoform 2 [Homo sapiens]; glycophorin C isoform 1 [Homo sapiens] Protein Accession gi|8051605 gi|4504229

Mean Expression Ratio 1.18 Median Expression Ratio 1.18 Credible Interval (0.727, 1.93) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.72 1.2 2.1 SEQ ID NO: 829 GTEFAESADAALQGDPALQ DAGDSSR 5.112 prolylcarboxypeptidase isoform 1 preproprotein [Homo sapiens]; prolylcarboxypeptidase isoform 2 preproprotein [Homo sapiens] Protein Accession gi|4826940 gi|117306169

Mean Expression Ratio 0.846 Median Expression Ratio 0.847 Credible Interval (0.677, 1.06) Associated Peptides 9 Associated Spectra 15 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.6 0.84 1.2 SEQ ID NO: 830 AMLVFAEHR 1 0.59 0.83 1.2 SEQ ID NO: 831 DITDTLVAVTISEGAH 1 0.59 0.83 1.2 SEQ ID NO: 832 DITDTLVAVTISEGAHHL 4 0.65 0.86 1.1 SEQ ID NO: 833 DITDTLVAVTISEGAHH LDLR 2 0.61 0.84 1.2 SEQ ID NO: 834 FLTSEQALADFAELIK 3 0.63 0.84 1.1 SEQ ID NO: 835 HLNFLTSEQALADFA ELIK 1 0.6 0.83 1.2 SEQ ID NO: 836 VDHFGFNTVK 1 0.59 0.82 1.2 SEQ ID NO: 837 YYGESLPFGDNSFK 1 0.62 0.87 1.2 SEQ ID NO: 838 NALDPMSVLLAR 5.113 collagen, type VI, alpha 1 precursor [Homo sapiens] Protein Accession gi|87196339

Mean Expression Ratio 0.85 Median Expression Ratio 0.848 Credible Interval (0.525, 1.37) Associated Peptides 1 Associated Spectra 1 Coverage 0.0175

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.5 0.82 1.3 SEQ ID NO: 839 DAEEAISQTIDTIVDMIK SEQ ID NO: 840 1 M R A A R A L L P L L L Q A C W T A A Q D E P E T P R A V A F Q D C P V D L F F V L D T S E S V A L R L K P Y G A L V D K V K S F T K R F I D N L R D R Y Y R C 81 D R N L V W N A G A L H Y S D E V E I I Q G L T R M P G G R D A L K S S V D A V K Y F G K G T Y T D C A I K K G L E Q L L V G G S H L K E N K Y L I V V T D G H 161 P L E G Y K E P C G G L E D A V N E A K H L G V K V F S V A I T P D H L E P R L S I I A T D H T Y R R N F T A A D W G Q S R D A E E A I S Q T I D T I V D M I K 241 N N V E Q V C C S F E C Q P A R G P P G L R G D P G F E G E R G K P G L P G E K G E A G D P G R P G D L G P V G Y Q G M K G E K G S R G E K G S R G P K G Y K G 321 E K G K R G I D G V D G V K G E M G Y P G L P G C K G S P G F D G I Q G P P G P K G D P G A F G L K G E K G E P G A D G E A G R P G S S G P S G D E G Q P G E P 401 G P P G E K G E A G D E G N P G P D G A P G E R G G P G E R G P R G T P G T R G P R G D P G E A G P Q G D Q G R E G P V G V P G D P G E A G P I G P K G Y R G D 481 E G P P G S E G A R G A P G P A G P P G D P G L M G E R G E D G P A G N G T E G F P G F P G Y P G N R G A P G I N G T K G Y P G L K G D E G E A G D P G D D N N 561 D I A P R G V K G A K G Y R G P E G P Q G P P G H Q G P P G P D E C E I L D I I M K M C S C C E C K C G P I D L L F V L D S S E S I G L Q N F E I A K D F V V K 641 V I D R L S R D E L V K F E P G Q S Y A G V V Q Y S H S Q M Q E H V S L R S P S I R N V Q E L K E A I K S L Q W M A G G T F T G E A L Q Y T R D Q L L P P S P N 721 N R I A L V I T D G R S D T Q R D T T P L N V L C S P G I Q V V S V G I K D V F D F I P G S D Q L N V I S C Q G L A P S Q G R P G L S L V K E N Y A E L L E D A 801 F L K N V T A Q I C I D K K C P D Y T C P I T F S S P A D I T I L L D G S A S V G S H N F D T T K R F A K R L A E R F L T A G R T D P A H D V R V A V V Q Y S G 881 T G Q Q R P E R A S L Q F L Q N Y T A L A S A V D A M D F I N D A T D V N D A L G Y V T R F Y R E A S S G A A K K R L L L F S D G N S Q G A T P A A I E K A V Q 961 E A Q R A G I E I F V V V V G R Q V N E P H I R V L V T G K T A E Y D V A Y G E S H L F R V P S Y Q A L L R G V F H Q T V S R K V A L G 5.114 calmodulin 1 [Homo sapiens]; calmodulin 3 [Homo sapiens]; calmodulin 2 [Homo sapiens] Protein Accession gi|5901912 gi|58218968 gi|4502549

Mean Expression Ratio 1.18 Median Expression Ratio 1.18 Credible Interval (0.728, 1.92) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.74 1.2 2.1 SEQ ID NO: 841 VFDKDGNGYISAAELR 5.115 annexin I [Homo sapiens] Protein Accession gi|4502101

Mean Expression Ratio 1.17 Median Expression Ratio 1.17 Credible Interval (0.795, 1.74) Associated Peptides 2 Associated Spectra 3 Coverage 0.078

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.8 1.2 1.8 SEQ ID NO: 842 GLGTDEDTLIEILASR 1 0.76 1.2 1.8 SEQ ID NO: 843 TPAQFDADELR SEQ ID NO: 844 1 M A M V S E F L K Q A W F I E N E E Q E Y V Q T V K S S K G G P G S A V S P Y P T F N P S S D V A A L H K A I M V K G V D E A T I I D I L T K R N N A Q R Q Q I 81 K A A Y L Q E T G K P L D E T L K K A L T G H L E E V V L A L L K T P A Q F D A D E L R A A M K G L G T D E D T L I E I L A S R T N K E I R D I N R V Y R E E L 161 K R D L A K D I T S D T S G D F R N A L L S L A K G D R S E D F G V N E D L A D S D A R A L Y E A G E R R K G T D V N V F N T I L T T R S Y P Q L R R V F Q K Y 241 T K Y S K H D M N K V L D L E L K G D I E K C L T A I V K C A T S K P A F F A E K L H Q A M K G V G T R H K A L I R I M V S R S E I D M N D I K A F Y Q K M Y G 321 I S L C Q A I L D E T K G D Y E K I L V A L C G G N 5.116 ras homolog gene family, member G [Homo sapiens] Protein Accession gi|46249393

Mean Expression Ratio 1.17 Median Expression Ratio 1.17 Credible Interval (0.723, 1.92) Associated Peptides 1 Associated Spectra 1 Coverage 0.089

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.73 1.2 2 SEQ ID NO: 845 TVNLNLWDTAGQEEYDR SEQ ID NO: 846 1 M Q S I K C V V V G D G A V G K T C L L I C Y T T N A F P K E Y I P T V F D N Y S A Q S A V D G R T V N L N L W D T A G Q E E Y D R L R T L S Y P Q T N V F V I 81 C F S I A S P P S Y E N V R H K W H P E V C H H C P D V P I L L V G T K K D L R A Q P D T L R R L K E Q G Q A P I T P Q Q G Q A L A K Q I H A V R Y L E C S A L 161 Q Q D G V K E V F A E A V R A V L N P T P I K R G R S C I L L 5.117 immunoglobulin superfamily, member 8 [Homo sapiens]

Protein Accession gi 16445029 Mean Expression Ratio 0.849 Median Expression Ratio 0.853 Credible Interval (0.548, 1.29) Associated Peptides 2 Associated Spectra 2 Coverage 0.0440

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.52 0.84 1.3 SEQ ID NO: 847 VLPDVLQVSAAPPGPR 1 0.52 0.83 1.3 SEQ ID NO: 848 EVLVPEGPLYR SEQ ID NO: 849 1 M G A L R P T L L P P S L P L L L L L M L G M G C W A R E V L V P E G P L Y R V A G T A V S I S C N V T G Y E G P A Q Q N F E W F L Y R P E A P D T A L G I V S 81 T K D T Q F S Y A V F K S R V V A G E V Q V Q R L Q G D A V V L K I A R L Q A Q D A G I Y E C H T P S T D T R Y L G S Y S G K V E L R V L P D V L Q V S A A P P 161 G P R G R Q A P T S P P R M T V H E G Q E L A L G C L A R T S T Q K H T H L A V S F G R S V P E A P V G R S T L Q E V V G I R S D L A V E A G A P Y A E R L A A 241 G E L R L G K E G T D R Y R M V V G G A Q A G D A G T Y H C T A A E W I Q D P D G S W A Q I A E K R A V L A H V D V Q T L S S Q L A V T V G P G E R R I G P G E 321 P L E L L C N V S G A L P P A G R H A A Y S V G W E M A P A G A P G P G R L V A Q L D T E G V G S L G P G Y E G R H I A M E K V A S R T Y R L R L E A A R P G D 401 A G T Y R C L A K A Y V R G S G T R L R E A A S A R S R P L P V H V R E E G V V L E A V A W L A G G T V Y R G E T A S L L C N I S V R G G P P G L R L A A S W W 481 V E R P E D G E L S S V P A Q L V G G V G Q D G V A E L G V R P G G G P V S V E L V G P R S H R L R L H S L G P E D E G V Y H C A P S A W V Q H A D Y S W Y Q A 561 G S A R S G P V T V Y P Y M H A L D T L F V P L L V G T G V A L V T G A T V L G T I T C C F M K R L R K R 5.118 Fc fragment of IgG binding protein [Homo sapiens] Protein Accession gi|154146262

Mean Expression Ratio 1.17 Median Expression Ratio 1.17 Credible Interval (0.839, 1.62) Associated Peptides 3 Associated Spectra 6 Coverage 0.00833

A 2.5 50 97.5 Sequence ID No. Sequence 4 0.84 1.2 1.6 SEQ ID NO: 850 VNGVLTALPVSVADGR 1 0.8 1.2 1.8 SEQ ID NO: 851 YYPLGEVFYPGPECER 1 0.8 1.2 1.8 SEQ ID NO: 852 APGWDPLCWDECR SEQ ID NO: 853 1 M G A L W S W W I L W A G A T L L W G L T Q E A S V D L K N T G R E E F L T A F L Q N Y Q L A Y S K A Y P R L L I S S L S E S P A S V S I L S Q A D N T S K K V 81 T V R P G E S V M V N I S A K A E M I G S K I F Q H A V V I H S D Y A I S V Q A L N A K P D T A E L T L L R P I Q A L G T E Y F V L T P P G T S A R N V K E F A 161 V V A G A A G A S V S V T L K G S V T F N G K F Y P A G D V L R V T L Q P Y N V A Q L Q S S V D L S G S K V T A S S P V A V L S G H S C A Q K H T T C N H V V E 241 Q L L P T S A W G T H Y V V P T L A S Q S R Y D L A F V V A S Q A T K L T Y N H G G I T G S R G L Q A G D V V E F E V R P S W P L Y L S A N V G I Q V L L F G T 321 G A I R N E V T Y D P Y L V L I P D V A A Y C P A Y V V K S V P G C E G V A L V V A Q T K A I S G L T I D G H A V G A K L T W E A V P G S E F S Y A E V E L G T 401 A D M I H T A E A T T N L G L L T F G L A K A I G Y A T A A D C G R T V L S P V E P S C E G M Q C A A G Q R C Q V V G G K A G C V A E S T A V C R A Q G D P H Y 481 T T F D G R R Y D M M G T C S Y T M V E L C S E D D T L P A F S V E A K N E H R G S R R V S Y V G L V T V R A Y S H S V S L T R G E V G F V L V D N Q R S R L P 561 V S L S E G R L R V Y Q S G P R A V V E L V F G L V V T Y D W D C Q L A L S L P A R F Q D Q V C G L C G N Y N G D P A D D F L T P D G A L A P D A V E F A S S W 641 K L D D G D Y L C E D G C Q N N C P A C T P G Q A Q H Y E G D R L C G M L T K L D G P F A V C H D T L D P R P F L E Q C V Y D L C V V G G E R L S L C R G L S A 721 Y A Q A C L E L G I S V G D W R S P A N C P L S C P A N S R Y E L C G P A C P T S C N G A A A P S N C S G R P C V E G C V C L P G F V A S G G A C V P A S S C G 801 C T F Q G L Q L A P G Q E V W A D E L C Q R R C T C N G A T H Q V T C R D K Q S C P A G E R C S V Q N G L L G C Y P D R F G T C Q G S G D P H Y V S F D G R R F 881 D F M G T C T Y L L V G S C G Q N A A L P A F R V L V E N E H R G S Q T V S Y T R A V R V E A R G V K V A V R R E Y P G Q V L V D D V L Q Y L P F Q A A D G Q V 961 Q V F R Q G R D A V V R T D F G L T V T Y D W N A R V T A K V P S S Y A E A L C G L C G N F N G D P A D D L A L R G G G Q A A N A L A F G N S W Q E E T R P G C 1041 G A T E P G D C P K L D S L V A Q Q L Q S K N E C G I L A D P K G P F R E C H S K L D P Q G A V R D C V Y D R C L L P G Q S G P L C D A L A T Y A A A C Q A A G 1121 A T V H P W R S E E L C P L S C P P H S H Y E A C S Y G C P L S C G D L P V P G G C G S E C H E G C V C D E G F A L S G E S C L P L A S C G C V H Q G T Y H P P 1201 G Q T F Y P G P G C D S L C H C Q E G G L V S C E S S S C G P H E A C Q P S G G S L G C V A V G S S T C Q A S G D P H Y T T F D G R R F D F M G T C V Y V L A Q 1281 T C G T R P G L H R F A V L Q E N V A W G N G R V S V T R V I T V Q V A N F T L R L E Q R Q W K V T V N G V D M K L P V V L A N G Q I R A S Q H G S D V V I E T 1361 D F G L R V A Y D L V Y Y V R V T V P G N Y Y Q Q M C G L C G N Y N G D P K D D F Q K P N G S Q A G N A N E F G N S W E E V V P D S P C L P P T P C P P G S E D 1441 C I P S H K C P P E L E K K Y Q K E E F C G L L S S P T G P L S S C H K L V D P Q G P L K D C I F D L C L G G G N L S I L C S N I H A Y V S A C Q A A G G H V E 1521 P W R T E T F C P M E C P P N S H Y E L C A D T C S L G C S A L S A P P Q C Q D G C A E G C Q C D S G F L Y N G Q A C V P I Q Q C G C Y H N G V Y Y E P E Q T V 1601 L I D N C R Q Q C T C H A G K G M V C Q E H S C K P G Q V C Q P S G G I L S C V T K D P C H G V T C R P Q E T C K E Q G G Q G V C L P N Y E A T C W L W G D P H 1681 Y H S F D G R K F D F Q G T C N Y V L A T T G C P G V S T Q G L T P F T V T T K N Q N R G N P A V S Y V R V V T V A A L G T N I S I H K D E I G K V R V N G V L 1761 T A L P V S V A D G R I S V T Q G A S K A L L V A D F G L Q V S Y D W N W R V D V T L P S S Y H G A V C G L C G N M D R N P N N D Q V F P N G T L A P S I P I W 1841 G G S W R A P G W D P L C W D E C R G S C P T C P E D R L E Q Y E G P G F C G P L A P G T G G P F T T C H A H V P P E S F F K G C V L D V C M G G G D R D I L C 1921 K A L A S Y V A A C Q A A G V V I E D W R A Q V G C E I T C P E N S H Y E V C G S P C P A S C P S P A P L T T P A V C E G P C V E G C Q C D A G F V L S A D R C 2001 V P L N N G C G C W A N G T Y H E A G S E F W A D G T C S Q W C R C G P G G G S L V C T P A S C G L G E V C G L L P S G Q H G C Q P V S T A E C Q A W G D P H Y 2081 V T L D G H R F N F Q G T C E Y L L S A P C H G P P L G A E N F T V T V A N E H R G S Q A V S Y T R S V T L Q I Y N H S L T L S A R W P R K L Q V D G V F V T L 2161 P F Q L D S L L H A H L S G A D V V V T T T S G L S L A F D G D S F V R L R V P A A Y A G S L C G L C G N Y N Q D P A D D L K A V G G K P A G W Q V G G A Q G C 2241 G E C V S K P C P S P C T P E Q Q E S F G G P D A C G V I S A T D G P L A P C H G L V P P A Q Y F Q G C L L D A C Q V Q G H P G G L C P A V A T Y V A A C Q A A 2321 G A Q L R E W R R P D F C P F Q C P A H S H Y E L C G D S C P G S C P S L S A P E G C E S A C R E G C V C D A G F V L S G D T C V P V G Q C G C L H D D R Y Y P 2401 L G Q T F Y P G P G C D S L C R C R E G G E V S C E P S S C G P H E T C R P S G G S L G C V A V G S T T C Q A S G D P H Y T T F D G R R F D F M G T C V Y V L A 2481 Q T C G T R P G L H R F A V L Q E N V A W G N G R V S V T R V I T V Q V A N F T L R L E Q R Q W K V T V N G V D M K L P V V L A N G Q I R A S Q H G S D V V I E 2561 T D F G L R V A Y D L V Y Y V R V T V P G N Y Y Q L M C G L C G N Y N G D P K D D F Q K P N G S Q A G N A N E F G N S W E E V V P D S P C L P P P T C P P G S E 2641 G C I P S E E C P P E L E K K Y Q K E E F C G L L S S P T G P L S S C H K L V D P Q G P L K D C I F D L C L G G G N L S I L C S N I H A Y V S A C Q A A G G Q V 2721 E P W R N E T F C P M E C P Q N S H Y E L C A D T C S L G C S A L S A P L Q C P D G C A E G C Q C D S G F L Y N G Q A C V P I Q Q C G C Y H N G A Y Y E P E Q T 2801 V L I D N C R Q Q C T C H V G K V V V C Q E H S C K P G Q V C Q P S G G I L S C V N K D P C H G V T C R P Q E T C K E Q G G Q G V C L P N Y E A T C W L W G D P 2881 H Y H S F D G R K F D F Q G T C N Y V L A T T G C P G V S T Q G L T P F T V T T K N Q N R G N P A V S Y V R V V T V A A L G T N I S I H K D E I G K V R V N G V 2961 L T A L P V S V A D G R I S V T Q G A S K A L L V A D F G L Q V S Y D W N W R V D V T L P S S Y H G A V C G L C G N M D R N P N N D Q V F P N G T L A P S I P I 3041 W G G S W R A P G W D P L C W D E C R G S C P T C P E D R L E Q Y E G P G F C G P L A P G T G G P F T T C H A H V P P E S F F K G C V L D V C M G G G D R D I L 3121 C K A L A S Y V A A C Q A A G V V I E D W R A Q V G C E I T C P E N S H Y E V C G P P C P A S C P S P A P L T T P A V C E G P C V E G C Q C D A G F V L S A D R 3201 C V P L N N G C G C W A N G T Y H E A G S E F W A D G T C S Q W C R C G P G G G S L V C T P A S C G L G E V C G L L P S G Q H G C Q P V S T A E C Q A W G D P H 3281 Y V T L D G H R F D F Q G T C E Y L L S A P C H G P P L G A E N F T V T V A N E H R G S Q A V S Y T R S V T L Q I Y N H S L T L S A R W P R K L Q V D G V F V T 3361 L P F Q L D S L L H A H L S G A D V V V T T T S G L S L A F D G D S F V R L R V P A A Y A G S L C G L C G N Y N Q D P A D D L K A V G G K P A G W Q V G G A Q G 3441 C G E C V S K P C P S P C T P E Q Q E S F G G P D A C G V I S A T D G P L A P C H G L V P P A Q Y F Q G C L L D A C Q V Q G H P G G L C P A V A T Y V A A C Q A 3521 A G A Q L R E W R R P D F C P F Q C P A H S H Y E L C G D S C P G S C P S L S A P E G C E S A C R E G C V C D A G F V L S G D T C V P V G Q C G C L H D D R Y Y 3601 P L G Q T F Y P G P G C D S L C R C R E G G E V S C E P S S C G P H E T C R P S G G S L G C V A V G S T T C Q A S G D P H Y T T F D G H R F D F M G T C V Y V L 3681 A Q T C G T R P G L H R F A V L Q E N V A W G N G R V S V T R V I T V Q V A N F T L R L E Q R Q W K V T V N G V D M K L P V V L A N G Q I R A S Q H G S D V V I 3761 E T D F G L R V A Y D L V Y Y V R V T V P G N Y Y Q L M C G L C G N Y N G D P K D D F Q K P N G S Q A G N A N E F G N S W E E V V P D S P C L P P P T C P P G S 3841 A G C I P S D K C P P E L E K K Y Q K E E F C G L L S S P T G P L S S C H K L V D P Q G P L K D C I F D L C L G G G N L S I L C S N I H A Y V S A C Q A A G G H 3921 V E P W R N E T F C P M E C P Q N S H Y E L C A D T C S L G C S A L S A P L Q C P D G C A E G C Q C D S G F L Y N G Q A C V P I Q Q C G C Y H N G V Y Y E P E Q 4001 T V L I D N C R Q Q C T C H V G K V V V C Q E H S C K P G Q V C Q P S G G I L S C V T K D P C H G V T C R P Q E T C K E Q G G Q G V C L P N Y E A T C W L W G D 4081 P H Y H S F D G R K F D F Q G T C N Y V L A T T G C P G V S T Q G L T P F T V T T K N Q N R G N P A V S Y V R V V T V A A L G T N I S I H K D E I G K V R V N G 4161 V L T A L P V S V A D G R I S V A Q G A S K A L L V A D F G L Q V S Y D W N W R V D V T L P S S Y H G A V C G L C G N M D R N P N N D Q V F P N G T L A P S I P 4241 I W G G S W R A P G W D P L C W D E C R G S C P T C P E D R L E Q Y E G P G F C G P L S S G T G G P F T T C H A H V P P E S F F K G C V L D V C M G G G D R D I 4321 L C K A L A S Y V A A C Q A A G V V I E D W R A Q V G C E I T C P E N S H Y E V C G P P C P A S C P S P A P L T T P A V C E G P C V E G C Q C D A G F V L S A D 4401 R C V P L N N G C G C W A N G T Y H E A G S E F W A D G T C S Q W C R C G P G G G S L V C T P A S C G L G E V C G L L P S G Q H G C Q P V S T A E C Q A W G D P 4481 H Y V T L D G H R F D F Q G T C E Y L L S A P C H G P P L G A E N F T V T V A N E H R G S Q A V S Y T R S V T L Q I Y N H S L T L S A R W P R K L Q V D G V F V 4561 A L P F Q L D S L L H A H L S G A D V V V T T T S G L S L A F D G D S F V R L R V P A A Y A A S L C G L C G N Y N Q D P A D D L K A V G G K P A G W Q V G G A Q 4641 G C G E C V S K P C P S P C T P E Q Q E S F G G P D A C G V I S A T D G P L A P C H G L V P P A Q Y F Q G C L L D A C Q V Q G H P G G L C P A V A T Y V A A C Q 4721 A A G A Q L G E W R R P D F C P L Q C P A H S H Y E L C G D S C P V S C P S L S A P E G C E S A C R E G C V C D A G F V L S G D T C V P V G Q C G C L H D G R Y 4801 Y P L G E V F Y P G P E C E R R C E C G P G G H V T C Q E G A A C G P H E E C R L E D G V Q A C H A T G C G R C L A N G G I H Y I T L D G R V Y D L H G S C S Y 4881 V L A Q V C H P K P G D E D F S I V L E K N A A G D L Q R L L V T V A G Q V V S L A Q G Q Q V T V D G E A V A L P V A V G R V R V T A E G R N M V L Q T T K G L 4961 R L L F D G D A H L L M S I P S P F R G R L C G L C G N F N G N W S D D F V L P N G S A A S S V E T F G A A W R A P G S S K G C G E G C G P Q G C P V C L A E E 5041 T A P Y E S N E A C G Q L R N P Q G P F A T C Q A V L S P S E Y F R Q C V Y D L C A Q K G D K A F L C R S L A A Y T A A C Q A A G V A V K P W R T D S F C P L H 5121 C P A H S H Y S I C T R T C Q G S C A A L S G L T G C T T R C F E G C E C D D R F L L S Q G V C I P V Q D C G C T H N G R Y L P V N S S L L T S D C S E R C S C 5201 S S S S G L T C Q A A G C P P G R V C E V K A E A R N C W A T R G L C V L S V G A N L T T F D G A R G A T T S P G V Y E L S S R C P G L Q N T I P W Y R V V A E 5281 V Q I C H G K T E A V G Q V H I F F Q D G M V T L T P N K G V W V N G L R V D L P A E K L A S V S V S R T P D G S L L V R Q K A G V Q V W L G A N G K V A V I V 5361 S N D H A G K L C G A C G N F D G D Q T N D W H D S Q E K P A M E K W R A Q D F S P C Y G 5.119 hypothetical protein LOC284422 [Homo sapiens] Protein Accession gi|211059425

Mean Expression Ratio 1.17 Median Expression Ratio 1.17 Credible Interval (0.796, 1.74) Associated Peptides 2 Associated Spectra 3 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 2 0.8 1.2 1.8 SEQ ID NO: 854 EGESNLGLDLEEKEPGDHER 1 0.78 1.2 1.9 SEQ ID NO: 855 MESNLYQDQSEDKR 5.120 vacuolar protein sorting 37D [Homo sapiens] Protein Accession gi|117938318

Mean Expression Ratio 1.17 Median Expression Ratio 1.17 Credible Interval (0.732, 1.91) Associated Peptides 1 Associated Spectra 1 Coverage 0.0558

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.73 1.2 2.0 SEQ ID NO: 856 SFPAAAVLPTGAAR SEQ ID NO: 857 1 M Y R A R A A R A G P E P G S P G R F G I L S T G Q L R D L L Q D E P K L D R I V R L S R K F Q G L Q L E R E A C L A S N Y A L A K E N L A L R P R L E M G R A 81 A L A I K Y Q E L R E V A E N C A D K L Q R L E E S M H R W S P H C A L G W L Q A E L E E A E Q E A E E Q M E Q L L L G E Q S L E A F L P A F Q R G R A L A H L 161 R R T Q A E K L Q E L L R R R E R S A Q P A P T S A A D P P K S F P A A A V L P T G A A R G P P A V P R S L P P L D S R P V P P L K G S P G C P L G P A P L L S 241 P R P S Q P E P P H R 5.121 protease, serine, 1 preproprotein [Homo sapiens] Protein Accession gi|4506145

Mean Expression Ratio 1.17 Median Expression Ratio 1.17 Credible Interval (0.811, 1.68) Associated Peptides 1 Associated Spectra 5 Coverage 0.0324

A 2.5 50 97.5 Sequence ID No. Sequence 5 0.88 1.2 1.7 SEQ ID NO: 858 NKPGVYTK SEQ ID NO: 859 1 M N P L L I L T F V A A A L A A P F D D D D K I V G G Y N C E E N S V P Y Q V S L N S G Y H F C G G S L I N E Q W V V S A G H C Y K S R I Q V R L G E H N I E V 81 L E G N E Q F I N A A K I I R H P Q Y D R K T L N N D I M L I K L S S R A V I N A R V S T I S L P T A P P A T G T K C L I S G W G N T A S S G A D Y P D E L Q C 161 L D A P V L S Q A K C E A S Y P G K I T S N M F C V G F L E G G K D S C Q G D S G G P V V C N G Q L Q G V V S W G D G C A Q K N K P G V Y T K V Y N Y V K W I K 241 N T I A A N S 5.122 prominin 2 [Homo sapiens] Protein Accession gi|21389623

Mean Expression Ratio 1.17 Median Expression Ratio 1.17 Credible Interval (0.766, 1.82) Associated Peptides 1 Associated Spectra 2 Coverage 0.03

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.79 1.2 1.9 SEQ ID NO: 860 TSMEQLAQELQGLAQAQDNSVLGQR SEQ ID NO: 861 1 M K H T L A L L A P L L G L G L G L A L S Q L A A G A T D C K F L G P A E H L T F T P A A R A R W L A P R V R A P G L L D S L Y G T V R R F L S V V Q L N P F P 81 S E L V K A L L N E L A S V K V N E V V R Y E A G Y V V C A V I A G L Y L L L V P T A G L C F C C C R C H R R C G G R V K T E H K A L A C E R A A L M V F L L L 161 T T L L L L I G V V C A F V T N Q R T H E Q M G P S I E A M P E T L L S L W G L V S D V P Q E L Q A V A Q Q F S L P Q E Q V S E E L D G V G V S I G S A I H T Q 241 L R S S V Y P L L A A V G S L G Q V L Q V S V H H L Q T L N A T V V E L Q A G Q Q D L E P A I R E H R D R L L E L L Q E A R C Q G D C A G A L S W A R T L E L G 321 A D F S Q V P S V D H V L H Q L K G V P E A N F S S M V Q E E N S T F N A L P A L A A M Q T S S V V Q E L K K A V A Q Q P E G V R T L A E G F P G L E A A S R W 401 A Q A L Q E V E E S S R P Y L Q E V Q R Y E T Y R W I V G C V L C S V V L F V V L C N L L G L N L G I W G L S A R D D P S H P E A K G E A G A R F L M A G V G L 481 S F L F A A P L I L L V F A T F L V G G N V Q T L V C R S W E N G E L F E F A D T P G N L P P S M N L S Q L L G L R K N I S I H Q A Y Q Q C K E G A A L W T V L 561 Q L N D S Y D L E E H L D I N Q Y T N K L R Q E L Q S L K V D T Q S L D L L S S A A R R D L E A L Q S S G L Q R I H Y P D F L V Q I Q R P V V K T S M E Q L A Q 641 E L Q G L A Q A Q D N S V L G Q R L Q E E A Q G L R N L H Q E K V V P Q Q S L V A K L N L S V R A L E S S A P N L Q L E T S D V L A N V T Y L K G E L P A W A A 721 R I L R N V S E C F L A R E M G Y F S Q Y V A W V R E E V T Q R I A T C Q P L S G A L D N S R V I L C D M M A D P W N A F W F C L A W C T F F L I P S I I F A V 801 K T S K Y F R P I R K R L S S T S S E E T Q L F H I P R V T S L K L 5.123 cathepsin B preproprotein [Homo sapiens]; cathepsin B preproprotein [Homo sapiens]; cathepsin B preproprotein [Homo sapiens]; cathepsin B preproprotein [Homo sapiens]; cathepsin B preproprotein [Homo sapiens] Protein Accession gi|4503139 gi|22538437 gi|22538435 gi|22538433 gi|22538431

Mean Expression Ratio 0.858 Median Expression Ratio 0.856 Credible Interval (0.556, 1.32) Associated Peptides 1 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.54 0.83 1.3 SEQ ID NO: 862 GQDHCGIESEVVAGIPR 5.124 radixin [Homo sapiens] Protein Accession gi|4506467

Mean Expression Ratio 1.16 Median Expression Ratio 1.16 Credible Interval (0.77, 1.75) Associated Peptides 1 Associated Spectra 3 Coverage 0.0292

SEQ ID NO: 863 A 2.5 50 97.5 Sequence 3 0.82 1.2 1.8 FFPEDVSEELIQEITQR SEQ ID NO: 864 1 M P K P I N V R V T T M D A E L E F A I Q P N T T G K Q L F D Q V V K T V G L R E V W F F G L Q Y V D S K G Y S T W L K L N K K V T Q Q D V K K E N P L Q F K F 81 R A K F F P E D V S E E L I Q E I T Q R L F F L Q V K E A I L N D E I Y C P P E T A V L L A S Y A V Q A K Y G D Y N K E I H K P G Y L A N D R L L P Q R V L E Q 161 H K L T K E Q W E E R I Q N W H E E H R G M L R E D S M M E Y L K I A Q D L E M Y G V N Y F E I K N K K G T E L W L G V D A L G L N I Y E H D D K L T P K I G F 241 P W S E I R N I S F N D K K F V I K P I D K K A P D F V F Y A P R L R I N K R I L A L C M G N H E L Y M R R R K P D T I E V Q Q M K A Q A R E E K H Q K Q L E R 321 A Q L E N E K K K R E I A E K E K E R I E R E K E E L M E R L K Q I E E Q T I K A Q K E L E E Q T R K A L E L D Q E R K R A K E E A E R L E K E R R A A E E A K 401 S A I A K Q A A D Q M K N Q E Q L A A E L A E F T A K I A L L E E A K K K K E E E A T E W Q H K A F A A Q E D L E K T K E E L K T V M S A P P P P P P P P V I P 481 P T E N E H D E H D E N N A E A S A E L S N E G V M N H R S E E E R V T E T Q K N E R V K K Q L Q A L S S E L A Q A R D E T K K T Q N D V L H A E N V K A G R D 561 K Y K T L R Q I R Q G N T K Q R I D E F E A M 5.125 annexin VI isoform 2 [Homo sapiens]; annexin VI isoform 1 [Homo sapiens] Protein Accession gi|71773415 gi|71773329

Mean Expression Ratio 1.16 Median Expression Ratio 1.16 Credible Interval (0.832, 1.60) Associated Peptides 3 Associated Spectra 6 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.77 1.1 1.7 SEQ ID NO: 865 EAILDIITSR 4 0.89 1.2 1.7 SEQ ID NO: 866 GLGTDEDTIIDIITHR 1 0.78 1.2 1.7 SEQ ID NO: 867 GSIHDFPGFDPNQDAEALY 5.126 cystatin C precursor [Homo sapiens] Protein Accession gi|4503107

Mean Expression Ratio 0.859 Median Expression Ratio 0.86 Credible Interval (0.716, 1.03) Associated Peptides 9 Associated Spectra 37 Coverage 0.425

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.63 0.88 1.2 SEQ ID NO: 868 ALDFAVGEYNK 3 0.63 0.83 1.1 SEQ ID NO: 869 KQIVAGVNYFLDVELGR 1 0.64 0.87 1.2 SEQ ID NO: 870 LDNCPFHDQPHLK 8 0.66 0.83 1.0 SEQ ID NO: 871 LVGGPMDASVEEEGVR 3 0.61 0.81 1.1 SEQ ID NO: 872 LVGGPMDASVEEEGVRR 15 0.72 0.87 1.1 SEQ ID NO: 873 QIVAGVNYFLDVELGR 4 0.65 0.84 1.1 SEQ ID NO: 874 TQPNLDNCPFHDQPHLK 1 0.66 0.9 1.2 SEQ ID NO: 875 VGGPMDASVEEEGVR 1 0.63 0.86 1.2 SEQ ID NO: 876 FLDVELGR SEQ ID NO: 877 1 M A G P L R A P L L L L A I L A V A L A V S P A A G S S P G K P P R L V G G P M D A S V E E E G V R R A L D F A V G E Y N K A S N D M Y H S R A L Q V V R A R K 81 Q I V A G V N Y F L D V E L G R T T C T K T Q P N L D N C P F H D Q P H L K R K A F C S F Q I Y A V P W Q G T M T L S K S T C Q D A 5.127 tweety 3 [Homo sapiens] Protein Accession gi|51100978

Mean Expression Ratio 0.86 Median Expression Ratio 0.86 Credible Interval (0.702, 1.06) Associated Peptides 8 Associated Spectra 21 Coverage 0.222

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.62 0.86 1.2 SEQ ID NO: 878 AANPFQQK 4 0.66 0.87 1.1 SEQ ID NO: 879 AAPWWVSLLHR 7 0.64 0.82 1.0 SEQ ID NO: 880 ALVEMQDVVAELLR 2 0.65 0.9 1.2 SEQ ID NO: 881 GPDEDGEEEAAPGPR 1 0.64 0.9 1.2 SEQ ID NO: 882 MVEEYSVLSGDILQYYLACSPR 3 0.57 0.77 1.0 SEQ ID NO: 883 QLAGRPEPLR 2 0.63 0.85 1.2 SEQ ID NO: 884 TVSNAPVTEYMSQNANFQNPR 1 0.65 0.9 1.3 SEQ ID NO: 885 TVPWEQPATKDPLLR SEQ ID NO: 886 1 M A G V S Y A A P W W V S L L H R L P H F D L S W E A T S S Q F R P E D T D Y Q Q A L L L L G A A A L A C L A L D L L F L L F Y S F W L C C R R R K S E E H L D 81 A D C C C T A W C V I I A T L V C S A G I A V G F Y G N G E T S D G I H R A T Y S L R H A N R T V A G V Q D R V W D T A V G L N H T A E P S L Q T L E R Q L A G 161 R P E P L R A V Q R L Q G L L E T L L G Y T A A I P F W R N T A V S L E V L A E Q V D L Y D W Y R W L G Y L G L L L L D V I I C L L V L V G L I R S S K G I L V 241 G V C L L G V L A L V I S W G A L G L E L A V S V G S S D F C V D P D A Y V T K M V E E Y S V L S G D I L Q Y Y L A C S P R A A N P F Q Q K L S G S H K A L V E 321 M Q D V V A E L L R T V P W E Q P A T K D P L L R V Q E V L N G T E V N L Q H L T A L V D C R S L H L D Y V Q A L T G F C Y D G V E G L I Y L A L F S F V T A L 401 M F S S I V C S V P H T W Q Q K R G P D E D G E E E A A P G P R Q A H D S L Y R V H M P S L Y S C G S S Y G S E T S I P A A A H T V S N A P V T E Y M S Q N A N 481 F Q N P R C E N T P L I G R E S P P P S Y T S S M R A K Y L A T S Q P R P D S S G S H 5.128 hypothetical protein LOC84418 [Homo sapiens] Protein Accession gi|14165278

Mean Expression Ratio 1.16 Median Expression Ratio 1.16 Credible Interval (0.761, 1.78) Associated Peptides 2 Associated Spectra 2 Coverage 0.278

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.74 1.2 1.9 SEQ ID NO: 887 QGYPQYGWQGGPQEPPK 1 0.74 1.2 1.9 SEQ ID NO: 888 TTVYVVEDQR SEQ ID NO: 889 1 M N Q E N P P P Y P G P G P T A P Y P P Y P P Q P M G P G P M G G P Y P P P Q G Y P Y Q G Y P Q Y G W Q G G P Q E P P K T T V Y V V E D Q R R D E L G P S T C L 81 T A C W T A L C C C C L W D M L T 5.129 CD82 antigen isoform 2 [Homo sapiens]; CD82 antigen isoform 1 [Homo sapiens] Protein Accession gi|67782354 gi|4504813

Mean Expression Ratio 1.16 Median Expression Ratio 1.16 Credible Interval (0.755, 1.79) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.74 1.2 1.8 SEQ ID NO: 890 EDSLQDAWDYVQAQVK 1 0.75 1.2 1.9 SEQ ID NO: 891 QEMGGIVTELIR 5.130 napsin A preproprotein [Homo sapiens] Protein Accession gi|4758754

Mean Expression Ratio 0.862 Median Expression Ratio 0.864 Credible Interval (0.674, 1.09) Associated Peptides 6 Associated Spectra 13 Coverage 0.207

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.59 0.83 1.1 SEQ ID NO: 892 DPEEPDGGELVLGGSDPAH 5 0.57 0.76 1 SEQ ID NO: 893 GCAAILDTGTSLITGPTEEIR 2 0.61 0.85 1.2 SEQ ID NO: 894 ILDTGTSLITGPTEEIR 1 0.65 0.92 1.3 SEQ ID NO: 895 SPGDKPIFVPLSNYR 1 0.6 0.85 1.2 SEQ ID NO: 896 TVAFDTGSSNLWVPSR 2 0.68 0.95 1.3 SEQ ID NO: 897 VDGILSEDKLTIGGIK SEQ ID NO: 898 1 M S P P P L L Q P L L L L L P L L N V E P S G A T L I R I P L H R V Q P G R R I L N L L R G W R E P A E L P K L G A P S P G D K P I F V P L S N Y R D V Q Y F G 81 E I G L G T P P Q N F T V A F D T G S S N L W V P S R R C H F F S V P C W L H H R F D P K A S S S F Q A N G T K F A I Q Y G T G R V D G I L S E D K L T I G G I 161 K G A S V I F G E A L W E P S L V F A F A H F D G I L G L G F P I L S V E G V R P P M D V L V E Q G L L D K P V F S F Y L N R D P E E P D G G E L V L G G S D P 241 A H Y I P P L T F V P V T V P A Y W Q I H M E R V K V G P G L T L C A K G C A A I L D T G T S L I T G P T E E I R A L H A A I G G I P L L A G E Y I I L C S E I 321 P K L P A V S F L L G G V W F N L T A H D Y V I Q T T R N G V R L C L S G F Q A L D V P P P A G P F W I L G D V F L G T Y V A V F D R G D M K S S A R V G L A R 401 A R T R G A D L G W G E T A Q A Q F P G 5.131 acid phosphatase 2, lysosomal isoform 1 precursor [Homo sapiens] Protein Accession gi|4557010

Mean Expression Ratio 0.864 Median Expression Ratio 0.864 Credible Interval (0.64, 1.17) Associated Peptides 4 Associated Spectra 7 Coverage 0.132

A 2.5 50 97.5 Sequence ID No. Sequence 4 0.6 0.83 1.1 SEQ ID NO: 899 EGMLQHWELGQALR 1 0.6 0.87 1.3 SEQ ID NO: 900 FVTLLYR 1 0.59 0.87 1.3 SEQ ID NO: 901 NVYDTLFCEQTHGLR 1 0.58 0.85 1.3 SEQ ID NO: 902 TLMSAEANLAGLFPPNGMQR SEQ ID NO: 903 1 M A G K R S G W S R A A L L Q L L L G V N L V V M P P T R A R S L R F V T L L Y R H G D R S P V K T Y P K D P Y Q E E E W P Q G F G Q L T K E G M L Q H W E L G 81 Q A L R Q R Y H G F L N T S Y H R Q E V Y V R S T D F D R T L M S A E A N L A G L F P P N G M Q R F N P N I S W Q P I P V H T V P I T E D R L L K F P L G P C P 161 R Y E Q L Q N E T R Q T P E Y Q N E S S R N A Q F L D M V A N E T G L T D L T L E T V W N V Y D T L F C E Q T H G L R L P P W A S P Q T M Q R L S R L K D F S F 241 R F L F G I Y Q Q A E K A R L Q G G V L L A Q I R K N L T L M A T T S Q L P K L L V Y S A H D T T L V A L Q M A L D V Y N G E Q A P Y A S C H I F E L Y Q E D S 321 G N F S V E M Y F R N E S D K A P W P L S L P G C P H R C P L Q D F L R L T E P V V P K D W Q Q E C Q L A S G P A D T E V I V A L A V C G S I L F L L I V L L L 401 T V L F R M Q A Q P P G Y R H V A D G E D H A 5.132 apolipoprotein E precursor [Homo sapiens] Protein Accession gi|4557325

Mean Expression Ratio 0.863 Median Expression Ratio 0.864 Credible Interval (0.56, 1.32) Associated Peptides 2 Associated Spectra 2 Coverage 0.110

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.55 0.87 1.4 SEQ ID NO: 904 SWFEPLVEDMQR 1 0.52 0.83 1.3 SEQ ID NO: 905 WVQTLSEQVQEELLSSQVTQELR SEQ ID NO: 906 1 M K V L W A A L L V T F L A G C Q A K V E Q A V E T E P E P E L R Q Q T E W Q S G Q R W E L A L G R F W D Y L R W V Q T L S E Q V Q E E L L S S Q V T Q E L R A 81 L M D E T M K E L K A Y K S E L E E Q L T P V A E E T R A R L S K E L Q A A Q A R L G A D M E D V C G R L V Q Y R G E V Q A M L G Q S T E E L R V R L A S H L R 161 K L R K R L L R D A D D L Q K R L A V Y Q A G A R E G A E R G L S A I R E R L G P L V E Q G R V R A A T V G S L A G Q P L Q E R A Q A W G E R L R A R M E E M G 241 S R T R D R L D E V K E Q V A E V R A K L E E Q A Q Q I R L Q A E A F Q A R L K S W F E P L V E D M Q R Q W A G L V E K V Q A A V G T S A A P V P S D N H 5.133 transmembrane protein 176B isoform b [Homo sapiens]; transmembrane protein 176B isoform a [Homo sapiens]; transmembrane protein 176B isoform a [Homo sapiens]; transmembrane protein 176B isoform a [Homo sapiens]; transmembrane protein 176B isoform a [Homo sapiens] Protein Accession gi|156416022 gi|56416020 gi|156416018 gi|156416016 gi|156416014

Mean Expression Ratio 0.864 Median Expression Ratio 0.865 Credible Interval (0.64, 1.17) Associated Peptides 3 Associated Spectra 8 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 5 0.6 0.82 1.1 SEQ ID NO: 907 FLFHPGDTVPSTAR 1 0.58 0.85 1.2 SEQ ID NO: 908 LFHPGDTVPSTAR 2 0.62 0.89 1.3 SEQ ID NO: 909 LLGENSVPPSPSR 5.134 GM2 ganglioside activator precursor [Homo sapiens] Protein Accession gi|39995109

Mean Expression Ratio 1.15 Median Expression Ratio 1.16 Credible Interval (0.703, 1.88) Associated Peptides 1 Associated Spectra 1 Coverage 0.104

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.71 1.2 2 SEQ ID NO: 910 SEFVVPDLELPSWLTTGNYR SEQ ID NO: 911 1 M Q S L M Q A P L L I A L G L L L A A P A Q A H L K K P S Q L S S F S W D N C D E G K D P A V I R S L T L E P D P I I V P G N V T L S V M G S T S V P L S S P L 81 K V D L V L E K E V A G L W I K I P C T D Y I G S C T F E H F C D V L D M L I P T G E P C P E P L R T Y G L P C H C P F K E G T Y S L P K S E F V V P D L E L P 161 S W L T T G N Y R I E S V L S S S G K R L G C I K I A A S L K G I 5.135 mercaptopyruvate sulfurtransferase isoform 2 [Homo sapiens]; mercaptopyruvate sulfurtransferase isoform 2 [Homo sapiens]; mercaptopyruvate sulfurtransferase isoform 1 [Homo sapiens] Protein Accession gi|61835204 gi|194473681 gi|194473668

Mean Expression Ratio 0.865 Median Expression Ratio 0.866 Credible Interval (0.564, 1.33) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.53 0.85 1.4 SEQ ID NO: 912 ALVSAQWVAEALR 1 0.53 0.85 1.4 SEQ ID NO: 913 HIPGAAFFDIDQCSDR 5.136 mannosidase, alpha, class 1A, member 1 [Homo sapiens] Protein Accession gi|24497519

Mean Expression Ratio 0.866 Median Expression Ratio 0.867 Credible Interval (0.556, 1.32) Associated Peptides 2 Associated Spectra 2 Coverage 0.0475

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.53 0.86 1.4 SEQ ID NO: 914 GLPPVDFVPPIGVESR 1 0.53 0.85 1.3 SEQ ID NO: 915 MYFDAVQAIETHLIR SEQ ID NO: 916 1 M P V G G L L P L F S S P A G G V L G G G L G G G G G R K G S G P A A L R L T E K F V L L L V F S A F I T L C F G A I F F L P D S S K L LS G V L F H S S P A L 81 Q P A A D H K P G P G A R A E D A A E G R A R R R E E G A P G D P E A A L E D N L A R I R E N H E R A L R E A K E T L Q K L P E E I Q R D I L L E K K K V A Q D 161 Q L R D K A P F R G L P P V D F V P P I G V E S R E P A D A A I R E K R A K I K E M M K H A W N N Y K G Y A W G L N E L K P I S K G G H S S S L F G N I K G A T 241 I V D A L D T L F I M E M K H E F E E A K S W V E E N L D F N V N A E I S V F E V N I R F V G G L L S A Y Y L S G E E I F R K K A V E L G V K L L P A F H T P S 321 G I P W A L L N M K S G I G R N W P W A S G G S S I L A E F G T L H L E F M H L S H L S G N P I F A E K V M N I R T V L N K L E K P Q G L Y P N Y L N P S S G Q 401 W G Q H H V S V G G L G D S F Y E Y L L K A W L M S D K T D L E A K K M Y F D A V Q A I E T H L I R K S S S G L T Y I A E W K G G L L E H K M G H L T C F A G G 481 M F A L G A D A A P E G M A Q H Y L E L G A E I A R T C H E S Y N R T F M K L G P E A F R F D G G V E A I A T R Q N E K Y Y I L R P E V M E T Y M Y M W R L T H 561 D P K Y R K W A W E A V E A L E N H C R V N G G Y S G L R D V Y L L H E S Y D D V Q Q S F F L A E T L K Y L Y L I F S D D D L L P L E H W I F N S E A H L L P I 641 L P K D K K E V E I R E E 5.137 integral membrane protein 2B [Homo sapiens] Protein Accession gi|11527402

Mean Expression Ratio 0.87 Median Expression Ratio 0.868 Credible Interval (0.571, 1.35) Associated Peptides 2 Associated Spectra 2 Coverage 0.109

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.53 0.85 1.4 SEQ ID NO: 917 SGEEALIIPPDAVAVDCK 1 0.54 0.86 1.4 SEQ ID NO: 918 DPDDVVPVGQR SEQ ID NO: 919 1 M V K V T F N S A L A Q K E A K K D E P K S G E E A L I I P P D A V A V D C K D P D D V V P V G Q R R A W C W C M C F G L A F M L A G V I L G G A Y L Y K Y F A 81 L Q P D D V Y Y C G I K Y I K D D V I L N E P S A D A P A A L Y Q T I E E N I K I F E E E E V E F I S V P V P E F A D S D P A N I V H D F N K K L T A Y L D L N 161 L D K C Y V I P L N T S I V M P P R N L L E L L I N I K A G T Y L P Q S Y L I H E H M V I T D R I E N I D H L G F F I Y R L C H D K E T Y K L Q R R E T I K G I 241 Q K R E A S N C F A I R H F E N K F A V E T L I C S 5.138 tetraspan 1 [Homo sapiens] Protein Accession gi|21264578

Mean Expression Ratio 1.16 Median Expression Ratio 1.15 Credible Interval (0.857, 1.57) Associated Peptides 4 Associated Spectra 8 Coverage 0.112

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.8 1.2 1.7 SEQ ID NO: 920 AHDQKVEGCFNQLLYDIR 1 0.77 1.1 1.7 SEQ ID NO: 921 QKAHDQK 5 0.92 1.2 1.7 SEQ ID NO: 922 VEGCFNQLLYDIR 1 0.77 1.1 1.7 SEQ ID NO: 923 LVVPAIK SEQ ID NO: 924 1 M Q C F S F I K T M M I L F N L L I F L C G A A L L A V G I W V S I D G A S F L K I F G P L S S S A M Q F V N V G Y F L I A A G V V V F A L G F L G C Y G A K T 81 E S K C A L V T F F F I L L L I F I A E V A A A V V A L V Y T T M A E H F L T L L V V P A I K K D Y G S Q E D F T Q V W N T T M K G L K C C G F T N Y T D F E D 161 S P Y F K E N S A F P P F C C N D N V T N T A N E T C T K Q K A H D Q K V E G C F N Q L L Y D I R T N A V T V G G V A A G I G G L E L A A M I V S M Y L Y C N L 241 Q 5.139 apolipoprotein D precursor [Homo sapiens] Protein Accession gi|4502163

Mean Expression Ratio 0.869 Median Expression Ratio 0.868 Credible Interval (0.709, 1.06) Associated Peptides 9 Associated Spectra 23 Coverage 0.344

A 2.5 50 97.5 Sequence ID No. Sequence 5 0.65 0.85 1.1 SEQ ID NO: 925 CPNPPVQENFDVNK 1 0.61 0.84 1.2 SEQ ID NO: 926 IPTTFENGR 4 0.73 0.97 1.3 SEQ ID NO: 927 KMTVTDQVNCPK 2 0.63 0.86 1.2 SEQ ID NO: 928 MTVTDQVNCPK 3 0.65 0.87 1.2 SEQ ID NO: 929 NILTSNNIDVK 2 0.62 0.83 1.1 SEQ ID NO: 930 NPNLPPETVDSLK 1 0.63 0.87 1.2 SEQ ID NO: 931 NPPVQENFDVNK 3 0.64 0.85 1.1 SEQ ID NO: 932 WYEIEK 2 0.64 0.86 1.2 SEQ ID NO: 933 WYEIEKIPTTFENGR SEQ ID NO: 934 1 M V M L L L L L S A L A G L F G A A E G Q A F H L G K C P N P P V Q E N F D V N K Y L G R W Y E I E K I P T T F E N G R C I Q A N Y S L M E N G K I K V L N Q E 81 L R A D G T V N Q I E G E A T P V N L T E P A K L E V K F S W F M P S A P Y W I L A T D Y E N Y A L V Y S C T C I I Q L F H V D F A W I L A R N P N L P P E T V 161 D S L K N I L T S N N I D V K K M T V T D Q V N C P K L S 5.140 stomatin isoform a [Homo sapiens] Protein Accession gi|38016911

Mean Expression Ratio 0.87 Median Expression Ratio 0.869 Credible Interval (0.7, 1.07) Associated Peptides 9 Associated Spectra 18 Coverage 0.417

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.67 0.92 1.3 SEQ ID NO: 935 EASMVITESPAALQLR 4 0.66 0.87 1.2 SEQ ID NO: 936 EEIAHNMQSTLDDATDAWGIK 1 0.62 0.87 1.2 SEQ ID NO: 937 FILPCTDSFIK 2 0.6 0.83 1.1 SEQ ID NO: 938 TISFDIPPQEILTK 1 0.63 0.88 1.2 SEQ ID NO: 939 VIAAEGEMNASR 4 0.6 0.8 1.1 SEQ ID NO: 940 VQNATLAVANITNADSATR 1 0.62 0.88 1.2 SEQ ID NO: 941 YLQTLTTIAAEK 2 0.65 0.89 1.2 SEQ ID NO: 942 LPVQLQR 1 0.61 0.87 1.2 SEQ ID NO: 943 LLAQTTLR SEQ ID NO: 944 1 M A E K R H T R D S E A Q R L P D S F K D S P S K G L G P C G W I L V A F S F L F T V I T F P I S I W M C I K I I K E Y E R A I I F R L G R I L Q G G A K G P G 81 L F F I L P C T D S F I K V D M R T I S F D I P P Q E I L T K D S V T I S V D G V V Y Y R V Q N A T L A V A N I T N A D S A T R L L A Q T T L R N V L G T K N L 161 S Q I L S D R E E I A H N M Q S T L D D A T D A W G I K V E R V E I K D V K L P V Q L Q R A M A A E A E A S R E A R A K V I A A E G E M N A S R A L K E A S M V 241 I T E S P A A L Q L R Y L Q T L T T I A A E K N S T I V F P L P I D M L Q G I I G A K H S H L G 5.141 eukaryotic translation initiation factor 6 isoform c [Homo sapiens] Protein Accession gi|31563374

Mean Expression Ratio 0.867 Median Expression Ratio 0.869 Credible Interval (0.534, 1.41) Associated Peptides 1 Associated Spectra 1 Coverage 0.106

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.5 0.84 1.4 SEQ ID NO: 945 TSIEDQDELSSLLQVPLVAGTVNR SEQ ID NO: 946 1 M A V R A S F E N N C E I G C F A K L T N T Y C L V A I G G S E N F Y R C G G S P G A Y G G G E A C A G V K S S G S G R V P A P L P R H H R V H V P T V C S R A 81 S S P I P S P W C T R L S P A A A S S G A C V W E T E E I L A D V L K V E V F R Q T V A D Q V L V G S Y C V F S N Q G G L V H P K T S I E D Q D E L S S L L Q V 161 P L V A G T V N R G S E V I A A G M V V N D W C A F C G L D T T S T E L S V V E S V F K L N E A Q P S T I A T S M R D S L I D S L T 5.142 kininogen 1 isoform 2 [Homo sapiens] Protein Accession gi|4504893

Mean Expression Ratio 0.876 Median Expression Ratio 0.869 Credible Interval (0.603, 1.30) Associated Peptides 3 Associated Spectra 3 Coverage 0.0937

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.55 0.84 1.3 SEQ ID NO: 947 DIPTNSPELEETLTHTITK 1 0.55 0.86 1.3 SEQ ID NO: 948 YFIDFVAR 1 0.58 0.89 1.4 SEQ ID NO: 949 IGEIKEETTSHLR SEQ ID NO: 950 1 M K L I T I L F L C S R L L L S L T Q E S Q S E E I D C N D K D L F K A V D A A L K K Y N S Q N Q S N N Q F V L Y R I T E A T K T V G S D T F Y S F K Y E I K E 81 G D C P V Q S G K T W Q D C E Y K D A A K A A T G E C T A T V G K R S S T K F S V A T Q T C Q I T P A E G P V V T A Q Y D C L G C V H P I S T Q S P D L E P I L 161 R H G I Q Y F N N N T Q H S S L F M L N E V K R A Q R Q V V A G L N F R I T Y S I V Q T N C S K E N F L F L T P D C K S L W N G D T G E C T D N A Y I D I Q L R 241 I A S F S Q N C D I Y P G K D F V Q P P T K I C V G C P R D I P T N S P E L E E T L T H T I T K L N A E N N A T F Y F K I D N V K K A R V Q V V A G K K Y F I D 321 F V A R E T T C S K E S N E E L T E S C E T K K L G Q S L D C N A E V Y V V P W E K K I Y P T V N C Q P L G M I S L M K R P P G F S P F R S S R I G E I K E E T 401 T S H L R S C E Y K G R P P K A G A E P A S E R E V S 5.143 syntenin isoform 3 [Homo sapiens]; syntenin isoform 3 [Homo sapiens] Protein Accession gi|55749523 gi|55749515

Mean Expression Ratio 1.15 Median Expression Ratio 1.15 Credible Interval (0.747, 1.77) Associated Peptides 1 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.77 1.2 1.8 SEQ ID NO: 951 ANVAVVSGAPLQGLVAR 5.144 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 [Homo sapiens] Protein Accession gi|4504041

Mean Expression Ratio 1.15 Median Expression Ratio 1.15 Credible Interval (0.8, 1.64) Associated Peptides 3 Associated Spectra 4 Coverage 0.101

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.77 1.2 1.8 SEQ ID NO: 952 ALSCTAEEQGVLPDDLSGVIR 1 0.78 1.2 1.8 SEQ ID NO: 953 IAQSDYIPTQQDVLR 2 0.77 1.1 1.7 SEQ ID NO: 954 SCTAEEQGVLPDDLSGVIR SEQ ID NO: 955 1 M G C T V S A E D K A A A E R S K M I D K N L R E D G E K A A R E V K L L L L G A G E S G K S T I V K Q M K I I H E D G Y S E E E C R Q Y R A V V Y S N T I Q S 81 I M A I V K A M G N L Q I D F A D P S R A D D A R Q L F A L S C T A E E Q G V L P D D L S G V I R R L W A D H G V Q A C F G R S R E Y Q L N D S A A Y Y L N D L 161 E R I A Q S D Y I P T Q Q D V L R T R V K T T G I V E T H F T F K D L H F K M F D V G G Q R S E R K K W I H C F E G V T A I I F C V A L S A Y D L V L A E D E E 241 M N R M H E S M K L F D S I C N N K W F T D T S I I L F L N K K D L F E E K I T H S P L T I C F P E Y T G A N K Y D E A A S Y I Q S K F E D L N K R K D T K E I 321 Y T H F T C A T D T K N V Q F V F D A V T D V I I K N N L K D C G L F 5.145 guanine nucleotide binding protein, alpha z polypeptide [Homo sapiens] Protein Accession gi|4504051

Mean Expression Ratio 1.15 Median Expression Ratio 1.15 Credible Interval (0.708, 1.89) Associated Peptides 1 Associated Spectra 1 Coverage 0.0423

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.72 1.2 2 SEQ ID NO: 956 IAAADYIPTVEDILR SEQ ID NO: 957 1 M G C R Q S S E E K E A A R R S R R I D R H L R S E S Q R Q R R E I K L L L L G T S N S G K S T I V K Q M K I I H S G G F N L E A C K E Y K P L I I Y N A I D S 81 L T R I I R A L A A L R I D F H N P D R A Y D A V Q L F A L T G P A E S K G E I T P E L L G V M R R L W A D P G A Q A C F S R S S E Y H L E D N A A Y Y L N D L 161 E R I A A A D Y I P T V E D I L R S R D M T T G I V E N K F T F K E L T F K M V D V G G Q R S E R K K W I H C F E G V T A I I F C V E L S G Y D L K L Y E D N Q 241 T S R M A E S L R L F D S I C N N N W F I N T S L I L F L N K K D L L A E K I R R I P L T I C F P E Y K G Q N T Y E E A A V Y I Q R Q F E D L N R N K E T K E I 321 Y S H F T C A T D T S N I Q F V F D A V T D V I I Q N N L K Y I G L C 5.146 cytochrome P450, family 4, subfamily A, polypeptide 11 [Homo sapiens] Protein Accession gi|158937242

Mean Expression Ratio 0.875 Median Expression Ratio 0.873 Credible Interval (0.54, 1.41) Associated Peptides 1 Associated Spectra 1 Coverage 0.0231

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.51 0.84 1.4 SEQ ID NO: 958 VWPNPEVFDPFR SEQ ID NO: 959 1 M S V S V L S P S R L L G D V S G I L Q A A S L L I L L L L L I K A V Q L Y L H R Q W L L K A L Q Q F P C P P S H W L F G H I Q E L Q Q D Q E L Q R I Q K W V E 81 T F P S A C P H W L W G G K V R V Q L Y D P D Y M K V I L G R S D P K S H G S Y R F L A P W I G Y G L L L L N G Q T W F Q H R R M L T P A F H Y D I L K P Y V G 161 L M A D S V R V M L D K W E E L L G Q D S P L E V F Q H V S L M T L D T I M K C A F S H Q G S I Q V D R N S Q S Y I Q A I S D L N N L V F S R V R N A F H Q N D 241 T I Y S L T S A G R W T H R A C Q L A H Q H T D Q V I Q L R K A Q L Q K E G E L E K I K R K R H L D F L D I L L L A K M E N G S I L S D K D L R A E V D T F M F 321 E G H D T T A S G I S W I L Y A L A T H P K H Q E R C R E E I H S L L G D G A S I T W N H L D Q M P Y T T M C I K E A L R L Y P P V P G I G R E L S T P V T F P 401 D G R S L P K G I M V L L S I Y G L H H N P K V W P N P E V F D P F R F A P G S A Q H S H A F L P F S G G S R N C I G K Q F A M N E L K V A T A L T L L R F E L 481 L P D P T R I P I P I A R L V L K S K N G I H L R L R R L P N P C E D K D Q L 5.147 olfactomedin 4 precursor [Homo sapiens] Protein Accession gi|32313593

Mean Expression Ratio 0.876 Median Expression Ratio 0.876 Credible Interval (0.784, 0.983) Associated Peptides 39 Associated Spectra 112 Coverage 0.657

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.63 0.84 1.1 SEQ ID NO: 960 DLGDVGPPIPSPGFSSFPGVDSSSSFSSS SR 1 0.64 0.86 1.1 SEQ ID NO: 961 DLSVLQKPQ 1 0.66 0.88 1.2 SEQ ID NO: 962 DQNTPVVHPPPTPGSC 1 0.67 0.89 1.2 SEQ ID NO: 963 DQNTPVVHPPPTPGSCGH 3 0.68 0.9 1.2 SEQ ID NO: 964 DTISYTELDFELIK 3 0.67 0.87 1.1 SEQ ID NO: 965 DYSPQHPNK 40  0.7 0.8 0.91 SEQ ID NO: 966 ESFGGSSEIVDQLEVEIR 1 0.65 0.87 1.2 SEQ ID NO: 967 EYVQLISVYEK 1 0.69 0.92 1.2 SEQ ID NO: 968 GFSYLYGAWGR 1 0.68 0.9 1.2 SEQ ID NO: 969 GLYWVAPLNTDGR 2 0.61 0.8 1.1 SEQ ID NO: 970 GTCQCSVSLPDTTFPVDR 1 0.65 0.86 1.1 SEQ ID NO: 971 ITYGQGSGTAVYNNNMYVNMYNTGN IAR 6 0.7 0.88 1.1 SEQ ID NO: 972 LDIVMHK 1 0.64 0.85 1.1 SEQ ID NO: 973 LEFTAHVL 4 0.72 0.92 1.2 SEQ ID NO: 974 LEFTAHVLSQK 1 0.67 0.89 1.2 SEQ ID NO: 975 LEFTAHVLSQKFEK 4 0.68 0.88 1.1 SEQ ID NO: 976 LETLDKNNVLAIR 2 0.67 0.88 1.1 SEQ ID NO: 977 LLEYYR 4 0.72 0.94 1.2 SEQ ID NO: 978 LYNTLDDLLLYINAR 3 0.68 0.9 1.2 SEQ ID NO: 979 LYVYNDGYLLNYDLSVLQKPQ 1 0.66 0.88 1.2 SEQ ID NO: 980 QCSVSLPDTTFPVDR 1 0.66 0.87 1.2 SEQ ID NO: 981 QYKPSASNAF 4 0.65 0.83 1.1 SEQ ID NO: 982 QYKPSASNAFMVCGVLYATR 2 0.67 0.89 1.2 SEQ ID NO: 983 SVSLPDTTFPVDR 1 0.64 0.85 1.1 SEQ ID NO: 984 TIAVTQTLPNAAYNNR 3 0.67 0.87 1.1 SEQ ID NO: 985 WVAPLNTDGR 2 0.66 0.87 1.1 SEQ ID NO: 986 TEEIFYYYDTNTGK 5 0.72 0.91 1.2 SEQ ID NO: 987 VQSINYNPFDQK 1 0.64 0.86 1.1 SEQ ID NO: 988 YYDTNTGK 1 0.67 0.9 1.2 SEQ ID NO: 989 LLNYDLSVLQKPQ 1 0.66 0.88 1.2 SEQ ID NO: 990 YYYDTNTGK 2 0.66 0.87 1.1 SEQ ID NO: 991 LKECEASK 1 0.67 0.9 1.2 SEQ ID NO: 992 EIVALK 1 0.66 0.89 1.2 SEQ ID NO: 993 IDIMEK 1 0.67 0.9 1.2 SEQ ID NO: 994 LETLDK 1 0.67 0.9 1.2 SEQ ID NO: 995 VYNDGYLLNYDLSVLQKPQ 1 0.67 0.9 1.2 SEQ ID NO: 996 YNPFDQK 1 0.66 0.87 1.2 SEQ ID NO: 997 LYNTLDDLLLY 1 0.63 0.83 1.1 SEQ ID NO: 998 VNMYNTGNIARVNLTTNTIAVTQTLP NAAYNNR SEQ ID NO: 999 1 M R P G L S F L L A L L F F L G Q A A G D L G D V G P P I P S P G F S S F P G V D S S S S F S S S S R S G S S S S R S L G S G G S V S Q L F S N F T G S V D D R 81 G T C Q C S V S L P D T T F P V D R V E R L E F T A H V L S Q K F E K E L S K V R E Y V Q L I S V Y E K K L L N L T V R I D I M E K D T I S Y T E L D F E L I K 161 V E V K E M E K L V I Q L K E S F G G S S E I V D Q L E V E I R N M T L L V E K L E T L D K N N V L A I R R E I V A L K T K L K E C E A S K D Q N T P V V H P P 241 P T P G S C G H G G V V N I S K P S V V Q L N W R G F S Y L Y G A W G R D Y S P Q H P N K G L Y W V A P L N T D G R L L E Y Y R L Y N T L D D L L L Y I N A R E 321 L R I T Y G Q G S G T A V Y N N N M Y V N M Y N T G N I A R V N L T T N T I A V T Q T L P N A A Y N N R F S Y A N V A W Q D I D F A V D E N G L W V I Y S T E A 401 S T G N M V I S K L N D T T L Q V L N T W Y T K Q Y K P S A S N A F M V C G V L Y A T R T M N T R T E E I F Y Y Y D T N T G K E G K L D I V M H K M Q E K V Q S 481 I N Y N P F D Q K L Y V Y N D G Y L L N Y D L S V L Q K P Q 5.148 peptidoglycan recognition protein 2 precursor [Homo sapiens] Protein Accession gi|56616294

Mean Expression Ratio 0.877 Median Expression Ratio 0.876 Credible Interval (0.542, 1.41) Associated Peptides 1 Associated Spectra 1 Coverage 0.0226

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.52 0.85 1.4 SEQ ID NO: 1000 TDCPGDALFDLLR SEQ ID NO: 1001 1 M A Q G V L W I L L G L L L W S D P G T A S L P L L M D S V I Q A L A E L E Q K V P A A K T R H T A S A W L M S A P N S G P H N R L Y H F L L G A W S L N A T E 81 L D P C P L S P E L L G L T K E V A R H D V R E G K E Y G V V L A P D G S T V A V E P L L A G L E A G L Q G R R V I N L P L D S M A A P W E T G D T F P D V V A 161 I A P D V R A T S S P G L R D G S P D V T T A D I G A N T P D A T K G C P D V Q A S L P D A K A K S P P T M V D S L L A V T L A G N L G L T F L R G S Q T Q S H 241 P D L G T E G C W D Q L S A P R T F T L L D P K A S L L T M A F L N G A L D G V I L G D Y L S R T P E P R P S L S H L L S Q Y Y G A G V A R D P G F R S N F R R 321 Q N G A A L T S A S I L A Q Q V W G T L V L L Q R L E P V H L Q L Q C M S Q E Q L A Q V A A N A T K E F T E A F L G C P A I H P R C R W G A A P Y R G R P K L L 401 Q L P L G F L Y V H H T Y V P A P P C T D F T R C A A N M R S M Q R Y H Q D T Q G W G D I G Y S F V V G S D G Y V Y E G R G W H W V G A H T L G H N S R G F G V 481 A I V G N Y T A A L P T E A A L R T V R D T L P S C A V R A G L L R P D Y A L L G H R Q L V R T D C P G D A L F D L L R T W P H F T A T V K P R P A R S V S K R 561 S R R E P P P R T L P A T D L Q 5.149 SMAD family member 9 isoform b [Homo sapiens]; SMAD family member 9 isoform a [Homo sapiens] Protein Accession gi|5174519 gi 187828357

Mean Expression Ratio 1.14 Median Expression Ratio 1.14 Credible Interval (0.696, 1.84) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.71 1.2 1.9 SEQ ID NO: 1002 VETPVLPPVLVPR 5.150 brain creatine kinase [Homo sapiens] Protein Accession gi|21536286

Mean Expression Ratio 1.14 Median Expression Ratio 1.14 Credible Interval (0.776, 1.69) Associated Peptides 3 Associated Spectra 3 Coverage 0.150

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.75 1.2 1.8 SEQ ID NO: 1003 GTGGVDTAAVGGVFDVSNADR 1 0.76 1.2 1.8 SEQ ID NO: 1004 TDLNPDNLQGGDDLDPNYVLSSR 1 0.74 1.1 1.8 SEQ ID NO: 1005 TFLVWVNEEDHLR SEQ ID NO: 1006 1 M P F S N S H N A L K L R F P A E D E F P D L S A H N N H M A K V L T P E L Y A E L R A K S T P S G F T L D D V I Q T G V D N P G H P Y I M T V G C V A G D E E 81 S Y E V F K D L F D P I I E D R H G G Y K P S D E H K T D L N P D N L Q G G D D L D P N Y V L S S R V R T G R S I R G F C L P P H C S R G E R R A I E K L A V E 161 A L S S L D G D L A G R Y Y A L K S M T E A E Q Q Q L I D D H F L F D K P V S P L L L A S G M A R D W P D A R G I W H N D N K T F L V W V N E E D H L R V I S M 241 Q K G G N M K E V F T R F C T G L T Q I E T L F K S K D Y E F M W N P H L G Y I L T C P S N L G T G L R A G V H I K L P N L G K H E K F S E V L K R L R L Q K R 321 G T G G V D T A A V G G V F D V S N A D R L G F S E V E L V Q M V V D G V K L L I E M E Q R L E Q G Q A I D D L M P A Q K 5.151 chromatin modifying protein 2A [Homo sapiens]; chromatin modifying protein 2A [Homo sapiens] Protein Accession gi|7656922 gi|38372933

Mean Expression Ratio 1.14 Median Expression Ratio 1.14 Credible Interval (0.798, 1.62) Associated Peptides 3 Associated Spectra 4 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.76 1.2 1.8 SEQ ID NO: 1007 AEAAASALADADADLEER 2 0.8 1.2 1.8 SEQ ID NO: 1008 KAEAAASALADADADLEER 1 0.73 1.1 1.6 SEQ ID NO: 1009 KIIADIK 5.152 solute carrier family 4, sodium bicarbonate cotransporter, member 4 isoform 2 [Homo sapiens] Protein Accession gi|4507025

Mean Expression Ratio 0.88 Median Expression Ratio 0.878 Credible Interval (0.573, 1.34) Associated Peptides 2 Associated Spectra 2 Coverage 0.0329

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.53 0.84 1.3 SEQ ID NO: 1010 LQQAVMLGALTEVPVPTR 1 0.55 0.9 1.4 SEQ ID NO: 1011 ILVATDASFLVQYFTR SEQ ID NO: 1012 1 M S T E N V E G K P S N L G E R G R A R S S T F L R V V Q P M F N H S I F T S A V S P A A E R I R F I L G E E D D S P A P P Q L F T E L D E L L A V D G Q E M E 81 W K E T A R W I K F E E K V E Q G G E R W S K P H V A T L S L H S L F E L R T C M E K G S I M L D R E A S S L P Q L V E M I V D H Q I E T G L L K P E L K D K V 161 T Y T L L R K H R H Q T K K S N L R S L A D I G K T V S S A S R M F T N P D N G S P A M T H R N L T S S S L N D I S D K P E K D Q L K N K F M K K L P R D A E A 241 S N V L V G E V D F L D T P F I A F V R L Q Q A V M L G A L T E V P V P T R F L F I L L G P K G K A K S Y H E I G R A I A T L M S D E V F H D I A Y K A K D R H 321 D L I A G I D E F L D E V I V L P P G E W D P A I R I E P P K S L P S S D K R K N M Y S G G E N V Q M N G D T P H D G G H G G G G H G D C E E L Q R T G R F C G 401 G L I K D I K R K A P F F A S D F Y D A L N I Q A L S A I L F I Y L A T V T N A I T F G G L L G D A T D N M Q G V L E S F L G T A V S G A I F C L F A G Q P L T 481 I L S S T G P V L V F E R L L F N F S K D N N F D Y L E F R L W I G L W S A F L C L I L V A T D A S F L V Q Y F T R F T E E G F S S L I S F I F I Y D A F K K M 561 I K L A D Y Y P I N S N F K V G Y N T L F S C T C V P P D P A N I S I S N D T T L A P E Y L P T M S S T D M Y H N T T F D W A F L S K K E C S K Y G G N L V G N 641 N C N F V P D I T L M S F I L F L G T Y T S S M A L K K F K T S P Y F P T T A R K L I S D F A I I L S I L I F C V I D A L V G V D T P K L I V P S E F K P T S P 721 N R G W F V P P F G E N P W W V C L A A A I P A L L V T I L I F M D Q Q I T A V I V N R K E H K L K K G A G Y H L D L F W V A I L M V I C S L M A L P W Y V A A 801 T V I S I A H I D S L K M E T E T S A P G E Q P K F L G V R E Q R V T G T L V F I L T G L S V F M A P I L K F I P M P V L Y G V F L Y M G V A S L N G V Q F M D 881 R L K L L L M P L K H Q P D F I Y L R H V P L R R V H L F T F L Q V L C L A L L W I L K S T V A A I I F P V M I L A L V A V R K G M D Y L F S Q H D L S F L D D 961 V I P E K D K K K K E D E K K K K K K K G S L D S D N D D S D C P Y S E K V P S I K I P M D I M E Q Q P F L S D S K P S D R E R S P T F L E R H T S C 5.153 phospholipid transfer protein isoform a precursor [Homo sapiens] Protein Accession gi|5453914

Mean Expression Ratio 0.875 Median Expression Ratio 0.878 Credible Interval (0.563, 1.35) Associated Peptides 1 Associated Spectra 2 Coverage 0.0304

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.54 0.84 1.3 SEQ ID NO: 1013 FLEQELETITIPDLR SEQ ID NO: 1014 1 M A L F G A L F L A L L A G A H A E F P G C K I R V T S K A L E L V K Q E G L R F L E Q E L E T I T I P D L R G K E G H F Y Y N I S E V K V T E L Q L T S S E L 81 D F Q P Q Q E L M L Q I T N A S L G L R F R R Q L L Y W F F Y D G G Y I N A S A E G V S I R T G L E L S R D P A G R M K V S N V S C Q A S V S R M H A A F G G T 161 F K K V Y D F L S T F I T S G M R F L L N Q Q I C P V L Y H A G T V L L N S L L D T V P V R S S V D E L V G I D Y S L M K D P V A S T S N L D M D F R G A F F P 241 L T E R N W S L P N R A V E P Q L Q E E E R M V Y V A F S E F F F D S A M E S Y F R A G A L Q L L L V G D K V P H D L D M L L R A T Y F G S I V L L S P A V I D 321 S P L K L E L R V L A P P R C T I K P S G T T I S V T A S V T I A L V P P D Q P E V Q L S S M T M D A R L S A K M A L R G K A L R T Q L D L R R F R I Y S N H S 401 A L E S L A L I P L Q A P L K T M L Q I G V M P M L N E R T W R G V Q I P L P E G I N F V H E V V T N H A G F L T I G A D L H F A K G L R E V I E K N R P A D V 481 R A S T A P T P S T A A V 5.154 ceruloplasmin precursor [Homo sapiens] Protein Accession gi|4557485

Mean Expression Ratio 0.879 Median Expression Ratio 0.878 Credible Interval (0.737, 1.05) Associated Peptides 20 Associated Spectra 27 Coverage 0.232

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.65 0.86 1.2 SEQ ID NO: 1015 AEEEHLGILGPQLHADVGDK 2 0.6 0.82 1.1 SEQ ID NO: 1016 ALYLQYTDETFR 1 0.65 0.9 1.2 SEQ ID NO: 1017 DIFTGLIGPMK 2 0.65 0.87 1.2 SEQ ID NO: 1018 DLYSGLIGPLIVCR 1 0.63 0.86 1.2 SEQ ID NO: 1019 DVDKEFYLFPTVFDENESLLLEDNIR 2 0.66 0.89 1.2 SEQ ID NO: 1020 EFYLFPTVFDENESLLLEDNIR 1 0.63 0.87 1.2 SEQ ID NO: 1021 GAYPLSIEPIGVR 2 0.65 0.86 1.2 SEQ ID NO: 1022 GPEEEHLGILGPVIWAEVGDTIR 1 0.62 0.86 1.2 SEQ ID NO: 1023 GVYSSDVFDIFPGTYQTLEMFPR 1 0.63 0.86 1.2 SEQ ID NO: 1024 IYHSHIDAPK 1 0.65 0.88 1.2 SEQ ID NO: 1025 KAEEEHLGILGPQLHADVGDK 1 0.65 0.88 1.2 SEQ ID NO: 1026 LFPTVFDENESLLLEDNIR 1 0.63 0.86 1.2 SEQ ID NO: 1027 MFTTAPDQVDKEDEDFQESNK 1 0.67 0.9 1.2 SEQ ID NO: 1028 MLLATEEQSPGEGDGNCVTR 1 0.64 0.87 1.2 SEQ ID NO: 1029 SVPPSASHVAPTETFTY 1 0.66 0.9 1.2 SEQ ID NO: 1030 TTIEKPVWLGFLGPIIK 3 0.69 0.9 1.2 SEQ ID NO: 1031 VNKDDEEFIESNK 1 0.64 0.88 1.2 SEQ ID NO: 1032 YLFPTVFDENESLLLEDNIR 1 0.64 0.88 1.2 SEQ ID NO: 1033 VTFHNK 1 0.69 0.93 1.3 SEQ ID NO: 1034 GPEEEHLGILGPVIW SEQ ID NO: 1035 1 M K I L I L G I F L F L C S T P A W A K E K H Y Y I G I I E T T W D Y A S D H G E K K L I S V D T E H S N I Y L Q N G P D R I G R L Y K K A L Y L Q Y T D E T F 81 R T T I E K P V W L G F L G P I I K A E T G D K V Y V H L K N L A S R P Y T F H S H G I T Y Y K E H E G A I Y P D N T T D F Q R A D D K V Y P G E Q Y T Y M L L 161 A T E E Q S P G E G D G N C V T R I Y H S H I D A P K D I A S G L I G P L I I C K K D S L D K E K E K H I D R E F V V M F S V V D E N F S W Y L E D N I K T Y C 241 S E P E K V D K D N E D F Q E S N R M Y S V N G Y T F G S L P G L S M C A E D R V K W Y L F G M G N E V D V H A A F F H G Q A L T N K N Y R I D T I N L F P A T 321 L F D A Y M V A Q N P G E W M L S C Q N L N H L K A G L Q A F F Q V Q E C N K S S S K D N I R G K H V R H Y Y I A A E E I I W N Y A P S G I D I F T K E N L T A 401 P G S D S A V F F E Q G T T R I G G S Y K K L V Y R E Y T D A S F T N R K E R G P E E E H L G I L G P V I W A E V G D T I R V T F H N K G A Y P L S I E P I G V 481 R F N K N N E G T Y Y S P N Y N P Q S R S V P P S A S H V A P T E T F T Y E W T V P K E V G P T N A D P V C L A K M Y Y S A V D P T K D I F T G L I G P M K I C 561 K K G S L H A N G R Q K D V D K E F Y L F P T V F D E N E S L L L E D N I R M F T T A P D Q V D K E D E D F Q E S N K M H S M N G F M Y G N Q P G L T M C K G D 641 S V V W Y L F S A G N E A D V H G I Y F S G N T Y L W R G E R R D T A N L F P Q T S L T L H M W P D T E G T F N V E C L T T D H Y T G G M K Q K Y T V N Q C R R 721 Q S E D S T F Y L G E R T Y Y I A A V E V E W D Y S P Q R E W E K E L H H L Q E Q N V S N A F L D K G E F Y I G S K Y K K V V Y R Q Y T D S T F R V P V E R K A 801 E E E H L G I L G P Q L H A D V G D K V K I I F K N M A T R P Y S I H A H G V Q T E S S T V T P T L P G E T L T Y V W K I P E R S G A G T E D S A C I P W A Y Y 881 S T V D Q V K D L Y S G L I G P L I V C R R P Y L K V F N P R R K L E F A L L F L V F D E N E S W Y L D D N I K T Y S D H P E K V N K D D E E F I E S N K M H A 961 I N G R M F G N L Q G L T M H V G D E V N W Y L M G M G N E I D L H T V H F H G H S F Q Y K H R G V Y S S D V F D I F P G T Y Q T L E M F P R T P G I W L L H C 1041 H V T D H I H A G M E T T Y T V L Q N E D T K S G 5.155 glycerophosphodiester phosphodiesterase domain containing 3 [Homo sapiens] Protein Accession gi|146198640

Mean Expression Ratio 0.88 Median Expression Ratio 0.88 Credible Interval (0.617, 1.25) Associated Peptides 4 Associated Spectra 4 Coverage 0.186

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.56 0.85 1.3 SEQ ID NO: 1036 GGSGELLENTMEAMENSMAQR 1 0.58 0.88 1.3 SEQ ID NO: 1037 SDLLELDCQLTR 1 0.57 0.87 1.3 SEQ ID NO: 1038 DVGSLDFEDLPLYK 1 0.58 0.9 1.4 SEQ ID NO: 1039 VVVVSHDENLCR SEQ ID NO: 1040 1 M S L L L Y Y A L P A L G S Y A M L S I F F L R R P H L L H T P R A P T F R I R L G A H R G G S G E L L E N T M E A M E N S M A Q R S D L L E L D C Q L T R D R 81 V V V V S H D E N L C R Q S G L N R D V G S L D F E D L P L Y K E K L E V Y F S P G H F A H G S D R R M V R L E D L F Q R F P R T P M S V E I K G K N E E L I R 161 E I A G L V R R Y D R N E I T I W A S E K S S V M K K C K A A N P E M P L S F T I S R G F W V L L S Y Y L G L L P F I P I P E K F F F C F L P N I I N R T Y F P 241 F S C S C L N Q L L A V V S K W L I M R K S L I R H L E E R G V Q V V F W C L N E E S D F E A A F S V G A T G V I T D Y P T A L R H Y L D N H G P A A R T S 5.156 glucuronidase, beta [Homo sapiens] Protein Accession gi|4504223

Mean Expression Ratio 1.14 Median Expression Ratio 1.14 Credible Interval (0.797, 1.61) Associated Peptides 4 Associated Spectra 4 Coverage 0.0707

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.74 1.1 1.7 SEQ ID NO: 1041 GFDWPLLVK 1 0.76 1.1 1.7 SEQ ID NO: 1042 NFADFMTEQSPTR 1 0.76 1.2 1.7 SEQ ID NO: 1043 YVVGELIWNFADFMTEQSPTR 1 0.75 1.1 1.7 SEQ ID NO: 1044 TSHYPYAEEVMQMCDR SEQ ID NO: 1045 1 M A R G S A V A W A A L G P L L W G C A L G L Q G G M L Y P Q E S P S R E C K E L D G L W S F R A D F S D N R R R G F E E Q W Y R R P L W E S G P T V D M P V P 81 S S F N D I S Q D W R L R H F V G W V W Y E R E V I L P E R W T Q D L R T R V V L R I G S A H S Y A I V W V N G V D T L E H E G G Y L P F E A D I S N L V Q V G 161 P L P S R L R I T I A I N N T L T P T T L P P G T I Q Y L T D T S K Y P K G Y F V Q N T Y F D F F N Y A G L Q R S V L L Y T T P T T Y I D D I T V T T S V E Q D 241 S G L V N Y Q I S V K G S N L F K L E V R L L D A E N K V V A N G T G T Q G Q L K V P G V S L W W P Y L M H E R P A Y L Y S L E V Q L T A Q T S L G P V S D F Y 321 T L P V G I R T V A V T K S Q F L I N G K P F Y F H G V N K H E D A D I R G K G F D W P L L V K D F N L L R W L G A N A F R T S H Y P Y A E E V M Q M C D R Y G 401 I V V I D E C P G V G L A L P Q F F N N V S L H H H M Q V M E E V V R R D K N H P A V V M W S V A N E P A S H L E S A G Y Y L K M V I A H T K S L D P S R P V T 481 F V S N S N Y A A D K G A P Y V D V I C L N S Y Y S W Y H D Y G H L E L I Q L Q L A T Q F E N W Y K K Y Q K P I I Q S E Y G A E T I A G F H Q D P P L M F T E E 561 Y Q K S L L E Q Y H L G L D Q K R R K Y V V G E L I W N F A D F M T E Q S P T R V L G N K K G I F T R Q R Q P K S A A F L L R E R Y W K I A N E T R Y P H S V A 641 K S Q C L E N S P F T 5.157 solute carrier family 4, anion exchanger, member 1 [Homo sapiens] Protein Accession gi|4507021

Mean Expression Ratio 1.13 Median Expression Ratio 1.14 Credible Interval (0.734, 1.73) Associated Peptides 2 Associated Spectra 2 Coverage 0.0329

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.72 1.1 1.8 SEQ ID NO: 1046 ADFLEQPVLGFVR 1 0.73 1.2 1.8 SEQ ID NO: 1047 LQEAAELEAVELPVPIR SEQ ID NO: 1048 1 M E E L Q D D Y E D M M E E N L E Q E E Y E D P D I P E S Q M E E P A A H D T E A T A T D Y H T T S H P G T H K V Y V E L Q E L V M D E K N Q E L R W M E A A R 81 W V Q L E E N L G E N G A W G R P H L S H L T F W S L L E L R R V F T K G T V L L D L Q E T S L A G V A N Q L L D R F I F E D Q I R P Q D R E E L L R A L L L K 161 H S H A G E L E A L G G V K P A V L T R S G D P S Q P L L P Q H S S L E T Q L F C E Q G D G G T E G H S P S G I L E K I P P D S E A T L V L V G R A D F L E Q P 241 V L G F V R L Q E A A E L E A V E L P V P I R F L F V L L G P E A P H I D Y T Q L G R A A A T L M S E R V F R I D A Y M A Q S R G E L L H S L E G F L D C S L V 321 L P P T D A P S E Q A L L S L V P V Q R E L L R R R Y Q S S P A K P D S S F Y K G L D L N G G P D D P L Q Q T G Q L F G G L V R D I R R R Y P Y Y L S D I T D A 401 F S P Q V L A A V I F I Y F A A L S P A I T F G G L L G E K T R N Q M G V S E L L I S T A V Q G I L F A L L G A Q P L L V V G F S G P L L V F E E A F F S F C E 481 T N G L E Y I V G R V W I G F W L I L L V V L V V A F E G S F L V R F I S R Y T Q E I F S F L I S L I F I Y E T F S K L I K I F Q D H P L Q K T Y N Y N V L M V 561 P K P Q G P L P N T A L L S L V L M A G T F F F A M M L R K F K N S S Y F P G K L R R V I G D F G V P I S I L I M V L V D F F I Q D T Y T Q K L S V P D G F K V 641 S N S S A R G W V I H P L G L R S E F P I W M M F A S A L P A L L V F I L I F L E S Q I T T L I V S K P E R K M V K G S G F H L D L L L V V G M G G V A A L F G 721 M P W L S A T T V R S V T H A N A L T V M G K A S T P G A A A Q I Q E V K E Q R I S G L L V A V L V G L S I L M E P I L S R I P L A V L F G I F L Y M G V T S L 801 S G I Q L F D R I L L L F K P P K Y H P D V P Y V K R V K T W R M H L F T G I Q I I C L A V L W V V K S T P A S L A L P F V L I L T V P L R R V L L P L I F R N 881 V E L Q C L D A D D A K A T F D E E E G R D E Y D E V A M P V 5.158 arylsulfatase A isoform a precursor [Homo sapiens]; arylsulfatase A isoform a precursor [Homo sapiens]; arylsulfatase A isoform a precursor [Homo sapiens]; arylsulfatase A isoform b [Homo sapiens]; arylsulfatase A isoform a precursor [Homo sapiens] Protein Accession gi|6005990 gi|146229331 gi|146229329 gi|146229327 gi|146229324

Mean Expression Ratio 1.14 Median Expression Ratio 1.14 Credible Interval (0.749, 1.77) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.72 1.1 1.8 SEQ ID NO: 1049 GGLPLEEVTVAEVLAAR 1 0.73 1.2 1.9 SEQ ID NO: 1050 YMAFAHDLMADAQR 5.159 guanine nucleotide binding protein (G protein) alpha 12 [Homo sapiens] Protein Accession gi|42476111

Mean Expression Ratio 1.14 Median Expression Ratio 1.14 Credible Interval (0.701, 1.86) Associated Peptides 1 Associated Spectra 1 Coverage 0.0341

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.7 1.2 2 SEQ ID NO: 1051 ATKGIVEHDFVIK SEQ ID NO: 1052 1 M S G V V R T L S R C L L P A E A G G A R E R R A G S G A R D A E R E A R R R S R D I D A L L A R E R R A V R R L V K I L L L G A G E S G K S T F L K Q M R I I 81 H G R E F D Q K A L L E F R D T I F D N I L K G S R V L V D A R D K L G I P W Q Y S E N E K H G M F L M A F E N K A G L P V E P A T F Q L Y V P A L S A L W R D 161 S G I R E A F S R R S E F Q L G E S V K Y F L D N L D R I G Q L N Y F P S K Q D I L L A R K A T K G I V E H D F V I K K I P F K M V D V G G Q R S Q R Q K W F Q 241 C F D G I T S I L F M V S S S E Y D Q V L M E D R R T N R L V E S M N I F E T I V N N K L F F N V S I I L F L N K M D L L V E K V K T V S I K K H F P D F R G D 321 P H R L E D V Q R Y L V Q C F D R K R R N R S K P L F H H F T T A I D T E N V R F V F H A V K D T I L Q E N L K D I M L Q 5.160 solute carrier family 1, member 1 [Homo sapiens] Protein Accession gi|66773030

Mean Expression Ratio 0.882 Median Expression Ratio 0.881 Credible Interval (0.541, 1.44) Associated Peptides 1 Associated Spectra 1 Coverage 0.0344

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.51 0.86 1.4 SEQ ID NO: 1053 TGSTPEVSTVDAMLDLIR SEQ ID NO: 1054 1 M G K P A R K G C E W K R F L K N N W V L L S T V A A V V L G I T T G V L V R E H S N L S T L E K F Y F A F P G E I L M R M L K L I I L P L I I S S M I T G V A 81 A L D S N V S G K I G L R A V V Y Y F C T T L I A V I L G I V L V V S I K P G V T Q K V G E I A R T G S T P E V S T V D A M L D L I R N M F P E N L V Q A C F Q 161 Q Y K T K R E E V K P P S D P E M N M T E E S F T A V M T T A I S K N K T K E Y K I V G M Y S D G I N V L G L I V F C L V F G L V I G K M G E K G Q I L V D F F 241 N A L S D A T M K I V Q I I M C Y M P L G I L F L I A G K I I E V E D W E I F R K L G L Y M A T V L T G L A I H S I V I L P L I Y F I V V R K N P F R F A M G M 321 A Q A L L T A L M I S S S S A T L P V T F R C A E E N N Q V D K R I T R F V L P V G A T I N M D G T A L Y E A V A A V F I A Q L N D L D L G I G Q I I T I S I T 401 A T S A S I G A A G V P Q A G L V T M V I V L S A V G L P A E D V T L I I A V D W L L D R F R T M V N V L G D A F G T G I V E K L S K K E L E Q M D V S S E V N 481 I V N P F A L E S T I L D N E D S D T K K S Y V N G G F A V D K S D T I S F T Q T S Q F 5.161 keratin 9 [Homo sapiens] Protein Accession gi|55956899

Mean Expression Ratio 0.881 Median Expression Ratio 0.882 Credible Interval (0.578, 1.34) Associated Peptides 2 Associated Spectra 2 Coverage 0.0642

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.54 0.86 1.4 SEQ ID NO: 1055 HGVQELEIELQSQLSK 1 0.55 0.87 1.4 SEQ ID NO: 1056 SYGGGSGGGFSASSLGGGFGGGSR SEQ ID NO: 1057 1 M S C R Q F S S S Y L S R S G G G G G G G L G S G G S I R S S Y S R F S S S G G G G G G G R F S S S S G Y G G G S S R V C G R G G G G S F G Y S Y G G G S G G G 81 F S A S S L G G G F G G G S R G F G G A S G G G Y S S S G G F G G G F G G G S G G G F G G G Y G S G F G G F G G F G G G A G G G D G G I L T A N E K S T M Q E L 161 N S R L A S Y L D K V Q A L E E A N N D L E N K I Q D W Y D K K G P A A I Q K N Y S P Y Y N T I D D L K D Q I V D L T V G N N K T L L D I D N T R M T L D D F R 241 I K F E M E Q N L R Q G V D A D I N G L R Q V L D N L T M E K S D L E M Q Y E T L Q E E L M A L K K N H K E E M S Q L T G Q N S G D V N V E I N V A P G K D L T 321 K T L N D M R Q E Y E Q L I A K N R K D I E N Q Y E T Q I T Q I E H E V S S S G Q E V Q S S A K E V T Q L R H G V Q E L E I E L Q S Q L S K K A A L E K S L E D 401 T K N R Y C G Q L Q M I Q E Q I S N L E A Q I T D V R Q E I E C Q N Q E Y S L L L S I K M R L E K E I E T Y H N L L E G G Q E D F E S S G A G K I G L G G R G G 481 S G G S Y G R G S R G G S G G S Y G G G G S G G G Y G G G S G S R G G S G G S Y G G G S G S G G G S G G G Y G G G S G G G H S G G S G G G H S G G S G G N Y G G 561 G S G S G G G S G G G Y G G G S G S R G G S G G S H G G G S G F G G E S G G S Y G G G E E A S G S G G G Y G G G S G K S S H S 5.162 pyruvate kinase, muscle isoform M2 [Homo sapiens] Protein Accession gi|33286418

Mean Expression Ratio 1.13 Median Expression Ratio 1.13 Credible Interval (0.83, 1.57) Associated Peptides 4 Associated Spectra 6 Coverage 0.0923

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.78 1.1 1.7 SEQ ID NO: 1058 DPVQEAWAEDVDLR 1 0.78 1.2 1.7 SEQ ID NO: 1059 FDEILEASDGIMVAR 3 0.8 1.1 1.6 SEQ ID NO: 1060 HLQLFEELR 1 0.76 1.1 1.7 SEQ ID NO: 1061 LDIDSPPITAR SEQ ID NO: 1062 1 M S K P H S E A G T A F I Q T Q Q L H A A M A D T F L E H M C R L D I D S P P I T A R N T G I I C T I G P A S R S V E T L K E M I K S G M N V A R L N F S H G T 81 H E Y H A E T I K N V R T A T E S F A S D P I L Y R P V A V A L D T K G P E I R T G L I K G S G T A E V E L K K G A T L K I T L D N A Y M E K C D E N I L W L D 161 Y K N I C K V V E V G S K I Y V D D G L I S L Q V K Q K G A D F L V T E V E N G G S L G S K K G V N L P G A A V D L P A V S E K D I Q D L K F G V E Q D V D M V 241 F A S F I R K A S D V H E V R K V L G E K G K N I K I I S K I E N H E G V R R F D E I L E A S D G I M V A R G D L G I E I P A E K V F L A Q K M M I G R C N R A 321 G K P V I C A T Q M L E S M I K K P R P T R A E G S D V A N A V L D G A D C I M L S G E T A K G D Y P L E A V R M Q H L I A R E A E A A I Y H L Q L F E E L R R 401 L A P I T S D P T E A T A V G A V E A S F K C C S G A I I V L T K S G R S A H Q V A R Y R P R A P I I A V T R N P Q T A R Q A H L Y R G I F P V L C K D P V Q E 481 A W A E D V D L R V N F A M N V G K A R G F F K K G D V V I V L T G W R P G S G F T N T M R V V P V P 5.163 solute carrier family 13 member 3 isoform b [Homo sapiens]; solute carrier family 13 member 3 isoform a [Homo sapiens] Protein Accession gi|58761541 gi|31377715

Mean Expression Ratio 0.884 Median Expression Ratio 0.883 Credible Interval (0.572, 1.37) Associated Peptides 1 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.55 0.86 1.3 SEQ ID NO: 1063 DHPGETEVPLDLPADSR 5.164 GTPase Rab14 [Homo sapiens] Protein Accession gi|19923483

Mean Expression Ratio 0.887 Median Expression Ratio 0.883 Credible Interval (0.541, 1.46) Associated Peptides 1 Associated Spectra 1 Coverage 0.140

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.51 0.86 1.5 SEQ ID NO: 1064 IYQNIQDGSLDLNAAESGVQHKPSAPQG GR SEQ ID NO: 1065 1 M A T A P Y N Y S Y I F K Y I I I G D M G V G K S C L L H Q F T E K K F M A D C P H T I G V E F G T R I I E V S G Q K I K L Q I W D T A G Q E R F R A V T R S Y 81 Y R G A A G A L M V Y D I T R R S T Y N H L S S W L T D A R N L T N P N T V I I L I G N K A D L E A Q R D V T Y E E A K Q F A E E N G L L F L E A S A K T G E N 161 V E D A F L E A A K K I Y Q N I Q D G S L D L N A A E S G V Q H K P S A P Q G G R L T S E P Q P Q R E G C G C 5.165 coagulation factor II preproprotein [Homo sapiens] Protein Accession gi|4503635

Mean Expression Ratio 0.887 Median Expression Ratio 0.885 Credible Interval (0.613, 1.30) Associated Peptides 3 Associated Spectra 3 Coverage 0.0836

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.57 0.88 1.4 SEQ ID NO: 1066 HQDFNSAVQLVENFCR 1 0.57 0.87 1.3 SEQ ID NO: 1067 SEGSSVNLSPPLEQCVPDR 1 0.58 0.88 1.4 SEQ ID NO: 1068 TFGSGEADCGLRPLFEK SEQ ID NO: 1069 1 M A H V R G L Q L P G C L A L A A L C S L V H S Q H V F L A P Q Q A R S L L Q R V R R A N T F L E E V R K G N L E R E C V E E T C S Y E E A F E A L E S S T A T 81 D V F W A K Y T A C E T A R T P R D K L A A C L E G N C A E G L G T N Y R G H V N I T R S G I E C Q L W R S R Y P H K P E I N S T T H P G A D L Q E N F C R N P 161 D S S T T G P W C Y T T D P T V R R Q E C S I P V C G Q D Q V T V A M T P R S E G S S V N L S P P L E Q C V P D R G Q Q Y Q G R L A V T T H G L P C L A W A S A 241 Q A K A L S K H Q D F N S A V Q L V E N F C R N P D G D E E G V W C Y V A G K P G D F G Y C D L N Y C E E A V E E E T G D G L D E D S D R A I E G R T A T S E Y 321 Q T F F N P R T F G S G E A D C G L R P L F E K K S L E D K T E R E L L E S Y I D G R I V E G S D A E I G M S P W Q V M L F R K S P Q E L L C G A S L I S D R W 401 V L T A A H C L L Y P P W D K N F T E N D L L V R I G K H S R T R Y E R N I E K I S M L E K I Y I H P R Y N W R E N L D R D I A L M K L K K P V A F S D Y I H P 481 V C L P D R E T A A S L L Q A G Y K G R V T G W G N L K E T W T A N V G K G Q P S V L Q V V N L P I V E R P V C K D S T R I R I T D N M F C A G Y K P D E G K R 561 G D A C E G D S G G P F V M K S P F N N R W Y Q M G I V S W G E G C D R D G K Y G F Y T H V F R L K K W I Q K V I D Q F G E 5.166 proteasome alpha 6 subunit [Homo sapiens] Protein Accession gi|23110944

Mean Expression Ratio 1.13 Median Expression Ratio 1.13 Credible Interval (0.738, 1.76) Associated Peptides 2 Associated Spectra 2 Coverage 0.122

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.72 1.2 1.9 SEQ ID NO: 1070 AINQGGLTSVAVR 1 0.71 1.1 1.8 SEQ ID NO: 1071 ILTEAEIDAHLVALAER SEQ ID NO: 1072 1 M S R G S S A G F D R H I T I F S P E G R L Y Q V E Y A F K A I N Q G G L T S V A V R G K D C A V I V T Q K K V P D K L L D S S T V T H L F K I T E N I G C V M 81 T G M T A D S R S Q V Q R A R Y E A A N W K Y K Y G Y E I P V D M L C K R I A D I S Q V Y T Q N A E M R P L G C C M I L I G I D E E Q G P Q V Y K C D P A G Y Y 161 C G F K A T A A G V K Q T E S T S F L E K K V K K K F D W T F E Q T V E T A I T C L S T V L S I D F K P S E I E V G V V T V E N P K F R I L T E A E I D A H L V 241 A L A E R D 5.167 tubulin, beta, 2 [Homo sapiens] Protein Accession gi|5174735

Mean Expression Ratio 1.13 Median Expression Ratio 1.13 Credible Interval (0.767, 1.67) Associated Peptides 2 Associated Spectra 3 Coverage 0.0742

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.78 1.2 1.8 SEQ ID NO: 1073 GHYTEGAELVDSVLDVVR 1 0.72 1.1 1.7 SEQ ID NO: 1074 AVLVDLEPGTMDSVR SEQ ID NO: 1075 1 M R E I V H L Q A G Q C G N Q I G A K F W E V I S D E H G I D P T G T Y H G D S D L Q L E R I N V Y Y N E A T G G K Y V P R A V L V D L E P G T M D S V R S G P 81 F G Q I F R P D N F V F G Q S G A G N N W A K G H Y T E G A E L V D S V L D V V R K E A E S C D C L Q G F Q L T H S L G G G T G S G M G T L L I S K I R E E Y P 161 D R I M N T F S V V P S P K V S D T V V E P Y N A T L S V H Q L V E N T D E T Y C I D N E A L Y D I C F R T L K L T T P T Y G D L N H L V S A T M S G V T T C L 241 R F P G Q L N A D L R K L A V N M V P F P R L H F F M P G F A P L T S R G S Q Q Y R A L T V P E L T Q Q M F D A K N M M A A C D P R H G R Y L T V A A V F R G R 321 M S M K E V D E Q M L N V Q N K N S S Y F V E W I P N N V K T A V C D I P P R G L K M S A T F I G N S T A I Q E L F K R I S E Q F T A M F R R K A F L H W Y T G 401 E G M D E M E F T E A E S N M N D L V S E Y Q Q Y Q D A T A E E E G E F E E E A E E E V A 5.168 solute carrier family 6, member 19 [Homo sapiens] Protein Accession gi|51468073

Mean Expression Ratio 0.887 Median Expression Ratio 0.887 Credible Interval (0.638, 1.24) Associated Peptides 4 Associated Spectra 5 Coverage 0.0489

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.58 0.87 1.3 SEQ ID NO: 1076 IPSLAELETIEQEEASSR 2 0.62 0.9 1.3 SEQ ID NO: 1077 IPSLAELETIEQEEASSRPK 1 0.6 0.9 1.4 SEQ ID NO: 1078 LVLPNPGLDAR 1 0.57 0.85 1.3 SEQ ID NO: 1079 VLPNPGLDAR SEQ ID NO: 1080 1 M V R L V L P N P G L D A R I P S L A E L E T I E Q E E A S S R P K W D N K A Q Y M L T C L G F C V G L G N V W R F P Y L C Q S H G G G A F M I P F L I L L V L 81 E G I P L L Y L E F A I G Q R L R R G S L G V W S S I H P A L K G L G L A S M L T S F M V G L Y Y N T I I S W I M W Y L F N S F Q E P L P W S D C P L N E N Q T 161 G Y V D E C A R S S P V D Y F W Y R E T L N I S T S I S D S G S I Q W W M L L C L A C A W S V L Y M C T I R G I E T T G K A V Y I T S T L P Y V V L T I F L I R 241 G L T L K G A T N G I V F L F T P N V T E L A Q P D T W L D A G A Q V F F S F S L A F G G L I S F S S Y N S V H N N C E K D S V I V S I I N G F T S V Y V A I V 321 V Y S V I G F R A T Q R Y D D C F S T N I L T L I N G F D L P E G N V T Q E N F V D M Q Q R C N A S D P A A Y A Q L V F Q T C D I N A F L S E A V E G T G L A F 401 I V F T E A I T K M P L S P L W S V L F F I M L F C L G L S S M F G N M E G V V V P L Q D L R V I P P K W P K E V L T G L I C L G T F L I G F I F T L N S G Q Y 481 W L S L L D S Y A G S I P L L I I A F C E M F S V V Y V Y G V D R F N K D I E F M I G H K P N I F W Q V T W R V V S P L L M L I I F L F F F V V E V S Q E L T Y 561 S I W D P G Y E E F P K S Q K I S Y P N W V Y V V V V I V A G V P S L T I P G Y A I Y K L I R N H C Q K P G D H Q G L V S T L S T A S M N G D L K Y 5.169 decay accelerating factor for complement isoform 2 precursor [Homo sapiens] Protein Accession gi|168693643

Mean Expression Ratio 1.13 Median Expression Ratio 1.13 Credible Interval (0.736, 1.71) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.7 1.2 1.8 SEQ ID NO: 1081 EIYCPAPPQIDNGIIQGER 1 0.72 1.1 1.8 SEQ ID NO: 1082 DCGLPPDVPNAQPALEGR 5.170 membrane alanine aminopeptidase precursor [Homo sapiens] Protein Accession gi|157266300

Mean Expression Ratio 1.13 Median Expression Ratio 1.13 Credible Interval (1.02, 1.25) Associated Peptides 54 Associated Spectra 111 Coverage 0.483

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.87 1.1 1.5 SEQ ID NO: 1083 AIAQGGEEEWDFAWEQFR 8 1.0 1.3 1.6 SEQ ID NO: 1084 AQIINDAFNLASAHK 1 0.81 1.1 1.4 SEQ ID NO: 1085 ASSHPLSTPASEINTPAQISELFDAISY 5 0.88 1.1 1.4 SEQ ID NO: 1086 CNAIAQGGEEEWDFAWEQFR 1 0.85 1.1 1.5 SEQ ID NO: 1087 DFAWEQFR 1 0.82 1.1 1.4 SEQ ID NO: 1088 DFVQSNWK 3 0.87 1.1 1.5 SEQ ID NO: 1089 DHSAIPVINR 2 0.87 1.2 1.5 SEQ ID NO: 1090 DLMVLNDVYR 1 0.86 1.1 1.5 SEQ ID NO: 1091 DLTALSNMLPK 1 0.82 1.1 1.5 SEQ ID NO: 1092 ELQQLEQFK 1 0.83 1.1 1.5 SEQ ID NO: 1093 ELWILNR 1 0.86 1.1 1.5 SEQ ID NO: 1094 ENSLLFDPLSSSSSNK 2 0.88 1.2 1.5 SEQ ID NO: 1095 EVVLQWFTENSK 2 0.82 1.1 1.4 SEQ ID NO: 1096 FFAGHYDTPYPLPK 1 0.86 1.1 1.5 SEQ ID NO: 1097 FSTEYELQQLEQFK 2 0.84 1.1 1.5 SEQ ID NO: 1098 FSTEYELQQLEQFKK 1 0.84 1.1 1.5 SEQ ID NO: 1099 GVGGSQPPDIDKTELVEPTEY 1 0.88 1.2 1.6 SEQ ID NO: 1100 GVGGSQPPDIDKTELVEPTEYLVVHLK 1 0.84 1.1 1.5 SEQ ID NO: 1101 IVSEFDYVEK 1 0.86 1.2 1.6 SEQ ID NO: 1102 KIQTQLQR 1 0.86 1.2 1.5 SEQ ID NO: 1103 KLFNDYGGGSFSFSNLIQAVTR 1 0.84 1.1 1.5 SEQ ID NO: 1104 KQVTPLFIHFR 5 0.9 1.1 1.4 SEQ ID NO: 1105 KVVATTQMQAADAR 4 0.87 1.1 1.4 SEQ ID NO: 1106 LFNDYGGGSFSFSNLIQAVTR 1 0.86 1.1 1.5 SEQ ID NO: 1107 LLAFIVSEFDYVEK 1 0.85 1.1 1.5 SEQ ID NO: 1108 LPNTLKPDSYR 2 0.86 1.1 1.5 SEQ ID NO: 1109 MLSSFLSEDVFK 1 0.85 1.1 1.5 SEQ ID NO: 1110 NAIAQGGEEEWDFAWEQFR 2 0.84 1.1 1.5 SEQ ID NO: 1111 NYVWIVPITSIR 2 0.88 1.2 1.5 SEQ ID NO: 1112 PSEFNYVWIVPITSIR 2 0.89 1.2 1.5 SEQ ID NO: 1113 QQQDYWLIDVR 2 0.79 1.0 1.4 SEQ ID NO: 1114 QVTPLFIHFR 1 0.83 1.1 1.5 SEQ ID NO: 1115 QWMENPNNNPIHPN 10  0.82 1 1.2 SEQ ID NO: 1116 QWMENPNNNPIHPNLR 4 0.96 1.2 1.6 SEQ ID NO: 1117 QYMPWEAALSSLSYFK 2 0.85 1.1 1.5 SEQ ID NO: 1118 RFSTEYELQQLEQFK 4 1.0 1.3 1.7 SEQ ID NO: 1119 SDQIGLPDFNAGAMENWGLVTYR 1 0.86 1.1 1.5 SEQ ID NO: 1120 SFPCFDEPAMK 2 0.81 1.1 1.4 SEQ ID NO: 1121 SFSNLIQAVTR 1 0.84 1.1 1.5 SEQ ID NO: 1122 SIQLPTTVR 3 0.82 1.1 1.4 SEQ ID NO: 1123 STVYCNAIAQGGEEEWDFAWEQFR 1 0.85 1.1 1.5 SEQ ID NO: 1124 VKDSQYEMDSEFEGELADDLAGFYR 1 0.85 1.1 1.5 SEQ ID NO: 1125 VNYDEENWR 1 0.85 1.1 1.5 SEQ ID NO: 1126 VVATTQMQAADAR 1 0.81 1.1 1.4 SEQ ID NO: 1127 VWIVPITSIR 1 0.85 1.1 1.5 SEQ ID NO: 1128 YLSYTLNPDLIR 8 0.91 1.1 1.4 SEQ ID NO: 1129 DSQYEMDSEFEGELADDLAGFYR 1 0.85 1.1 1.5 SEQ ID NO: 1130 AGHYDTPYPLPK 1 0.84 1.1 1.5 SEQ ID NO: 1131 EATDVIIIHSK 3 0.87 1.1 1.5 SEQ ID NO: 1132 LVVHLK 1 0.86 1.1 1.5 SEQ ID NO: 1134 RFSTEYELQQLEQFKK 1 0.84 1.1 1.5 SEQ ID NO: 1135 YVWIVPITSIR 1 0.85 1.1 1.5 SEQ ID NO: 1136 GFYISK 1 0.87 1.2 1.5 SEQ ID NO: 1137 KDNEETGFGSGTR SEQ ID NO: 1138 1 M A K G F Y I S K S L G I L G I L L G V A A V C T I I A L S V V Y S Q E K N K N A N S S P V A S T T P S A S A T T N P A S A T T L D Q S K A W N R Y R L P N T L 81 K P D S Y R V T L R P Y L T P N D R G L Y V F K G S S T V R F T C K E A T D V I I I H S K K L N Y T L S Q G H R V V L R G V G G S Q P P D I D K T E L V E P T E 161 Y L V V H L K G S L V K D S Q Y E M D S E F E G E L A D D L A G F Y R S E Y M E G N V R K V V A T T Q M Q A A D A R K S F P C F D E P A M K A E F N I T L I H P 241 K D L T A L S N M L P K G P S T P L P E D P N W N V T E F H T T P K M S T Y L L A F I V S E F D Y V E K Q A S N G V L I R I W A R P S A I A A G H G D Y A L N V 321 T G P I L N F F A G H Y D T P Y P L P K S D Q I G L P D F N A G A M E N W G L V T Y R E N S L L F D P L S S S S S N K E R V V T V I A H E L A H Q W F G N L V T 401 I E W W N D L W L N E G F A S Y V E Y L G A D Y A E P T W N L K D L M V L N D V Y R V M A V D A L A S S H P L S T P A S E I N T P A Q I S E L F D A I S Y S K G 481 A S V L R M L S S F L S E D V F K Q G L A S Y L H T F A Y Q N T I Y L N L W D H L Q E A V N N R S I Q L P T T V R D I M N R W T L Q M G F P V I T V D T S T G T 561 L S Q E H F L L D P D S N V T R P S E F N Y V W I V P I T S I R D G R Q Q Q D Y W L I D V R A Q N D L F S T S G N E W V L L N L N V T G Y Y R V N Y D E E N W R 641 K I Q T Q L Q R D H S A I P V I N R A Q I I N D A F N L A S A H K V P V T L A L N N T L F L I E E R Q Y M P W E A A L S S L S Y F K L M F D R S E V Y G P M K N 721 Y L K K Q V T P L F I H F R N N T N N W R E I P E N L M D Q Y S E V N A I S T A C S N G V P E C E E M V S G L F K Q W M E N P N N N P I H P N L R S T V Y C N A 801 I A Q G G E E E W D F A W E Q F R N A T L V N E A D K L R A A L A C S K E L W I L N R Y L S Y T L N P D L I R K Q D A T S T I I S I T N N V I G Q G L V W D F V 881 Q S N W K K L F N D Y G G G S F S F S N L I Q A V T R R F S T E Y E L Q Q L E Q F K K D N E E T G F G S G T R A L E Q A L E K T K A N I K W V K E N K E V V L Q 961 W F T E N S K 5.171 transmembrane protein 9 [Homo sapiens] Protein Accession gi|7705999

Mean Expression Ratio 0.888 Median Expression Ratio 0.888 Credible Interval (0.541, 1.42) Associated Peptides 1 Associated Spectra 1 Coverage 0.104

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.52 0.87 1.4 SEQ ID NO: 1139 KPDAYTEQLHNEEENEDAR SEQ ID NO: 1140 1 M K L L S L V A V V G C L L V P P A E A N K S S E D I R C K C I C P P Y R N I S G H I Y N Q N V S Q K D C N C L H V V E P M P V P G H D V E A Y C L L C E C R Y 81 E E R S T T T I K V I I V I Y L S V V G A L L L Y M A F L M L V D P L I R K P D A Y T E Q L H N E E E N E D A R S M A A A A A S L G G P R A N T V L E R V E G A 161 Q Q R W K L Q V Q E Q R K T V F D R H K M L S 5.172 toll interacting protein [Homo sapiens] Protein Accession gi|21361619

Mean Expression Ratio 1.13 Median Expression Ratio 1.12 Credible Interval (0.772, 1.68) Associated Peptides 3 Associated Spectra 3 Coverage 0.106

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.72 1.1 1.7 SEQ ID NO: 1141 AIQDMFPNMDQEVIR 1 0.78 1.2 1.9 SEQ ID NO: 1142 GPVYIGELPQDFLR 1 0.72 1.1 1.7 SEQ ID NO: 1143 IGELPQDFLR SEQ ID NO: 1144 1 M A T T V S T Q R G P V Y I G E L P Q D F L R I T P T Q Q Q R Q V Q L D A Q A A Q Q L Q Y G G A V G T V G R L N I T V V Q A K L A K N Y G M T R M D P Y C R L R 81 L G Y A V Y E T P T A H N G A K N P R W N K V I H C T V P P G V D S F Y L E I F D E R A F S M D D R I A W T H I T I P E S L R Q G K V E D K W Y S L S G R Q G D 161 D K E G M I N L V M S Y A L L P A A M V M P P Q P V V L M P T V Y Q Q G V G Y V P I T G M P A V C S P G M V P V A L P P A A V N A Q P R C S E E D L K A I Q D M 241 F P N M D Q E V I R S V L E A Q R G N K D A A I N S L L Q M G E E P 5.173 arylsulfatase F precursor [Homo sapiens] Protein Accession gi|31742482

Mean Expression Ratio 0.893 Median Expression Ratio 0.89 Credible Interval (0.584, 1.38) Associated Peptides 2 Associated Spectra 2 Coverage 0.0593

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.57 0.9 1.5 SEQ ID NO: 1145 ILDAIDDFGLR 1 0.53 0.85 1.4 SEQ ID NO: 1146 EPTSLMDILPTVASVSGGSLPQDR SEQ ID NO: 1147 1 M R P R R P L V F M S L V C A L L N T C Q A H R V H D D K P N I V L I M V D D L G I G D L G C Y G N D T M R T P H I D R L A R E G V R L T Q H I S A A S L C S P 81 S R S A F L T G R Y P I R S G M V S S G N R R V I Q N L A V P A G L P L N E T T L A A L L K K Q G Y S T G L I G K W H Q G L N C D S R S D Q C H H P Y N Y G F D 161 Y Y Y G M P F T L V D S C W P D P S R N T E L A F E S Q L W L C V Q L V A I A I L T L T F G K L S G W V S V P W L L I F S M I L F I F L L G Y A W F S S H T S P 241 L Y W D C L L M R G H E I T E Q P M K A E R A G S I M V K E A I S F L E R H S K E T F L L F F S F L H V H T P L P T T D D F T G T S K H G L Y G D N V E E M D S 321 M V G K I L D A I D D F G L R N N T L V Y F T S D H G G H L E A R R G H A Q L G G W N G I Y K G G K G M G G W E G G I R V P G I V R W P G K V P A G R L I K E P 401 T S L M D I L P T V A S V S G G S L P Q D R V I D G R D L M P L L Q G N V R H S E H E F L F H Y C G S Y L H A V R W I P K D D S G S V W K A H Y V T P V F Q P P 481 A S G G C Y V T S L C R C F G E Q V T Y H N P P L L F D L S R D P S E S T P L T P A T E P L H D F V I K K V A N A L K E H Q E T I V P V T Y Q L S E L N Q G R T 561 W L K P C C G V F P F C L C D K E E E V S Q P R G P N E K R 5.174 calcium binding protein 39 [Homo sapiens]; calcium binding protein 39 [Homo sapiens]; calcium binding protein 39 [Homo sapiens] Protein Accession gi|7706481 gi|195927022 gi|195927020

Mean Expression Ratio 1.12 Median Expression Ratio 1.12 Credible Interval (0.693, 1.81) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.69 1.2 1.9 SEQ ID NO: 1148 LLSAEFLEQHYDR 5.175 hemicentin 1 [Homo sapiens] Protein Accession gi|118572606

Mean Expression Ratio 0.889 Median Expression Ratio 0.89 Credible Interval (0.544, 1.45) Associated Peptides 1 Associated Spectra 1 Coverage 0.00284

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.51 0.86 1.4 SEQ ID NO: 1149 LVSLPFGIATNQDLIR SEQ ID NO: 1150 1 M I S W E V V H T V F L F A L L Y S S L A Q D A S P Q S E I R A E E I P E G A S T L A F V F D V T G S M Y D D L V Q V I E G A S K I L E T S L K R P K R P L F N 81 F A L V P F H D P E I G P V T I T T D P K K F Q Y E L R E L Y V Q G G G D C P E M S I G A I K I A L E I S L P G S F I Y V F T D A R S K D Y R L T H E V L Q L I 161 Q Q K Q S Q V V F V L T G D C D D R T H I G Y K V Y E E I A S T S S G Q V F H L D K K Q V N E V L K W V E E A V Q A S K V H L L S T D H L E Q A V N T W R I P F 241 D P S L K E V T V S L S G P S P M I E I R N P L G K L I K K G F G L H E L L N I H N S A K V V N V K E P E A G M W T V K T S S S G R H S V R I T G L S T I D F R 321 A G F S R K P T L D F K K T V S R P V Q G I P T Y V L L N T S G I S T P A R I D L L E L L S I S G S S L K T I P V K Y Y P H R K P Y G I W N I S D F V P P N E A 401 F F L K V T G Y D K D D Y L F Q R V S S V S F S S I V P D A P K V T M P E K T P G Y Y L Q P G Q I P C S V D S L L P F T L S F V R N G V T L G V D Q Y L K E S A 481 S V N L D I A K V T L S D E G F Y E C I A V S S A G T G R A Q T F F D V S E P P P V I Q V P N N V T V T P G E R A V L T C L I I S A V D Y N L T W Q R N D R D V 561 R L A E P A R I R T L A N L S L E L K S V K F N D A G E Y H C M V S S E G G S S A A S V F L T V Q E P P K V T V M P K N Q S F T G G S E V S I M C S A T G Y P K 641 P K I A W T V N D M F I V G S H R Y R M T S D G T L F I K N A A P K D A G I Y G C L A S N S A G T D K Q N S T L R Y I E A P K L M V V Q S E L L V A L G D I T V 721 M E C K T S G I P P P Q V K W F K G D L E L R P S T F L I I D P L L G L L K I Q E T Q D L D A G D Y T C V A I N E A G R A T G K I T L D V G S P P V F I Q E P A 801 D V S M E I G S N V T L P C Y V Q G Y P E P T I K W R R L D N M P I F S R P F S V S S I S Q L R T G A L F I L N L W A S D K G T Y I C E A E N Q F G K I Q S E T 881 T V T V T G L V A P L I G I S P S V A N V I E G Q Q L T L P C T L L A G N P I P E R R W I K N S A M L L Q N P Y I T V R S D G S L H I E R V Q L Q D G G E Y T C 961 V A S N V A G T N N K T T S V V V H V L P T I Q H G Q Q I L S T I E G I P V T L P C K A S G N P K P S V I W S K K G E L I S T S S A K F S A G A D G S L Y V V S 1041 P G G E E S G E Y V C T A T N T A G Y A K R K V Q L T V Y V R P R V F G D Q R G L S Q D K P V E I S V L A G E E V T L P C E V K S L P P P I I T W A K E T Q L I 1121 S P F S P R H T F L P S G S M K I T E T R T S D S G M Y L C V A T N I A G N V T Q A V K L N V H V P P K I Q R G P K H L K V Q V G Q R V D I P C N A Q G T P L P 1201 V I T W S K G G S T M L V D G E H H V S N P D G T L S I D Q A T P S D A G I Y T C V A T N I A G T D E T E I T L H V Q E P P T V E D L E P P Y N T T F Q E R V A 1281 N Q R I E F P C P A K G T P K P T I K W L H N G R E L T G R E P G I S I L E D G T L L V I A S V T P Y D N G E Y I C V A V N E A G T T E R K Y N L K V H V P P V 1361 I K D K E Q V T N V S V L L N Q L T N L F C E V E G T P S P I I M W Y K D N V Q V T E S S T I Q T V N N G K I L K L F R A T P E D A G R Y S C K A I N I A G T S 1441 Q K Y F N I D V L V P P T I I G T N F P N E V S V V L N R D V A L E C Q V K G T P F P D I H W F K D G K P L F L G D P N V E L L D R G Q V L H L K N A R R N D K 1521 G R Y Q C T V S N A A G K Q A K D I K L T I Y I P P S I K G G N V T T D I S V L I N S L I K L E C E T R G L P M P A I T W Y K D G Q P I M S S S Q A L Y I D K G 1601 Q Y L H I P R A Q V S D S A T Y T C H V A N V A G T A E K S F H V D V Y V P P M I E G N L A T P L N K Q V V I A H S L T L E C K A A G N P S P I L T W L K D G V 1681 P V K A N D N I R I E A G G K K L E I M S A Q E I D R G Q Y I C V A T S V A G E K E I K Y E V D V L V P P A I E G G D E T S Y F I V M V N N L L E L D C H V T G 1761 5 P P P T I M W L K D G Q L I D E R D G F K I L L N G R K L V I A Q A Q V S N T G L Y R C M A A N T A G D H K K E F E V T V H V P P T I K S S G L S E R V V V K 1841 Y K P V A L Q C I A N G I P N P S I T W L K D D Q P V N T A Q G N L K I Q S S G R V L Q I A K T L L E D A G R Y T C V A T N A A G E T Q Q H I Q L H V H E P P S 1921 L E D A G K M L N E T V L V S N P V Q L E C K A A G N P V P V I T W Y K D N R L L S G S T S M T F L N R G Q I I D I E S A Q I S D A G I Y K C V A I N S A G A T 2001 E L F Y S L Q V H V A P S I S G S N N M V A V V V N N P V R L E C E A R G I P A P S L T W L K D G S P V S S F S N G L Q V L S G G R I L A L T S A Q I S D T G R 2081 Y T C V A V N A A G E K Q R D I D L R V Y V P P N I M G E E Q N V S V L I S Q A V E L L C Q S D A I P P P T L T W L K D G H P L L K K P G L S I S E N R S V L K 2161 I E D A Q V Q D T G R Y T C E A T N V A G K T E K N Y N V N I W V P P N I G G S D E L T Q L T V I E G N L I S L L C E S S G I P P P N L I W K K K G S P V L T D 2241 S M G R V R I L S G G R Q L Q I S I A E K S D A A L Y S C V A S N V A G T A K K E Y N L Q V Y I R P T I T N S G S H P T E I I V T R G K S I S L E C E V Q G I P 2321 P P T V T W M K D G H P L I K A K G V E I L D E G H I L Q L K N I H V S D T G R Y V C V A V N V A G M T D K K Y D L S V H A P P S I I G N H R S P E N I S V V E 2401 K N S V S L T C E A S P S I S I T W F K D G W P V S L S N S V R I L S G G R M L R L M Q T T M E D A G Q Y T C V V R N A A G E E R K I F G L S V L V P P H I 2481 V G E N T L E D V K V K E K Q S V T L T C E V T G N P V P E I T W H K D G Q P L Q E D E A H H I I S G G R F L Q I T N V Q V P H T G R Y T C L A S S P A G H K S 2561 R S F S L N V F V S P T I A G V G S D G N P E D V T V I L N S P T S L V C E A Y S Y P P A T I T W F K D G T P L E S N R N I R I L P G G R T L Q I L N A Q E D N 2641 A G R Y S C V A T N E A G E M I K H Y E V K V Y I P P I I N K G D L W G P G L S P K E V K I K V N N T L T L E C E A Y A I P S A S L S W Y K D G Q P L K S D D H 2721 V N I A A N G H T L Q I K E A Q I S D T G R Y T C V A S N I A G E D E L D F D V N I Q V P P S F Q K L W E I G N M L D T G R N G E A K D V I I N N P I S L Y C E 2801 T N A A P P P T L T W Y K D G H P L T S S D K V L I L P G G R V L Q I P R A K V E D A G R Y T C V A V N E A G E D S L Q Y D V R V L V P P I I K G A N S D L P E 2881 E V T V L V N K S A L I E C L S S G S P A P R N S W Q K D G Q P L L E D D H H K F L S N G R I L Q I L N T Q I T D I G R Y V C V A E N T A G S A K K Y F N L N V 2961 H V P P S V I G P K S E N L T V V V N N F I S L T C E V S G F P P P D L S W L K N E Q P I K L N T N T L I V P G G R T L Q I I R A K V S D G G E Y T C I A I N Q 3041 A G E S K K K F S L T V Y V P P S I K D H D S E S L S V V N V R E G T S V S L E C E S N A V P P P V I T W Y K N G R M I T E S T H V E I L A D G Q M L H I K K A 3121 E V S D T G Q Y V C R A I N V A G R D D K N F H L N V Y V P P S I E G P E R E V I V E T I S N P V T L T C D A T G I P P P T I A W L K N H K R I E N S D S L E V 3201 R I L S G G S K L Q I A R S Q H S D S G N Y T C I A S N M E G K A Q K Y Y F L S I Q V P P S V A G A E I P S D V S V L L G E N V E L V C N A N G I P T P L I Q W 3281 L K D G K P I A S G E T E R I R V S A N G S T L N I Y G A L T S D T G K Y T C V A T N P A G E E D R I F N L N V Y V T P T I R G N K D E A E K L M T L V D T S I 3361 N I E C R A T G T P P P Q I N W L K N G L P L P L S S H I R L L A A G Q V I R I V R A Q V S D V A V Y T C V A S N R A G V D N K H Y N L Q V F A P P N M D N S M 3441 G T E E I T V L K G S S T S M A C I T D G T P A P S M A W L R D G Q P L G L D A H L T V S T H G M V L Q L L K A E T E D S G K Y T C I A S N E A G E V S K H F I 3521 L K V L E P P H I N G S E E H E E I S V I V N N P L E L T C I A S G I P A P K M T W M K D G R P L P Q T D Q V Q T L G G G E V L R I S T A Q V E D T G R Y T C L 3601 A S S P A G D D D K E Y L V R V H V P P N I A G T D E P R D I T V L R N R Q V T L E C K S D A V P P P V I T W L R N G E R L Q A T P R V R I L S G G R Y L Q I N 3681 N A D L G D T A N Y T C V A S N I A G K T T R E F I L T V N V P P N I K G G P Q S L V I L L N K S T V L E C I A E G V P T P R I T W R K D G A V L A G N H A R Y 3761 S I L E N G F L H I Q S A H V T D T G R Y L C M A T N A A G T D R R R I D L Q V H V P P S I A P G P T N M T V I V N V Q T T L A C E A T G I P K P S I N W R K N 3841 G H L L N V D Q N Q N S Y R L L S S G S L V I I S P S V D D T A T Y E C T V T N G A G D D K R T V D L T V Q V P P S I A D E P T D F L V T K H A P A V I T C T A 3921 S G V P F P S I H W T K N G I R L L P R G D G Y R I L S S G A I E I L A T Q L N H A G R Y T C V A R N A A G S A H R H V T L H V H E P P V I Q P Q P S E L H V I 4001 L N N P I L L P C E A T G T P S P F I T W Q K E G I N V N T S G R N H A V L P S G G L Q I S R A V R E D A G T Y M C V A Q N P A G T A L G K I K L N V Q V P P V 4081 I S P H L K E Y V I A V D K P I T L S C E A D G L P P P D I T W H K D G R A I V E S I R Q R V L S S G S L Q I A F V Q P G D A G H Y T C M A A N V A G S S S T S 4161 T K L T V H V P P R I R S T E G H Y T V N E N S Q A I L P C V A D G I P T P A I N W K K D N V L L A N L L G K Y T A E P Y G E L I L E N V V L E D S G F Y T C V 4241 A N N A A G E D T H T V S L T V H V L P T F T E L P G D V S L N K G E Q L R L S C K A T G I P L P K L T W T F N N N I I P A H F D S V N G H S E L V I E R V S K 4321 E D S G T Y V C T A E N S V G F V K A I G F V Y V K E P P V F K G D Y P S N W I E P L G G N A I L N C E V K G D P T P T I Q W N R K G V D I E I S H R I R Q L G 4401 N G S L A I Y G T V N E D A G D Y T C V A T N E A G V V E R S M S L T L Q S P P I I T L E P V E T V I N A G G K I I L N C Q A T G E P Q P T I T W S R Q G H S I 4481 S W D D R V N V L S N N S L Y I A D A Q K E D T S E F E C V A R N L M G S V L V R V P V I V Q V H G G F S Q W S A W R A C S V T C G K G I Q K R S R L C N Q P L 4561 P A N G G K P C Q G S D L E M R N C Q N K P C P V D G S W S E W S L W E E C T R S C G R G N Q T R T R T C N N P S V Q H G G R P C E G N A V E I I M C N I R P C 4641 P V H G A W S A W Q P W G T C S E S C G K G T Q T R A R L C N N P P P A F G G S Y C D G A E T Q M Q V C N E R N C P I H G K W A T W A S W S A C S V S C G G G A 4721 R Q R T R G C S D P V P Q Y G G R K C E G S D V Q S D F C N S D P C P T H G N W S P W S G W G T C S R T C N G G Q M R R Y R T C D N P P P S N G G R A C G G P D 4801 S Q I Q R C N T D M C P V D G S W G S W H S W S Q C S A S C G G G E K T R K R L C D H P V P V K G G R P C P G D T T Q V T R C N V Q A C P G G P Q R A R G S V I 4881 G N I N D V E F G I A F L N A T I T D S P N S D T R I I R A K I T N V P R S L G S A M R K I V S I L N P I Y W T T A K E I G E A V N G F T L T N A V F K R E T Q 4961 V E F A T G E I L Q M S H I A R G L D S D G S L L L D I V V S G Y V L Q L Q S P A E V T V K D Y T E D Y I Q T G P G Q L Y A Y S T R L F T I D G I S I P Y T W N 5041 H T V F Y D Q A Q G R M P F L V E T L H A S S V E S D Y N Q I E E T L G F K I H A S I S K G D R S N Q C P S G F T L D S V G P F C A D E D E C A A G N P C S H S 5121 C H N A M G T Y Y C S C P K G L T I A A D G R T C Q D I D E C A L G R H T C H A G Q D C D N T I G S Y R C V V R C G S G F R R T S D G L S C Q D I N E C Q E S S 5201 P C H Q R C F N A I G S F H C G C E P G Y Q L K G R K C M D V N E C R Q N V C R P D Q H C K N T R G G Y K C I D L C P N G M T K A E N G T C I D I D E C K D G T 5281 H Q C R Y N Q I C E N T R G S Y R C V C P R G Y R S Q G V G R P C M D I N E C E Q V P K P C A H Q C S N T P G S F K C I C P P G Q H L L G D G K S C A G L E R L 5361 P N Y G T Q Y S S Y N L A R F S P V R N N Y Q P Q Q H Y R Q Y S H L Y S S Y S E Y R N S R T S L S R T R R T I R K T C P E G S E A S H D T C V D I D E C E N T D 5441 A C Q H E C K N T F G S Y Q C I C P P G Y Q L T H N G K T C Q D I D E C L E Q N V H C G P N R M C F N M R G S Y Q C I D T P C P P N Y Q R D P V S G F C L K N C 5521 P P N D L E C A L S P Y A L E Y K L V S L P F G I A T N Q D L I R L V A Y T Q D G V M H P R T T F L M V D E E Q T V P F A L R D E N L K G V V Y T T R P L R E A 5601 E T Y R M R V R A S S Y S A N G T I E Y Q T T F I V Y I A V S A Y P Y 5.176 prostate stem cell antigen preproprotein [Homo sapiens] Protein Accession gi|5031995

Mean Expression Ratio 1.12 Median Expression Ratio 1.12 Credible Interval (0.692, 1.81) Associated Peptides 1 Associated Spectra 1 Coverage 0.0813

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.7 1.2 1.9 SEQ ID NO: 1151 AVGLLTVISK SEQ ID NO: 1152 1 M K A V L L A L L M A G L A L Q P G T A L L C Y S C K A Q V S N E D C L Q V E N C T Q L G E Q C W T A R I R A V G L L T V I S K G C S L N C V D D S Q D Y Y V G 81 K K N I T C C D T D L C N A S G A H A L Q P A A A I L A L L P A L G L L L W G P G Q L 5.177 solute carrier family 47, member 1 [Homo sapiens] Protein Accession gi|22907060

Mean Expression Ratio 1.12 Median Expression Ratio 1.12 Credible Interval (0.725, 1.74) Associated Peptides 1 Associated Spectra 2 Coverage 0.0246

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.74 1.2 1.8 SEQ ID NO: 1153 QEEPLPEHPQDGAK SEQ ID NO: 1154 1 M E A P E E P A P V R G G P E A T L E V R G S R C L R L S A F R E E L R A L L V L A G P A F L V Q L M V F L I S F I S S V F C G H L G K L E L D A V T L A I A V 81 I N V T G V S V G F G L S S A C D T L I S Q T Y G S Q N L K H V G V I L Q R S A L V L L L C C F P C W A L F L N T Q H I L L L F R Q D P D V S R L T Q T Y V T I 161 F I P A L P A T F L Y M L Q V K Y L L N Q G I V L P Q I V T G V A A N L V N A L A N Y L F L H Q L H L G V I G S A L A N L I S Q Y T L A L L L F L Y I L G K K L 241 H Q A T W G G W S L E C L Q D W A S F L R L A I P S M L M L C M E W W A Y E V G S F L S G I L G M V E L G A Q S I V Y E L A I I V Y M V P A G F S V A A S V R V 321 G N A L G A G D M E Q A R K S S T V S L L I T V L F A V A F S V L L L S C K D H V G Y I F T T D R D I I N L V A Q V V P I Y A V S H L F E A L A C T S G G V L R 401 G S G N Q K V G A I V N T I G Y Y V V G L P I G I A L M F A T T L G V M G L W S G I I I C T V F Q A V C F L G F I I Q L N W K K A C Q Q A Q V H A N L K V N N V 481 P R S G N S A L P Q D P L H P G C P E N L E G I L T N D V G K T G E P Q S D Q Q M R Q E E P L P E H P Q D G A K L S R K Q L V L R R G L L L L G V F L I L L V G 561 I L V R F Y V R I Q 5.178 polymeric immunoglobulin receptor [Homo sapiens] Protein Accession gi|31377806

Mean Expression Ratio 1.12 Median Expression Ratio 1.12 Credible Interval (0.926, 1.35) Associated Peptides 16 Associated Spectra 25 Coverage 0.234

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.83 1.1 1.6 SEQ ID NO: 1155 DGSFSVVITGLR 2 0.78 1.0 1.4 SEQ ID NO: 1156 ILLNPQDKDGSFSVVITGLR 1 0.83 1.1 1.6 SEQ ID NO: 1157 LDIQGTGQLLFSVVINQLR 1 0.8 1.1 1.5 SEQ ID NO: 1158 LVSLTLNLVTR 9 0.9 1.1 1.4 SEQ ID NO: 1159 NADLQVLKPEPELVYEDLR 1 0.83 1.2 1.6 SEQ ID NO: 1160 QLFVNEESTIPR 1 0.8 1.1 1.5 SEQ ID NO: 1161 QSSGENCDVVVNTLGK 1 0.85 1.2 1.6 SEQ ID NO: 1162 TVTINCPFK 1 0.81 1.1 1.5 SEQ ID NO: 1163 VVNIAQLSQDDSGR 1 0.78 1.1 1.5 SEQ ID NO: 1164 YLCGAHSDGQLQEGSPIQAW 1 0.8 1.1 1.5 SEQ ID NO: 1165 YWCLWEGAQNGR 1 0.82 1.1 1.6 SEQ ID NO: 1166 SVVINQLR 1 0.83 1.1 1.6 SEQ ID NO: 1167 KTENAQK 1 0.79 1.1 1.5 SEQ ID NO: 1168 HCALGPEVANVAK 1 0.82 1.1 1.5 SEQ ID NO: 1169 ILLNPQDK 1 0.8 1.1 1.5 SEQ ID NO: 1170 ADAAPDEK SEQ ID NO: 1171 1 M L L F V L T C L L A V F P A I S T K S P I F G P E E V N S V E G N S V S I T C Y Y P P T S V N R H T R K Y W C R Q G A R G G C I T L I S S E G Y V S S K Y A G 81 R A N L T N F P E N G T F V V N I A Q L S Q D D S G R Y K C G L G I N S R G L S F D V S L E V S Q G P G L L N D T K V Y T V D L G R T V T I N C P F K T E N A Q 161 K R K S L Y K Q I G L Y P V L V I D S S G Y V N P N Y T G R I R L D I Q G T G Q L L F S V V I N Q L R L S D A G Q Y L C Q A G D D S N S N K K N A D L Q V L K P 241 E P E L V Y E D L R G S V T F H C A L G P E V A N V A K F L C R Q S S G E N C D V V V N T L G K R A P A F E G R I L L N P Q D K D G S F S V V I T G L R K E D A 321 G R Y L C G A H S D G Q L Q E G S P I Q A W Q L F V N E E S T I P R S P T V V K G V A G G S V A V L C P Y N R K E S K S I K Y W C L W E G A Q N G R C P L L V D 401 S E G W V K A Q Y E G R L S L L E E P G N G T F T V I L N Q L T S R D A G F Y W C L T N G D T L W R T T V E I K I I E G E P N L K V P G N V T A V L G E T L K V 481 P C H F P C K F S S Y E K Y W C K W N N T G C Q A L P S Q D E G P S K A F V N C D E N S R L V S L T L N L V T R A D E G W Y W C G V K Q G H F Y G E T A A V Y V 561 A V E E R K A A G S R D V S L A K A D A A P D E K V L D S G F R E I E N K A I Q D P R L F A E E K A V A D T R D Q A D G S R A S V D S G S S E E Q G G S S R A L 641 V S T L V P L G L V L A V G A V A V G V A R A R H R K N V D R V S I R S Y R T D I S M S D F E N S R E F G A N D N M G A S S I T Q E T S L G G K E E F V A T T E 721 S T T E T K E P K K A K R S S K E E A E M A Y K D F L L Q S S T V A A E A Q D G P Q E A 5.179 cathepsin C isoform a preproprotein [Homo sapiens] Protein Accession gi|189083844

Mean Expression Ratio 1.12 Median Expression Ratio 1.12 Credible Interval (0.874, 1.43) Associated Peptides 6 Associated Spectra 13 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 4 0.83 1.1 1.5 SEQ ID NO: 1172 AVAFEVYDDFLHYK 2 0.78 1.1 1.5 SEQ ID NO: 1173 EVYDDFLHYK 1 0.79 1.1 1.6 SEQ ID NO: 1174 GTDECAIESIAVAATPIPK 3 0.83 1.1 1.6 SEQ ID NO: 1175 NVHGINFVSPVR 1 0.8 1.1 1.6 SEQ ID NO: 1176 WFAFFK 2 0.84 1.1 1.6 SEQ ID NO: 1177 LELVHHGPMAVAF 5.180 biliverdin reductase B (flavin reductase (NADPH)) [Homo sapiens] Protein Accession gi|4502419

Mean Expression Ratio 0.897 Median Expression Ratio 0.896 Credible Interval (0.551, 1.46) Associated Peptides 1 Associated Spectra 1 Coverage 0.0728

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.52 0.87 1.5 SEQ ID NO: 1178 TVAGQDAVIVLLGTR SEQ ID NO: 1179 1 M A V K K I A I F G A T G Q T G L T T L A Q A V Q A G Y E V T V L V R D S S R L P S E G P R P A H V V V G D V L Q A A D V D K T V A G Q D A V I V L L G T R N D 81 L S P T T V M S E G A R N I V A A M K A H G V D K V V A C T S A F L L W D P T K V P P R L Q A V T D D H I R M H K V L R E S G L K Y V A V M P P H I G D Q P L T 161 G A Y T V T L D G R G P S R V I S K H D L G H F M L R C L T T D E Y D G H S T Y P S H Q Y Q 5.181 prostatic binding protein [Homo sapiens] Protein Accession gi|4505621

Mean Expression Ratio 1.12 Median Expression Ratio 1.12 Credible Interval (0.79, 1.59) Associated Peptides 2 Associated Spectra 5 Coverage 0.144

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.78 1.1 1.7 SEQ ID NO: 1180 LYTLVLTDPDAPSR 3 0.78 1.1 1.6 SEQ ID NO: 1181 YVWLVYEQDRPLK SEQ ID NO: 1182 1 M P V D L S K W S G P L S L Q E V D E Q P Q H P L H V T Y A G A A V D E L G K V L T P T Q V K N R P T S I S W D G L D S G K L Y T L V L T D P D A P S R K D P K 81 Y R E W H H F L V V N M K G N D I S S G T V L S D Y V G S G P P K G T G L H R Y V W L V Y E Q D R P L K C D E P I L S N R S G D H R G K F K V A S F R K K Y E L 161 R A P V A G T C Y Q A E W D D Y V P K L Y E Q L S G K 5.182 proteasome alpha 4 subunit isoform 1 [Homo sapiens]; proteasome alpha 4 subunit isoform 1 [Homo sapiens] Protein Accession gi|4506185 gi|156713442

Mean Expression Ratio 1.12 Median Expression Ratio 1.12 Credible Interval (0.696, 1.82) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.69 1.2 1.9 SEQ ID NO: 1183 LLDEVFFSEK 5.183 palate, lung and nasal epithelium associated precursor [Homo sapiens]; palate, lung and nasal epithelium associated precursor [Homo sapiens] Protein Accession gi|7706119 gi|18765705

Mean Expression Ratio 0.896 Median Expression Ratio 0.897 Credible Interval (0.552, 1.44) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.52 0.87 1.5 SEQ ID NO: 1184 LQVNTPLVGASLLR 5.184 vacuolar protein sorting factor 4A [Homo sapiens] Protein Accession gi|7019569

Mean Expression Ratio 1.12 Median Expression Ratio 1.12 Credible Interval (0.773, 1.59) Associated Peptides 4 Associated Spectra 4 Coverage 0.144

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.74 1.1 1.7 SEQ ID NO: 1185 IYIPLPEEAAR 1 0.74 1.1 1.7 SEQ ID NO: 1186 LHLGSTPHNLTDANIHELAR 1 0.75 1.1 1.7 SEQ ID NO: 1187 QHKPSIIFIDEVDSLCGSR 1 0.73 1.1 1.7 SEQ ID NO: 1188 LLEPVVCMSDMLR SEQ ID NO: 1189 1 M T T S T L Q K A I D L V T K A T E E D K A K N Y E E A L R L Y Q H A V E Y F L H A I K Y E A H S D K A K E S I R A K C V Q Y L D R A E K L K D Y L R S K E K H 81 G K K P V K E N Q S E G K G S D S D S E G D N P E K K K L Q E Q L M G A V V M E K P N I R W N D V A G L E G A K E A L K E A V I L P I K F P H L F T G K R T P W 161 R G I L L F G P P G T G K S Y L A K A V A T E A N N S T F F S V S S S D L M S K W L G E S E K L V K N L F E L A R Q H K P S I I F I D E V D S L C G S R N E N E 241 S E A A R R I K T E F L V Q M Q G V G N N N D G T L V L G A T N I P W V L D S A I R R R F E K R I Y I P L P E E A A R A Q M F R L H L G S T P H N L T D A N I H 321 E L A R K T E G Y S G A D I S I I V R D S L M Q P V R K V Q S A T H F K K V C G P S R T N P S M M I D D L L T P C S P G D P G A M E M T W M D V P G D K L L E P 401 V V C M S D M L R S L A T T R P T V N A D D L L K V K K F S E D F G Q E S 5.185 transmembrane protein 192 [Homo sapiens] Protein Accession gi|154240704

Mean Expression Ratio 0.899 Median Expression Ratio 0.899 Credible Interval (0.586, 1.35) Associated Peptides 2 Associated Spectra 2 Coverage 0.0996

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.57 0.9 1.4 SEQ ID NO: 1190 IYAYPSNITSETGFR 1 0.55 0.88 1.4 SEQ ID NO: 1191 AKPEPDILEEEK SEQ ID NO: 1192 1 M A A G G R M E D G S L D I T Q S I E D D P L L D A Q L L P H H S L Q A H F R P R F H P L P T V I I V N L L W F I H L V F V V L A F L T G V L C S Y P N P N E D 81 K C P G N Y T N P L K V Q T V I I L G K V I L W I L H L L L E C Y I Q Y H H S K I R N R G Y N L I Y R S T R H L K R L A L M I Q S S G N T V L L L I L C M Q H S 161 F P E P G R L Y L D L I L A I L A L E L I C S L I C L L I Y T V K I R R F N K A K P E P D I L E E E K I Y A Y P S N I T S E T G F R T I S S L E E I V E K Q G D 241 T I E Y L K R H N A L L S K R L L A L T S S D L G C Q P S R T 5.186 vitronectin precursor [Homo sapiens] Protein Accession gi|88853069

Mean Expression Ratio 0.901 Median Expression Ratio 0.9 Credible Interval (0.619, 1.31) Associated Peptides 3 Associated Spectra 3 Coverage 0.09

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.57 0.87 1.3 SEQ ID NO: 1193 DVWGIEGPIDAAFTR 1 0.58 0.9 1.4 SEQ ID NO: 1194 DWHGVPGQVDAAMAGR 1 0.59 0.91 1.4 SEQ ID NO: 1195 FEDGVLDPDYPR SEQ ID NO: 1196 1 M A P L R P L L I L A L L A W V A L A D Q E S C K G R C T E G F N V D K K C Q C D E L C S Y Y Q S C C T D Y T A E C K P Q V T R G D V F T M P E D E Y T V Y D D 81 G E E K N N A T V H E Q V G G P S L T S D L Q A Q S K G N P E Q T P V L K P E E E A P A P E V G A S K P E G I D S R P E T L H P G R P Q P P A E E E L C S G K P 161 F D A F T D L K N G S L F A F R G Q Y C Y E L D E K A V R P G Y P K L I R D V W G I E G P I D A A F T R I N C Q G K T Y L F K G S Q Y W R F E D G V L D P D Y P 241 R N I S D G F D G I P D N V D A A L A L P A H S Y S G R E R V Y F F K G K Q Y W E Y Q F Q H Q P S Q E E C E G S S L S A V F E H F A M M Q R D S W E D I F E L L 321 F W G R T S A G T R Q P Q F I S R D W H G V P G Q V D A A M A G R I Y I S G M A P R P S L A K K Q R F R H R N R K G Y R S Q R G H S R G R N Q N S R R P S R A T 401 W L5 L F5 S E E S N L G A N N Y D D Y R M D W L V P A T C E P I Q S V F F F S G D K Y Y R V N L R T R R V D T V D P P Y P R S I A Q Y W L G C P A P G H L 5.187 von Willebrand factor preproprotein [Homo sapiens] Protein Accession gi|89191868

Mean Expression Ratio 1.11 Median Expression Ratio 1.11 Credible Interval (0.866, 1.41) Associated Peptides 7 Associated Spectra 13 Coverage 0.0387

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.81 1.1 1.6 SEQ ID NO: 1197 AFVLSSVDELEQQR 2 0.8 1.1 1.5 SEQ ID NO: 1198 APILIQDFETLPR 4 0.8 1.1 1.4 SEQ ID NO: 1199 AVVILVTDVSVDSVDAAADAAR 1 0.78 1.1 1.6 SEQ ID NO: 1200 LLDLVFLLDGSSR 3 0.81 1.1 1.5 SEQ ID NO: 1201 LP GDIQVVPIGVGPNANVQELER 1 0.81 1.1 1.6 SEQ ID NO: 1202 VIVIPVGIGPHANLK 1 0.81 1.1 1.6 SEQ ID NO: 1203 EAPDLVLQR SEQ ID NO: 1204 1 M I P A R F A G V L L A L A L I L P G T L C A E G T R G R S S T A R C S L F G S D F V N T F D G S M Y S F A G Y C S Y L L A G G C Q K R S F S I I G D F Q N G K 81 R V S L S V Y L G E F F D I H L F V N G T V T Q G D Q R V S M P Y A S K G L Y L E T E A G Y Y K L S G E A Y G F V A R I D G S G N F Q V L L S D R Y F N K T C G 161 L C G N F N I F A E D D F M T Q E G T L T S D P Y D F A N S W A L S S G E Q W C E R A S P P S S S C N I S S G E M Q K G L W E Q C Q L L K S T S V F A R C H P L 241 V D P E P F V A L C E K T L C E C A G G L E C A C P A L L E Y A R T C A Q E G M V L Y G W T D H S A C S P V C P A G M E Y R Q C V S P C A R T C Q S L H I N E M 321 C Q E R C V D G C S C P E G Q L L D E G L C V E S T E C P C V H S G K R Y P P G T S L S R D C N T C I C R N S Q W I C S N E E C P G E C L V T G Q S H F K S F D 401 N R Y F T F S G I C Q Y L L A R D C Q D H S F S I V I E T V Q C A D D R D A V C T R S V T V R L P G L H N S L V K L K H G A G V A M D G Q D V Q L P L L K G D L 481 R I Q H T V T A S V R L S Y G E D L Q M D W D G R G R L L V K L S P V Y A G K T C G L C G N Y N G N Q G D D F L T P S G L A E P R V E D F G N A W K L H G D C Q 561 D L Q K Q H S D P C A L N P R M T R F S E E A C A V L T S P T F E A C H R A V S P L P Y L R N C R Y D V C S C S D G R E C L C G A L A S Y A A A C A G R G V R V 641 A W R E P G R C E L N C P K G Q V Y L Q C G T P C N L T C R S L S Y P D E E C N E A C L E G C F C P P G L Y M D E R G D C V P K A Q C P C Y Y D G E I F Q P E D 721 I F S D H H T M C Y C E D G F M H C T M S G V P G S L L P D A V L S S P L S H R S K R S L S C R P P M V K L V C P A D N L R A E G L E C T K T C Q N Y D L E C M 801 S M G C V S G C L C P P G M V R H E N R C V A L E R C P C F H Q G K E Y A P G E T V K I G C N T C V C R D R K W N C T D H V C D A T C S T I G M A H Y L T F D G 881 L K Y L F P G E C Q Y V L V Q D Y C G S N P G T F R I L V G N K G C S H P S V K C K K R V T I L V E G G E I E L F D G E V N V K R P M K D E T H F E V V E S G R 961 Y I I L L L G K A L S V V W D R H L S I S V V L K Q T Y Q E K V C G L C G N F D G I Q N N D L T S S N L Q V E E D P V D F G N S W K V S S Q C A D T R K V P L D 1041 S S P A T C H N N I M K Q T M V D S S C R I L T S D V F Q D C N K L V D P E P Y L D V C I Y D T C S C E S I G D C A C F C D T I A A Y A H V C A Q H G K V V T W 1121 R T A T L C P Q S C E E R N L R E N G Y E C E W R Y N S C A P A C Q V T C Q H P E P L A C P V Q C V E G C H A H C P P G K I L D E L L Q T C V D P E D C P V C E 1201 V A G R R F A S G K K V T L N P S D P E H C Q I C H C D V V N L T C E A C Q E P G G L V V P P T D A P V S P T T L Y V E D I S E P P L H D F Y C S R L L D L V F 1281 L L D G S S R L S E A E F E V L K A F V V D M M E R L R I S Q K W V R V A V V E Y H D G S H A Y I G L K D R K R P S E L R R I A S Q V K Y A G S Q V A S T S E V 1361 L K Y T L F Q I F S K I D R P E A S R I T L L L M A S Q E P Q R M S R N F V R Y V Q G L K K K K V I V I P V G I G P H A N L K Q I R L I E K Q A P E N K A F V L 1441 S S V D E L E Q Q R D E I V S Y L C D L A P E A P P P T L P P D M A Q V T V G P G L L G V S T L G P K R N S M V L D V A F V L E G S D K I G E A D F N R S K E F 1521 M E E V I Q R M D V G Q D S I H V T V L Q Y S Y M V T V E Y P F S E A Q S K G D I L Q R V R E I R Y Q G G N R T N T G L A L R Y L S D H S F L V S Q G D R E Q A 1601 P N L V Y M V T G N P A S D E I K R L P G D I Q V V P I G V G P N A N V Q E L E R I G W P N A P I L I Q D F E T L P R E A P D L V L Q R C C S G E G L Q I P T L 1681 S P A P D C S Q P L D V I L L L D G S S S F P A S Y F D E M K S F A K A F I S K A N I G P R L T Q V S V L Q Y G S I T T I D V P W N V V P E K A H L L S L V D V 1761 M Q R E G G P S Q I G D A L G F A V R Y L T S E M H G A R P G A S K A V V I L V T D V S V D S V D A A A D A A R S N R V T V F P I G I G D R Y D A A Q L R I L A 1841 G P A G D S N V V K L Q R I E D L P T M V T L G N S F L H K L C S G F V R I C M D E D G N E K R P G D V W T L P D Q C H T V T C Q P D G Q T L L K S H R V N C D 1921 R G L R P S C P N S Q S P V K V E E T C G C R W T C P C V C T G S S T R H I V T F D G Q N F K L T G S C S Y V L F Q N K E Q D L E V I L H N G A C S P G A R Q G 2001 C M K S I E V K H S A L S V E L H S D M E V T V N G R L V S V P Y V G G N M E V N V Y G A I M H E V R F N H L G H I F T F T P Q N N E F Q L Q L S P K T F A S K 2081 T Y G L C G I C D E N G A N D F M L R D G T V T T D W K T L V Q E W T V Q R P G Q T C Q P I L E E Q C L V P D S S H C Q V L L L P L F A E C H K V L A P A T F Y 2161 A I C Q Q D S C H Q E Q V C E V I A S Y A H L C R T N G V C V D W R T P D F C A M S C P P S L V Y N H C E H G C P R H C D G N V S S C G D H P S E G C F C P P D 2241 K V M L E G S C V P E E A C T Q C I G E D G V Q H Q F L E A W V P D H Q P C Q I C T C L S G R K V N C T T Q P C P T A K A P T C G L C E V A R L R Q N A D Q C C 2321 P E Y E C V C D P V S C D L P P V P H C E R G L Q P T L T N P G E C R P N F T C A C R K E E C K R V S P P S C P P H R L P T L R K T Q C C D E Y E C A C N C V N 2401 S T V S C P L G Y L A S T A T N D C G C T T T T C L P D K V C V H R S T I Y P V G Q F W E E G C D V C T C T D M E D A V M G L R V A Q C S Q K P C E D S C R S G 2481 F T Y V L H E G E C C G R C L P S A C E V V T G S P R G D S Q S S W K S V G S Q W A S P E N P C L I N E C V R V K E E V F I Q Q R N V S C P Q L E V P V C P S G 2561 F Q L S C K T S A C C P S C R C E R M E A C M L N G T V I G P G K T V M I D V C T T C R C M V Q V G V I S G F K L E C R K T T C N P C P L G Y K E E N N T G E C 2641 C G R C L P T A C T I Q L R G G Q I M T L K R D E T L Q D G C D T H F C K V N E R G E Y F W E K R V T G C P P F D E H K C L A E G G K I M K I P G T C C D T C E 2721 E P E C N D I T A R L Q Y V K V G S C K S E V E V D I H Y C Q G K C A S K A M Y S I D I N D V Q D Q C S C C S P T R T E P M Q V A L H C T N G S V V Y H E V L N 2801 A M E C K C S P R K C S K 5.188 tripartite motif protein TRIM14 isoform alpha [Homo sapiens]; tripartite motif protein TRIM14 isoform alpha [Homo sapiens]; tripartite motif protein TRIM14 isoform alpha [Homo sapiens] Protein Accession gi|15208667 gi|15208665 gi|15208663

Mean Expression Ratio 0.9 Median Expression Ratio 0.9 Credible Interval (0.61, 1.35) Associated Peptides 2 Associated Spectra 3 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.61 0.9 1.4 SEQ ID NO: 1205 GLVEAVESTLQTPLDIR 1 0.57 0.88 1.4 SEQ ID NO: 1206 ATFQEPLYPALR 5.189 PREDICTED: similar to hCG1642538 [Homo sapiens]; PREDICTED: similar to hCG1642538 [Homo sapiens] Protein Accession gi|169216113 gi|169215489

Mean Expression Ratio 1.11 Median Expression Ratio 1.11 Credible Interval (0.773, 1.61) Associated Peptides 1 Associated Spectra 5 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 5 0.82 1.1 1.6 SEQ ID NO: 1207 DIQMTQSPSSLSASVGDR 5.190 actin, alpha 1, skeletal muscle [Homo sapiens] Protein Accession gi|4501881

Mean Expression Ratio 1.11 Median Expression Ratio 1.11 Credible Interval (0.691, 1.82) Associated Peptides 1 Associated Spectra 1 Coverage 0.0424

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.69 1.1 1.9 SEQ ID NO: 1208 YPIEHGIITNWDDMEK SEQ ID NO: 1209 1 M C D E D E T T A L V C D N G S G L V K A G F A G D D A P R A V F P S I V G R P R H Q G V M V G M G Q K D S Y V G D E A Q S K R G I L T L K Y P I E H G I I T N 81 W D D M E K I W H H T F Y N E L R V A P E E H P T L L T E A P L N P K A N R E K M T Q I M F E T F N V P A M Y V A I Q A V L S L Y A S G R T T G I V L D S G D G 161 V T H N V P I Y E G Y A L P H A I M R L D L A G R D L T D Y L M K I L T E R G Y S F V T T A E R E I V R D I K E K L C Y V A L D F E N E M A T A A S S S S L E K 241 S Y E L P D G Q V I T I G N E R F R C P E T L F Q P S F I G M E S A G I H E T T Y N S I M K C D I D I R K D L Y A N N V M S G G T T M Y P G I A D R M Q K E I T 321 A L A P S T M K I K I I A P P E R K Y S V W I G G S I L A S L S T F Q Q M W I T K Q E Y D E A G P S I V H R K C F 5.191 RAP2B, member of RAS oncogene family [Homo sapiens] Protein Accession gi|38201690

Mean Expression Ratio 1.11 Median Expression Ratio 1.11 Credible Interval (0.688, 1.78) Associated Peptides 1 Associated Spectra 1 Coverage 0.0656

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.68 1.1 1.9 SEQ ID NO: 1210 ASVDELFAEIVR SEQ ID NO: 1211 1 M R E Y K V V V L G S G G V G K S A L T V Q F V T G S F I E K Y D P T I E D F Y R K E I E V D S S P S V L E I L D T A G T E Q F A S M R D L Y I K N G Q G F I L 81 V Y S L V N Q Q S F Q D I K P M R D Q I I R V K R Y E R V P M I L V G N K V D L E G E R E V S Y G E G K A L A E E W S C P F M E T S A K N K A S V D E L F A E I 161 V R Q M N Y A A Q P N G D E G C C S A C V I L 5.192 ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) [Homo sapiens] Protein Accession gi|7662358

Mean Expression Ratio 0.907 Median Expression Ratio 0.905 Credible Interval (0.622, 1.33) Associated Peptides 3 Associated Spectra 3 Coverage 0.0486

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.58 0.9 1.4 SEQ ID NO: 1212 IDDLIGDLVQR 1 0.58 0.9 1.4 SEQ ID NO: 1213 LLLVSFDGFR 1 0.58 0.9 1.4 SEQ ID NO: 1214 KIDDLIGDLVQR SEQ ID NO: 1215 1 M K L L V I L L F S G L I T G F R S D S S S S L P P K L L L V S F D G F R A D Y L K N Y E F P H L Q N F I K E G V L V E H V K N V F I T K T F P N H Y S I V T G 81 L Y E E S H G I V A N S M Y D A V T K K H F S D S N D K D P F W W N E A V P I W V T N Q L Q E N R S S A A A M W P G T D V P I H D T I S S Y F M N Y N S S V S F 161 E E R L N N I T M W L N N S N P P V T F A T L Y W E E P D A S G H K Y G P E D K E N M S R V L K K I D D L I G D L V Q R L K M L G L W E N L N V I I T S D H G M 241 T Q C S Q D R L I N L D S C I D H S Y Y T L I D L S P V A A I L P K I N R T E V Y N K L K N C S P H M N V Y L K E D I P N R F Y Y Q H N D R I Q P I I L V A D E 321 G W T I V L N E S S Q K L G D H G Y D N S L P S M H P F L A A H G P A F H K G Y K H S T I N I V D I Y P M M C H I L G L K P H P N N G T F G H T K C L L V D Q W 401 C I N L P E A I A I V I G S L L V L T M L T C L I I I M Q N R L S V P R P F S R L Q L Q E D D D D P L I G 5.193 transmembrane BAX inhibitor motif containing 1 [Homo sapiens] Protein Accession gi|50593008

Mean Expression Ratio 0.905 Median Expression Ratio 0.906 Credible Interval (0.645, 1.27) Associated Peptides 1 Associated Spectra 8 Coverage 0.045

A 2.5 50 97.5 Sequence ID No. Sequence 8 0.67 0.88 1.2 SEQ ID NO: 1216 AVSDSFGPGEWDDR SEQ ID NO: 1217 1 M S N P S A P P P Y E D R N P L Y P G P P P P G G Y G Q P S V L P G G Y P A Y P G Y P Q P G Y G H P A G Y P Q P M P P T H P M P M N Y G P G H G Y D G E E R A V 81 S D S F G P G E W D D R K V R H T F I R K V Y S I I S V Q L L I T V A I I A I F T F V E P V S A F V R R N V A V Y Y V S Y A V F V V T Y L I L A C C Q G P R R R 161 F P W N I I L L T L F T F A M G F M T G T I S S M Y Q T K A V I I A M I I T A V V S I S V T I F C F Q T K V D F T S C T G L F C V L G I V L L V T G I V T S I V 241 L Y F Q Y V Y W L H M L Y A A L G A I C F T L F L A Y D T Q L V L G N R K H T I S P E D Y I T G A L Q I Y T D I I Y I F T F V L Q L M G D R N 5.194 mucolipin 1 [Homo sapiens] Protein Accession gi|10092597

Mean Expression Ratio 1.1 Median Expression Ratio 1.10 Credible Interval (0.676, 1.79) Associated Peptides 1 Associated Spectra 1 Coverage 0.0483

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.67 1.1 1.9 SEQ ID NO: 1218 LLTPNPGYGTQAGPSPAPPTPPEEEDLR SEQ ID NO: 1219 1 M T A P A G P R G S E T E R L L T P N P G Y G T Q A G P S P A P P T P P E E E D L R R R L K Y F F M S P C D K F R A K G R K P C K L M L Q V V K I L V V T V Q L 81 I L F G L S N Q L A V T F R E E N T I A F R H L F L L G Y S D G A D D T F A A Y T R R E Q L Y Q A I F H A V D Q Y L A L P D V S L G R Y A Y V R G G G D P W T N G 161 S G L A L C Q R Y Y H R G H V D P A N D T F D I D P M V V T D C I Q V D P P E R P P P P P S D D L T L L E S S S S Y K N L T L K F H K L V N V T I H F R L K T I 241 N L Q S L I N N E I P D C Y T F S V L I T F D N K A H S G R I P I S L E T Q A H I Q E C K H P S V F Q H G D N S F R L L F D V V V I L T C S L S F L L C A R S L 321 L R G F L L Q N E F V G F M W R Q R G R V I S L W E R L E F V N G W Y I L L V T S D V L T I S G T I M K I G I E A K N L A S Y D V C S I L L G T S T L L V W V G 401 V I R Y L T F F H N Y N I L I A T L R V A L P S V M R F C C C V A V I Y L G Y C F C G W I V L G P Y H V K F R S L S M V S E C L F S L I N G D D M F V T F A A M 481 Q A Q Q G R S S L V W L F S Q L Y L Y S F I S L F I Y M V L S L F I A L I T G A Y D T I K H P G G A G A E E S E L Q A Y I A Q C Q D S P T S G K F R R G S G S A 561 C S L L C C C G R D P S E E H S L L V N 5.195 annexin IV [Homo sapiens] Protein Accession gi|4502105

Mean Expression Ratio 1.10 Median Expression Ratio 1.10 Credible Interval (0.674, 1.81) Associated Peptides 1 Associated Spectra 1 Coverage 0.0343

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.67 1.1 1.9 SEQ ID NO: 1220 NHLLHVFDEYK SEQ ID NO: 1221 1 M A M A T K G G T V K A A S G F N A M E D A Q T L R K A M K G L G T D E D A I I S V L A Y R N T A Q R Q E I R T A Y K S T I G R D L I D D L K S E L S G N F E Q 81 V I V G M M T P T V L Y D V Q E L R R A M K G A G T D E G C L I E I L A S R T P E E I R R I S Q T Y Q Q Q Y G R S L E D D I R S D T S F M F Q R V L V S L S A G 161 G R D E G N Y L D D A L V R Q D A Q D L Y E A G E K K W G T D E V K F L T V L C S R N R N H L L H V F D E Y K R I S Q K D I E Q S I K S E T S G S F E D A L L A 241 I V K C M R N K S A Y F A E K L Y K S M K G L G T D D N T L I R V M V S R A E I D M L D I R A H F K R L Y G K S L Y S F I K G D T S G D Y R K V L L V L C G G D 321 D 5.196 PREDICTED: similar to kappa immunoglobulin (subgroup V kappa I) [Homo sapiens] Protein Accession gi|169218204

Mean Expression Ratio 0.907 Median Expression Ratio 0.908 Credible Interval (0.615, 1.35) Associated Peptides 2 Associated Spectra 3 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.57 0.89 1.4 SEQ ID NO: DIQLTQSPSFLSASVGDR 1222 2 0.6 0.9 1.3 SEQ ID NO: LLIYAASTLQSGVPSR 1223 5.197 diazepam binding inhibitor isoform 2 [Homo sapiens]; diazepam binding inhibitor isoform 3 [Homo sapiens]; diazepam binding inhibitor isoform 1 [Homo sapiens] Protein Accession gi|120433593 gi|120433590 gi|10140853

Mean Expression Ratio 1.1 Median Expression Ratio 1.10 Credible Interval (0.677, 1.80) Associated Peptides 1 Associated Spectra 1 Coverage NaN

Sequence ID A 2.5 50 97.5 No. Sequence 1 0.67 1.1 1.9 SEQ ID NO: QATVGDINTERPGMLDFTGK 1224 5.198 CD63 antigen isoform B [Homo sapiens]; CD63 antigen isoform A [Homo sapiens] Protein Accession gi|91199546 gi|4502679

Mean Expression Ratio 1.10 Median Expression Ratio 1.10 Credible Interval (0.871, 1.40) Associated Peptides 8 Associated Spectra 15 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.78 1.1 1.6 SEQ ID NO: 1225 DKVMSEFNNNFR 7 0.83 1.1 1.4 SEQ ID NO: 1226 VMSEFNNNFR 2 0.84 1.2 1.6 SEQ ID NO: 1227 QQMENYPK 1 0.8 1.1 1.6 SEQ ID NO: 1228 MQADFK 1 0.78 1.1 1.5 SEQ ID NO: 1229 GINFNEK 1 0.78 1.1 1.5 SEQ ID NO: 1230 EGCVEK 1 0.78 1.1 1.6 SEQ ID NO: 1231 IGGWLR 1 0.77 1.1 1.5 SEQ ID NO: 1232 AIHKEGCVEK 5.199 tubulin, alpha 4a [Homo sapiens] Protein Accession gi|17921989

Mean Expression Ratio 1.10 Median Expression Ratio 1.1 Credible Interval (0.715, 1.69) Associated Peptides 1 Associated Spectra 2 Coverage 0.0335

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.71 1.1 1.7 SEQ ID NO: 1233 AVFVDLEPTVIDEIR SEQ ID NO: 1234 1 M R E C I S V H V G Q A G V Q M G N A C W E L Y C L E H G I Q P D G Q M P S D K T I G G G D D S F T T F F C E T G A G K H V P R A V F V D L E P T V I D E I R N 81 G P Y R Q L F H P E Q L I T G K E D A A N N Y A R G H Y T I G K E I I D P V L D R I R K L S D Q C T G L Q G F L V F H S F G G G T G S G F T S L L M E R L S V D 161 Y G K K S K L E F S I Y P A P Q V S T A V V E P Y N S I L T T H T T L E H S D C A F M V D N E A I Y D I C R R N L D I E R P T Y T N L N R L I S Q I V S S I T A 241 S L R F D G A L N V D L T E F Q T N L V P Y P R I H F P L A T Y A P V I S A E K A Y H E Q L S V A E I T N A C F E P A N Q M V K C D P R H G K Y M A C C L L Y R 321 G D V V P K D V N A A I A A I K T K R S I Q F V D W C P T G F K V G I N Y Q P P T V V P G G D L A K V Q R A V C M L S N T T A I A E A W A R L D H K F D L M Y A 401 K R A F V H W Y V G E G M E E G E F S E A R E D M A A L E K D Y E E V G I D S Y E D E D E G E E 5.200 MARVEL domain containing 3 isoform 1 [Homo sapiens] Protein Accession gi|65301122

Mean Expression Ratio 1.10 Median Expression Ratio 1.1 Credible Interval (0.737, 1.62) Associated Peptides 2 Associated Spectra 3 Coverage 0.061

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.69 1.1 1.7 SEQ ID NO: 1235 EAPEPPQPQR 2 0.75 1.1 1.7 SEQ ID NO: 1236 GLTWDAAAPPGPAPWEAPEPPQPQR SEQ ID NO: 1237 1 M E D P S G A R E P R A R P R E R D P G R R P H P D Q G R T H D R P R D R P G D P R R K R S S D G N R R R D G D R D P E R D Q E R D G N R D R N R D R E R E R E 81 R E R D P D R G P R R D T H R D A G P R A G E H G V W E K P R Q S R T R D G A R G L T W D A A A P P G P A P W E A P E P P Q P Q R K G D P G R R R P E S E P P S 161 E R Y L P S T P R P G R E E V E Y Y Q S E A E G L L E C H K C K Y L C T G R G V V Q I V E V V L N G M V L I C I V A S Y F V L A G F S A S F S S G G G F G N N Y 241 Y S P F E G T E L E Q V R Q L D Q Q Y T I L R S P L I Y G G V A V S L G L G V L T M G V L L Q G A K S R T M L S G K W L L T E A A F S L L A A V G Y C T G I G V 321 Y L H V A L Q I N S T D T C K T R E R L Y A R K G L T W M D C Q L A G T D G A A A T F A C L L V I M Y G A S V V L A L R S Y R E Q K R Y K G S R E Q P G S Y S D 401 A P E Y L W S G T L 5.201 sialin [Homo sapiens] Protein Accession gi|6912666

Mean Expression Ratio 0.91 Median Expression Ratio 0.91 Credible Interval (0.65, 1.25) Associated Peptides 4 Associated Spectra 5 Coverage 0.0848

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.64 0.94 1.4 SEQ ID NO: 1238 ACPEHSAPIK 1 0.6 0.91 1.4 SEQ ID NO: 1239 ALEGLGEGVTFPAMH 1 0.58 0.87 1.3 SEQ ID NO: 1240 EYILSSLR 1 0.6 0.9 1.4 SEQ ID NO: 1241 TPLLPGAPR SEQ ID NO: 1242 1 M R S P V R D L A R N D G E E S T D R T P L L P G A P R A E A A P V C C S A R Y N L A I L A F F G F F I V Y A L R V N L S V A L V D M V D S N T T L E D N R T S 81 K A C P E H S A P I K V H H N Q T G K K Y Q W D A E T Q G W I L G S F F Y G Y I I T Q I P G G Y V A S K I G G K M L L G F G I L G T A V L T L F T P I A A D L G 161 V G P L I V L R A L E G L G E G V T F P A M H A M W S S W A P P L E R S K L L S I S Y A G A Q L G T V I S L P L S G I I C Y Y M N W T Y V F Y F F G T I G I F W 241 F L L W I W L V S D T P Q K H K R I S H Y E K E Y I L S S L R N Q L S S Q K S V P W V P I L K S L P L W A I V V A H F S Y N W T F Y T L L T L L P T Y M K E I L 321 R F N V Q E N G F L S S L P Y L G S W L C M I L S G Q A A D N L R A K W N F S T L C V R R I F S L I G M I G P A V F L V A A G F I G C D Y S L A V A F L T I S T 401 T L G G F C S S G F S I N H L D I A P S Y A G I L L G I T N T F A T I P G M V G P V I A K S L T P D N T V G E W Q T V F Y I A A A I N V F G A I F F T L F A K G 481 E V Q N W A L N D H H G H R H 5.202 solute carrier family 1 (neutral amino acid transporter), member 5 [Homo sapiens] Protein Accession gi|5032093

Mean Expression Ratio 0.912 Median Expression Ratio 0.91 Credible Interval (0.561, 1.48) Associated Peptides 1 Associated Spectra 1 Coverage 0.0203

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.54 0.89 1.5 SEQ ID NO: 1243 EVLDSFLDLAR SEQ ID NO: 1244 1 M V A D P P R D S K G L A A A E P T A N G G L A L A S I E D Q G A A A G G Y C G S R D Q V R R C L R A N L L V L L T V V A V V A G V A L G L G V S G A G G A L A 81 L G P E R L S A F V F P G E L L L R L L R M I I L P L V V C S L I G G A A S L D P G A L G R L G A W A L L F F L V T T L L A S A L G V G L A L A L Q P G A A S A 161 A I N A S V G A A G S A E N A P S K E V L D S F L D L A R N I F P S N L V S A A F R S Y S T T Y E E R N I T G T R V K V P V G Q E V E G M N I L G L V V F A I V 241 F G V A L R K L G P E G E L L I R F F N S F N E A T M V L V S W I M W Y A P V G I M F L V A G K I V E M E D V G L L F A R L G K Y I L C C L L G H A I H G L L V 321 L P L I Y F L F T R K N P Y R F L W G I V T P L A T A F G T S S S S A T L P L M M K C V E E N N G V A K H I S R F I L P I G A T V N M D G A A L F Q C V A A V F 401 I A Q L S Q Q S L D F V K I I T I L V T A T A S S V G A A G I P A G G V L T L A I I L E A V N L P V D H I S L I L A V D W L V D R S C T V L N V E G D A L G A G 481 L L Q N Y V D R T E S R S T E P E L I Q V K S E L P L D P L P V P T E E G N P L L K H Y R G P A G D A T V A S E K E S V M 5.203 claudin 2 [Homo sapiens] Protein Accession gi|9966781

Mean Expression Ratio 1.10 Median Expression Ratio 1.10 Credible Interval (0.686, 1.79) Associated Peptides 1 Associated Spectra 1 Coverage 0.0652

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.68 1.1 1.9 SEQ ID NO: 1245 SNYYDAYQAQPLATR SEQ ID NO: 1246 1 M A S L G L Q L V G Y I L G L L G L L G T L V A M L L P S W K T S S Y V G A S I V T A V G F S K G L W M E C A T H S T G I T Q C D I Y S T L L G L P A D I Q A A 81 Q A M M V T S S A I S S L A C I I S V V G M R C T V F C Q E S R A K D R V A V A G G V F F I L G G L L G F I P V A W N L H G I L R D F Y S P L V P D S M K F E I 161 G E A L Y L G I I S S L F S L I A G I I L C F S C S S Q R N R S N Y Y D A Y Q A Q P L A T R S S P R P G Q P P K V K S E F N S Y S L T G Y V 5.204 myoferlin isoform a [Homo sapiens]; myoferlin isoform b [Homo sapiens] Protein Accession gi|7305053 gi|9718759

Mean Expression Ratio 1.10 Median Expression Ratio 1.10 Credible Interval (0.677, 1.78) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.66 1.1 1.9 SEQ ID NO: 1247 IYPLPDDPSVPAPPR 5.205 tubulin, alpha 1a [Homo sapiens] Protein Accession gi|17986283

Mean Expression Ratio 1.10 Median Expression Ratio 1.10 Credible Interval (0.708, 1.68) Associated Peptides 2 Associated Spectra 2 Coverage 0.0532

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.7 1.1 1.8 SEQ ID NO: 1248 AVFVDLEPTVIDEVR 1 0.67 1.1 1.7 SEQ ID NO: 1249 EIIDLVLDR SEQ ID NO: 1250 1 M R E C I S I H V G Q A G V Q I G N A C W E L Y C L E H G I Q P D G Q M P S D K T I G G G D D S F N T F F S E T G A G K H V P R A V F V D L E P T V I D E V R T 81 G T Y R Q L F H P E Q L I T G K E D A A N N Y A R G H Y T I G K E I I D L V L D R I R K L A D Q C T G L Q G F L V F H S F G G G T G S G F T S L L M E R L S V D 161 Y G K K S K L E F S I Y P A P Q V S T A V V E P Y N S I L T T H T T L E H S D C A F M V D N E A I Y D I C R R N L D I E R P T Y T N L N R L I G Q I V S S I T A 241 S L R F D G A L N V D L T E F Q T N L V P Y P R I H F P L A T Y A P V I S A E K A Y H E Q L S V A E I T N A C F E P A N Q M V K C D P R H G K Y M A C C L L Y R 321 G D V V P K D V N A A I A T I K T K R T I Q F V D W C P T G F K V G I N Y Q P P T V V P G G D L A K V Q R A V C M L S N T T A I A E A W A R L D H K F D L M Y A 401 K R A F V H W Y V G E G M E E G E F S E A R E D M A A L E K D Y E E V G V D S V E G E G E E E G E E Y 5.206 PDZ domain containing 1 [Homo sapiens] Protein Accession gi|21361142

Mean Expression Ratio 0.913 Median Expression Ratio 0.915 Credible Interval (0.722, 1.15) Associated Peptides 8 Associated Spectra 14 Coverage 0.212

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.66 0.9 1.2 SEQ ID NO: 1251 AGVLADDHLIEVNGENVEDASHEEVVEK 2 0.63 0.87 1.2 SEQ ID NO: 1252 EAPAPTPTSLEVSSPPDTTEEVDHKPK 5 0.66 0.87 1.2 SEQ ID NO: 1253 INGVFVDKEEHMQVVDLVR 1 0.66 0.93 1.3 SEQ ID NO: 1254 GVYMTDITPQGVAMR 1 0.66 0.93 1.3 SEQ ID NO: 1255 MTDITPQGVAMR 1 0.63 0.89 1.3 SEQ ID NO: 1256 VMFLLVDK 1 0.66 0.94 1.3 SEQ ID NO: 1257 VMFLLVDKETDKR 1 0.67 0.95 1.3 SEQ ID NO: 1258 AYDYFQAK SEQ ID NO: 1259 1 M T S T F N P R E C K L S K Q E G Q N Y G F F L R I E K D T E G H L V R V V E K C S P A E K A G L Q D G D R V L R I N G V F V D K E E H M Q V V D L V R K S G N 81 S V T L L V L D G D S Y E K A V K T R V D L K E L G Q S Q K E Q G L S D N I L S P V M N G G V Q T W T Q P R L C Y L V K E G G S Y G F S L K T V Q G K K G V Y M 161 T D I T P Q G V A M R A G V L A D D H L I E V N G E N V E D A S H E E V V E K V K K S G S R V M F L L V D K E T D K R H V E Q K I Q F K R E T A S L K L L P H Q 241 P R I V E M K K G S N G Y G F Y L R A G S E Q K G Q I I K D I D S G S P A E E A G L K N N D L V V A V N G E S V E T L D H D S V V E M I R K G G D Q T S L L V V 321 D K E T D N M Y R L A H F S P F L Y Y Q S Q E L P N G S V K E A P A P T P T S L E V S S P P D T T E E V D H K P K L C R L A K G E N G Y G F H L N A I R G L P G 401 S F I K E V Q K G G P A D L A G L E D E D V I I E V N G V N V L D E P Y E K V V D R I Q S S G K N V T L L V C G K K A Y D Y F Q A K K I P I V S S L A D P L D T 481 P P D S K E G I V V E S N H D S H M A K E R A H S T A S H S S S N S E D T E M 5.207 deleted in malignant brain tumors 1 isoform c precursor [Homo sapiens]; deleted in malignant brain tumors 1 isoform b precursor [Homo sapiens] Protein Accession gi|148539844 gi|148539842

Mean Expression Ratio 1.09 Median Expression Ratio 1.09 Credible Interval (0.668, 1.80) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.67 1.1 1.9 SEQ ID NO: 1260 FGQGSGPIVLDDVR 5.208 galactosylceramidase isoform a precursor [Homo sapiens] Protein Accession gi|83281450

Mean Expression Ratio 0.915 Median Expression Ratio 0.916 Credible Interval (0.556, 1.50) Associated Peptides 1 Associated Spectra 1 Coverage 0.0234

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.53 0.9 1.5 SEQ ID NO: 1261 EFDGIGAVSGGGATSR SEQ ID NO: 1262 1 M A E W L L S A S W Q R R A K A M T A A A G S A G R A A V P L L L C A L L A P G G A Y V L D D S D G L G R E F D G I G A V S G G G A T S R L L V N Y P E P Y R S 81 Q I L D Y L F K P N F G A S L H I L K V E I G G D G Q T T D G T E P S H M H Y A L D E N Y F R G Y E W W L M K E A K K R N P N I T L I G L P W S F P G W L G K G 161 F D W P Y V N L Q L T A Y Y V V T W I V G A K R Y H D L D I D Y I G I W N E R S Y N A N Y I K I L R K M L N Y Q G L Q R V K I I A S D N L W E S I S A S M L L D 241 A E L F K V V D V I G A H Y P G T H S A K D A K L T G K K L W S S E D F S T L N S D M G A G C W G R I L N Q N Y I N G Y M T S T I A W N L V A S Y Y E Q L P Y G 321 R C G L M T A Q E P W S G H Y V V E S P V W V S A H T T Q F T Q P G W Y Y L K T V G H L E K G G S Y V A L T D G L G N L T I I I E T M S H K H S K C I R P F L P 401 Y F N V S Q Q F A T F V L K G S F S E I P E L Q V W Y T K L G K T S E R F L F K Q L D S L W L L D S D G S F T L S L H E D E L F T L T T L T T G R K G S Y P L P 481 P K S Q P F P S T Y K D D F N V D Y P F F S E A P N F A D Q T G V F E Y F T N I E D P G E H H F T L R Q V L N Q R P I T W A A D A S N T I S I I G D Y N W T N L 561 T I K C D V Y I E T P D T G G V F I A G R V N K G G I L I R S A R G I F F W I F A N G S Y R V T G D L A G W I I Y A L G R V E V T A K K W Y T L T L T I K G H F 641 T S G M L N D K S L W T D I P V N F P K N G W A A I G T H S F E F A Q F D N F L V E A T R 5.209 target of myb1 isoform 1 [Homo sapiens]; target of myb1 isoform 2 [Homo sapiens] Protein Accession gi|4885637 gi|209180457

Mean Expression Ratio 0.916 Median Expression Ratio 0.917 Credible Interval (0.615, 1.34) Associated Peptides 2 Associated Spectra 3 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.58 0.89 1.3 SEQ ID NO: 1263 LPNLSSPSAEGPPGPPSG PAPR 1 0.6 0.93 1.5 SEQ ID NO: 1264 SSPDLTGVVTIYEDLR 5.210 hypothetical protein LOC55194 [Homo sapiens]; PREDICTED: hypothetical protein [Homo sapiens] Protein Accession gi|8922567 gi|169160626

Mean Expression Ratio 1.09 Median Expression Ratio 1.09 Credible Interval (0.666, 1.81) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.67 1.1 1.9 SEQ ID NO: 1265 TGQPDLLGTGTLGPSPTAT GTLGR 5.211 cystin 1 [Homo sapiens] Protein Accession gi|81158080

Mean Expression Ratio 1.09 Median Expression Ratio 1.09 Credible Interval (0.737, 1.62) Associated Peptides 2 Associated Spectra 3 Coverage 0.241

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.71 1.1 1.7 SEQ ID NO: 1266 SPESLPAGPGAAALEGGTR 2 0.73 1.1 1.7 SEQ ID NO: 1267 VPVAAAEVPGAAAEEAPGR SEQ ID NO: 1268 1 M G S G S S R S S R T L R R R R S P E S L P A G P G A A A L E G G T R R R V P V A A A E V P G A A A E E A P G R D P S P V A P P D G R D E T L R L L D E L L A E 81 S A A W G P P E P A P R R P A R L R P T A V A G S A V C A E Q S T E G H P G S G N V S E A P G S G R K K P E R P A A I S Y D H S E E G L M A S I E R E Y C R 5.212 CD151 antigen [Homo sapiens]; CD151 antigen [Homo sapiens]; CD151 antigen [Homo sapiens]; CD151 antigen [Homo sapiens] Protein Accession gi|87159824 gi|87159822 gi|21237751 gi|21237748

Mean Expression Ratio 1.09 Median Expression Ratio 1.09 Credible Interval (0.733, 1.62) Associated Peptides 1 Associated Spectra 3 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.76 1.1 1.6 SEQ ID NO: 1269 LETFIQEHLR 5.213 RAB2A, member RAS oncogene family [Homo sapiens] Protein Accession gi|4506365

Mean Expression Ratio 0.921 Median Expression Ratio 0.921 Credible Interval (0.596, 1.43) Associated Peptides 1 Associated Spectra 2 Coverage 0.066

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.58 0.9 1.4 SEQ ID NO: 1270 DTFNHLTTWLEDAR SEQ ID NO: 1271 1 M A Y A Y L F K Y I I I G D T G V G K S C L L L Q F T D K R F Q P V H D L T I G V E F G A R M I T I D G K Q I K L Q I W D T A G Q E S F R S I T R S Y Y R G A A 81 G A L L V Y D I T R R D T F N H L T T W L E D A R Q H S N S N M V I M L I G N K S D L E S R R E V K K E E G E A F A R E H G L I F M E T S A K T A S N V E E A F 161 I N T A K E I Y E K I Q E G V F D I N N E A N G I K I G P Q H A A T N A T H A G N Q G G Q Q A G G G C C 5.214 CNDP dipeptidase 2 [Homo sapiens] Protein Accession gi|8922699

Mean Expression Ratio 1.08 Median Expression Ratio 1.09 Credible Interval (0.811, 1.46) Associated Peptides 5 Associated Spectra 8 Coverage 0.135

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.75 1.1 1.6 SEQ ID NO: 1272 GNILIPGINEAVAAVTEEEHK 3 0.77 1.1 1.5 SEQ ID NO: 1273 LPDGSEIPLPPILLGR 1 0.74 1.1 1.6 SEQ ID NO: 1274 LYDDIDFDIEEFAK 2 0.77 1.1 1.6 SEQ ID NO: 1275 QKLPDGSEIPLPPILLGR 1 0.76 1.1 1.6 SEQ ID NO: 1276 TVFGVEPDLTR SEQ ID NO: 1277 1 M A A L T T L F K Y I D E N Q D R Y I K K L A K W V A I Q S V S A W P E K R G E I R R M M E V A A A D V K Q L G G S V E L V D I G K Q K L P D G S E I P L P P I 81 L L G R L G S D P Q K K T V C I Y G H L D V Q P A A L E D G W D S E P F T L V E R D G K L Y G G G S T D D K G P V A G W I N A L E A Y Q K T G Q E I P V N V R F 161 C L E G M E E S G S E G L D E L I F A R K D T F F K D V D Y V C I S D N Y W L G K K K P C I T Y G L R G I C Y F F I E V E C S N K D L H S G V Y G G S V H E A M 241 T D L I L L M G S L V D K R G N I L I P G I N E A V A A V T E E E H K L Y D D I D F D I E E F A K D V G A Q I L L H S H K K D I L M H R W R Y P S L S L H G I E 321 G A F S G S G A K T V I P R K V V G K F S I R L V P N M T P E V V G E Q V T S Y L T K K F A E L R S P N E F K V Y M G H G G K P W V S D F S H P H Y L A G R R A 401 M K T V F G V E P D L T R E G G S I P V T L T F Q E A T G K N V M L L P V G S A D D G A H S Q N E K L N R Y N Y I E G T K M L A A Y L Y E V S Q L K D 5.215 syntaxin binding protein 2 isoform b [Homo sapiens]; syntaxin binding protein 2 isoform a [Homo sapiens] Protein Accession gi|188528901 gi|188528689

Mean Expression Ratio 1.09 Median Expression Ratio 1.09 Credible Interval (0.709, 1.67) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.7 1.1 1.8 SEQ ID NO: 1278 NLEQLGGTVTNPGGSGT SSR 1 0.67 1.1 1.7 SEQ ID NO: 1279 VLLLYILLR 5.216 actinin, alpha 4 [Homo sapiens] Protein Accession gi|12025678

Mean Expression Ratio 1.09 Median Expression Ratio 1.08 Credible Interval (0.672, 1.74) Associated Peptides 1 Associated Spectra 1 Coverage 0.0132

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.65 1.1 1.8 SEQ ID NO: 1280 VGWEQLLTTIAR SEQ ID NO: 1281 1 M V D Y H A A N Q S Y Q Y G P S S A G N G A G G G G S M G D Y M A Q E D D W D R D L L L D P A W E K Q Q R K T F T A W C N S H L R K A G T Q I E N I D E D F R D 81 G L K L M L L L E V I S G E R L P K P E R G K M R V H K I N N V N K A L D F I A S K G V K L V S I G A E E I V D G N A K M T L G M I W T I I L R F A I Q D I S V 161 E E T S A K E G L L L W C Q R K T A P Y K N V N V Q N F H I S W K D G L A F N A L I H R H R P E L I E Y D K L R K D D P V T N L N N A F E V A E K Y L D I P K M 241 L D A E D I V N T A R P D E K A I M T Y V S S F Y H A F S G A Q K A E T A A N R I C K V L A V N Q E N E H L M E D Y E K L A S D L L E W I R R T I P W L E D R V 321 P Q K T I Q E M Q Q K L E D F R D Y R R V H K P P K V Q E K C Q L E I N F N T L Q T K L R L S N R P A F M P S E G K M V S D I N N G W Q H L E Q A E K G Y E E W 401 L L N E I R R L E R L D H L A E K F R Q K A S I H E A W T D G K E A M L K H R D Y E T A T L S D I K A L I R K H E A F E S D L A A H Q D R V E Q I A A I A Q E L 481 N E L D Y Y D S H N V N T R C Q K I C D Q W D A L G S L T H S R R E A L E K T E K Q L E A I D Q L H L E Y A K R A A P F N N W M E S A M E D L Q D M F I V H T I 561 E E I E G L I S A H D Q F K S T L P D A D R E R E A I L A I H K E A Q R I A E S N H I K L S G S N P Y T T V T P Q I I N S K W E K V Q Q L V P K R D H A L L E E 641 Q S K Q Q S N E H L R R Q F A S Q A N V V G P W I Q T K M E E I G R I S I E M N G T L E D Q L S H L K Q Y E R S I V D Y K P N L D L L E Q Q H Q L I Q E A L I F 721 D N K H T N Y T M E H I R V G W E Q L L T T I A R T I N E V E N Q I L T R D A K G I S Q E Q M Q E F R A S F N H F D K D H G G A L G P E E F K A C L I S L G Y D 801 V E N D R Q G E A E F N R I M S L V D P N H S G L V T F Q A F I D F M S R E T T D T D T A D Q V I A S F K V L A G D K N F I T A E E L R R E L P P D Q A E Y C I 881 A R M A P Y Q G P D A V P G A L D Y K S F S T A L Y G E S D L 5.217 matrix metalloproteinase 7 preproprotein [Homo sapiens] Protein Accession gi|4505219

Mean Expression Ratio 0.919 Median Expression Ratio 0.923 Credible Interval (0.603, 1.41) Associated Peptides 2 Associated Spectra 2 Coverage 0.120

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.57 0.9 1.4 SEQ ID NO: 1282 AFAPGTGLGGDAHFDEDER 1 0.57 0.91 1.5 SEQ ID NO: 1283 FFGLPITGMLNSR SEQ ID NO: 1284 1 M R L T V L C A V C L L P G S L A L P L P Q E A G G M S E L Q W E Q A Q D Y L K R F Y L Y D S E T K N A N S L E A K L K E M Q K F F G L P I T G M L N S R V I E 81 I M Q K P R C G V P D V A E Y S L F P N S P K W T S K V V T Y R I V S Y T R D L P H I T V D R L V S K A L N M W G K E I P L H F R K V V W G T A D I M I G F A R 161 G A H G D S Y P F D G P G N T L A H A F A P G T G L G G D A H F D E D E R W T D G S S L G I N F L Y A A T H E L G H S L G M G H S S D P N A V M Y P T Y G N G D 241 P Q N F K L S Q D D I K G I Q K L Y G K R S N S R K K 5.218 keratin 1 [Homo sapiens] Protein Accession gi|119395750

Mean Expression Ratio 0.923 Median Expression Ratio 0.923 Credible Interval (0.668, 1.28) Associated Peptides 3 Associated Spectra 6 Coverage 0.0637

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.6 0.9 1.3 SEQ ID NO: 1285 QISNLQQSISDAEQR 4 0.68 0.94 1.3 SEQ ID NO: 1286 THNLEPYFESFINNLR 1 0.62 0.91 1.4 SEQ ID NO: 1287 NKYEDEINKR SEQ ID NO: 1288 1 M S R Q F S S R S G Y R S G G G F S S G S A G I I N Y Q R R T T S S S T R R S G G G G G R F S S C G G G G G S F G A G G G F G S R S L V N L G G S K S I S I S V 81 A R G G G R G S G F G G G Y G G G G F G G G G F G G G G F G G G G I G G G G F G G F G S G G G G F G G G G F G G G G Y G G G Y G P V C P P G G I Q E V T I N Q S 161 L L Q P L N V E I D P E I Q K V K S R E R E Q I K S L N N Q F A S F I D K V R F L E Q Q N Q V L Q T K W E L L Q Q V D T S T R T H N L E P Y F E S F I N N L R R 241 R V D Q L K S D Q S R L D S E L K N M Q D M V E D Y R N K Y E D E I N K R T N A E N E F V T I K K D V D G A Y M T K V D L Q A K L D N L Q Q E I D F L T A L Y Q 321 A E L S Q M Q T Q I S E T N V I L S M D N N R S L D L D S I I A E V K A Q Y E D I A Q K S K A E A E S L Y Q S K Y E E L Q I T A G R H G D S V R N S K I E I S E 401 L N R V I Q R L R S E I D N V K K Q I S N L Q Q S I S D A E Q R G E N A L K D A K N K L N D L E D A L Q Q A K E D L A R L L R D Y Q E L M N T K L A L D L E I A 481 T Y R T L L E G E E S R M S G E C A P N V S V S V S T S H T T I S G G G S R G G G G G G Y G S G G S S Y G S G G G S Y G S G G G G G G G R G S Y G S G G S S Y G 561 S G G G S Y G S G G G G G G H G S Y G S G S S S G G Y R G G S G G G G G G S S G G R G S G G G S S G G S I G G R G S S S G G V K S S G G S S S V K F V S T T Y S 641 G V T R 5.219 lactotransferrin precursor [Homo sapiens] Protein Accession gi|54607120

Mean Expression Ratio 0.925 Median Expression Ratio 0.924 Credible Interval (0.744, 1.15) Associated Peptides 12 Associated Spectra 16 Coverage 0.217

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.66 0.9 1.2 SEQ ID NO: 1289 CSTSPLLEACEFLR 2 0.69 0.94 1.3 SEQ ID NO: 1290 DEYELLCPDNTR 1 0.67 0.94 1.3 SEQ ID NO: 1291 DSPIQCIQAIAENR 1 0.65 0.92 1.3 SEQ ID NO: 1292 DVTVLQNTDGNNNEAWAK 1 0.68 0.95 1.3 SEQ ID NO: 1293 ESTVFEDLSDEAER 2 0.63 0.85 1.2 SEQ ID NO: 1294 ESTVFEDLSDEAERDEYELLCPDNTR 1 0.66 0.93 1.3 SEQ ID NO: 1295 FDEYFSQSCAPGSDPR 1 0.68 0.95 1.3 SEQ ID NO: 1296 FQLFGSPSGQK 1 0.66 0.93 1.3 SEQ ID NO: 1297 GGSFQLNELQGLK 1 0.65 0.91 1.3 SEQ ID NO: 1298 IDSGLYLGSGYFTAIQNLR 2 0.69 0.94 1.3 SEQ ID NO: 1299 QVLLHQQAK 1 0.67 0.93 1.3 SEQ ID NO: 1300 YLGPQYVAGITNLK SEQ ID NO: 1301 1 M K L V F L V L L F L G A L G L C L A G R R R S V Q W C A V S Q P E A T K C F Q W Q R N M R K V R G P P V S C I K R D S P I Q C I Q A I A E N R A D A V T L D G 81 G F I Y E A G L A P Y K L R P V A A E V Y G T E R Q P R T H Y Y A V A V V K K G G S F Q L N E L Q G L K S C H T G L R R T A G W N V P I G T L R P F L N W T G P 161 P E P I E A A V A R F F S A S C V P G A D K G Q F P N L C R L C A G T G E N K C A F S S Q E P Y F S Y S G A F K C L R D G A G D V A F I R E S T V F E D L S D E 241 A E R D E Y E L L C P D N T R K P V D K F K D C H L A R V P S H A V V A R S V N G K E D A I W N L L R Q A Q E K F G K D K S P K F Q L F G S P S G Q K D L L F K 321 D S A I G F S R V P P R I D S G L Y L G S G Y F T A I Q N L R K S E E E V A A R R A R V V W C A V G E Q E L R K C N Q W S G L S E G S V T C S S A S T T E D C I 401 A L V L K G E A D A M S L D G G Y V Y T A G K C G L V P V L A E N Y K S Q Q S S D P D P N C V D R P V E G Y L A V A V V R R S D T S L T W N S V K G K K S C H T 481 A V D R T A G W N I P M G L L F N Q T G S C K F D E Y F S Q S C A P G S D P R S N L C A L C I G D E Q G E N K C V P N S N E R Y Y G Y T G A F R C L A E N A G D 561 V A F V K D V T V L Q N T D G N N N E A W A K D L K L A D F A L L C L D G K R K P V T E A R S C H L A M A P N H A V V S R M D K V E R L K Q V L L H Q Q A K F G 641 R N G S D C P D K F C L F Q S E T K N L L F N D N T E C L A R L H G K T T Y E K Y L G P Q Y V A G I T N L K K C S T S P L L E A C E F L R K 5.220 tumor differentially expressed protein 1 [Homo sapiens]; tumor differentially expressed protein 1 [Homo sapiens] Protein Accession gi|5803193 gi|39812106

Mean Expression Ratio 0.926 Median Expression Ratio 0.926 Credible Interval (0.567, 1.51) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.54 0.9 1.5 SEQ ID NO: 1302 LTLSGSDSVILGDTTTSG ASDEEDGQPR 5.221 phosphodiesterase 8A isoform 2 [Homo sapiens]; phosphodiesterase 8A isoform 1 [Homo sapiens] Protein Accession gi|47132537 gi|27734721

Mean Expression Ratio 1.08 Median Expression Ratio 1.08 Credible Interval (0.667, 1.74) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.66 1.1 1.8 SEQ ID NO: 1303 LVAEDAPSPAAPPLSSGG PR 5.222 SH3 domain and tetratricopeptide repeats 1 [Homo sapiens] Protein Accession gi|1145386551

Mean Expression Ratio 0.928 Median Expression Ratio 0.927 Credible Interval (0.572, 1.50) Associated Peptides 1 Associated Spectra 1 Coverage 0.0112

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.54 0.9 1.5 SEQ ID NO: 1304 QALASLTPGTGQALR SEQ ID NO: 1305 1 M E N L P A V T T E E P T P M G R G P V G P S G G G S T R D Q V R T V V M R P S V S W E K A G P E E A K A P V R G D E A P P A R V A G P A A G T P P C Q M G V Y 81 P T D L T L Q L L A V R R K S R L R D P G L Q Q T L R G Q L R L L E N D S R E M A R V L G E L S A R L L S I H S D Q D R I V V T F K T F E E I W K F S T Y H A L 161 G F T H H C L A N L L M D Q A F W L L L P S E E E E T A I Q V H V D E N A L R L T H E S L L I Q E G P F F V L C P D H H V R V M T G P R D A G N G P Q A L R Q A 241 S G A P Q G E A A P E T D S S P P S P S V S S E E V A V A A A P E P L I P F H Q W A L R I P Q D P I D D A M G G P V M P G N P L M A V G L A S A L A D F Q G S G 321 P E E M T F R G G D L I E I L G A Q V P S L P W C V G R H A A S G R V G F V R S S L I S M Q G P V S E L E S A I F L N E E E K S F F S E G C F S E E D A R Q L L 401 R R M S G T D V C S V Y S L D S V E E A E T E Q P Q E K E I P P P C L S P E P Q E T L Q K V K N V L E Q C K T C P G C P Q E P A S W G L C A A S S D V S L Q D P 481 E E P S F C L E A E D D W E D P E A L S S L L L F L N A P G Y K A S F R G L Y D V A L P W L S S V F R S F S D E E E L T G R L A Q A R G A A K K A G L L M A L A 561 R L C F L L G R L C S R R L K L S Q A R V Y F E E A L G A L E G S F G D L F L V V A V Y A N L A S I Y R K Q K N R E K C A Q V V P K A M A L L L G T P D H I C S 641 T E A E G E L L Q L A L R R A V G G Q S L Q A E A R A C F L L A R H H V H L K Q P E E A L P F L E R L L L L H R D S G A P E A A W L S D C Y L L L A D I Y S R K 721 C L P H L V L S C V K V A S L R T R G S L A G S L R S V N L V L Q N A P Q P H S L P A Q T S H Y L R Q A L A S L T P G T G Q A L R G P L Y T S L A Q L Y S H H G 801 C H G P A I T F M T Q A V E A S A I A G V R A I V D H L V A L A W L H V L H G Q S P V A L D I L Q S V R D A V V A S E D Q E G V I A N M V A V A L K R T G R T R 881 Q A A E S Y Y R A L R V A R D L G Q Q R N Q A V G L A N F G A L C L H A G A S R L A Q H Y L L E A V R L F S R L P L G E C G R D F T H V L L Q L G H L C T R Q G 961 P A Q Q G K G Y Y E W A L L V A V E M G H V E S Q L R A V Q R L C H F Y S A V M P S E A Q C V I Y H E L Q L S L A C K V A D K V L E G Q L L E T I S Q L Y L S L 1041 G T E R A Y K S A L D Y T K R S L G I F I D L Q K K E K E A H A W L Q A G K I Y Y I L R Q S E L V D L Y I Q V A Q N V A L Y T G D P N L G L E L F E A A G D I F 1121 F D G A W E R E K A V S F Y R D R A L P L A V T T G N R K A E L R L C N K L V A L L A T L E E P Q E G L E F A H M A L A L S I T L G D R L N E R V A Y H R L A A 1201 L Q H R L G H G E L A E H F Y L K A L S L C N S P L E F D E E T L Y Y V K V Y L V L G D I I F Y D L K D P F D A A G Y Y Q L A L A A A V D L G N K K A Q L K I Y 1281 T R L A T I Y H N F L L D R E K S L F F Y Q K A R T F A T E L N V R R V N L P P L P L C G W A P W L A P S H P R 5.223 aminoacylase 1 [Homo sapiens] Protein Accession gi|4501901

Mean Expression Ratio 0.926 Median Expression Ratio 0.927 Credible Interval (0.649, 1.32) Associated Peptides 3 Associated Spectra 4 Coverage 0.125

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.59 0.91 1.4 SEQ ID NO: 1306 DMNLTLEPEIMPAATDNR 1 0.61 0.92 1.4 SEQ ID NO: 1307 GPEEEHPSVTLFR 2 0.63 0.93 1.4 SEQ ID NO: 1308 TVQPKPDYGAAVAFFEETAR SEQ ID NO: 1309 1 M T S K G P E E E H P S V T L F R Q Y L R I R T V Q P K P D Y G A A V A F F E E T A R Q L G L G C Q K V E V A P G Y V V T V L T W P G T N P T L S S I L L N S H 81 T D V V P V F K E H W S H D P F E A F K D S E G Y I Y A R G A Q D M K C V S I Q Y L E A V R R L K V E G H R F P R T I H M T F V P D E E V G G H Q G M E L F V Q 161 R P E F H A L R A G F A L D E G I A N P T D A F T V F Y S E R S P W W V R V T S T G R P G H A S R F M E D T A A E K L H K V V N S I L A F R E K E W Q R L Q S N 241 P H L K E G S V T S V N L T K L E G G V A Y N V I P A T M S A S F D F R V A P D V D F K A F E E Q L Q S W C Q A A G E G V T L E F A Q K W M H P Q V T P T D D S 321 N P W W A A F S R V C K D M N L T L E P E I M P A A T D N R Y I R A V G V P A L G F S P M N R T P V L L H D H D E R L H E A V F L R G V D I Y T R L L P A L A S 401 V P A L P S D S 5.224 cathepsin A isoform a precursor [Homo sapiens] Protein Accession gi|119395729

Mean Expression Ratio 0.928 Median Expression Ratio 0.928 Credible Interval (0.708, 1.21) Associated Peptides 9 Associated Spectra 9 Coverage 0.207

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.66 0.94 1.3 SEQ ID NO: 1310 CNFYDNK 1 0.65 0.94 1.3 SEQ ID NO: 1311 DLECVTNLQEVAR 1 0.67 0.96 1.4 SEQ ID NO: 1312 HLHYWFVESQK 1 0.64 0.91 1.3 SEQ ID NO: 1313 NFLVNLQYR 1 0.66 0.93 1.3 SEQ ID NO: 1314 QYSGYLK 1 0.65 0.94 1.3 SEQ ID NO: 1315 YGDSGEQIAGFVK 1 0.61 0.88 1.3 SEQ ID NO: 1316 YATNDTEVAQSNFEALQDFFR 1 0.64 0.91 1.3 SEQ ID NO: 1317 ALNIPEQLPQWDMCNFLVNLQYR 1 0.63 0.9 1.3 SEQ ID NO: 1318 EFSHIAFL SEQ ID NO: 1319 1 M T S S P R A P P G E Q G R G G A E M I R A A P P P L F L L L L L L L L L V S W A S R G E A A P D Q D E I Q R L P G L A K Q P S F R Q Y S G Y L K G S G S K H L 81 H Y W F V E S Q K D P E N S P V V L W L N G G P G C S S L D G L L T E H G P F L V Q P D G V T L E Y N P Y S W N L I A N V L Y L E S P A G V G F S Y S D D K F Y 161 A T N D T E V A Q S N F E A L Q D F F R L F P E Y K N N K L F L T G E S Y A G I Y I P T L A V L V M Q D P S M N L Q G L A V G N G L S S Y E Q N D N S L V Y F A 241 Y Y H G L L G N R L W S S L Q T H C C S Q N K C N F Y D N K D L E C V T N L Q E V A R I V G N S G L N I Y N L Y A P C A G G V P S H F R Y E K D T V V V Q D L G 321 N I F T R L P L K R M W H Q A L L R S G D K V R M D P P C T N T T A A S T Y L N N P Y V R K A L N I P E Q L P Q W D M C N F L V N L Q Y R R L Y R S M N S Q Y L 401 K L L S S Q K Y Q I L L Y N G D V D M A C N F M G D E W F V D S L N Q K M E V Q R R P W L V K Y G D S G E Q I A G F V K E F S H I A F L T I K G A G H M V P T D 481 K P L A A F T M F S R F L N K Q P Y 5.225 pleckstrin homology domain containing, family B (evectins) member 2 isoform 3 [Homo sapiens]; pleckstrin homology domain containing, family B (evectins) member 2 isoform 2 [Homo sapiens] Protein Accession gi 154800478 gi|54800476

Mean Expression Ratio 0.93 Median Expression Ratio 0.929 Credible Interval (0.652, 1.32) Associated Peptides 4 Associated Spectra 4 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.62 0.93 1.4 SEQ ID NO: 1320 AGLYGQQPANQVIIR 1 0.61 0.93 1.4 SEQ ID NO: 1321 GQQPANQVIIR 1 0.6 0.91 1.4 SEQ ID NO: 1322 NWFDLWSDGHLIYYD DQTR 1 0.61 0.93 1.4 SEQ ID NO: 1323 VHMPMDCINIR 5.226 BH3 interacting domain death agonist isoform 2 [Homo sapiens]; BH3 interacting domain death agonist isoform 3 [Homo sapiens]; BH3 interacting domain death agonist isoform 1 [Homo sapiens] Protein Accession gi|4557361 gi|37574728 gi|37574726

Mean Expression Ratio 0.929 Median Expression Ratio 0.93 Credible Interval (0.572, 1.52) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.54 0.9 1.5 SEQ ID NO: 1324 DLATALEQLLQAYPR 5.227 enolase 1 [Homo sapiens] Protein Accession gi|4503571

Mean Expression Ratio 1.08 Median Expression Ratio 1.08 Credible Interval (0.799, 1.44) Associated Peptides 5 Associated Spectra 7 Coverage 0.184

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.75 1.1 1.5 SEQ ID NO: 1325 AAVPSGASTGIYEALELR 2 0.75 1.1 1.5 SEQ ID NO: 1326 HIADLAGNSEVILPVPAFNVINGGSHAGNK 1 0.76 1.1 1.6 SEQ ID NO: 1327 YISPDQLADLYK 1 0.73 1.1 1.5 SEQ ID NO: 1328 VVIGMDVAASEFFR 1 0.74 1.1 1.6 SEQ ID NO: 1329 YDLDFK SEQ ID NO: 1330 1 M S I L K I H A R E I F D S R G N P T V E V D L F T S K G L F R A A V P S G A S T G I Y E A L E L R D N D K T R Y M G K G V S K A V E H I N K T I A P A L V S K 81 K L N V T E Q E K I D K L M I E M D G T E N K S K F G A N A I L G V S L A V C K A G A V E K G V P L Y R H I A D L A G N S E V I L P V P A F N V I N G G S H A G 161 N K L A M Q E F M I L P V G A A N F R E A M R I G A E V Y H N L K N V I K E K Y G K D A T N V G D E G G F A P N I L E N K E G L E L L K T A I G K A G Y T D K V 241 V I G M D V A A S E F F R S G K Y D L D F K S P D D P S R Y I S P D Q L A D L Y K S F I K D Y P V V S I E D P F D Q D D W G A W Q K F T A S A G I Q V V G D D L 321 T V T N P K R I A K A V N E K S C N C L L L K V N Q I G S V T E S L Q A C K L A Q A N G W G V M V S H R S G E T E D T F I A D L V V G L C T G Q I K T G A P C R 401 S E R L A K Y N Q L L R I E E E L G S K A K F A G R N F R N P L A K 5.228 hypothetical protein LOC64855 isoform 2 [Homo sapiens]; hypothetical protein LOC64855 isoform 1 [Homo sapiens] Protein Accession gi|79750824 gi|51093863

Mean Expression Ratio 1.08 Median Expression Ratio 1.08 Credible Interval (0.708, 1.64) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.68 1.1 1.7 SEQ ID NO: 1331 FQELIFEDFAR 1 0.68 1.1 1.7 SEQ ID NO: 1332 EASPESPPPASPDGVTE IR 5.229 ribophorin II isoform 2 precursor [Homo sapiens] Protein Accession gi|209413738

Mean Expression Ratio 0.93 Median Expression Ratio 0.93 Credible Interval (0.573, 1.5) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.56 0.91 1.5 SEQ ID NO: 1333 SIVEEIEDLVAR 5.230 urate anion exchanger 1 isoform a [Homo sapiens] Protein Accession gi|24497485

Mean Expression Ratio 0.93 Median Expression Ratio 0.932 Credible Interval (0.608, 1.41) Associated Peptides 2 Associated Spectra 2 Coverage 0.0561

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.57 0.92 1.5 SEQ ID NO: 1334 AFSELLDLVGGLGR 1 0.59 0.93 1.5 SEQ ID NO: 1335 GAVQDTLTPEVLLSAMR SEQ ID NO: 1336 1 M A F S E L L D L V G G L G R F Q V L Q T M A L M V S I M W L C T Q S M L E N F S A A V P S H R C W A P L L D N S T A Q A S I L G S L S P E A L L A I S I P P G 81 P N Q R P H Q C R R F R Q P Q W Q L L D P N A T A T S W S E A D T E P C V D G W V Y D R S I F T S T I V A K W N L V C D S H A L K P M A Q S I Y L A G I L V G A 161 A A C G P A S D R F G R R L V L T W S Y L Q M A V M G T A A A F A P A F P V Y C L F R F L L A F A V A G V M M N T G T L L M E W T A A R A R P L V M T L N S L G 241 F S F G H G L T A A V A Y G V R D W T L L Q L V V S V P F F L C F L Y S W W L A E S A R W L L T T G R L D W G L Q E L W R V A A I N G K G A V Q D T L T P E V L 321 L S A M R E E L S M G Q P P A S L G T L L R M P G L R F R T C I S T L C W F A F G F T F F G L A L D L Q A L G S N I F L L Q M F I G V V D I P A K M G A L L L L 401 S H L G R R P T L A A S L L L A G L C I L A N T L V P H E M G A L R S A L A V L G L G G V G A A F T C I T I Y S S E L F P T V L R M T A V G L G Q M A A R G G A 481 I L G P L V R L L G V H G P W L P L L V Y G T V P V L S G L A A L L L P E T Q S L P L P D T I Q D V Q N Q A V K K A T H G T L G N S V L K S T Q F 5.231 chromatin modifying protein 4C [Homo sapiens] Protein Accession gi|22748643

Mean Expression Ratio 1.07 Median Expression Ratio 1.07 Credible Interval (0.65, 1.75) Associated Peptides 1 Associated Spectra 1 Coverage 0.0687

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.66 1.1 1.8 SEQ ID NO: 1337 QLTQIDGTLSTIEFQR SEQ ID NO: 1338 1 M S K L G K F F K G G G S S K S R A A P S P Q E A L V R L R E T E E M L G K K Q E Y L E N R I Q R E I A L A K K H G T Q N K R A A L Q A L K R K K R F E K Q L T 81 Q I D G T L S T I E F Q R E A L E N S H T N T E V L R N M G F A A K A M K S V H E N M D L N K I D D L M Q E I T E Q Q D I A Q E I S E A F S Q R V G F G D D F D 161 E D E L M A E L E E L E Q E E L N K K M T N I R L P N V P S S S L P A Q P N R K P G M S S T A R R S R A A S S Q R A E E E D D D I K Q L A A W A T 5.232 sacsin [Homo sapiens] Protein Accession gi|163659918

Mean Expression Ratio 0.932 Median Expression Ratio 0.932 Credible Interval (0.577, 1.52) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.55 0.91 1.5 SEQ ID NO: 1339 NHPSVSWLK 5.233 lumican precursor [Homo sapiens] Protein Accession gi|4505047

Mean Expression Ratio 0.936 Median Expression Ratio 0.932 Credible Interval (0.577, 1.53) Associated Peptides 1 Associated Spectra 1 Coverage 0.0444

SEQ ID NO: 1340 A 2.5 50 97.5 Sequence 1 0.55 0.92 1.5 ISETSLPPDMYECLR SEQ ID NO: 1341 1 M S L S A F T L F L A L I G G T S G Q Y Y D Y D F P L S I Y G Q S S P N C A P E C N C P E S Y P S A M Y C D E L K L K S V P M V P P G I K Y L Y L R N N Q I D H 81 I D E K A F E N V T D L Q W L I L D H N L L E N S K I K G R V F S K L K Q L K K L H I N H N N L T E S V G P L P K S L E D L Q L T H N K I T K L G S F E G L V N 161 L T F I H L Q H N R L K E D A V S A A F K G L K S L E Y L D L S F N Q I A R L P S G L P V S L L T L Y L D N N K I S N I P D E Y F K R F N A L Q Y L R L S H N E 241 L A D S G I P G N S F N V S S L V E L D L S Y N K L K N I P T V N E N L E N Y Y L E V N Q L E K F D I K S F C K I L G P L S Y S K I K H L R L D G N R I S E T S 321 L P P D M Y E C L R V A N E V T L N 5.234 chromatin modifying protein 1B [Homo sapiens] Protein Accession gi|31542306

Mean Expression Ratio 1.07 Median Expression Ratio 1.07 Credible Interval (0.662, 1.73) Associated Peptides 1 Associated Spectra 1 Coverage 0.0302

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.65 1.1 1.8 SEQ ID NO: 1342 HLFNLK SEQ ID NO: 1343 1 M S N M E K H L F N L K F A A K E L S R S A K K C D K E E K A E K A K I K K A I Q K G N M E V A R I H A E N A I R Q K N Q A V N F L R M S A R V D A V A A R V Q 81 T A V T M G K V T K S M A G V V K S M D A T L K T M N L E K I S A L M D K F E H Q F E T L D V Q T Q Q M E D T M S S T T T L T T P Q N Q V D M L L Q E M A D E A 161 G L D L N M E L P Q G Q T G S V G T S V A S A E Q D E L S Q R L A R L R D Q V 5.235 SHC (Src homology 2 domain containing) transforming protein 1 isoform 2 [Homo sapiens]; SHC (Src homology 2 domain containing) transforming protein 1 isoform 3 [Homo sapiens] Protein Accession gi|32261324 gi|194239664

Mean Expression Ratio 0.933 Median Expression Ratio 0.936 Credible Interval (0.571, 1.50) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.55 0.92 1.5 SEQ ID NO: 1344 QAVGGAGPPNPAINGSA PR 5.236 hypothetical protein LOC28970 [Homo sapiens] Protein Accession gi|21361495

Mean Expression Ratio 1.07 Median Expression Ratio 1.07 Credible Interval (0.755, 1.53) Associated Peptides 3 Associated Spectra 4 Coverage 0.109

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.7 1.0 1.5 SEQ ID NO: 1345 APLVCLPVFVSR 1 0.73 1.1 1.7 SEQ ID NO: 1346 FLPAEFLYR 1 0.71 1.1 1.6 SEQ ID NO: 1347 WLHFYEMK SEQ ID NO: 1348 1 M A C A E F S F H V P S L E E L A G V M Q K G L K D N F A D V Q V S V V D C P D L T K E P F T F P V K G I C G K T R I A E V G G V P Y L L P L V N Q K K V Y D L 81 N K I A K E I K L P G A F I L G A G A G P F Q T L G F N S E F M P V I Q T E S E H K P P V N G S Y F A H V N P A D G G C L L E K Y S E K C H D F Q C A L L A N L 161 F A S E G Q P G K P A E F S S C P L N S D E E V N K W L H F Y E M K A P L V C L P V F V S R D P G F D L R L E H T H F F S R H G E G G H Y H Y D T T P D I V E Y 241 L G Y F L P A E F L Y R I D Q P K E T H S I G R D 5.237 ATPase, H+ transporting, lysosomal V0 subunit a4 [Homo sapiens]; ATPase, H+ transporting, lysosomal V0 subunit a4 [Homo sapiens]; ATPase, H+ transporting, lysosomal V0 subunit a4 [Homo sapiens] Protein Accession gi|85386547 gi|85386056 gi|85386053

Mean Expression Ratio 1.07 Median Expression Ratio 1.07 Credible Interval (0.659, 1.76) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.65 1.1 1.8 SEQ ID NO: 1349 LEDLITVITQTESHR 5.238 chloride channel 7 isoform b [Homo sapiens]; chloride channel 7 isoform a [Homo sapiens] Protein Accession gi|167466160 gi|14149607

Mean Expression Ratio 0.934 Median Expression Ratio 0.937 Credible Interval (0.616, 1.43) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.59 0.93 1.5 SEQ ID NO: 1350 IFEYFR 1 0.58 0.92 1.4 SEQ ID NO: 1351 YESLDYDNSENQLFLEE ER 5.239 solute carrier family 34 (sodium phosphate), member 2 [Homo sapiens] Protein Accession gi|110611906

Mean Expression Ratio 1.07 Median Expression Ratio 1.07 Credible Interval (0.785, 1.44) Associated Peptides 5 Associated Spectra 7 Coverage 0.058

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.72 1.1 1.5 SEQ ID NO: 1352 APETFDNITISR 3 0.86 1.2 1.7 SEQ ID NO: 1353 KLQNWNFLPLWMR 1 0.71 1.0 1.5 SEQ ID NO: 1354 YLEGAAGQQPTAPDK 1 0.72 1.1 1.5 SEQ ID NO: 1355 LQNWNFLPLWMR 1 0.7 1 1.5 SEQ ID NO: 1356 NFLPLWMR SEQ ID NO: 1357 1 M A P W P E L G D A Q P N P D K Y L E G A A G Q Q P T A P D K S K E T N K T D N T E A P V T K I E L L P S Y S T A T L I D E P T E V D D P W N L P T L Q D S G I 81 K W S E R D T K G K I L C F F Q G I G R L I L L L G F L Y F F V C S L D I L S S A F Q L V G G K M A G Q F F S N S S I M S N P L L G L V I G V L V T V L V Q S S 161 S T S T S I V V S M V S S S L L T V R A A I P I I M G A N I G T S I T N T I V A L M Q V G D R S E F R R A F A G A T V H D F F N W L S V L V L L P V E V A T H Y 241 L E I I T Q L I V E S F H F K N G E D A P D L L K V I T K P F T K L I V Q L D K K V I S Q I A M N D E K A K N K S L V K I W C K T F T N K T Q I N V T V P S T A 321 N C T S P S L C W T D G I Q N W T M K N V T Y K E N I A K C Q H I F V N F H L P D L A V G T I L L I L S L L V L C G C L I M I V K I L G S V L K G Q V A T V I K 401 K T I N T D F P F P F A W L T G Y L A I L V G A G M T F I V Q S S S V F T S A L T P L I G I G V I T I E R A Y P L T L G S N I G T T T T A I L A A L A S P G N A 481 L R S S L Q I A L C H F F F N I S G I L L W Y P I P F T R L P I R M A K G L G N I S A K Y R W F A V F Y L I I F F F L I P L T V F G L S L A G W R V L V G V G V 561 P V V F I I I L V L C L R L L Q S R C P R V L P K K L Q N W N F L P L W M R S L K P W D A V V S K F T G C F Q M R C C C C C R V C C R A C C L L C G C P K C C R 641 C S K C C E D L E E A Q E G Q D V P V K A P E T F D N I T I S R E A Q G E V P A S D S K T E C T A L 5.240 UBX domain protein 6 [Homo sapiens] Protein Accession gi|13376854

Mean Expression Ratio 1.07 Median Expression Ratio 1.07 Credible Interval (0.666, 1.74) Associated Peptides 1 Associated Spectra 1 Coverage 0.0544

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.66 1.1 1.8 SEQ ID NO: 1358 ELQAEATVSGSPEAPGTNVVSEPR SEQ ID NO: 1359 1 M K K F F Q E F K A D I K F K S A G P G Q K L K E S V G E K A H K E K P N Q P A P R P P R Q G P T N E A Q M A A A A A L A R L E Q K Q S R A W G P T S Q D T I R 81 N Q V R K E L Q A E A T V S G S P E A P G T N V V S E P R E E G S A H L A V P G V Y F T C P L T G A T L R K D Q R D A C I K E A I L L H F S T D P V A A S I M K 161 I Y T F N K D Q D R V K L G V D T I A K Y L D N I H L H P E E E K Y R K I K L Q N K V F Q E R I N C L E G T H E F F E A I G F Q K V L L P A Q D Q E D P E E F Y 241 V L S E T T L A Q P Q S L E R H K E Q L L A A E P V R A K L D R Q R R V F Q P S P L A S Q F E L P G D F F N L T A E E I K R E Q R L R S E A V E R L S V L R T K 321 A M R E K E E Q R G L R K Y N Y T L L R V R L P D G C L L Q G T F Y A R E R L G A V Y G F V R E A L Q S D W L P F E L L A S G G Q K L S E D E N L A L N E C G L 401 V P S A L L T F S W D M A V L E D I K A A G A E P D S I L K P E L L S A I E K L L 5.241 tetratricopeptide repeat domain 38 [Homo sapiens]

Protein Accession gi 116812608 Mean Expression Ratio 0.935 Median Expression Ratio 0.938 Credible Interval (0.577, 1.50) Associated Peptides 1 Associated Spectra 1 Coverage 0.0192

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.55 0.92 1.5 SEQ ID NO: 1360 VLELLLPIR SEQ ID NO: 1361 1 M A A A S P L R D C Q A W K D A R L P L S T T S N E A C K L F D A T L T Q Y V K W T N D K S L G G I E G C L S K L K A A D P T F V M G H A M A T G L V L I G T G 81 S S V K L D K E L D L A V K T M V E I S R T Q P L T R R E Q L H V S A V E T F A N G N F P K A C E L W E Q I L Q D H P T D M L A L K F S H D A Y F Y L G Y Q E Q 161 M R D S V A R I Y P F W T P D I P L S S Y V K G I Y S F G L M E T N F Y D Q A E K L A K E A L S I N P T D A W S V H T V A H I H E M K A E I K D G L E F M Q H S 241 E T L W K D S D M L A C H N Y W H W A L Y L I E K G E Y E A A L T I Y D T H I L P S L Q A N D A M L D V V D S C S M L Y R L Q M E G V S V G Q R W Q D V L P V A 321 R K H S R D H I L L F N D A H F L M A S L G A H D P Q T T Q E L L T T L R D A S E S P G E N C Q H L L A R D V G L P L C Q A L V E A E D G N P D R V L E L L L P 5.242 crystallin, alpha B [Homo sapiens] Protein Accession gi|4503057

Mean Expression Ratio 1.06 Median Expression Ratio 1.07 Credible Interval (0.686, 1.63) Associated Peptides 1 Associated Spectra 2 Coverage 0.0629

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.69 1.1 1.7 SEQ ID NO: 1362 VLGDVIEVHGK SEQ ID NO: 1363 1 M D I A I H H P W I R R P F F P F H S P S R L F D Q F F G E H L L E S D L F P T S T S L S P F Y L R P P S F L R A P S W F D T G L S E M R L E K D R F S V N L D 81 V K H F S P E E L K V K V L G D V I E V H G K H E E R Q D E H G F I S R E F H R K Y R I P A D V D P L T I T S S L S S D G V L T V N G P R K Q V S G P E R T I P 161 I T R E E K P A V T A A P K K 5.243 dual oxidase 2 precursor [Homo sapiens] Protein Accession gi|132566532

Mean Expression Ratio 1.07 Median Expression Ratio 1.07 Credible Interval (0.658, 1.73) Associated Peptides 1 Associated Spectra 1 Coverage 0.00775

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.65 1.1 1.8 SEQ ID NO: 1364 AQLAEVVESMFR SEQ ID NO: 1365 1 M L R A R P E A L M L L G A L L T G S L G P S G N Q D A L S L P W E V Q R Y D G W F N N L R H H E R G A V G C R L Q R R V P A N Y A D G V Y Q A L E E P Q L P N 81 P R R L S N A A T R G I A G L P S L H N R T V L G V F F G Y H V L S D V V S V E T P G C P A E F L N I R I P P G D P V F D P D Q R G D V V L P F Q R S R W D P E 161 T G R S P S N P R D L A N Q V T G W L D G S A I Y G S S H S W S D A L R S F S G G Q L A S G P D P A F P R D S Q N P L L M W A A P D P A T G Q N G P R G L Y A F 241 G A E R G N R E P F L Q A L G L L W F R Y H N L W A Q R L A R Q H P D W E D E E L F Q H A R K R V I A T Y Q N I A V Y E W L P S F L Q K T L P E Y T G Y R P F L 321 D P S I S P E F V V A S E Q F F S T M V P P G V Y M R N A S C H F R K V L N K G F Q S S Q A L R V C N N Y W I R E N P N L N S T Q E V N E L L L G M A S Q I S E 401 L E D N I V V E D L R D Y W P G P G K F S R T D Y V A S S I Q R G R D M G L P S Y S Q A L L A F G L D I P R N W S D L N P N V D P Q V L E A T A A L Y N Q D L S 481 Q L E L L L G G L L E S H G D P G P L F S A I V L D Q F V R L R D G D R Y W F E N T R N G L F S K K E I E D I R N T T L R D V L V A V I N I D P S A L Q P N V F 561 V W H K G A P C P Q P K Q L T T D G L P Q C A P L T V L D F F E G S S P G F A I T I I A L C C L P L V S L L L S G V V A Y F R G R E H K K L Q K K L K E S V K K 641 E A A K D G V P A M E W P G P K E R S S P I I I Q L L S D R C L Q V L N R H L T V L R V V Q L Q P L Q Q V N L I L S N N R G C R T L L L K I P K E Y D L V L L F 721 S S E E E R G A F V Q Q L W D F C V R W A L G L H V A E M S E K E L F R K A V T K Q Q R E R I L E I F F R H L F A Q V L D I N Q A D A G T L P L D S S Q K V R E 801 A L T C E L S R A E F A E S L G L K P Q D M F V E S M F S L A D K D G N G Y L S F R E F L D I L V V F M K G S P E D K S R L M F T M Y D L D E N G F L S K D E F 881 F T M M R S F I E I S N N C L S K A Q L A E V V E S M F R E S G F Q D K E E L T W E D F H F M L R D H D S E L R F T Q L C V K G G G G G G N G I R D I F K Q N I 961 S C R V S F I T R T P G E R S H P Q G L G P P A P E A P E L G G P G L K K R F G K K A A V P T P R L Y T E A L Q E K M Q R G F L A Q K L Q Q Y K R F V E N Y R R 1041 H I V C V A I F S A I C V G V F A D R A Y Y Y G F A S P P S D I A Q T T L V G I I L S R G T A A S V S F M F S Y I L L T M C R N L I T F L R E T F L N R Y V P F 1121 D A A V D F H R W I A M A A V V L A I L H S A G H A V N V Y I F S V S P L S L L A C I F P N V F V N D G S K L P Q K F Y W W F F Q T V P G M T G V L L L L V L A 1201 I M Y V F A S H H F R R R S F R G F W L T H H L Y I L L Y A L L I I H G S Y A L I Q L P T F H I Y F L V P A I I Y G G D K L V S L S R K K V E I S V V K A E L L 1281 P S G V T Y L Q F Q R P Q G F E Y K S G Q W V R I A C L A L G T T E Y H P F T L T S A P H E D T L S L H I R A V G P W T T R L R E I Y S S P K G N G C A G Y P K 1361 L Y L D G P F G E G H Q E W H K F E V S V L V G G G I G V T P F A S I L K D L V F K S S L G S Q M L C K K I Y F I W V T R T Q R Q F E W L A D I I Q E V E E N D 1441 H Q D L V S V H I Y V T Q L A E K F D L R T T M L Y I C E R H F Q K V L N R S L F T G L R S I T H F G R P P F E P F F N S L Q E V H P Q V R K I G V F S C G P P 5.244 DnaJ (Hsp40) homolog, subfamily C, member 5 [Homo sapiens] Protein Accession gi|45504382

Mean Expression Ratio 0.938 Median Expression Ratio 0.938 Credible Interval (0.626, 1.41) Associated Peptides 1 Associated Spectra 3 Coverage 0.126

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.62 0.92 1.4 SEQ ID NO: 1366 APEGEETEFYVSPEDLEAQLQSDER SEQ ID NO: 1367 1 M A D Q R Q R S L S T S G E S L Y H V L G L D K N A T S D D I K K S Y R K L A L K Y H P D K N P D N P E A A D K F K E I N N A H A I L T D A T K R N I Y D K Y G 81 S L G L Y V A E Q F G E E N V N T Y F V L S S W W A K A L F V F C G L L T C C Y C C C C L C C C F N C C C G K C K P K A P E G E E T E F Y V S P E D L E A Q L Q 161 S D E R E A T D T P I V I Q P A S A T E T T Q L T A D S H P S Y H T D G F N 5.245 vacuolar H+ATPase B2 [Homo sapiens] Protein Accession gi|19913428

Mean Expression Ratio 0.939 Median Expression Ratio 0.939 Credible Interval (0.652, 1.36) Associated Peptides 3 Associated Spectra 4 Coverage 0.110

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.62 0.9 1.3 SEQ ID NO: 1368 GIVNGAAPELPVPTGGPAVGAR 1 0.63 0.95 1.5 SEQ ID NO: 1369 IPIFSAAGLPHNEIAAQICR 1 0.61 0.94 1.4 SEQ ID NO: 1370 QIYPPINVLPSLSR SEQ ID NO: 1371 1 M A L R A M R G I V N G A A P E L P V P T G G P A V G A R E Q A L A V S R N Y L S Q P R L T Y K T V S G V N G P L V I L D H V K F P R Y A E I V H L T L P D G T 81 K R S G Q V L E V S G S K A V V Q V F E G T S G I D A K K T S C E F T G D I L R T P V S E D M L G R V F N G S G K P I D R G P V V L A E D F L D I M G Q P I N P 161 Q C R I Y P E E M I Q T G I S A I D G M N S I A R G Q K I P I F S A A G L P H N E I A A Q I C R Q A G L V K K S K D V V D Y S E E N F A I V F A A M G V N M E T 241 A R F F K S D F E E N G S M D N V C L F L N L A N D P T I E R I I T P R L A L T T A E F L A Y Q C E K H V L V I L T D M S S Y A E A L R E V S A A R E E V P G R 321 R G F P G Y M Y T D L A T I Y E R A G R V E G R N G S I T Q I P I L T M P N D D I T H P I P D L T G Y I T E G Q I Y V D R Q L H N R Q I Y P P I N V L P S L S R 401 L M K S A I G E G M T R K D H A D V S N Q L Y A C Y A I G K D V Q A M K A V V G E E A L T S D D L L Y L E F L Q K F E R N F I A Q G P Y E N R T V F E T L D I G 481 W Q L L R I F P K E M L K R I P Q S T L S E F Y P R D S A K H 5.246 angiotensin I converting enzyme 2 precursor [Homo sapiens] Protein Accession gi|11225609

Mean Expression Ratio 0.939 Median Expression Ratio 0.939 Credible Interval (0.697, 1.27) Associated Peptides 5 Associated Spectra 7 Coverage 0.0745

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.63 0.92 1.3 SEQ ID NO: 1372 GQKPNIDVTDAMVDQAWDAQR 2 0.66 0.93 1.3 SEQ ID NO: 1373 LWAWESWR 1 0.66 0.97 1.4 SEQ ID NO: 1374 NQMILFGEEDVR 2 0.68 0.98 1.4 SEQ ID NO: 1375 QLRPLYEEYVVLK 1 0.6 0.88 1.3 SEQ ID NO: 1376 WSAFLK SEQ ID NO: 1377 1 M S S S S W L L L S L V A V T A A Q S T I E E Q A K T F L D K F N H E A E D L F Y Q S S L A S W N Y N T N I T E E N V Q N M N N A G D K W S A F L K E Q S T L A 81 Q M Y P L Q E I Q N L T V K L Q L Q A L Q Q N G S S V L S E D K S K R L N T I L N T M S T I Y S T G K V C N P D N P Q E C L L L E P G L N E I M A N S L D Y N E 161 R L W A W E S W R S E V G K Q L R P L Y E E Y V V L K N E M A R A N H Y E D Y G D Y W R G D Y E V N G V D G Y D Y S R G Q L I E D V E H T F E E I K P L Y E H L 241 H A Y V R A K L M N A Y P S Y I S P I G C L P A H L L G D M W G R F W T N L Y S L T V P F G Q K P N I D V T D A M V D Q A W D A Q R I F K E A E K F F V S V G L 321 P N M T Q G F W E N S M L T D P G N V Q K A V C H P T A W D L G K G D F R I L M C T K V T M D D F L T A H H E M G H I Q Y D M A Y A A Q P F L L R N G A N E G F 401 H E A V G E I M S L S A A T P K H L K S I G L L S P D F Q E D N E T E I N F L L K Q A L T I V G T L P F T Y M L E K W R W M V F K G E I P K D Q W M K K W W E M 481 K R E I V G V V E P V P H D E T Y C D P A S L F H V S N D Y S F I R Y Y T R T L Y Q F Q F Q E A L C Q A A K H E G P L H K C D I S N S T E A G Q K L F N M L R L 561 G K S E P W T L A L E N V V G A K N M N V R P L L N Y F E P L F T W L K D Q N K N S F V G W S T D W S P Y A D Q S I K V R I S L K S A L G D K A Y E W N D N E M 641 Y L F R S S V A Y A M R Q Y F L K V K N Q M I L F G E E D V R V A N L K P R I S F N F F V T A P K N V S D I I P R T E V E K A I R M S R S R I N D A F R L N D N 721 S L E F L G I Q P T L G P P N Q P P V S I W L I V F G V V M G V I V V G I V I L I F T G I R D R K K K N K A R S G E N P Y A S I D I S K G E N N P G F Q N T D D 801 V Q T S F 5.247 aquaporin 1 [Homo sapiens] Protein Accession gi|37694062

Mean Expression Ratio 1.07 Median Expression Ratio 1.07 Credible Interval (0.791, 1.44) Associated Peptides 3 Associated Spectra 10 Coverage 0.145

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.75 1.1 1.6 SEQ ID NO: 1378 DLGGSAPLAIGLSVALGHL 1 0.71 1.1 1.5 SEQ ID NO: 1379 TSGQVEEYDLDADDINSR 8 0.83 1.1 1.4 SEQ ID NO: 1380 VWTSGQVEEYDLDADDINSR SEQ ID NO: 1381 1 M A S E F K K K L F W R A V V A E F L A T T L F V F I S I G S A L G F K Y P V G N N Q T A V Q D N V K V S L A F G L S I A T L A Q S V G H I S G A H L N P A V T 81 L G L L L S C Q I S I F R A L M V I I A Q C V G A I V A T A I L S G I T S S L T G N S L G R N D L A D G V N S G Q G L G I E I I G T L Q L V L C V L A T T D R R 161 R R D L G G S A P L A I G L S V A L G H L L A I D Y T G C G I N P A R S F G S A V I T H N F S N H W I F W V G P F I G G A L A V L I Y D F I L A P R S S D L T D 241 R V K V W T S G Q V E E Y D L D A D D I N S R V E M K P K 5.248 secretoglobin, family 1A, member 1 (uteroglobin) [Homo sapiens] Protein Accession gi|4507809

Mean Expression Ratio 0.938 Median Expression Ratio 0.939 Credible Interval (0.586, 1.51) Associated Peptides 1 Associated Spectra 1 Coverage 0.11

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.56 0.92 1.5 SEQ ID NO: 1382 LVDTLPQKPR SEQ ID NO: 1383 1 M K L A V T L T L V T L A L C C S S A S A E I C P S F Q R V I E T L L M D T P S S Y E A A M E L F S P D Q D M R E A G A Q L K K L V D T L P Q K P R E S I I K L 81 M E K I A Q S S L C N 5.249 structural maintenance of chromosomes 2 [Homo sapiens]; structural maintenance of chromosomes 2 [Homo sapiens]; structural maintenance of chromosomes 2 [Homo sapiens] Protein Accession gi 110347425 gi 110347420 gi|110347418

Mean Expression Ratio 1.06 Median Expression Ratio 1.06 Credible Interval (0.654, 1.72) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.64 1.1 1.8 SEQ ID NO: 1384 LGRNVNMRAMNVLTEAEER 5.250 superoxide dismutase 1, soluble [Homo sapiens] Protein Accession gi|4507149

Mean Expression Ratio 1.07 Median Expression Ratio 1.06 Credible Interval (0.661, 1.73) Associated Peptides 1 Associated Spectra 1 Coverage 0.091

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.65 1.1 1.8 SEQ ID NO: 1385 GDGPVQGIINFEQK SEQ ID NO: 1386 1 M A T K A V C V L K G D G P V Q G I I N F E Q K E S N G P V K V W G S I K G L T E G L H G F H V H E F G D N T A G C T S A G P H F N P L S R K H G G P K D E E R 81 H V G D L G N V T A D K D G V A D V S I E D S V I S L S G D H C I I G R T L V V H E K A D D L G K G G N E E S T K T G N A G S R L A C G V I G I A Q 5.251 phospholipid scramblase 1 [Homo sapiens] Protein Accession gi|10863877

Mean Expression Ratio 1.06 Median Expression Ratio 1.06 Credible Interval (0.774, 1.46) Associated Peptides 4 Associated Spectra 6 Coverage 0.170

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.72 1.1 1.6 SEQ ID NO: 1387 EAFTDADNFGIQFPLDLDVK 3 0.76 1.1 1.5 SEQ ID NO: 1388 IIDNMGQEVITLER 1 0.71 1.0 1.5 SEQ ID NO: 1389 SGYPGPQVSYPPPPAGH 1 0.74 1.1 1.6 SEQ ID NO: 1390 IIDNMGQEVITLERPLR SEQ ID NO: 1391 1 M D K Q N S Q M N A S H P E T N L P V G Y P P Q Y P P T A F Q G P P G Y S G Y P G P Q V S Y P P P P A G H S G P G P A G F P V P N Q P V Y N Q P V Y N Q P V G A 81 A G V P W M P A P Q P P L N C P P G L E Y L S Q I D Q I L I H Q Q I E L L E V L T G F E T N N K Y E I K N S F G Q R V Y F A A E D T D C C T R N C C G P S R P F 161 T L R I I D N M G Q E V I T L E R P L R C S S C C C P C C L Q E I E I Q A P P G V P I G Y V I Q T W H P C L P K F T I Q N E K R E D V L K I S G P C V V C S C C 241 G D V D F E I K S L D E Q C V V G K I S K H W T G I L R E A F T D A D N F G I Q F P L D L D V K M K A V M I G A C F L I D F M F F E S T G S Q E Q K S G V W 5.252 ATPase, H+ transporting, lysosomal V0 subunit al isoform c [Homo sapiens]; ATPase, H+ transporting, lysosomal V0 subunit al isoform b [Homo sapiens]; ATPase, H+ transporting, lysosomal V0 subunit al isoform a [Homo sapiens] Protein Accession gi|19913418 gi|194097403 gi|194097401

Mean Expression Ratio 0.94 Median Expression Ratio 0.94 Credible Interval (0.663, 1.34) Associated Peptides 4 Associated Spectra 4 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.62 0.94 1.4 SEQ ID ANIPIMDTGENPEVPFPR NO: 1392 1 0.62 0.94 1.4 SEQ ID ASLYPCPETPQER NO: 1393 1 0.61 0.92 1.4 SEQ ID IDDLQMVLNQTEDHR NO: 1394 1 0.63 0.95 1.5 SEQ ID KANIPIMDTGENPEVPFPR NO: 1395 5.253 solute carrier family 44, member 2 [Homo sapiens] Protein Accession gi|31377727

Mean Expression Ratio 1.06 Median Expression Ratio 1.06 Credible Interval (0.646, 1.73) Associated Peptides 1 Associated Spectra 1 Coverage 0.0227

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.65 1.1 1.8 SEQ ID NO: 1396 DGDCPAVLIPSKPLAR SEQ ID NO: 1397 1 M G D E R P H Y Y G K H G T P Q K Y D P T F K G P I Y N R G C T D I I C C V F L L L A I V G Y V A V G I I A W T H G D P R K V I Y P T D S R G E F C G Q K G T K 81 N E N K P Y L F V F N I V K C A S P L V L L E F Q C P T P Q I C V E K C P D R Y L T Y L N A R S S R D F E Y Y K Q F C V P G F K N N K G V A E V L R D G D C P A 161 V L I P S K P L A R R C F P A I H A Y K G V L M V G N E T T Y E D G H G S R K N I T D L V E G A K K A N G V L E A R Q L A M R I F E D Y T V S W Y W I I I G L V 241 I A M A M S L L F I I L L R F L A G I M V W V M I I M V I L V L G Y G I F H C Y M E Y S R L R G E A G S D V S L V D L G F Q T D F R V Y L H L R Q T W L A F M I 321 I L S I L E V I I I L L L I F L R K R I L I A I A L I K E A S R A V G Y V M C S L L Y P L V T F F L L C L C I A Y W A S T A V F L S T S N E A V Y K I F D D S P 401 C P F T A K T C N P E T F P S S N E S R Q C P N A R C Q F A F Y G G E S G Y H R A L L G L Q I F N A F M F F W L A N F V L A L G Q V T L A G A F A S Y Y W A L R 481 K P D D L P A F P L F S A F G R A L R Y H T G S L A F G A L I L A I V Q I I R V I L E Y L D Q R L K A A E N K F A K C L M T C L K C C F W C L E K F I K F L N R 561 N A Y I M I A I Y G T N F C T S A R N A F F L L M R N I I R V A V L D K V T D F L F L L G K L L I V G S V G I L A F F F F T H R I R I V Q D T A P P L N Y Y W V 641 P I L T V I V G S Y L I A H G F F S V Y G M C V D T L F L C F L E D L E R N D G S A E R P Y F M S S T L K K P L N K T N K K A A E S 5.254 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 [Homo sapiens] Protein Accession gi|5729850

Mean Expression Ratio 1.07 Median Expression Ratio 1.06 Credible Interval (0.702, 1.63) Associated Peptides 2 Associated Spectra 2 Coverage 0.0763

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.66 1.1 1.7 SEQ ID NO: 1398 ISQSNYIPTQQDVLR 1 0.68 1.1 1.7 SEQ ID NO: 1399 SNTIQSIIAIIR SEQ ID NO: 1400 1 M G C T L S A E D K A A V E R S K M I D R N L R E D G E K A A K E V K L L L L G A G E S G K S T I V K Q M K I I H E D G Y S E D E C K Q Y K V V V Y S N T I Q S 81 I I A I I R A M G R L K I D F G E A A R A D D A R Q L F V L A G S A E E G V M T P E L A G V I K R L W R D G G V Q A C F S R S R E Y Q L N D S A S Y Y L N D L D 161 R I S Q S N Y I P T Q Q D V L R T R V K T T G I V E T H F T F K D L Y F K M F D V G G Q R S E R K K W I H C F E G V T A I I F C V A L S D Y D L V L A E D E E M 241 N R M H E S M K L F D S I C N N K W F T E T S I I L F L N K K D L F E E K I K R S P L T I C Y P E Y T G S N T Y E E A A A Y I Q C Q F E D L N R R K D T K E I Y 321 T H F T C A T D T K N V Q F V F D A V T D V I I K N N L K E C G L Y 5.255 PREDICTED: hypothetical protein [Homo sapiens] Protein Accession gi|1169217813

Mean Expression Ratio 1.06 Median Expression Ratio 1.06 Credible Interval (0.685, 1.62) Associated Peptides 1 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.69 1.1 1.7 SEQ ID NO: 1401 YNRITLNNDIMLIK 5.256 dipeptidyl peptidase 7 preproprotein [Homo sapiens] Protein Accession gi|62420888

Mean Expression Ratio 0.94 Median Expression Ratio 0.943 Credible Interval (0.655, 1.34) Associated Peptides 2 Associated Spectra 4 Coverage 0.065

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.63 0.92 1.3 SEQ ID NO: 1402 GHTELLTVEQALADFAELLR 1 0.62 0.95 1.4 SEQ ID NO: 1403 DLFLQGAYDTVR SEQ ID NO: 1404 1 M G S A P W A P V L L L A L G L R G L Q A G A R R A P D P G F Q E R F F Q Q R L D H F N F E R F G N K T F P Q R F L V S D R F W V R G E G P I F F Y T G N E G D 81 V W A F A N N S A F V A E L A A E R G A L L V F A E H R Y Y G K S L P F G A Q S T Q R G H T E L L T V E Q A L A D F A E L L R A L R R D L G A Q D A P A I A F G 161 G S Y G G M L S A Y L R M K Y P H L V A G A L A A S A P V L A V A G L G D S N Q F F R D V T A D F E G Q S P K C T Q G V R E A F R Q I K D L F L Q G A Y D T V R 241 W E F G T C Q P L S D E K D L T Q L F M F A R N A F T V L A M M D Y P Y P T D F L G P L P A N P V K V G C D R L L S E A Q R I T G L R A L A G L V Y N A S G S E 321 H C Y D I Y R L Y H S C A D P T G C G T G P D A R A W D Y Q A C T E I N L T F A S N N V T D M F P D L P F T D E L R Q R Y C L D T W G V W P R P D W L L T S F W 401 G G D L R A A S N I I F S N G N L D P W A G G G I R R N L S A S V I A V T I Q G G A H H L D L R A S H P E D P A S V V E A R K L E A T I I G E W V K A A R R E Q 481 Q P A L R G G P R L S L 5.257 tropomyosin 4 [Homo sapiens] Protein Accession gi|4507651

Mean Expression Ratio 1.06 Median Expression Ratio 1.06 Credible Interval (0.66, 1.71) Associated Peptides 1 Associated Spectra 1 Coverage 0.0403

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.65 1.1 1.8 SEQ ID NO: 1405 IQLVEEELDR SEQ ID NO: 1406 1 M A G L N S L E A V K R K I Q A L Q Q Q A D E A E D R A Q G L Q R E L D G E R E R R E K A E G D V A A L N R R I Q L V E E E L D R A Q E R L A T A L Q K L E E A 81 E K A A D E S E R G M K V I E N R A M K D E E K M E I Q E M Q L K E A K H I A E E A D R K Y E E V A R K L V I L E G E L E R A E E R A E V S E L K C G D L E E E 161 L K N V T N N L K S L E A A S E K Y S E K E D K Y E E E I K L L S D K L K E A E T R A E F A E R T V A K L E K T I D D L E E K L A Q A K E E N V G L H Q T L D Q 241 T L N E L N C I 5.258 keratin 10 [Homo sapiens] Protein Accession gi|195972866

Mean Expression Ratio 0.945 Median Expression Ratio 0.944 Credible Interval (0.663, 1.35) Associated Peptides 3 Associated Spectra 4 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 2 0.65 0.95 1.4 SEQ ID NQILNLTTDNANILLQIDNAR NO: 1407 1 0.61 0.92 1.4 SEQ ID SQYEQLAEQNRK NO: 1408 1 0.63 0.95 1.4 SEQ ID SQYEQLAEQNR NO: 1409 5.259 myosin VI [Homo sapiens] Protein Accession gi|92859701

Mean Expression Ratio 1.05 Median Expression Ratio 1.06 Credible Interval (0.647, 1.72) Associated Peptides 1 Associated Spectra 1 Coverage 0.0101

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.64 1.1 1.8 SEQ ID NO: 1410 LVGILDILDEENR SEQ ID NO: 1411 1 M E D G K P V W A P H P T D G F Q M G N I V D I G P D S L T I E P L N Q K G K T F L A L I N Q V F P A E E D S K K D V E D N C S L M Y L N E A T L L H N I K V R 81 Y S K D R I Y T Y V A N I L I A V N P Y F D I P K I Y S S E A I K S Y Q G K S L G T R P P H V F A I A D K A F R D M K V L K M S Q S I I V S G E S G A G K T E N 161 T K F V L R Y L T E S Y G T G Q D I D D R I V E A N P L L E A F G N A K T V R N N N S S R F G K F V E I H F N E K S S V V G G F V S H Y L L E K S R I C V Q G K 241 E E R N Y H I F Y R L C A G A S E D I R E K L H L S S P D N F R Y L N R G C T R Y F A N K E T D K Q I L Q N R K S P E Y L K A G S M K D P L L D D H G D F I R M 321 C T A M K K I G L D D E E K L D L F R V V A G V L H L G N I D F E E A G S T S G G C N L K N K S A Q S L E Y C A E L L G L D Q D D L R V S L T T R V M L T T A G 401 G T K G T V I K V P L K V E Q A N N A R D A L A K T V Y S H L F D H V V N R V N Q C F P F E T S S Y F I G V L D I A G F E Y F E H N S F E Q F C I N Y C N E K L 481 Q Q F F N E R I L K E E Q E L Y Q K E G L G V N E V H Y V D N Q D C I D L I E A K L V G I L D I L D E E N R L P Q P S D Q H F T S A V H Q K H K D H F R L T I P 561 R K S K L A V H R N I R D D E G F I I R H F A G A V C Y E T T Q F V E K N N D A L H M S L E S L I C E S R D K F I R E L F E S S T N N N K D T K Q K A G K L S F 641 I S V G N K F K T Q L N L L L D K L R S T G A S F I R C I K P N L K M T S H H F E G A Q I L S Q L Q C S G M V S V L D L M Q G G Y P S R A S F H E L Y N M Y K K 721 Y M P D K L A R L D P R L F C K A L F K A L G L N E N D Y K F G L T K V F F R P G K F A E F D Q I M K S D P D H L A E L V K R V N H W L T C S R W K K V Q W C S 801 L S V I K L K N K I K Y R A E A C I K M Q K T I R M W L C K R R H K P R I D G L V K V G T L K K R L D K F N E V V S V L K D G K P E M N K Q I K N L E I S I D T 881 L M A K I K S T M M T Q E Q I Q K E Y D A L V K S S E E L L S A L Q K K K Q Q E E E A E R L R R I Q E E M E K E R K R R E E D E K R R R K E E E E R R M K L E M 961 E A K R K Q E E E E R K K R E D D E K R I Q A E V E A Q L A R Q K E E E S Q Q Q A V L E Q E R R D R E L A L R I A Q S E A E L I S D E A Q A D L A L R R N D G T 1041 R P K M T P E Q M A K E M S E F L S R G P A V L A T K A A A G T K K Y D L S K W K Y A E L R D T I N T S C D I E L L A A C R E E F H R R L K V Y H A W K S K N K 1121 K R N T E T E Q R A P K S V T D Y D F A P F L N N S P Q Q N P A A Q I P A R Q R E I E M N R Q Q R F F R I P F I R P A D Q Y K D P Q S K K K G W W Y A H F D G P 1201 W I A R Q M E L H P D K P P I L L V A G K D D M E M C E L N L E E T G L T R K R G A E I L P R Q F E E I W E R C G G I Q Y L Q N A I E S R Q A R P T Y A T A M L 1281 Q S L L K 5.260 heat shock protein 90 kDa alpha (cytosolic), class A member 1 isoform 1 [Homo sapiens] Protein Accession gi|153792590

Mean Expression Ratio 1.06 Median Expression Ratio 1.06 Credible Interval (0.65, 1.72) Associated Peptides 1 Associated Spectra 1 Coverage 0.0176

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.65 1.1 1.8 SEQ ID NO: 1412 HLEINPDHSIIETLR SEQ ID NO: 1413 1 M P P C S G G D G S T P P G P S L R D R D C P A Q S A E Y P R D R L D P R P G S P S E A S S P P F L R S R A P V N W Y Q E K A Q V F L W H L M V S G S T T L L C 81 L W K Q P F H V S A F P V T A S L A F R Q S Q G A G Q H L Y K D L Q P F I L L R L L M P E E T Q T Q D Q P M E E E E V E T F A F Q A E I A Q L M S L I I N T F Y 161 S N K E I F L R E L I S N S S D A L D K I R Y E S L T D P S K L D S G K E L H I N L I P N K Q D R T L T I V D T G I G M T K A D L I N N L G T I A K S G T K A F 241 M E A L Q A G A D I S M I G Q F G V G F Y S A Y L V A E K V T V I T K H N D D E Q Y A W E S S A G G S F T V R T D T G E P M G R G T K V I L H L K E D Q T E Y L 321 E E R R I K E I V K K H S Q F I G Y P I T L F V E K E R D K E V S D D E A E E K E D K E E E K E K E E K E S E D K P E I E D V G S D E E E E K K D G D K K K K K 401 K I K E K V I D Q E E L N K T K P I W T R N P D D I T N E E Y G E F Y K S L T N D W E D H L A V K H F S V E G Q L E F R A L L F V P R R A P F D L F E N R K K K 481 N N I K L Y V R R V F I M D N C E E L I P E Y L N F I R G V V D S E D L P L N I S R E M L Q Q S K I L K V I R K N L V K K C L E L F T E L A E D K E N Y K K F Y 561 E Q F S K N I K L G I H E D S Q N R K K L S E L L R Y Y T S A S G D E M V S L K D Y C T R M K E N Q K H I Y Y I T G E T K D Q V A N S A F V E R L R K H G L E V 641 I Y M I E P I D E Y C V Q Q L K E F E G K T L V S V T K E G L E L P E D E E E K K K Q E E K K T K F E N L C K I M K D I L E K K V E K V V V S N R L V T S P C C 721 I V T S T Y G W T A N M E R I M K A Q A L R D N S T M G Y M A A K K H L E I N P D H S I I E T L R Q K A E A D K N D K S V K D L V I L L Y E T A L L S S G F S L 801 E D P Q T H A N R I Y R M I K L G L G I D E D D P T A D D T S A A V T E E M P P L E G D D D T S R M E E V D 5.261 RAB1A, member RAS oncogene family isoform 1 [Homo sapiens]; RAB1B, member RAS oncogene family [Homo sapiens] Protein Accession gi|4758988 gi 13569962

Mean Expression Ratio 1.06 Median Expression Ratio 1.06 Credible Interval (0.65, 1.70) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.64 1.1 1.8 SEQ ID NO: 1414 EFADSLGIPFLETSAK 5.262 villin 1 [Homo sapiens] Protein Accession gi|194394237

Mean Expression Ratio 1.05 Median Expression Ratio 1.05 Credible Interval (0.685, 1.62) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.65 1.0 1.7 SEQ ID NO: 1415 LMEVMNHVLGK 1 0.66 1.1 1.7 SEQ ID NO: 1416 LQEENLVITPR 5.263 PREDICTED: similar to hCG1992647, partial [Homo sapiens] Protein Accession gi|169217452

Mean Expression Ratio 0.95 Median Expression Ratio 0.95 Credible Interval (0.604, 1.47) Associated Peptides 1 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.6 0.94 1.5 SEQ ID NO: 1417 AVTELGRPDAEYWNSQK 5.264 aldehyde dehydrogenase 1A1 [Homo sapiens] Protein Accession gi|21361176

Mean Expression Ratio 1.05 Median Expression Ratio 1.05 Credible Interval (0.723, 1.55) Associated Peptides 2 Associated Spectra 3 Coverage 0.0439

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.7  1.0 1.6 SEQ ID NO: 1418 IFVEESIYDEFVR 1 0.69 1.1 1.7 SEQ ID NO: 1419 ILDLIESGK SEQ ID NO: 1420 1 M S S S G T P D L P V L L T D L K I Q Y T K I F I N N E W H D S V S G K K F P V F N P A T E E E L C Q V E E G D K E D V D K A V K A A R Q A F Q I G S P W R T M 81 D A S E R G R L L Y K L A D L I E R D R L L L A T M E S M N G G K L Y S N A Y L N D L A G C I K T L R Y C A G W A D K I Q G R T I P I D G N F F T Y T R H E P I 161 G V C G Q I I P W N F P L V M L I W K I G P A L S C G N T V V V K P A E Q T P L T A L H V A S L I K E A G F P P G V V N I V P G Y G P T A G A A I S S H M D I D 241 K V A F T G S T E V G K L I K E A A G K S N L K R V T L E L G G K S P C I V L A D A D L D N A V E F A H H G V F Y H Q G Q C C I A A S R I F V E E S I Y D E F V 321 R R S V E R A K K Y I L G N P L T P G V T Q G P Q I D K E Q Y D K I L D L I E S G K K E G A K L E C G G G P W G N K G Y F V Q P T V F S N V T D E M R I A K E E 401 I F G P V Q Q I M K F K S L D D V I K R A N N T F Y G L S A G V F T K D I D K A I T I S S A L Q A G T V W V N C Y G V V S A Q C P F G G F K M S G N G R E L G E 481 Y G F H E Y T E V K T V T V K I S Q K N S 5.265 phosphoglycerate kinase 1 [Homo sapiens] Protein Accession gi|4505763

Mean Expression Ratio 1.05 Median Expression Ratio 1.05 Credible Interval (0.758, 1.47) Associated Peptides 4 Associated Spectra 5 Coverage 0.161

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.72 1.0 1.5 SEQ ID NO: 1421 ACANPAAGSVILLENLR 1 0.72 1.1 1.6 SEQ ID NO: 1422 ALESPERPFLAILGGAK 1 0.74 1.1 1.6 SEQ ID NO: 1423 ITLPVDFVTADKFDENAK 1 0.68 1.0 1.5 SEQ ID NO: 1424 LGDVYVNDAFGTAHR SEQ ID NO: 1425 1 M S L S N K L T L D K L D V K G K R V V M R V D F N V P M K N N Q I T N N Q R I K A A V P S I K F C L D N G A K S V V L M S H L G R P D G V P M P D K Y S L E P 81 V A V E L K S L L G K D V L F L K D C V G P E V E K A C A N P A A G S V I L L E N L R F H V E E E G K G K D A S G N K V K A E P A K I E A F R A S L S K L G D V 161 Y V N D A F G T A H R A H S S M V G V N L P Q K A G G F L M K K E L N Y F A K A L E S P E R P F L A I L G G A K V A D K I Q L I N N M L D K V N E M I I G G G M 241 A F T F L K V L N N M E I G T S L F D E E G A K I V K D L M S K A E K N G V K I T L P V D F V T A D K F D E N A K T G Q A T V A S G I P A G W M G L D C G P E S 321 S K K Y A E A V T R A K Q I V W N G P V G V F E W E A F A R G T K A L M D E V V K A T S R G C I T I I G G G D T A T C C A K W N T E D K V S H V S T G G G A S L 401 E L L E G K V L P G V D A L S N I 5.266 eukaryotic translation initiation factor 5A isoform A [Homo sapiens] Protein Accession gi|219555707

Mean Expression Ratio 1.05 Median Expression Ratio 1.05 Credible Interval (0.636, 1.73) Associated Peptides 1 Associated Spectra 1 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.65 1.1 1.8 SEQ ID NO: NDFQLIGIQDGYLSLLQDSGEVR 1426 5.267 heat shock 70 kDa protein 1A [Homo sapiens]; heat shock 70 kDa protein 1B [Homo sapiens] Protein Accession gi 194248072 gi|167466173

Mean Expression Ratio 1.05 Median Expression Ratio 1.05 Credible Interval (0.861, 1.29) Associated Peptides 12 Associated Spectra 21 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.74 1.0 1.4 SEQ ID NO: 1427 AQIHDLVLVGGSTR 2 0.77 1.1 1.4 SEQ ID NO: 1428 ATAGDTHLGGEDFDNR 1 0.74 1.0 1.4 SEQ ID NO: 1429 AVITVPAYFNDSQR 2 0.79 1.1 1.4 SEQ ID NO: 1430 EIAEAYLGYPVTNAVITVP AYFNDSQR 3 0.78 1.1 1.4 SEQ ID NO: 1431 FEELCSDLFR 1 0.76 1.1 1.5 SEQ ID NO: 1432 FELSGIPPAPR 1 0.77 1.1 1.5 SEQ ID NO: 1433 HWPFQVINDGDKPK 3 0.77 1.0 1.4 SEQ ID NO: 1434 LLQDFFNGR 3 0.78 1.0 1.4 SEQ ID NO: 1435 LVNHFVEEFK 1 0.79 1.1 1.5 SEQ ID NO: 1436 LVNHFVEEFKR 1 0.75 1.0 1.4 SEQ ID NO: 1437 NQVALNPQNTVFDAK 1 0.77 1.1 1.5 SEQ ID NO: 1438 QTQIFTTYSDNQPGVLIQV YEGER 5.268 hypothetical protein LOC126321 isoform b [Homo sapiens]; hypothetical protein LOC126321 isoform c [Homo sapiens]; hypothetical protein LOC126321 isoform a [Homo sapiens] Protein Accession gi|111378395 gi|111378391 gi|111378386

Mean Expression Ratio 0.954 Median Expression Ratio 0.952 Credible Interval (0.647, 1.41) Associated Peptides 2 Associated Spectra 3 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.62 0.96 1.5 SEQ ID NO: 1439 GPGPPAAGAAPSPR 2 0.63 0.94 1.4 SEQ ID NO: 1440 VEPTQDISISDQLGGQD VPVFR 5.269 PDZK1 interacting protein 1 [Homo sapiens] Protein Accession gi|5031657

Mean Expression Ratio 0.954 Median Expression Ratio 0.954 Credible Interval (0.637, 1.43) Associated Peptides 1 Associated Spectra 3 Coverage 0.149

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.64 0.94 1.4 SEQ ID NO: 1441 SSEHENAYENVPEEEGK SEQ ID NO: 1442 1 M S A L S L L I L G L L T A V P P A S C Q Q G L G N L Q P W M Q G L I A V A V F L V L V A I A F A V N H F W C Q E E P E P A H M I L T V G N K A D G V L V G T D 81 G R Y S S M A A S F R S S E H E N A Y E N V P E E E G K V R S T P M 5.270 hexosaminidase A preproprotein [Homo sapiens] Protein Accession gi|189181666

Mean Expression Ratio 0.954 Median Expression Ratio 0.954 Credible Interval (0.589, 1.53) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.57 0.95 1.6 SEQ ID NO: 1443 IQPDTIIQVWR 5.271 paralemmin isoform 1 [Homo sapiens] Protein Accession gi|93141031

Mean Expression Ratio 1.05 Median Expression Ratio 1.05 Credible Interval (0.637, 1.73) Associated Peptides 1 Associated Spectra 1 Coverage 0.0491

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.63 1.1 1.8 SEQ ID NO: 1444 EPAPPNGSAAEPPTEAASR SEQ ID NO: 1445 1 M E V L A A E T T S Q Q E R L Q A I A E K R K R Q A E I E N K R R Q L E D E R R Q L Q H L K S K A L R E R W L L E G T P S S A S E G D E D L R R Q M Q D D E Q K 81 T R L L E D S V S R L E K E I E V L E R G D S A P A T A K E N A A A P S P V R A P A P S P A K E E R K T E V V M N S Q Q T P V G T P K D K R V S N T P L R T V D 161 G S P M M K A A M Y S V E I T V E K D K V T G E T R V L S S T T L L P R Q P L P L G I K V Y E D E T K V V H A V D G T A E N G I H P L S S S E V D E L I H K A D 241 E V T L S E A G S T A G A A E T R G A V E G A A R T T P S R R E I T G V Q A Q P G E A T S G P P G I Q P G Q E P P V T M I F M G Y Q N V E D E A E T K K V L G L 321 Q D T I T A E L V V I E D A A E P K E P A P P N G S A A E P P T E A A S R E E N Q A G P E A T T S D P Q D L D M K K H R C K C C S I M 5.272 mannosidase, alpha, class 2B, member 2 [Homo sapiens] Protein Accession gi|50659093

Mean Expression Ratio 1.04 Median Expression Ratio 1.05 Credible Interval (0.676, 1.62) Associated Peptides 2 Associated Spectra 2 Coverage 0.0238

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.66 1.1 1.7 SEQ ID NO: 1446 FIAVEQEFFR 1 0.65 1.0 1.7 SEQ ID NO: 1447 IEQEYQAGPLELNR SEQ ID NO: 1448 1 M G Q L C W L P L L A P L L L L R P P G V Q S A G P I R A F V V P H S H M D V G W V Y T V Q E S M R A Y A A N V Y T S V V E E L A R G Q Q R R F I A V E Q E F F 81 R L W W D G V A S D Q Q K Y Q V R Q L L E E G R L E F V I G G Q V M H D E A V T H L D D Q I L Q L T E G H G F L Y E T F G I R P Q F S W H V D P F G A S A T T P 161 T L F A L A G F N A H L G S R I D Y D L K A A M Q E A R G L Q F V W R G S P S L S E R Q E I F T H I M D Q Y S Y C T P S H I P F S N R S G F Y W N G V A V F P K 241 P P Q D G V Y P N M S E P V T P A N I N L Y A E A L V A N V K Q R A A W F R T P H V L W P W G C D K Q F F N A S V Q F A N M D P L L D H I N S H A A E L G V S V 321 Q Y A T L G D Y F R A L H A L N V T W R V R D H H D F L P Y S T E P F Q A W T G F Y T S R S S L K G L A R R A S A L L Y A G E S M F T R Y L W P A P R G H L D P 401 T W A L Q Q L Q Q L R W A V S E V Q H H D A I T G T E S P K V R D M Y A T H L A S G M L G M R K L M A S I V L D E L Q P Q A P M A A S S D A G P A G H F A S V Y 481 N P L A W T V T T I V T L T V G F P G V R V T D E A G H P V P S Q I Q N S T E T P S A Y D L L I L T T I P G L S Y R H Y N I R P T A G A Q E G T Q E P A A T V A 561 S T L Q F G R R L R R R T S H A G R Y L V P V A N D C Y I V L L D Q D T N L M H S I W E R Q S N R T V R V T Q E F L E Y H V N G D V K Q G P I S D N Y L F T P G 641 K A A V P A W E A V E M E I V A G Q L V T E I R Q Y F Y R N M T A Q N Y T Y A I R S R L T H V P Q G H D G E L L C H R I E Q E Y Q A G P L E L N R E A V L R T S 721 T N L N S Q Q V I Y S D N N G Y Q M Q R R P Y V S Y V N N S I A R N Y Y P M V Q S A F M E D G K S R L V L L S E R A H G I S S Q G N G Q V E V M L H R R L W N N 801 F D W D L G Y N L T L N D T S V V H P V L W L L L G S W S L T T A L R Q R S A L A L Q H R P V V L F G D L A G T A P K L P G P Q Q Q E A V T L P P N L H L Q I L 881 S I P G W R Y S S N H T E H S Q N L R K G H R G E A Q A D L R R V L L R L Y H L Y E V G E D P V L S Q P V T V N L E A V L Q A L G S V V A V E E R S L T G T W D 961 L S M L H R W S W R T G P G R H R G D T T S P S R P P G G P I I T V H P K E I R T F F I H F Q Q Q 5.273 CD74 antigen isoform a [Homo sapiens]; CD74 antigen isoform c [Homo sapiens]; CD74 antigen isoform b [Homo sapiens] Protein Accession gi|68448544 gi|68448537 gi|10835071

Mean Expression Ratio 1.04 Median Expression Ratio 1.04 Credible Interval (0.672, 1.58) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.65 1.1 1.7 SEQ ID NO: 1449 DLISNNEQLPMLGR 1 0.66 1.1 1.7 SEQ ID NO: 1450 RPGAPESK 5.274 dipeptidylpeptidase IV [Homo sapiens] Protein Accession gi|18765694

Mean Expression Ratio 0.958 Median Expression Ratio 0.957 Credible Interval (0.749, 1.22) Associated Peptides 9 Associated Spectra 12 Coverage 0.141

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.68 0.96 1.4 SEQ ID NO: 1451 CGIAVAPVSR 1 0.71 0.98 1.4 SEQ ID NO: 1452 FRPSEPHFTLDGNSFYK 1 0.66 0.94 1.3 SEQ ID NO: 1453 ISLQWLR 2 0.63 0.87 1.2 SEQ ID NO: 1454 LGTFEVEDQIEAAR 1 0.67 0.95 1.4 SEQ ID NO: 1455 SFYSDESLQYPK 1 0.7 0.98 1.4 SEQ ID NO: 1456 VWNNDIYVK 1 0.68 0.97 1.4 SEQ ID NO: 1457 WEYYDSVYTER 2 0.71 0.99 1.4 SEQ ID NO: 1458 YMGLPTPEDNLDHYR 2 0.7 0.97 1.3 SEQ ID NO: 1459 FWYQMILPPHFDK SEQ ID NO: 1460 1 M K T P W K V L L G L L G A A A L V T I I T V P V V L L N K G T D D A T A D S R K T Y T L T D Y L K N T Y R L K L Y S L R W I S D H E Y L Y K Q E N N I L V F N 81 A E Y G N S S V F L E N S T F D E F G H S I N D Y S I S P D G Q F I L L E Y N Y V K Q W R H S Y T A S Y D I Y D L N K R Q L I T E E R I P N N T Q W V T W S P V 161 G H K L A Y V W N N D I Y V K I E P N L P S Y R I T W T G K E D I I Y N G I T D W V Y E E E V F S A Y S A L W W S P N G T F L A Y A Q F N D T E V P L I E Y S F 241 Y S D E S L Q Y P K T V R V P Y P K A G A V N P T V K F F V V N T D S L S S V T N A T S I Q I T A P A S M L I G D H Y L C D V T W A T Q E R I S L Q W L R R I Q 321 N Y S V M D I C D Y D E S S G R W N C L V A R Q H I E M S T T G W V G R F R P S E P H F T L D G N S F Y K I I S N E E G Y R H I C Y F Q I D K K D C T F I T K G 401 T W E V I G I E A L T S D Y L Y Y I S N E Y K G M P G G R N L Y K I Q L S D Y T K V T C L S C E L N P E R C Q Y Y S V S F S K E A K Y Y Q L R C S G P G L P L Y 481 T L H S S V N D K G L R V L E D N S A L D K M L Q N V Q M P S K K L D F I I L N E T K F W Y Q M I L P P H F D K S K K Y P L L L D V Y A G P C S Q K A D T V F R 561 L N W A T Y L A S T E N I I V A S F D G R G S G Y Q G D K I M H A I N R R L G T F E V E D Q I E A A R Q F S K M G F V D N K R I A I W G W S Y G G Y V T S M V L 641 G S G S G V F K C G I A V A P V S R W E Y Y D S V Y T E R Y M G L P T P E D N L D H Y R N S T V M S R A E N F K Q V E Y L L I H G T A D D N V H F Q Q S A Q I S 721 K A L V D V G V D F Q A M W Y T D E D H G I A S S T A H Q H I Y T H M S H F I K Q C F S L P 5.275 lipocalin 2 [Homo sapiens] Protein Accession gi|38455402

Mean Expression Ratio 0.955 Median Expression Ratio 0.959 Credible Interval (0.658, 1.37) Associated Peptides 3 Associated Spectra 4 Coverage 0.247

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.63 0.93 1.4 SEQ ID NO: 1461 SLGLPENHIVFPVPIDQCIDG 1 0.64 0.96 1.5 SEQ ID NO: 1462 VPLQQNFQDNQFQGK 1 0.63 0.97 1.5 SEQ ID NO: 1463 WYVVGLAGNAILR SEQ ID NO: 1464 1 M P L G L L W L G L A L L G A L H A Q A Q D S T S D L I P A P P L S K V P L Q Q N F Q D N Q F Q G K W Y V V G L A G N A I L R E D K D P Q K M Y A T I Y E L K E 81 D K S Y N V T S V L F R K K K C D Y W I R T F V P G C Q P G E F T L G N I K S Y P G L T S Y L V R V V S T N Y N Q H A M V F F K K V S Q N R E Y F K I T L Y G R 161 T K E L T S E L K E N F I R F S K S L G L P E N H I V F P V P I D Q C I D G 5.276 zinc finger protein 262 [Homo sapiens] Protein Accession gi|44890068

Mean Expression Ratio 0.956 Median Expression Ratio 0.959 Credible Interval (0.585, 1.54) Associated Peptides 1 Associated Spectra 1 Coverage 0.00904

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.57 0.95 1.6 SEQ ID NO: 1465 SSAEMIENTNSLGK SEQ ID NO: 1466 1 M A E R E V E S G P R K R F E Q K S G A V F D E I V E N C G G I M D T E M S E D I D H N L T P T L D S M S Y G M P N Q T G S E N S L L D E D D Y F L N S G D L A 81 G I P V V G S D N E D E Q D F S S K D N L V S S I H T D D S L E V E R R V T Q H E S D N E N E I Q I Q N K L K K D F P K Q F D Q V S V F K S I R K D F S L V R E 161 N S K E T F S G K E K N R D L T Y E R E K R L D K P H K D L D S R L K S S F F D K A A N Q V E E T L H T H L P Q T P E T N F R D S S Y P F A N K E S I G S E L G 241 N S F A S N I R I K E E P L D D E Y D K A M A P Q Q G L L D K I K D E P D N A Q E Y S H G Q Q Q K T Q E G E L K I S A V F S V S G S P L A P Q L T T G F Q P S L 321 A S S G M N K M L P S V P A T A V R V S C S G C K K I L Q K G Q T A Y Q R K G S T Q L F C S T L C L T G Y T V P P A R P P P P L T K K T C S S C S K D I L N P K 401 D V I S A Q F E N T T T S K D F C S Q S C L S T Y E L K K K P I V T I N T N S I S T K C S M C Q K N A V I R H E V N Y Q N V V H K L C S D A C F S K F R S A N N 481 L T M N C C E N C G G Y C Y S G S G Q C H M L Q I E G Q S K K F C S S S C I T A Y K Q K S A K I T P C A L C K S L R S S A E M I E N T N S L G K T E L F C S V N 561 C L S A Y R V K M V T S A G V Q V Q C N S C K T S A I P Q Y H L A M S D G S I R N F C S Y S C V V A F Q N L F N K P T G M N S S V V P L S Q G Q V I V S I P T G 641 S T V S A G G G S T S A V S P T S I S S S A A A G L Q R L A A Q S Q H V G F A R S V V K L K C Q H C N R L F A T K P E L L D Y K G K M F Q F C G K N C S D E Y K 721 K I N N V M A M C E Y C K I E K I V K E T V R F S G A D K S F C S E G C K L L Y K H D L A K R W G N H C K M C S Y C L Q T S P K L V Q N N L G G K V E E F C C E 801 E C M S K Y T V L F Y Q M A K C D A C K R Q G K L S E S L K W R G E M K H F C N L L C I L M F C N Q Q S V C D P P S Q N N A A N I S M V Q A A S A G P P S L R K 881 D S T P V I A N V V S L A S A P A A Q P T V N S N S V L Q G A V P T V T A K I I G D A S T Q T D A L K L P P S Q P P R L L K N K A L L C K P I T Q T K A T S C K 961 P H T Q N K E C Q T E D T P S Q P Q I I V V P V P V P V F V P I P L H L Y T Q Y A P V P F G I P V P M P V P M L I P S S M D S E D K V T E S I E D I K E K L P T 1041 H P F E A D L L E M A E M I A E D E E K K T L S Q G E S Q T S E H E L F L D T K I F E K D Q G S T Y S G D L E S E A V S T P H S W E E E L N H Y A L K S N A V Q 1121 E A D S E L K Q F S K G E T E Q D L E A D F P S D S F D P L N K G Q G I Q A R S R T R R R H R D G F P Q P R R R G R K K S I V A V E P R S L I Q G A F Q G C S V 1201 S G M T L K Y M Y G V N A W K N W V Q W K N A K E E Q G D L K C G G V E Q A S S S P R S D P L G S T Q D H A L S Q E S S E P G C R V R S I K L K E D I L S C T F 1281 A E L S L G L C Q F I Q E V R R P N G E K Y D P D S I L Y L C L G I Q Q Y L F E N G R I D N I F T E P Y S R F M I E L T K L L K I W E P T I L P N G Y M F S R I 1361 E E E H L W E C K Q L G A Y S P I V L L N T L L F F N T K Y F Q L K N V T E H L K L S F A H V M R R T R T L K Y S T K M T Y L R F F P P L Q K Q E S E P D K L T 1441 V G K R K R N E D D E V P V G V E M A E N T D N P L R C P V R L Y E F Y L S K C S E S V K Q R N D V F Y L Q P E R S C V P N S P M W Y S T F P I D P G T L D T M 1521 L T R I L M V R E V H E E L A K A K S E D S D V E L S D 5.277 angiotensin I converting enzyme isoform 1 precursor [Homo sapiens] Protein Accession gi|4503273

Mean Expression Ratio 1.04 Median Expression Ratio 1.04 Credible Interval (0.681, 1.59) Associated Peptides 2 Associated Spectra 2 Coverage 0.0253

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.65 1.0 1.7 SEQ ID NO: 1467 SMYETPSLEQDLER 1 0.65 1.1 1.7 SEQ ID NO: 1468 RQEEAALLSQEFAEAWGQK SEQ ID NO: 1469 1 M G A A S G R R G P G L L L P L P L L L L L P P Q P A L A L D P G L Q P G N F S A D E A G A Q L F A Q S Y N S S A E Q V L F Q S V A A S W A H D T N I T A E N A 81 R R Q E E A A L L S Q E F A E A W G Q K A K E L Y E P I W Q N F T D P Q L R R I I G A V R T L G S A N L P L A K R Q Q Y N A L L S N M S R I Y S T A K V C L P N 161 K T A T C W S L D P D L T N I L A S S R S Y A M L L F A W E G W H N A A G I P L K P L Y E D F T A L S N E A Y K Q D G F T D T G A Y W R S W Y N S P T F E D D L 241 E H L Y Q Q L E P L Y L N L H A F V R R A L H R R Y G D R Y I N L R G P I P A H L L G D M W A Q S W E N I Y D M V V P F P D K P N L D V T S T M L Q Q G W N A T 321 H M F R V A E E F F T S L E L S P M P P E F W E G S M L E K P A D G R E V V C H A S A W D F Y N R K D F R I K Q C T R V T M D Q L S T V H H E M G H I Q Y Y L Q 401 Y K D L P V S L R R G A N P G F H E A I G D V L A L S V S T P E H L H K I G L L D R V T N D T E S D I N Y L L K M A L E K I A F L P F G Y L V D Q W R W G V F S 481 G R T P P S R Y N F D W W Y L R T K Y Q G I C P P V T R N E T H F D A G A K F H V P N V T P Y I R Y F V S F V L Q F Q F H E A L C K E A G Y E G P L H Q C D I Y 561 R S T K A G A K L R K V L Q A G S S R P W Q E V L K D M V G L D A L D A Q P L L K Y F Q P V T Q W L Q E Q N Q Q N G E V L G W P E Y Q W H P P L P D N Y P E G I 641 D L V T D E A E A S K F V E E Y D R T S Q V V W N E Y A E A N W N Y N T N I T T E T S K I L L Q K N M Q I A N H T L K Y G T Q A R K F D V N Q L Q N T T I K R I 721 I K K V Q D L E R A A L P A Q E L E E Y N K I L L D M E T T Y S V A T V C H P N G S C L Q L E P D L T N V M A T S R K Y E D L L W A W E G W R D K A G R A I L Q 801 F Y P K Y V E L I N Q A A R L N G Y V D A G D S W R S M Y E T P S L E Q D L E R L F Q E L Q P L Y L N L H A Y V R R A L H R H Y G A Q H I N L E G P I P A H L L 881 G N M W A Q T W S N I Y D L V V P F P S A P S M D T T E A M L K Q G W T P R R M F K E A D D F F T S L G L L P V P P E F W N K S M L E K P T D G R E V V C H A S 961 A W D F Y N G K D F R I K Q C T T V N L E D L V V A H H E M G H I Q Y F M Q Y K D L P V A L R E G A N P G F H E A I G D V L A L S V S T P K H L H S L N L L S S 1041 E G G S D E H D I N F L M K M A L D K I A F I P F S Y L V D Q W R W R V F D G S I T K E N Y N Q E W W S L R L K Y Q G L C P P V P R T Q G D F D P G A K F H I P 1121 S S V P Y I R Y F V S F I I Q F Q F H E A L C Q A A G H T G P L H K C D I Y Q S K E A G Q R L A T A M K L G F S R P W P E A M Q L I T G Q P N M S A S A M L S Y 1201 F K P L L D W L R T E N E L H G E K L G W P Q Y N W T P N S A R S E G P L P D S G R V S F L G L D L D A Q Q A R V G Q W L L L F L G I A L L V A T L G L S Q R L 1281 F S I R H R S L H R H S H G P Q F G S E V E L R H S 5.278 skeletal muscle receptor tyrosine kinase [Homo sapiens] Protein Accession gi|5031927

Mean Expression Ratio 0.956 Median Expression Ratio 0.96 Credible Interval (0.579, 1.54) Associated Peptides 1 Associated Spectra 1 Coverage 0.0196

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.56 0.94 1.6 SEQ ID NO: 1470 CIARQVAAGMAYLSERK SEQ ID NO: 1471 1 M R E L V N I P L V H I L T L V A F S G T E K L P K A P V I T T P L E T V D A L V E E V A T F M C A V E S Y P Q P E I S W T R N K I L I K L F D T R Y S I R E N 81 G Q L L T I L S V E D S D D G I Y C C T A N N G V G G A V E S C G A L Q V K M K P K I T R P P I N V K I I E G L K A V L P C T T M G N P K P S V S W I K G D S P 161 L R E N S R I A V L E S G S L R I H N V Q K E D A G Q Y R C V A K N S L G T A Y S K V V K L E V E V F A R I L R A P E S H N V T F G S F V T L H C T A T G I P V 241 P T I T W I E N G N A V S S G S I Q E S V K D R V I D S R L Q L F I T K P G L Y T C I A T N K H G E K F S T A K A A A T I S I A E W S K P Q K D N K G Y C A Q Y 321 R G E V C N A V L A K D A L V F L N T S Y A D P E E A Q E L L V H T A W N E L K V V S P V C R P A A E A L L C N H I F Q E C S P G V V P T P I P I C R E Y C L A 401 V K E L F C A K E W L V M E E K T H R G L Y R S E M H L L S V P E C S K L P S M H W D P T A C A R L P H L D Y N K E N L K T F P P M T S S K P S V D I P N L P S 481 S S S S S F S V S P T Y S M T V I I S I M S S F A I F V L L T I T T L Y C C R R R K Q W K N K K R E S A A V T L T T L P S E L L L D R L H P N P M Y Q R M P L L 561 L N P K L L S L E Y P R N N I E Y V R D I G E G A F G R V F Q A R A P G L L P Y E P F T M V A V K M L K E E A S A D M Q A D F Q R E A A L M A E F D N P N I V K 641 L L G V C A V G K P M C L L F E Y M A Y G D L N E F L R S M S P H T V C S L S H S D L S M R A Q V S S P G P P P L S C A E Q L C I A R Q V A A G M A Y L S E R K 721 F V H R D L A T R N C L V G E N M V V K I A D F G L S R N I Y S A D Y Y K A N E N D A I P I R W M P P E S I F Y N R Y T T E S D V W A Y G V V L W E I F S Y G L 801 Q P Y Y G M A H E E V I Y Y V R D G N I L S C P E N C P V E L Y N L M R L C W S K L P A D R P S F T S I H R I L E R M C E R A E G T V S V 5.279 spastin isoform 2 [Homo sapiens]; spastin isoform 1 [Homo sapiens] Protein Accession gi|40806170 gi|11875211

Mean Expression Ratio 1.04 Median Expression Ratio 1.04 Credible Interval (0.638, 1.69) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.64 1.0 1.8 SEQ ID NO: 1472 SSGAAPAPASASAPAPVPG GEAER 5.280 allograft inflammatory factor 1 isoform 3 [Homo sapiens] Protein Accession gi|14574568

Mean Expression Ratio 1.05 Median Expression Ratio 1.04 Credible Interval (0.698, 1.57) Associated Peptides 1 Associated Spectra 3 Coverage 0.0748

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.71 1.1 1.6 SEQ ID NO: 1473 MSQTRDLQGGK SEQ ID NO: 1474 1 M S Q T R D L Q G G K A F G L L K A Q Q E E R L D E I N K Q F L D D P K Y S S D E D L P S K L E G F K E K Y M E F D L N G N G D I D I M S L K R M L E K L G V P 81 K T H L E L K K L I G E V S S G S G E T F S Y P D F L R M M L G K R S A I L K M I L M Y E E K A R E K E K P T G P P A K K A I S E L P 5.281 carbonyl reductase 1 [Homo sapiens] Protein Accession gi|4502599

Mean Expression Ratio 1.05 Median Expression Ratio 1.04 Credible Interval (0.726, 1.51) Associated Peptides 2 Associated Spectra 4 Coverage 0.105

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.73 1.0 1.5 SEQ ID NO: 1475 FHQLDIDDLQSIR 1 0.68 1.1 1.6 SEQ ID NO: 1476 GQAAVQQLQAEGLSPR SEQ ID NO: 1477 1 M S S G I H V A L V T G G N K G I G L A I V R D L C R L F S G D V V L T A R D V T R G Q A A V Q Q L Q A E G L S P R F H Q L D I D D L Q S I R A L R D F L R K E 81 Y G G L D V L V N N A G I A F K V A D P T P F H I Q A E V T M K T N F F G T R D V C T E L L P L I K P Q G R V V N V S S I M S V R A L K S C S P E L Q Q K F R S 161 E T I T E E E L V G L M N K F V E D T K K G V H Q K E G W P S S A Y G V T K I G V T V L S R I H A R K L S E Q R K G D K I L L N A C C P G W V R T D M A G P K A 241 T K S P E E G A E T P V Y L A L L P P D A E G P H G Q F V S E K R V E Q W 5.282 sodium/hydrogen exchanger regulatory factor 1 [Homo sapiens] Protein Accession gi|4759140

Mean Expression Ratio 0.961 Median Expression Ratio 0.96 Credible Interval (0.78, 1.19) Associated Peptides 10 Associated Spectra 19 Coverage 0.26

A 2.5 50 97.5 Sequence ID NO. Sequence 6 0.75 0.97 1.2 SEQ ID NO: 1478 AQEAPGQAEPPAAAEVQGAGNENEPR 1 0.72 1 1.4 SEQ ID NO: 1479 EADKSHPEQR 1 0.69 0.96 1.4 SEQ ID NO: 1480 EALAEAALESPR 1 0.65 0.9 1.2 SEQ ID NO: 1481 EAPGQAEPPAAAEVQGAGNENEPR 3 0.75 1 1.4 SEQ ID NO: 1482 EPPAAAEVQGAGNENEPR 1 0.68 0.93 1.3 SEQ ID NO: 1483 QEAPGQAEPPAAAEVQGAGNENEPR 1 0.73 1.0 1.4 SEQ ID NO: 1484 SKPGQFIR 3 0.68 0.9 1.2 SEQ ID NO: 1485 VIPSQEHLNGPLPVPF 1 0.7 0.97 1.3 SEQ ID NO: 1486 ETDEFFK 1 0.69 0.97 1.3 SEQ ID NO: 1487 SVDPDSPAEASGLR SEQ ID NO: 1488 1 M S A D A A A G A P L P R L C C L E K G P N G Y G F H L H G E K G K L G Q Y I R L V E P G S P A E K A G L L A G D R L V E V N G E N V E K E T H Q Q V V S R I R 81 A A L N A V R L L V V D P E T D E Q L Q K L G V Q V R E E L L R A Q E A P G Q A E P P A A A E V Q G A G N E N E P R E A D K S H P E Q R E L R P R L C T M K K G 161 P S G Y G F N L H S D K S K P G Q F I R S V D P D S P A E A S G L R A Q D R I V E V N G V C M E G K Q H G D V V S A I R A G G D E T K L L V V D R E T D E F F K 241 K C R V I P S Q E H L N G P L P V P F T N G E I Q K E N S R E A L A E A A L E S P R P A L V R S A S S D T S E E L N S Q D S P P K Q D S T A P S S T S S S D P I 321 L D F N I S L A M A K E R A H Q K R S S K R A P Q M D W S K K N E L F S N L 5.283 argininosuccinate synthetase 1 [Homo sapiens]; argininosuccinate synthetase 1 [Homo sapiens] Protein Accession gi|53759107 gi|16950633

Mean Expression Ratio 1.04 Median Expression Ratio 1.04 Credible Interval (0.682, 1.58) Associated Peptides 2 Associated Spectra 2 Coverage NaN

A 2.5 50 97.5 Sequence ID NO. Sequence 1 0.65 1.1 1.7 SEQ ID NO: 1489 EFVEEFIWPAIQSSALYED R 1 0.64 1.0 1.7 SEQ ID NO: 1490 APNTPDILEIEFK 5.284 spinster homolog 1 isoform 1 [Homo sapiens]; spinster homolog 1 isoform 1 [Homo sapiens] Protein Accession gi|215490096 gi|14042968

Mean Expression Ratio 1.04 Median Expression Ratio 1.04 Credible Interval (0.707, 1.55) Associated Peptides 2 Associated Spectra 3 Coverage NaN

A 2.5 50 97.5 Sequence ID NO. Sequence 1 0.66 1.0 1.6 SEQ ID NO: 1491 AQLHVQGLLHEAGSTDDR 2 0.7 1.1 1.6 SEQ ID NO: 1492 SEEPEVPDQEGLQR 5.285 quinolinate phosphoribosyltransferase [Homo sapiens] Protein Accession gi|45269149

Mean Expression Ratio 1.04 Median Expression Ratio 1.04 Credible Interval (0.64, 1.67) Associated Peptides 1 Associated Spectra 1 Coverage 0.0539

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.63 1.0 1.7 SEQ ID NO: 1493 CSGIASAAAAAVEAAR SEQ ID NO: 1494 1 M D A E G L A L L L P P V T L A A L V D S W L R E D C P G L N Y A A L V S G A G P S Q A A L W A K S P G V L A G Q P F F D A I F T Q L N C Q V S W F L P E G S K 81 L V P V A R V A E V R G P A H C L L L G E R V A L N T L A R C S G I A S A A A A A V E A A R G A G W T G H V A G T R K T T P G F R L V E K Y G L L V G G A A S H 161 R Y D L G G L V M V K D N H V V A A G G V E K A V R A A R Q A A D F A L K V E V E C S S L Q E A V Q A A E A G A D L V L L D N F K P E E L H P T A T V L K A Q F 241 P S V A V E A S G G I T L D N L P Q F C G P H I D V I S M G M L T Q A A P A L D F S L K L F A K E V A P V P K I H 5.286 transmembrane protein 106A [Homo sapiens]; PREDICTED: similar to Transmembrane protein 106A [Homo sapiens]; PREDICTED: similar to Transmembrane protein 106A isoform 3 [Homo sapiens] Protein Accession gi|21450796 gi|169211133 gi 113427131

Mean Expression Ratio 0.97 Median Expression Ratio 0.965 Credible Interval (0.601, 1.58) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.58 0.96 1.6 SEQ ID NO: 1495 QLVALIPYGDQR 5.287 uroplakin 1A [Homo sapiens] Protein Accession gi|5902148

Mean Expression Ratio 1.04 Median Expression Ratio 1.04 Credible Interval (0.64, 1.70) Associated Peptides 1 Associated Spectra 1 Coverage 0.062

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.63 1.1 1.8 SEQ ID NO: 1496 AATPEVVFPWPPLCCR SEQ ID NO: 1497 1 M A S A A A A E A E K G S P V V V G L L V V G N I I I L L S G L S L F A E T I W V T A D Q Y R V Y P L M G V S G K D D V F A G A W I A I F C G F S F F M V A S F 81 G V G A A L C R R R S M V L T Y L V L M L I V Y I F E C A S C I T S Y T H R D Y M V S N P S L I T K Q M L T F Y S A D T D Q G Q E L T R L W D R V M I E Q E C C 161 G T S G P M D W V N F T S A F R A A T P E V V F P W P P L C C R R T G N F I P L N E E G C R L G H M D Y L F T K G C F E H I G H A I D S Y T W G I S W F G F A I 241 L M W T L P V M L I A M Y F Y T M L 5.288 secretory carrier membrane protein 3 isoform 1 [Homo sapiens] Protein Accession gi|16445419

Mean Expression Ratio 0.964 Median Expression Ratio 0.965 Credible Interval (0.593, 1.56) Associated Peptides 1 Associated Spectra 1 Coverage 0.075

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.57 0.95 1.6 SEQ ID NO: 1498 EPPPAYEPPAPAPLPPPSAPSLQPSR SEQ ID NO: 1499 1 M A Q S R D G G N P F A E P S E L D N P F Q D P A V I Q H R P S R Q Y A T L D V Y N P F E T R E P P P A Y E P P A P A P L P P P S A P S L Q P S R K L S P T E P 81 K N Y G S Y S T Q A S A A A A T A E L L K K Q E E L N R K A E E L D R R E R E L Q H A A L G G T A T R Q N N W P P L P S F C P V Q P C F F Q D I S M E I P Q E F 161 Q K T V S T M Y Y L W M C S T L A L L L N F L A C L A S F C V E T N N G A G F G L S I L W V L L F T P C S F V C W Y R P M Y K A F R S D S S F N F F V F F F I F 241 F V Q D V L F V L Q A I G I P G W G F S G W I S A L V V P K G N T A V S V L M L L V A L L F T G I A V L G I V M L K R I H S L Y R R T G A S F Q K A Q Q E F A A 321 G V F S N P A V R T A A A N A A A G A A E N A F R A P 5.289 guanine nucleotide binding protein (G protein), gamma 2 [Homo sapiens] Protein Accession gi|54114974

Mean Expression Ratio 1.04 Median Expression Ratio 1.04 Credible Interval (0.635, 1.69) Associated Peptides 1 Associated Spectra 1 Coverage 0.225

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.62 1.0 1.8 SEQ ID NO: 1500 EDPLLTPVPASENPFR SEQ ID NO: 1501 1 M A S N N T A S I A Q A R K L V E Q L K M E A N I D R I K V S K A A A D L M A Y C E A H A K E D P L L T P V P A S E N P F R E K K F F C A I L 5.290 sorbitol dehydrogenase [Homo sapiens] Protein Accession gi|156627571

Mean Expression Ratio 0.967 Median Expression Ratio 0.967 Credible Interval (0.601, 1.58) Associated Peptides 1 Associated Spectra 1 Coverage 0.0476

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.58 0.95 1.6 SEQ ID NO: 1502 LENYPIPEPGPNEVLLR SEQ ID NO: 1503 1 M A A A A K P N N L S L V V H G P G D L R L E N Y P I P E P G P N E V L L R M H S V G I C G S D V H Y W E Y G R I G N F I V K K P M V L G H E A S G T V E K V G 81 S S V K H L K P G D R V A I E P G A P R E N D E F C K M G R Y N L S P S I F F C A T P P D D G N L C R F Y K H N A A F C Y K L P D N V T F E E G A L I E P L S V 161 G I H A C R R G G V T L G H K V L V C G A G P I G M V T L L V A K A M G A A Q V V V T D L S A T R L S K A K E I G A D L V L Q I S K E S P Q E I A R K V E G Q L 241 G C K P E V T I E C T G A E A S I Q A G I Y A T R S G G N L V L V G L G S E M T T V P L L H A A I R E V D I K G V F R Y C N T W P V A I S M L A S K S V N V K P 321 L V T H R F P L E K A L E A F E T F K K G L G L K I M L K C D P S D Q N P 5.291 major facilitator superfamily domain containing 1 [Homo sapiens] Protein Accession gi|112232393

Mean Expression Ratio 0.97 Median Expression Ratio 0.967 Credible Interval (0.601, 1.6) Associated Peptides 1 Associated Spectra 1 Coverage 0.0258

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.56 0.96 1.6 SEQ ID NO: 1504 ALLAGGPDEADR SEQ ID NO: 1505 1 M E E E D E E A R A L L A G G P D E A D R G A P A A P G A L P A L C D P S R L A H R L L V L L L M C F L G F G S Y F C Y D N P A A L Q T Q V K R D M Q V N T T K 81 F M L L Y A W Y S W P N V V L C F F G G F L I D R V F G I R W G T I I F S C F V C I G Q V V F A L G G I F N A F W L M E F G R F V F G I G G E S L A V A Q N T Y 161 A V S W F K G K E L N L V F G L Q L S M A R I G S T V N M N L M G W L Y S K I E A L L G S A G H T T L G I T L M I G G V T C I L S L I C A L A L A Y L D Q R A E 241 R I L H K E Q G K T G E V I K L T D V K D F S L P L W L I F I I C V C Y Y V A V F P F I G L G K V F F T E K F G F S S Q A A S A I N S V V Y V I S A P M S P V F 321 G L L V D K T G K N I I W V L C A V A A T L V S H M M L A F T M W N P W I A M C L L G L S Y S L L A C A L W P M V A F V V P E H Q L G T A Y G F M Q S I Q N L G 401 L A I I S I I A G M I L D S R G Y L F L E V F F I A C V S L S L L S V V L L Y L V N R A Q G G N L N Y S A R Q R E E I K F S H T E 5.292 superoxide dismutase 3, extracellular precursor [Homo sapiens] Protein Accession gi|118582275

Mean Expression Ratio 1.03 Median Expression Ratio 1.03 Credible Interval (0.669, 1.6) Associated Peptides 2 Associated Spectra 2 Coverage 0.1

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.65 1.1 1.7 SEQ ID NO: 1506 VTEIWQEVMQR 1 0.64 1.0 1.7 SEQ ID NO: 1507 AVVVHAGEDDLGR SEQ ID NO: 1508 1 M L A L L C S C L L L A A G A S D A W T G E D S A E P N S D S A E W I R D M Y A K V T E I W Q E V M Q R R D D D G A L H A A C Q V Q P S A T L D A A Q P R V T G 81 V V L F R Q L A P R A K L D A F F A L E G F P T E P N S S S R A I H V H Q F G D L S Q G C E S T G P H Y N P L A V P H P Q H P G D F G N F A V R D G S L W R Y R 161 A G L A A S L A G P H S I V G R A V V V H A G E D D L G R G G N Q A S V E N G N A G R R L A C C V V G V C G P G L W E R Q A R E H S E R K K R R R E S E C K A A 5.293 nuclear transport factor 2 [Homo sapiens] Protein Accession gi|5031985

Mean Expression Ratio 0.967 Median Expression Ratio 0.967 Credible Interval (0.599, 1.58) Associated Peptides 1 Associated Spectra 1 Coverage 0.110

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.57 0.96 1.6 SEQ ID NO: 1509 NINDAWVCTNDMFR SEQ ID NO: 1510 1 M G D K P I W E Q I G S S F I Q H Y Y Q L F D N D R T Q L G A I Y I D A S C L T W E G Q Q F Q G K A A I V E K L S S L P F Q K I Q H S I T A Q D H Q P T P D S C 81 I I S M V V G Q L K A D E D P I M G F H Q M F L L K N I N D A W V C T N D M F R L A L H N F G 5.294 hexosaminidase B preproprotein [Homo sapiens] Protein Accession gi|4504373

Mean Expression Ratio 0.967 Median Expression Ratio 0.967 Credible Interval (0.686, 1.36) Associated Peptides 4 Associated Spectra 4 Coverage 0.0971

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.64 0.97 1.4 SEQ ID NO: 1511 EISEVFPDQFIHLGGDEVEFK 1 0.63 0.96 1.5 SEQ ID NO: 1512 LAPGTIVEVWK 1 0.64 0.97 1.5 SEQ ID NO: 1513 VLDIIATINK 1 0.63 0.96 1.4 SEQ ID NO: 1514 YLDLISYGQDWR SEQ ID NO: 1515 1 M E L C G L G L P R P P M L L A L L L A T L L A A M L A L L T Q V A L V V Q V A E A A R A P S V S A K P G P A L W P L P L S V K M T P N L L H L A P E N F Y I S 81 H S P N S T A G P S C T L L E E A F R R Y H G Y I F G F Y K W H H E P A E F Q A K T Q V Q Q L L V S I T L Q S E C D A F P N I S S D E S Y T L L V K E P V A V L 161 K A N R V W G A L R G L E T F S Q L V Y Q D S Y G T F T I N E S T I I D S P R F S H R G I L I D T S R H Y L P V K I I L K T L D A M A F N K F N V L H W H I V D 241 D Q S F P Y Q S I T F P E L S N K G S Y S L S H V Y T P N D V R M V I E Y A R L R G I R V L P E F D T P G H T L S W G K G Q K D L L T P C Y S R Q N K L D S F G 321 P I N P T L N T T Y S F L T T F F K E I S E V F P D Q F I H L G G D E V E F K C W E S N P K I Q D F M R Q K G F G T D F K K L E S F Y I Q K V L D I I A T I N K 401 G S I V W Q E V F D D K A K L A P G T I V E V W K D S A Y P E E L S R V T A S G F P V I L S A P W Y L D L I S Y G Q D W R K Y Y K V E P L D F G G T Q K Q K Q L 481 F I G G E A C L W G E Y V D A T N L T P R L W P R A S A V G E R L W S S K D V R D M D D A Y D R L T R H R C R M V E R G I A A Q P L Y A G Y C N H E N M 5.295 nucleoporin 188 kDa [Homo sapiens] Protein Accession gi|62955803

Mean Expression Ratio 0.967 Median Expression Ratio 0.967 Credible Interval (0.665, 1.41) Associated Peptides 1 Associated Spectra 4 Coverage 0.00515

A 2.5 50 97.5 Sequence ID No. Sequence 4 0.67 0.96 1.4 SEQ ID NO: 1516 MLQHYLQNK SEQ ID NO: 1517 1 M A A A A G G P C V R S S R E L W T I L L G R S A L R E L S Q I E A E L N K H W R R L L E G L S Y Y K P P S P S S A E K V K A N K D V A S P L K E L G L R I S K 81 F L G L D E E Q S V Q L L Q C Y L Q E D Y R G T R D S V K T V L Q D E R Q S Q A L I L K I A D Y Y Y E E R T C I L R C V L H L L T Y F Q D E R H P Y R V E Y A D 161 C V D K L E K E L V S K Y R Q Q F E E L Y K T E A P T W E T H G N L M T E R Q V S R W F V Q C L R E Q S M L L E I I F L Y Y A Y F E M A P S D L L V L T K M F K 241 E Q G F G S R Q T N R H L V D E T M D P F V D R I G Y F S A L I L V E G M D I E S L H K C A L D D R R E L H Q F A Q D G L I C Q D M D C L M L T F G D I P H H A 321 P V L L A W A L L R H T L N P E E T S S V V R K I G G T A I Q L N V F Q Y L T R L L Q S L A S G G N D C T T S T A C M C V Y G L L S F V L T S L E L H T L G N Q 401 Q D I I D T A C E V L A D P S L P E L F W G T E P T S G L G I I L D S V C G M F P H L L S P L L Q L L R A L V S G K S T A K K V Y S F L D K M S F Y N E L Y K H 481 K P H D V I S H E D G T L W R R Q T P K L L Y P L G G Q T N L R I P Q G T V G Q V M L D D R A Y L V R W E Y S Y S S W T L F T C E I E M L L H V V S T A D V I Q 561 H C Q R V K P I I D L V H K V I S T D L S I A D C L L P I T S R I Y M L L Q R L T T V I S P P V D V I A S C V N C L T V L A A R N P A K V W T D L R H T G F L P 641 F V A H P V S S L S Q M I S A E G M N A G G Y G N L L M N S E Q P Q G E Y G V T I A F L R L I T T L V K G Q L G S T Q S Q G L V P C V M F V L K E M L P S Y H K 721 W R Y N S H G V R E Q I G C L I L E L I H A I L N L C H E T D L H S S H T P S L Q F L C I C S L A Y T E A G Q T V I N I M G I G V D T I D M V M A A Q P R S D G 801 A E G Q G Q G Q L L I K T V K L A F S V T N N V I R L K P P S N V V S P L E Q A L S Q H G A H G N N L I A V L A K Y I Y H K H D P A L P R L A I Q L L K R L A T 881 V A P M S V Y A C L G N D A A A I R D A F L T R L Q S K I E D M R I K V M I L E F L T V A V E T Q P G L I E L F L N L E V K D G S D G S K E F S L G M W S C L H 961 A V L E L I D S Q Q Q D R Y W C P P L L H R A A I A F L H A L W Q D R R D S A M L V L R T K P K F W E N L T S P L F G T L S P P S E T S E P S I L E T C A L I M 1041 K I I C L E I Y Y V V K G S L D Q S L K D T L K K F S I E K R F A Y W S G Y V K S L A V H V A E T E G S S C T S L L E Y Q M L V S A W R M L L I I A T T H A D I 1121 M H L T D S V V R R Q L F L D V L D G T K A L L L V P A S V N C L R L G S M K C T L L L I L L R Q W K R E L G S V D E I L G P L T E I L E G V L Q A D Q Q L M E 1201 K T K A K V F S A F I T V L Q M K E M K V S D I P Q Y S Q L V L N V C E T L Q E E V I A L F D Q T R H S L A L G S A T E D K D S M E T D D C S R S R H R D Q R D 1281 G V C V L G L H L A K E L C E V D E D G D S W L Q V T R R L P I L P T L L T T L E V S L R M K Q N L H F T E A T L H L L L T L A R T Q Q G A T A V A G A G I T Q 1361 S I C L P L L S V Y Q L S T N G T A Q T P S A S R K S L D A P S W P G V Y R L S M S L M E Q L L K T L R Y N F L P E A L D F V G V H Q E R T L Q C L N A V R T V 1441 Q S L A C L E E A D H T V G F I L Q L S N F M K E W H F H L P Q L M R D I Q V N L G Y L C Q A C T S L L H S R K M L Q H Y L Q N K N G D G L P S A V A Q R V Q R 1521 P P S A A S A A P S S S K Q P A A D T E A S E Q Q A L H T V Q Y G L L K I L S K T L A A L R H F T P D V C Q I L L D Q S L D L A E Y N F L F A L S F T T P T F D 1601 S E V A P S F G T L L A T V N V A L N M L G E L D K K K E P L T Q A V G L S T Q A E G T R T L K S L L M F T M E N C F Y L L I S Q A M R Y L R D P A V H P R D K 1681 Q R M K Q E L S S E L S T L L S S L S R Y F R R G A P S S P A T G V L P S P Q G K S T S L S K A S P E S Q E P L I Q L V Q A F V R H M Q R 5.296 hypothetical protein LOC54978 [Homo sapiens] Protein Accession gi|31542711

Mean Expression Ratio 0.965 Median Expression Ratio 0.967 Credible Interval (0.589, 1.58) Associated Peptides 1 Associated Spectra 1 Coverage 0.0323

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.57 0.95 1.6 SEQ ID NO: 1518 GRPLAEESEQER SEQ ID NO: 1519 1 M A W T K Y Q L F L A G L M L V T G S I N T L S A K W A D N F M A E G C G G S K E H S F Q H P F L Q A V G M F L G E F S C L A A F Y L L R C R A A G Q S D S S V 81 D P Q Q P F N P L L F L P P A L C D M T G T S L M Y V A L N M T S A S S F Q M L R G A V I I F T G L F S V A F L G R R L V L S Q W L G I L A T I A G L V V V G L 161 A D L L S K H D S Q H K L S E V I T G D L L I I M A Q I I V A I Q M V L E E K F V Y K H N V H P L R A V G T E G L F G F V I L S L L L V P M Y Y I P A G S F S G 241 N P R G T L E D A L D A F C Q V G Q Q P L I A V A L L G N I S S I A F F N F A G I S V T K E L S A T T R M V L D S L R T V V I W A L S L A L G W E A F H A L Q I 321 L G F L I L L I G T A L Y N G L H R P L L G R L S R G R P L A E E S E Q E R L L G G T R T P I N D A S 5.297 disrupted in renal carcinoma 2 [Homo sapiens] Protein Accession gi|14249552

Mean Expression Ratio 1.03 Median Expression Ratio 1.03 Credible Interval (0.705, 1.52) Associated Peptides 2 Associated Spectra 3 Coverage 0.069

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.7 1.0 1.6 SEQ ID NO: 1520 EAAAAALPAAVPGPGR 1 0.66 1.0 1.6 SEQ ID NO: 1521 QPLLGPGLGPGLGASWR SEQ ID NO: 1522 1 M G S R W S S E E E R Q P L L G P G L G P G L G A S W R S R E A A A A A L P A A V P G P G R V Y G R R W L V L L L F S L L A F V Q G L V W N T W G P I Q N S A R 81 Q A Y G F S S W D I A L L V L W G P I G F L P C F A F M W L L D K R G L R I T V L L T S F L M V L G T G L R C I P I S D L I L K R R L I H G G Q M L N G L A G P 161 T V M N A A P F L S T T W F S A D E R A T A T A I A S M L S Y L G G A C A F L V G P L V V P A P N G T S P L L A A E S S R A H I K D R I E A V L Y A E F G V V C 241 L I F S A T L A Y F P P R P P L P P S V A A A S Q R L S Y R R S V C R L L S N F R F L M I A L A Y A I P L G V F A G W S G V L D L I L T P A H V S Q V D A G W I 321 G F W S I V G G C V V G I A M A R F A D F I R G M L K L I L L L L F S G A T L S S T W F T L T C L N S I T H L P L T T V T L Y A S C I L L G V F L N S S V P I F 401 F E L F V E T V Y P V P E G I T C G V V T F L S N M F M G V L L F F L T F Y H T E L S W F N W C L P G S C L L S L L L I L C F R E S Y D R L Y L D V V V S V 5.298 adenine phosphoribosyltransferase isoform b [Homo sapiens] Protein Accession gi|71773201

Mean Expression Ratio 1.03 Median Expression Ratio 1.03 Credible Interval (0.636, 1.69) Associated Peptides 1 Associated Spectra 1 Coverage 0.097

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.62 1.0 1.7 SEQ ID NO: 1523 SFPDFPTPGVVFR SEQ ID NO: 1524 1 M A D S E L Q L V E Q R I R S F P D F P T P G V V F R D I S P V L K D P A S F R A A I G L L A R H L K A T H G G R I D Y I A G L D S R G F L F G P S L A Q E L G 81 L G C V L I R K R G K L P G P T L W A S Y S L E Y G K A E L E I Q K D A L E P G Q R V V V V D D L L A T G V 5.299 GNAS complex locus XLas [Homo sapiens] Protein Accession gi|117938759

Mean Expression Ratio 1.03 Median Expression Ratio 1.03 Credible Interval (0.755, 1.40) Associated Peptides 4 Associated Spectra 7 Coverage 0.0501

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.7 0.98 1.4 SEQ ID NO: 1525 IEDYFPEFAR 1 0.69 1.0 1.5 SEQ ID NO: 1526 SNLVPPVELANPENQFR 2 0.8 1.1 1.6 SEQ ID NO: 1527 YTTPEDATPEPGEDPR 1 0.7 1.0 1.5 SEQ ID NO: 1528 LQEALNLFK SEQ ID NO: 1529 1 M G V R N C L Y G N N M S G Q R D I P P E I G E Q P E Q P P L E A P G A A A P G A G P S P A E E M E T E P P H N E P I P V E N D G E A C G P P E V S R P N F Q V 81 L N P A F R E A G A H G S Y S P P P E E A M P F E A E Q P S L G G F W P T L E Q P G F P S G V H A G L E A F G P A L M E P G A F S G A R P G L G G Y S P P P E E 161 A M P F E F D Q P A Q R G C S Q L L L Q V P D L A P G G P G A A G V P G A P P E E P Q A L R P A K A G S R G G Y S P P P E E T M P F E L D G E G F G D D S P P P 241 G L S R V I A Q V D G S S Q F A A V A A S S A V R L T P A A N A P P L W V P G A I G S P S Q E A V R P P S N F T G S S P W M E I S G P P F E I G S A P A G V D D 321 T P V N M D S P P I A L D G P P I K V S G A P D K R E R A E R P P V E E E A A E M E G A A D A A E G G K V P S P G Y G S P A A G A A S A D T A A R A A P A A P A 401 D P D S G A T P E D P D S G T A P A D P D S G A F A A D P D S G A A P A A P A D P D S G A A P D A P A D P D S G A A P D A P A D P D A G A A P E A P A A P A A A 481 E T R A A H V A P A A P D A G A P T A P A A S A T R A A Q V R R A A S A A P A S G A R R K I H L R P P S P E I Q A A D P P T P R P T R A S A W R G K S E S S R G 561 R R V Y Y D E G V A S S D D D S S G D E S D D G T S G C L R W F Q H R R N R R R R K P Q R N L L R N F L V Q A F G G C F G R S E S P Q P K A S R S L K V K K V P 641 L A E K R R Q M R K E A L E K R A Q K R A E K K R S K L I D K Q L Q D E K M G Y M C T H R L L L L G A G E S G K S T I V K Q M R I L H V N G F N G E G G E E D P 721 Q A A R S N S D G E K A T K V Q D I K N N L K E A I E T I V A A M S N L V P P V E L A N P E N Q F R V D Y I L S V M N V P D F D F P P E F Y E H A K A L W E D E 801 G V R A C Y E R S N E Y Q L I D C A Q Y F L D K I D V I K Q A D Y V P S D Q D L L R C R V L T S G I F E T K F Q V D K V N F H M F D V G G Q R D E R R K W I Q C 881 F N D V T A I I F V V A S S S Y N M V I R E D N Q T N R L Q E A L N L F K S I W N N R W L R T I S V I L F L N K Q D L L A E K V L A G K S K I E D Y F P E F A R 961 Y T T P E D A T P E P G E D P R V T R A K Y F I R D E F L R I S T A S G D G R H Y C Y P H F T C A V D T E N I R R V F N D C R D I I Q R M H L R Q Y E L L 5.300 A kinase (PRKA) anchor protein 12 isoform 2 [Homo sapiens] Protein Accession gi|21493024

Mean Expression Ratio 1.03 Median Expression Ratio 1.03 Credible Interval (0.673, 1.58) Associated Peptides 2 Associated Spectra 2 Coverage 0.0232

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.64 1.0 1.6 SEQ ID NO: 1530 EESQLPGTGGPEDVLQPVQR 1 0.65 1.0 1.7 SEQ ID NO: 1531 EVIAEEEPPTVTEPLPENR SEQ ID NO: 1532 1 M L G T I T I T V G Q R D S E D V S K R D S D K E M A T K S A V V H D I T D D G Q E E T P E I I E Q I P S S E S N L E E L T Q P T E S Q A N D I G F K K V F K F 81 V G F K F T V K K D K T E K P D T V Q L L T V K K D E G E G A A G A G D H K D P S L G A G E A A S K E S E P K Q S T E K P E E T L K R E Q S H A E I S P P A E S 161 G Q A V E E C K E E G E E K Q E K E P S K S A E S P T S P V T S E T G S T F K K F F T Q G W A G W R K K T S F R K P K E D E V E A S E K K K E Q E P E K V D T E 241 E D G K A E V A S E K L T A S E Q A H P Q E P A E S A H E P R L S A E Y E K V E L P S E E Q V S G S Q G P S E E K P A P L A T E V F D E K I E V H Q E E V V A E 321 V H V S T V E E R T E E Q K T E V E E T A G S V P A E E L V E M D A E P Q E A E P A K E L V K L K E T C V S G E D P T Q G A D L S P D E K V L S K P P E G V V S 401 E V E M L S S Q E R M K V Q G S P L K K L F T S T G L K K L S G K K Q K G K R G G G D E E S G E H T Q V P A D S P D S Q E E Q K G E S S A S S P E E P E E I T C 481 L E K G L A E V Q Q D G E A E E G A T S D G E K K R E G V T P W A S F K K M V T P K K R V R R P S E S D K E D E L D K V K S A T L S S T E S T A S E M Q E E M K 561 G S V E E P K P E E P K R K V D T S V S W E A L I C V G S S K K R A R R G S S S D E E G G P K A M G G D H Q K A D E A G K D K E T G T D G I L A G S Q E H D P G 641 Q G S S S P E Q A G S P T E G E G V S T W E S F K R L V T P R K K S K S K L E E K S E D S I A G S G V E H S T P D T E P G K E E S W V S I K K F I P G R R K K R 721 P D G K Q E Q A P V E D A G P T G A N E D D S D V P A V V P L S E Y D A V E R E K M E A Q Q A Q K S A E Q P E Q K A A T E V S K E L S E S Q V H M M A A A V A D 801 G T R A A T I I E E R S P S W I S A S V T E P L E Q V E A E A A L L T E E V L E R E V I A E E E P P T V T E P L P E N R E A R G D T V V S E A E L T P E A V T A 881 A E T A G P L G A E E G T E A S A A E E T T E M V S A V S Q L T D S P D T T E E A T P V Q E V E G G V P D I E E Q E R R T Q E V L Q A V A E K V K E E S Q L P G 961 T G G P E D V L Q P V Q R A E A E R P E E Q A E A S G L K K E T D V V L K V D A Q E A K T E P F T Q G K V V G Q T T P E S F E K A P Q V T E S I E S S E L V T T 1041 C Q A E T L A G V K S Q E M V M E Q A I P P D S V E T P T D S E T D G S T P V A D F D A P G T T Q K D E I V E I H E E N E V A S G T Q S G G T E A E A V P A Q K 1121 E R P P A P S S F V F Q E E T K E Q S K M E D T L E H T D K E V S V E T V S I L S K T E G T Q E A D Q Y A D E K T K D V P F F E G L E G S I D T G I T V S R E K 1201 V T E V A L K G E G T E E A E C K K D D A L E L Q S H A K S P P S P V E R E M V V Q V E R E K T E A E P T H V N E E K L E H E T A V T V S E E V S K Q L L Q T V 1281 N V P I I D G A K E V S S L E G S P P P C L G Q E E A V C T K I Q V Q S S E A S F T L T A A A E E E K V L G E T A N I L E T G E T L E P A G A H L V L E E K S S 1361 E K N E D F A A H P G E D A V P T G P D C Q A K S T P V I V S A T T K K G L S S D L E G E K T T S L K W K S D E V D E Q V A C Q E V K V S V A I E D L E P E N G 1441 I L E L E T K S S K L V Q N I I Q T A V D Q F V R T E E T A T E M L T S E L Q T Q A H V I K A D S Q D A G Q E T E K E G E E P Q A S A Q D E T P I T S A K E E S 1521 E S T A V G Q A H S D I S K D M S E A S E K T M T V E V E G S T V N D Q Q L E E V V L P S E E E G G G A G T K S V P E D D G H A L L A E R I E K S L V E P K E D 1601 E K G D D V D D P E N Q N S A L A D T D A S G G L T K E S P D T N G P K Q K E K E D A Q E V E L Q E G K V H S E S D K A I T P Q A Q E E L Q K Q E R E S A K S E 1681 L T E S 5.301 orosomucoid 1 precursor [Homo sapiens] Protein Accession gi|167857790

Mean Expression Ratio 0.97 Median Expression Ratio 0.97 Credible Interval (0.666, 1.44) Associated Peptides 3 Associated Spectra 3 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.63 0.97 1.5 SEQ ID NO: 1533 WFYIASAFR 1 0.64 0.99 1.5 SEQ ID NO: 1534 EQLGEFYEALDCLR 1 0.61 0.95 1.5 SEQ ID NO: 1535 YVGGQEHFAHLLILR 5.302 lysozyme precursor [Homo sapiens] Protein Accession gi|4557894

Mean Expression Ratio 0.969 Median Expression Ratio 0.97 Credible Interval (0.6, 1.57) Associated Peptides 1 Associated Spectra 1 Coverage 0.0811

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.58 0.96 1.6 SEQ ID NO: 1536 STDYGIFQINSR SEQ ID NO: 1537 1 M K A L I V L G L V L L S V T V Q G K V F E R C E L A R T L K R L G M D G Y R G I S L A N W M C L A K W E S G Y N T R A T N Y N A G D R S T D Y G I F Q I N S R 81 Y W C N D G K T P G A V N A C H L S C S A L L Q D N I A D A V A C A K R V V R D P Q G I R A W V A W R N R C Q N R D V R Q Y V Q G C G V 5.303 vacuolar protein sorting 37C [Homo sapiens] Protein Accession gi|57863314

Mean Expression Ratio 0.972 Median Expression Ratio 0.97 Credible Interval (0.658, 1.44) Associated Peptides 3 Associated Spectra 3 Coverage 0.177

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.62 0.97 1.5 SEQ ID NO: 1538 FLEGEVPLETFLENFSSMR 1 0.64 1 1.6 SEQ ID NO: 1539 NLEFQGPLEISR 1 0.6 0.93 1.4 SEQ ID NO: 1540 TLQELEELQNDSEAIDQLALESPE VQDLQLER SEQ ID NO: 1541 1 M E T L K D K T L Q E L E E L Q N D S E A I D Q L A L E S P E V Q D L Q L E R E M A L A T N R S L A E R N L E F Q G P L E I S R S N L S D R Y Q E L R K L V E R 81 C Q E Q K A K L E K F S S A L Q P G T L L D L L Q V E G M K I E E E S E A M A E K F L E G E V P L E T F L E N F S S M R M L S H L R R V R V E K L Q E V V R K P 161 R A S Q E L A G D A P P P R P P P P V R P V P Q G T P P V V E E Q P Q P P L A M P P Y P L P Y S P S P S L P V G P T A H G A L P P A P F P V V S Q P S F Y S G P 241 L G P T Y P A A Q L G P R G A A G Y S W S P Q R S M P P R P G Y P G T P M G A S G P G Y P L R G G R A P S P G Y P Q Q S P Y P A T G G K P P Y P I Q P Q L P S F 321 P G Q P Q P S V P L Q P P Y P P G P A P P Y G F P P P P G P A W P G Y 5.304 NAD(P)H dehydrogenase, quinone 2 [Homo sapiens] Protein Accession gi|156564357

Mean Expression Ratio 0.972 Median Expression Ratio 0.97 Credible Interval (0.596, 1.58) Associated Peptides 1 Associated Spectra 1 Coverage 0.0779

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.58 0.97 1.6 SEQ ID NO: 1542 VLAPQISFAPEIASEEER SEQ ID NO: 1543 1 M A G K K V L I V Y A H Q E P K S F N G S L K N V A V D E L S R Q G C T V T V S D L Y A M N L E P R A T D K D I T G T L S N P E V F N Y G V E T H E A Y K Q R S 81 L A S D I T D E Q K K V R E A D L V I F Q F P L Y W F S V P A I L K G W M D R V L C Q G F A F D I P G F Y D S G L L Q G K L A L L S V T T G G T A E M Y T K T G 161 V N G D S R Y F L W P L Q H G T L H F C G F K V L A P Q I S F A P E I A S E E E R K G M V A A W S Q R L Q T I W K E E P I P C T A H W H F G Q 5.305 cystatin B [Homo sapiens] Protein Accession gi|4503117

Mean Expression Ratio 0.97 Median Expression Ratio 0.97 Credible Interval (0.603, 1.59) Associated Peptides 1 Associated Spectra 1 Coverage 0.122

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.58 0.96 1.6 SEQ ID NO: 1544 VHVGDEDFVHLR SEQ ID NO: 1545 1 M M C G A P S A T Q P A T A E T Q H I A D Q V R S Q L E E K E N K K F P V F K A V S F K S Q V V A G T N Y F I K V H V G D E D F V H L R V F Q S L P H E N K P L 81 T L S N Y Q T N K A K H D E L T Y F 5.306 triosephosphate isomerase 1 [Homo sapiens] Protein Accession gi|4507645

Mean Expression Ratio 1.03 Median Expression Ratio 1.03 Credible Interval (0.635, 1.68) Associated Peptides 1 Associated Spectra 1 Coverage 0.0522

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.62 1.0 1.7 SEQ ID NO: 1546 TATPQQAQEVHEK SEQ ID NO: 1547 1 M A P S R K F F V G G N W K M N G R K Q S L G E L I G T L N A A K V P A D T E V V C A P P T A Y I D F A R Q K L D P K I A V A A Q N C Y K V T N G A F T G E I S 81 P G M I K D C G A T W V V L G H S E R R H V F G E S D E L I G Q K V A H A L A E G L G V I A C I G E K L D E R E A G I T E K V V F E Q T K V I A D N V K D W S K 161 V V L A Y E P V W A I G T G K T A T P Q Q A Q E V H E K L R G W L K S N V S D A V A Q S T R I I Y G G S V T G A T C K E L A S Q P D V D G F L V G G A S L K P E 241 F V D I I N A K Q 5.307 nucleoside phosphorylase [Homo sapiens] Protein Accession gi|157168362

Mean Expression Ratio 1.03 Median Expression Ratio 1.03 Credible Interval (0.725, 1.45) Associated Peptides 4 Associated Spectra 5 Coverage 0.208

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.68 1.0 1.6 SEQ ID NO: 1548 LGADAVGMSTVPEVIVAR 1 0.68 1.0 1.5 SEQ ID NO: 1549 LTQAQIFDYGEIPNFPR 2 0.71 1.0 1.5 SEQ ID NO: 1550 DHINLPGFSGQNPLR 1 0.67 1.0 1.5 SEQ ID NO: 1551 FEVGDIMLIR SEQ ID NO: 1552 1 M E N G Y T Y E D Y K N T A E W L L S H T K H R P Q V A I I C G S G L G G L T D K L T Q A Q I F D Y G E I P N F P R S T V P G H A G R L V F G F L N G R A C V M 81 M Q G R F H M Y E G Y P L W K V T F P V R V F H L L G V D T L V V T N A A G G L N P K F E V G D I M L I R D H I N L P G F S G Q N P L R G P N D E R F G D R F P 161 A M S D A Y D R T M R Q R A L S T W K Q M G E Q R E L Q E G T Y V M V A G P S F E T V A E C R V L Q K L G A D A V G M S T V P E V I V A R H C G L R V F G F S L 241 I T N K V I M D Y E S L E K A N H E E V L A A G K Q A A Q K L E Q F V S I L M A S I P L P D K A S 5.308 guanine nucleotide binding protein (G protein), alpha 13 [Homo sapiens] Protein Accession gi|24111250

Mean Expression Ratio 0.97 Median Expression Ratio 0.972 Credible Interval (0.686, 1.38) Associated Peptides 4 Associated Spectra 4 Coverage 0.138

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.61 0.93 1.4 SEQ ID NO: 1553 IIHGQDFDQR 1 0.63 0.96 1.5 SEQ ID NO: 1554 LGEPDYIPSQQDILLAR 1 0.65 0.98 1.5 SEQ ID NO: 1555 LTESLNIFETIVNNR 1 0.66 1 1.5 SEQ ID NO: 1556 VFLQYLPAIR SEQ ID NO: 1557 1 M A D F L P S R S V L S V C F P G C L L T S G E A E Q Q R K S K E I D K C L S R E K T Y V K R L V K I L L L G A G E S G K S T F L K Q M R I I H G Q D F D Q R A 81 R E E F R P T I V S N V I K G M R V L V D A R E K L H I P W G D N S N Q Q H G D K M M S F D T R A P M A A Q G M V E T R V F L Q Y L P A I R A L W A D S G I Q N 161 A Y D R R R E F Q L G E S V K Y F L D N L D K L G E P D Y I P S Q Q D I L L A R R P T K G I H E Y D F E I K N V P F K M V D V G G Q R S E R K R W F E C F D S V 241 T S I L F L V S S S E F D Q V L M E D R L T N R L T E S L N I F E T I V N N R V F S N V S I I L F L N K T D L L E E K V Q I V S I K D Y F L E F E G D P H C L R 321 D V Q K F L V E C F R N K R R D Q Q Q K P L Y H H F T T A I N T E N I R L V F R D V K D T I L H D N L K Q L M L Q 5.309 phospholipid scramblase 3 [Homo sapiens] Protein Accession gi|31543417

Mean Expression Ratio 1.03 Median Expression Ratio 1.03 Credible Interval (0.687, 1.54) Associated Peptides 1 Associated Spectra 3 Coverage 0.0678

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.7 1.0 1.5 SEQ ID NO: 1558 EALTDADDFGLQFPLDLDVR SEQ ID NO: 1559 1 M A G Y L P P K G Y A P S P P P P Y P V T P G Y P E P A L H P G P G Q A P V P A Q V P A P A P G F A L F P S P G P V A L G S A A P F L P L P G V P S G L E F L V 81 Q I D Q I L I H Q K A E R V E T F L G W E T C N R Y E L R S G A G Q P L G Q A A E E S N C C A R L C C G A R R P L R V R L A D P G D R E V L R L L R P L H C G C 161 S C C P C G L Q E M E V Q A P P G T T I G H V L Q T W H P F L P K F S I Q D A D R Q T V L R V V G P C W T C G C G T D T N F E V K T R D E S R S V G R I S K Q W 241 G G L V R E A L T D A D D F G L Q F P L D L D V R V K A V L L G A T F L I D Y M F F E K R G G A G P S A V T S 5.310 plasma glutamate carboxypeptidase [Homo sapiens] Protein Accession gi|7706387

Mean Expression Ratio 0.974 Median Expression Ratio 0.972 Credible Interval (0.602, 1.57) Associated Peptides 1 Associated Spectra 1 Coverage 0.0233

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.59 0.96 1.6 SEQ ID NO: 1560 LALLVDTVGPR SEQ ID NO: 1561 1 M K F L I F A F F G G V H L L S L C S G K A I C K N G I S K R T F E E I K E E I A S C G D V A K A I I N L A V Y G K A Q N R S Y E R L A L L V D T V G P R L S G 81 S K N L E K A I Q I M Y Q N L Q Q D G L E K V H L E P V R I P H W E R G E E S A V M L E P R I H K I A I L G L G S S I G T P P E G I T A E V L V V T S F D E L Q 161 R R A S E A R G K I V V Y N Q P Y I N Y S R T V Q Y R T Q G A V E A A K V G A L A S L I R S V A S F S I Y S P H T G I Q E Y Q D G V P K I P T A C I T V E D A E 241 M M S R M A S H G I K I V I Q L K M G A K T Y P D T D S F N T V A E I T G S K Y P E Q V V L V S G H L D S W D V G Q G A M D D G G G A F I S W E A L S L I K D L 321 G L R P K R T L R L V L W T A E E Q G G V G A F Q Y Y Q L H K V N I S N Y S L V M E S D A G T F L P T G L Q F T G S E K A R A I M E E V M S L L Q P L N I T Q V 401 L S H G E G T D I N F W I Q A G V P G A S L L D D L Y K Y F F F H H S H G D T M T V M D P K Q M N V A A A V W A V V S Y V V A D M E E M L P R S 5.311 bone marrow stromal cell antigen 1 precursor [Homo sapiens] Protein Accession gi|168229159

Mean Expression Ratio 1.02 Median Expression Ratio 1.03 Credible Interval (0.626, 1.66) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.61 1.0 1.7 SEQ ID NO: 1562 SLFWENSHLLVNSFADNTR 5.312 solute carrier organic anion transporter family, member 4C1 [Homo sapiens] Protein Accession gi|38679890

Mean Expression Ratio 0.974 Median Expression Ratio 0.973 Credible Interval (0.595, 1.57) Associated Peptides 1 Associated Spectra 1 Coverage 0.0221

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.58 0.97 1.6 SEQ ID NO: 1563 GIENLAFVPSSPDILR SEQ ID NO: 1564 1 M K S A K G I E N L A F V P S S P D I L R R L S A S P S Q I E V S A L S S D P Q R E N S Q P Q E L Q K P Q E P Q K S P E P S L P S A P P N V S E E K L R S L S L 81 S E F E E G S Y G W R N F H P Q C L Q R C N T P G G F L L H Y C L L A V T Q G I V V N G L V N I S I S T V E K R Y E M K S S L T G L I S S S Y D I S F C L L S L 161 F V S F F G E R G H K P R W L A F A A F M I G L G A L V F S L P Q F F S G E Y K L G S L F E D T C V T T R N S T S C T S S T S S L S N Y L Y V F I L G Q L L L G 241 A G G T P L Y T L G T A F L D D S V P T H K S S L Y I G T G Y A M S I L G P A I G Y V L G G Q L L T I Y I D V A M G E S T D V T E D D P R W L G A W W I G F L L 321 S W I F A W S L I I P F S C F P K H L P G T A E I Q A G K T S Q A H Q S N S N A D V K F G K S I K D F P A A L K N L M K N A V F M C L V L S T S S E A L I T T G 401 F A T F L P K F I E N Q F G L T S S F A A T L G G A V L I P G A A L G Q I L G G F L V S K F R M T C K N T M K F A L F T S G V A L T L S F V F M Y A K C E N E P 481 F A G V S E S Y N G T G E L G N L I A P C N A N C N C S R S Y Y Y P V C G D G V Q Y F S P C F A G C S N P V A H R K P K V Y Y N C S C I E R K T E I T S T A E T 561 F G F E A K A G K C E T H C A K L P I F L C I F F I V I I F T F M A G T P I T V S I L R C V N H R Q R S L A L G I Q F M V L R L L G T I P G P I I F G F T I D S 641 T C I L W D I N D C G I K G A C W I Y D N I K M A H M L V A I S V T C K V I T M F F N G F A I F L Y K P P P S A T D V S F H K E N A V V T N V L A E Q D L N K I 721 V K E G 5.313 glucose transporter 14 [Homo sapiens] Protein Accession gi|23592238

Mean Expression Ratio 1.03 Median Expression Ratio 1.03 Credible Interval (0.626, 1.68) Associated Peptides 1 Associated Spectra 1 Coverage 0.0173

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.62 1.0 1.7 SEQ ID NO: 1565 QVTVLELFR SEQ ID NO: 1566 1 M E F H N G G H V S G I G G F L V S L T S R M K P H T L A V T P A L I F A I T V A T I G S F Q F G Y N T G V I N A P E T I I K E F I N K T L T D K A N A P P S E 81 V L L T N L W S L S V A I F S V G G M I G S F S V G L F V N R F G R R N S M L I V N L L A A T G G C L M G L C K I A E S V E M L I L G R L V I G L F C G L C T G 161 F V P M Y I G E I S P T A L R G A F G T L N Q L G I V I G I L V A Q I F G L E L I L G S E E L W P V L L G F T I L P A I L Q S A A L P C C P E S P R F L L I N R 241 K K E E N A T R I L Q R L W G T Q D V S Q D I Q E M K D E S A R M S Q E K Q V T V L E L F R V S S Y R Q P I I I S I V L Q L S Q Q L S G I N A V F Y Y S T G I F 321 K D A G V Q Q P I Y A T I S A G V V N T I F T L L S L F L V E R A G R R T L H M I G L G G M A F C S T L M T V S L L L K N H Y N G M S F V C I G A I L V F V A C 401 F E I G P G P I P W F I V A E L F S Q G P R P A A M A V A G C S N W T S N F L V G L L F P S A A Y Y L G A Y V F I I F T G F L I T F L A F T F F K V P E T R G R 481 T F E D I T R A F E G Q A H G A D R S G K D G V M G M N S I E P A K E T T T N V 5.314 PREDICTED: hypothetical protein [Homo sapiens] Protein Accession gi|169218200

Mean Expression Ratio 1.03 Median Expression Ratio 1.03 Credible Interval (0.79, 1.35) Associated Peptides 4 Associated Spectra 13 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.78 1.1 1.5 SEQ ID NO: 1567 ESNGQPENNYK 9 0.83 1.1 1.3 SEQ ID NO: 1568 GFYPSDIAVEWESNGQP ENNYK 1 0.7 1 1.4 SEQ ID NO: 1569 NQVSLTCLVK 1 0.68 0.98 1.4 SEQ ID NO: 1570 TTPPMLDSDGSFFLYSK 5.315 serine hydroxymethyltransferase 1 (soluble) isoform 2 [Homo sapiens]; serine hydroxymethyltransferase 1 (soluble) isoform 1 [Homo sapiens] Protein Accession gi|22547189 gi|22547186

Mean Expression Ratio 0.972 Median Expression Ratio 0.974 Credible Interval (0.599, 1.56) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.58 0.97 1.6 SEQ ID NO: 1571 VNPDTGYINYDQLEENAR 5.316 calcium binding protein P22 [Homo sapiens] Protein Accession gi|6005731

Mean Expression Ratio 1.02 Median Expression Ratio 1.03 Credible Interval (0.625, 1.65) Associated Peptides 1 Associated Spectra 1 Coverage 0.082

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.61 1.0 1.7 SEQ ID NO: 1572 IINAFFPEGEDQVNFR SEQ ID NO: 1573 1 M G S R A S T L L R D E E L E E I K K E T G F S H S Q I T R L Y S R F T S L D K G E N G T L S R E D F Q R I P E L A I N P L G D R I I N A F F P E G E D Q V N F 81 R G F M R T L A H F R P I E D N E K S K D V N G P E P L N S R S N K L H F A F R L Y D L D K D E K I S R D E L L Q V L R M M V G V N I S D E Q L G S I A D R T I 161 Q E A D Q D G D S A I S F T E F V K V L E K V D V E Q K M S I R F L H 5.317 sushi domain containing 2 [Homo sapiens] Protein Accession gi|10092665

Mean Expression Ratio 0.975 Median Expression Ratio 0.975 Credible Interval (0.594, 1.57) Associated Peptides 1 Associated Spectra 1 Coverage 0.0170

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.57 0.97 1.6 SEQ ID NO: 1574 GEYVLLEAALTDLR SEQ ID NO: 1575 1 M K P A L L P W A L L L L A T A L G P G P G P T A D A Q E S C S M R C G A L D G P C S C H P T C S G L G T C C L D F R D F C L E I L P Y S G S M M G G K D F V V 81 R H F K M S S P T D A S V I C R F K D S I Q T L G H V D S S G Q V H C V S P L L Y E S G R I P F T V S L D N G H S F P R A G T W L A V H P N K V S M M E K S E L 161 V N E T R W Q Y Y G T A N T S G N L S L T W H V K S L P T Q T I T I E L W G Y E E T G M P Y S Q E W T A K W S Y L Y P L A T H I P N S G S F T F T P K P A P P S 241 Y Q R W R V G A L R I I D S K N Y A G Q K D V Q A L W T N D H A L A W H L S D D F R E D P V A W A R T Q C Q A W E E L E D Q L P N F L E E L P D C P C T L T Q A 321 R A D S G R F F T D Y G C D M E Q G S V C T Y H P G A V H C V R S V Q A S L R Y G S G Q Q C C Y T A D G T Q L L T A D S S G G S T P D R G H D W G A P P F R T P 401 P R V P S M S H W L Y D V L S F Y Y C C L W A P D C P R Y M Q R R P S N D C R N Y R P P R L A S A F G D P H F V T F D G T N F T F N G R G E Y V L L E A A L T D 481 L R V Q A R A Q P G T M S N G T E T R G T G L T A V A V Q E G N S D V V E V R L A N R T G G L E V L L N Q E V L S F T E Q S W M D L K G M F L S V A A G D R V S 561 I M L A S G A G L E V S V Q G P F L S V S V L L P E K F L T H T H G L L G T L N N D P T D D F T L H S G R V L P P G T S P Q E L F L F G A N W T V H N A S S L L 641 T Y D S W F L V H N F L Y Q P K H D P T F E P L F P S E T T L N P S L A Q E A A K L C G D D H F C N F D V A A T G S L S T G T A T R V A H Q L H Q R R M Q S L Q 721 P V V S C G W L A P P P N G Q K E G N R Y L A G S T I Y F H C D N G Y S L A G A E T S T C Q A D G T W S S P T P K C Q P G R S Y A V L L G I I F G G L A V V A A 801 V A L V Y V L L R R R K G N T H V W G A Q P 5.318 occludin [Homo sapiens] Protein Accession gi|4505487

Mean Expression Ratio 1.03 Median Expression Ratio 1.03 Credible Interval (0.708, 1.48) Associated Peptides 2 Associated Spectra 4 Coverage 0.0766

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.71    1.1 1.6 SEQ ID NO: 1576 NVSAGTQDVPSPPSDYVER 2 0.67 1 1. 5 SEQ ID NO: 1577 STPVPEVVQELPLTSPVDDFR SEQ ID NO: 1578 1 M S S R P L E S P P P Y R P D E F K P N H Y A P S N D I Y G G E M H V R P M L S Q P A Y S F Y P E D E I L H F Y K W T S P P G V I R I L S M L I I V M C I A I F 81 A C V A S T L A W D R G Y G T S L L G G S V G Y P Y G G S G F G S Y G S G Y G Y G Y G Y G Y G Y G G Y T D P R A A K G F M L A M A A F C F I A A L V I F V T S V 161 I R S E M S R T R R Y Y L S V I I V S A I L G I M V F I A T I V Y I M G V N P T A Q S S G S L Y G S Q I Y A L C N Q F Y T P A A T G L Y V D Q Y L Y H Y C V V D 241 P Q E A I A I V L G F M I I V A F A L I I F F A V K T R R K M D R Y D K S N I L W D K E H I Y D E Q P P N V E E W V K N V S A G T Q D V P S P P S D Y V E R V D 321 S P M A Y S S N G K V N D K R F Y P E S S Y K S T P V P E V V Q E L P L T S P V D D F R Q P R Y S S G G N F E T P S K R A P A K G R A G R S K R T E Q D H Y E T 401 D Y T T G G E S C D E L E E D W I R E Y P P I T S D Q Q R Q L Y K R N F D T G L Q E Y K S L Q S E L D E I N K E L S R L D K E L D D Y R E E S E E Y M A A A D E 481 Y N R L K Q V K G S A D Y K S K K N H C K Q L K S K L S H I K K M V G D Y D R Q K T 5.319 CD81 antigen [Homo sapiens] Protein Accession gi|4757944

Mean Expression Ratio 1.03 Median Expression Ratio 1.03 Credible Interval (0.623, 1.68) Associated Peptides 1 Associated Spectra 1 Coverage 0.0847

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.62 1.0 1.7 SEQ ID NO: 1579 QFYDQALQQAVVDDDANNAK SEQ ID NO: 1580 1 M G V E G C T K C I K Y L L F V F N F V F W L A G G V I L G V A L W L R H D P Q T T N L L Y L E L G D K P A P N T F Y V G I Y I L I A V G A V M M F V G F L G C 81 Y G A I Q E S Q C L L G T F F T C L V I L F A C E V A A G I W G F V N K D Q I A K D V K Q F Y D Q A L Q Q A V V D D D A N N A K A V V K T F H E T L D C C G S S 161 T L T A L T T S V L K N N L C P S G S N I I S N L F K E D C H Q K I D D L F S G K L Y L I G I A A I V V A V I M I F E M I L S M V L C C G I R N S S V Y 5.320 ectonucleotide pyrophosphatase/phosphodiesterase 6 [Homo sapiens] Protein Accession gi|23503267

Mean Expression Ratio 0.977 Median Expression Ratio 0.976 Credible Interval (0.745, 1.27) Associated Peptides 8 Associated Spectra 9 Coverage 0.225

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.72 1.0 1.5 SEQ ID NO: 1581 FVSPLTLVADEGWFITENR 1 0.69 0.99 1.4 SEQ ID NO: 1582 GIFLAFGPDFK 1 0.69 0.98 1.4 SEQ ID NO: 1583 IDVEGHHYGPASPQR 2 0.7 0.99 1.4 SEQ ID NO: 1584 LLVFLLDGFR 1 0.68 0.97 1.4 SEQ ID NO: 1585 NVPTDINFANAVSDALDSFK 1 0.66 0.97 1.4 SEQ ID NO: 1586 YISLNDLQQVK 1 0.68 0.96 1.4 SEQ ID NO: 1587 GWHGYDNELMDMR 1 0.64 0.92 1.3 SEQ ID NO: 1588 AFGPDFK SEQ ID NO: 1589 1 M A V K L G T L L L A L A L G L A Q P A S A R R K L L V F L L D G F R S D Y I S D E A L E S L P G F K E I V S R G V K V D Y L T P D F P S L S Y P N Y Y T L M T 81 G R H C E V H Q M I G N Y M W D P T T N K S F D I G V N K D S L M P L W W N G S E P L W V T L T K A K R K V Y M Y Y W P G C E V E I L G V R P T Y C L E Y K N V 161 P T D I N F A N A V S D A L D S F K S G R A D L A A I Y H E R I D V E G H H Y G P A S P Q R K D A L K A V D T V L K Y M T K W I Q E R G L Q D R L N V I I F S D 241 H G M T D I F W M D K V I E L N K Y I S L N D L Q Q V K D R G P V V S L W P A P G K H S E I Y N K L S T V E H M T V Y E K E A I P S R F Y Y K K G K F V S P L T 321 L V A D E G W F I T E N R E M L P F W M N S T G R R E G W Q R G W H G Y D N E L M D M R G I F L A F G P D F K S N F R A A P I R S V D V Y N V M C N V V G I T P 401 L P N N G S W S R V M C M L K G R A S T A P P V W P S H C A L A L I L L F L L A 5.321 solute carrier family 5 (sodium/glucose cotransporter), member 2 [Homo sapiens] Protein Accession gi|4507033

Mean Expression Ratio 1.02 Median Expression Ratio 1.02 Credible Interval (0.661, 1.58) Associated Peptides 1 Associated Spectra 2 Coverage 0.0283

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.66 1.0 1.6 SEQ ID NO: 1590 GGVGSPPPLTQEEAAAAAR SEQ ID NO: 1591 1 M E E H T E A G S A P E M G A Q K A L I D N P A D I L V I A A Y F L L V I G V G L W S M C R T N R G T V G G Y F L A G R S M V W W P V G A S L F A S N I G S G H 81 F V G L A G T G A A S G L A V A G F E W N A L F V V L L L G W L F A P V Y L T A G V I T M P Q Y L R K R F G G R R I R L Y L S V L S L F L Y I F T K I S V D M F 161 S G A V F I Q Q A L G W N I Y A S V I A L L G I T M I Y T V T G G L A A L M Y T D T V Q T F V I L G G A C I L M G Y A F H E V G G Y S G L F D K Y L G A A T S L 241 T V S E D P A V G N I S S F C Y R P R P D S Y H L L R H P V T G D L P W P A L L L G L T I V S G W Y W C S D Q V I V Q R C L A G K S L T H I K A G C I L C G Y L 321 K L T P M F L M V M P G M I S R I L Y P D E V A C V V P E V C R R V C G T E V G C S N I A Y P R L V V K L M P N G L R G L M L A V M L A A L M S S L A S I F N S 401 S S T L F T M D I Y T R L R P R A G D R E L L L V G R L W V V F I V V V S V A W L P V V Q A A Q G G Q L F D Y I Q A V S S Y L A P P V S A V F V L A L F V P R V 481 N E Q G A F W G L I G G L L M G L A R L I P E F S F G S G S C V Q P S A C P A F L C G V H Y L Y F A I V L F F C S G L L T L T V S L C T A P I P R K H L H R L V 561 F S L R H S K E E R E D L D A D E Q Q G S S L P V Q N G C P E S A M E M N E P Q A P A P S L F R Q C L L W F C G M S R G G V G S P P P L T Q E E A A A A A R R L 641 E D I S E D P S W A R V V N L N A L L M M A V A V F L W G F Y A 5.322 MIT, microtubule interacting and transport, domain containing 1 [Homo sapiens] Protein Accession gi|20270349

Mean Expression Ratio 1.03 Median Expression Ratio 1.02 Credible Interval (0.627, 1.65) Associated Peptides 1 Associated Spectra 1 Coverage 0.0723

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.62 1.0 1.7 SEQ ID NO: 1592 EYLNETVTEVWIEDPYIR SEQ ID NO: 1593 1 M A K S G L R Q D P Q S T A A A T V L K R A V E L D S E S R Y P Q A L V C Y Q E G I D L L L Q V L K G T K D N T K R C N L R E K I S K Y M D R A E N I K K Y L D 81 Q E K E D G K Y H K Q I K I E E N A T G F S Y E S L F R E Y L N E T V T E V W I E D P Y I R H T H Q L Y N F L R F C E M L I K R P C K V K T I H L L T S L D E G 161 I E Q V Q Q S R G L Q E I E E S L R S H G V L L E V Q Y S S S I H D R E I R F N N G W M I K I G R G L D Y F K K P Q S R F S L G Y C D F D L R P C H E T T V D I 241 F H K K H T K N I 5.323 ring finger protein 167 [Homo sapiens] Protein Accession gi|14149702

Mean Expression Ratio 0.976 Median Expression Ratio 0.98 Credible Interval (0.67, 1.40) Associated Peptides 2 Associated Spectra 4 Coverage 0.0657

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.63 0.97 1.5 SEQ ID NO: 1594 GDEDQEEETQGQEEGDEGEPR 3 0.67 0.97 1.4 SEQ ID NO: 1595 GPGDEDQEEETQGQEEGDEGEPR SEQ ID NO: 1596 1 M H P A A F P L P V V V A A V L W G A A P T R G L I R A T S D H N A S M D F A D L P A L F G A T L S Q E G L Q G F L V E A H P D N A C S P I A P P P P A P V N G 81 S V F I A L L R R F D C N F D L K V L N A Q K A G Y G A A V V H N V N S N E L L N M V W N S E E I Q Q Q I W I P S V F I G E R S S E Y L R A L F V Y E K G A R V 161 L L V P D N T F P L G Y Y L I P F T G I V G L L V L A M G A V M I A R C I Q H R K R L Q R N R L T K E Q L K Q I P T H D Y Q K G D Q Y D V C A I C L D E Y E D G 241 D K L R V L P C A H A Y H S R C V D P W L T Q T R K T C P I C K Q P V H R G P G D E D Q E E E T Q G Q E E G D E G E P R D H P A S E R T P L L G S S P T L P T S 321 F G S L A P A P L V F P G P S T D P P L S P P S S P V I L V 5.324 ubiquitin protein ligase E3C [Homo sapiens] Protein Accession gi|187960100

Mean Expression Ratio 0.98 Median Expression Ratio 0.98 Credible Interval (0.6, 1.59) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.58 0.98 1.6 SEQ ID NO: 1597 LNRQIRQHCLAFR 5.325 syntaxin 8 [Homo sapiens] Protein Accession gi|4759188

Mean Expression Ratio 0.98 Median Expression Ratio 0.98 Credible Interval (0.609, 1.57) Associated Peptides 1 Associated Spectra 1 Coverage 0.0763

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.59 0.98 1.6 SEQ ID NO: 1598 IIQEQDAGLDALSSIISR SEQ ID NO: 1599 1 M A P D P W F S T Y D S T C Q I A Q E I A E K I Q Q R N Q Y E R K G E K A P K L T V T I R A L L Q N L K E K I A L L K D L L L R A V S T H Q I T Q L E G D R R Q 81 N L L D D L V T R E R L L L A S F K N E G A E P D L I R S S L M S E E A K R G A P N P W L F E E P E E T R G L G F D E I R Q Q Q Q K I I Q E Q D A G L D A L S S 161 I I S R Q K Q M G Q E I G N E L D E Q N E I I D D L A N L V E N T D E K L R N E T R R V N M V D R K S A S C G M I M V I L L L L V A I V V V A V W P T N 5.326 sorting nexin 3 [Homo sapiens] Protein Accession gi|4507143

Mean Expression Ratio 0.981 Median Expression Ratio 0.98 Credible Interval (0.603, 1.60) Associated Peptides 1 Associated Spectra 1 Coverage 0.0494

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.59 0.98 1.6 SEQ ID NO: 1600 YSDFEWLR SEQ ID NO: 1601 1 M A E T V A D T R R L I T K P Q N L N D A Y G P P S N F L E I D V S N P Q T V G V G R G R F T T Y E I R V K T N L P I F K L K E S T V R R R Y S D F E W L R S E 81 L E R E S K V V V P P L P G K A F L R Q L P F R G D D G I F D D N F I E E R K Q G L E Q F I N K V A G H P L A Q N E R C L H M F L Q D E I I D K S Y T P S K I R 161 H A 5.327 RAB7, member RAS oncogene family [Homo sapiens] Protein Accession gi|34147513

Mean Expression Ratio 1.02 Median Expression Ratio 1.02 Credible Interval (0.798, 1.3) Associated Peptides 9 Associated Spectra 12 Coverage 0.483

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.74 1 1.4 SEQ ID NO: 1602 DEFLIQASPR 1 0.72 1.0 1.5 SEQ ID NO: 1603 DPENFPFVVLGNK 2 0.77 1.1 1.5 SEQ ID NO: 1604 EAINVEQAFQTIAR 1 0.71 1.0 1.4 SEQ ID NO: 1605 FQSLGVAFYR 1 0.72 1.0 1.4 SEQ ID NO: 1606 LVTMQIWDTAGQER 2 0.72 1 1.4 SEQ ID NO: 1607 QETEVELYNEFPEPIK 1 0.71 1 1.4 SEQ ID NO: 1608 TLDSWRDEFLIQASPR 1 0.71 1 1.4 SEQ ID NO: 1609 FSNQYK 1 0.71 1.0 1.4 SEQ ID NO: 1610 NNIPYFETSAK SEQ ID NO: 1611 1 M T S R K K V L L K V I I L G D S G V G K T S L M N Q Y V N K K F S N Q Y K A T I G A D F L T K E V M V D D R L V T M Q I W D T A G Q E R F Q S L G V A F Y R G 81 A D C C V L V F D V T A P N T F K T L D S W R D E F L I Q A S P R D P E N F P F V V L G N K I D L E N R Q V A T K R A Q A W C Y S K N N I P Y F E T S A K E A I 161 N V E Q A F Q T I A R N A L K Q E T E V E L Y N E F P E P I K L D K N D R A K A S A E S C S C 5.328 prenylcysteine oxidase 1 [Homo sapiens] Protein Accession gi|166795301

Mean Expression Ratio 1.02 Median Expression Ratio 1.02 Credible Interval (0.714, 1.44) Associated Peptides 4 Associated Spectra 4 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.65 1 1.5 SEQ ID NO: 1612 FGLNTVLTTDNS DLFINSIGIVPSVR 1 0.66 1 1.5 SEQ ID NO: 1613 FLNEMIAPVMR 1 0.66 1.0 1.5 SEQ ID NO: 1614 MHMWVEDVLDK 1 0.7 1.1 1.6 SEQ ID NO: 1615 SDFYDIVLVATPLNR 5.329 glucose phosphate isomerase [Homo sapiens] Protein Accession gi|18201905

Mean Expression Ratio 1.02 Median Expression Ratio 1.02 Credible Interval (0.62, 1.63) Associated Peptides 1 Associated Spectra 1 Coverage 0.0305

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.61 1.0 1.7 SEQ ID NO: 1616 MIPCDFLIPVQTQHPIR SEQ ID NO: 1617 1 M A A L T R D P Q F Q K L Q Q W Y R E H R S E L N L R R L F D A N K D R F N H F S L T L N T N H G H I L V D Y S K N L V T E D V M R M L V D L A K S R G V E A A 81 R E R M F N G E K I N Y T E G R A V L H V A L R N R S N T P I L V D G K D V M P E V N K V L D K M K S F C Q R V R S G D W K G Y T G K T I T D V I N I G I G G S 161 D L G P L M V T E A L K P Y S S G G P R V W Y V S N I D G T H I A K T L A Q L N P E S S L F I I A S K T F T T Q E T I T N A E T A K E W F L Q A A K D P S A V A 241 K H F V A L S T N T T K V K E F G I D P Q N M F E F W D W V G G R Y S L W S A I G L S I A L H V G F D N F E Q L L S G A H W M D Q H F R T T P L E K N A P V L L 321 A L L G I W Y I N C F G C E T H A M L P Y D Q Y L H R F A A Y F Q Q G D M E S N G K Y I T K S G T R V D H Q T G P I V W G E P G T N G Q H A F Y Q L I H Q G T K 401 M I P C D F L I P V Q T Q H P I R K G L H H K I L L A N F L A Q T E A L M R G K S T E E A R K E L Q A A G K S P E D L E R L L P H K V F E G N R P T N S I V F T 481 K L T P F M L G A L V A M Y E H K I F V Q G I I W D I N S F D Q W G V E L G K Q L A K K I E P E L D G S A Q V T S H D A S T N G L I N F I K Q Q R E A R V Q 5.330 galactosidase, beta 1 isoform a preproprotein [Homo sapiens] Protein Accession gi|119372308

Mean Expression Ratio 0.981 Median Expression Ratio 0.982 Credible Interval (0.798, 1.20) Associated Peptides 12 Associated Spectra 17 Coverage 0.183

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.74 1 1.4 SEQ ID NO: 1618 AGATLDLLVENMGR 2 0.73 0.99 1.3 SEQ ID NO: 1619 AYVAVDGIPQGVLER 2 0.79 1.1 1.5 SEQ ID NO: 1620 GQVWINGFNLGR 1 0.71 0.99 1.4 SEQ ID NO: 1621 LAHELGLLVILRPGPY 1 0.71 0.98 1.3 SEQ ID NO: 1622 TEAVASSLYDILAR 1 0.72 1 1.4 SEQ ID NO: 1623 TVGAALDILCPSGPIK 1 0.71 0.98 1.4 SEQ ID NO: 1624 VAVDGIPQGVLER 1 0.7 0.98 1.4 SEQ ID NO: 1625 WLGVLLPK 2 0.69 0.92 1.3 SEQ ID NO: 1626 HHLGDDVVLF 1 0.7 0.97 1.3 SEQ ID NO: 1627 ACDFDYLR 1 0.71 0.98 1.4 SEQ ID NO: 1628 VNYGAYINDFK 2 0.67 0.9 1.2 SEQ ID NO: 1629 LAHELGLLVILR SEQ ID NO: 1630 1 M P G F L V R I L P L L L V L L L L G P T R G L R N A T Q R M F E I D Y S R D S F L K D G Q P F R Y I S G S I H Y S R V P R F Y W K D R L L K M K M A G L N A I 81 Q T Y V P W N F H E P W P G Q Y Q F S E D H D V E Y F L R L A H E L G L L V I L R P G P Y I C A E W E M G G L P A W L L E K E S I L L R S S D P D Y L A A V D K 161 W L G V L L P K M K P L L Y Q N G G P V I T V Q V E N E Y G S Y F A C D F D Y L R F L Q K R F R H H L G D D V V L F T T D G A H K T F L K C G A L Q G L Y T T V 241 D F G T G S N I T D A F L S Q R K C E P K G P L I N S E F Y T G W L D H W G Q P H S T I K T E A V A S S L Y D I L A R G A S V N L Y M F I G G T N F A Y W N G A 321 N S P Y A A Q P T S Y D Y D A P L S E A G D L T E K Y F A L R N I I Q K F E K V P E G P I P P S T P K F A Y G K V T L E K L K T V G A A L D I L C P S G P I K S 401 L Y P L T F I Q V K Q H Y G F V L Y R T T L P Q D C S N P A P L S S P L N G V H D R A Y V A V D G I P Q G V L E R N N V I T L N I T G K A G A T L D L L V E N M 481 G R V N Y G A Y I N D F K G L V S N L T L S S N I L T D W T I F P L D T E D A V R S H L G G W G H R D S G H H D E A W A H N S S N Y T L P A F Y M G N F S I P S 561 G I P D L P Q D T F I Q F P G W T K G Q V W I N G F N L G R Y W P A R G P Q L T L F V P Q H I L M T S A P N T I T V L E L E W A P C S S D D P E L C A V T F V D 641 R P V I G S S V T Y D H P S K P V E K R L M P P P P Q K N K D S W L D H V 5.331 GDP dissociation inhibitor 2 isoform 1 [Homo sapiens] Protein Accession gi|6598323

Mean Expression Ratio 0.986 Median Expression Ratio 0.983 Credible Interval (0.61, 1.63) Associated Peptides 1 Associated Spectra 1 Coverage 0.0337

A 2.5 50 97.5 Sequence ID No. 1631 Sequence 1 0.59 0.98 1.6 SEQ ID NO: 1632 TDDYLDQPCYETINR SEQ ID NO: 1633 1 M N E E Y D V I V L G T G L T E C I L S G I M S V N G K K V L H M D R N P Y Y G G E S A S I T P L E D L Y K R F K I P G S P P E S M G R G R D W N V D L I P K F 81 L M A N G Q L V K M L L Y T E V T R Y L D F K V T E G S F V Y K G G K I Y K V P S T E A E A L A S S L M G L F E K R R F R K F L V Y V A N F D E K D P R T F E G 161 I D P K K T T M R D V Y K K F D L G Q D V I D F T G H A L A L Y R T D D Y L D Q P C Y E T I N R I K L Y S E S L A R Y G K S P Y L Y P L Y G L G E L P Q G F A R 241 L S A I Y G G T Y M L N K P I E E I I V Q N G K V I G V K S E G E I A R C K Q L I C D P S Y V K D R V E K V G Q V I R V I C I L S H P I K N T N D A N S C Q I I 321 I P Q N Q V N R K S D I Y V C M I S F A H N V A A Q G K Y I A I V S T T V E T K E P E K E I R P A L E L L E P I E Q K F V S I S D L L V P K D L G T E S Q I F I 401 S R T Y D A T T H F E T T C D D I K N I Y K R M T G S E F D F E E M K R K K N D I Y G E D 5.332 solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform c [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform f [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform e [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform d [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform b [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform a [Homo sapiens] Protein Accession gi|65506891 gi|61744483 gi|61744481 gi|61744479 gi|61744477 gi|61744475

Mean Expression Ratio 1.02 Median Expression Ratio 1.02 Credible Interval (0.627, 1.64) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.61 1.0 1.7 SEQ ID NO: 1634 LLTSFLPAQLLR 5.333 heat shock 70 kDa protein 8 isoform 1 [Homo sapiens] Protein Accession gi|5729877

Mean Expression Ratio 1.02 Median Expression Ratio 1.02 Credible Interval (0.866, 1.20) Associated Peptides 18 Associated Spectra 36 Coverage 0.302

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.75 1.0 1.4 SEQ ID NO: 1635 AVVTVPAYFNDSQR 2 0.74  0.98 1.3 SEQ ID NO: 1636 CNEIINWLDK 1 0.75 1.0 1.4 SEQ ID NO: 1637 DAGTIAGLNVLR 1 0.74 1.0 1.4 SEQ ID NO: 1638 FDDAVVQSDMK 5 0.8  1.0 1.3 SEQ ID NO: 1639 FEELNADLFR 1 0.75 1.0 1.4 SEQ ID NO: 1640 FELTGIPPAPR 2 0.76 1.0 1.4 SEQ ID NO: 1641 LLQDFFNGK 2 0.78 1.0 1.4 SEQ ID NO: 1642 MVNHFIAEFK 1 0.74 1.0 1.4 SEQ ID NO: 1643 NQTAEKEEFEHQQK 1 0.74 1 1.4 SEQ ID NO: 1644 NQVAMNPTNTVFDAK 1 0.75 1.0 1.4 SEQ ID NO: 1645 QTQTFTTYSDNQPGVLIQVYEGER 2 0.77 1.0 1.4 SEQ ID NO: 1646 RFDDAVVQSDMK 2 0.78 1.0 1.4 SEQ ID NO: 1647 SQIHDIVLVGGSTR 5 0.76 0.98 1.3 SEQ ID NO: 1648 STAGDTHLGGEDFDNR 6 0.77 0.98 1.2 SEQ ID NO: 1649 TVTNAVVTVPAYFNDSQR 1 0.77 1.0 1.4 SEQ ID NO: 1650 MVVNDAGRPK 1 0.76 1.0 1.4 SEQ ID NO: 1651 VQVEYK 1 0.77 1.0 1.4 SEQ ID NO: 1652 HWPFMVVNDAGRPK SEQ ID NO: 1653 1 M S K G P A V G I D L G T T Y S C V G V F Q H G K V E I I A N D Q G N R T T P S Y V A F T D T E R L I G D A A K N Q V A M N P T N T V F D A K R L I G R R F D D 81 A V V Q S D M K H W P F M V V N D A G R P K V Q V E Y K G E T K S F Y P E E V S S M V L T K M K E I A E A Y L G K T V T N A V V T V P A Y F N D S Q R Q A T K D 161 A G T I A G L N V L R I I N E P T A A A I A Y G L D K K V G A E R N V L I F D L G G G T F D V S I L T I E D G I F E V K S T A G D T H L G G E D F D N R M V N H 241 F I A E F K R K H K K D I S E N K R A V R R L R T A C E R A K R T L S S S T Q A S I E I D S L Y E G I D F Y T S I T R A R F E E L N A D L F R G T L D P V E K A 321 L R D A K L D K S Q I H D I V L V G G S T R I P K I Q K L L Q D F F N G K E L N K S I N P D E A V A Y G A A V Q A A I L S G D K S E N V Q D L L L L D V T P L S 401 L G I E T A G G V M T V L I K R N T T I P T K Q T Q T F T T Y S D N Q P G V L I Q V Y E G E R A M T K D N N L L G K F E L T G I P P A P R G V P Q I E V T F D I 481 D A N G I L N V S A V D K S T G K E N K I T I T N D K G R L S K E D I E R M V Q E A E K Y K A E D E K Q R D K V S S K N S L E S Y A F N M K A T V E D E K L Q G 561 K I N D E D K Q K I L D K C N E I I N W L D K N Q T A E K E E F E H Q Q K E L E K V C N P I I T K L Y Q S A G G M P G G M P G G F P G G G A P P S G G A S S G P 641 T I E E V D 5.334 RAB9A, member RAS oncogene family [Homo sapiens] Protein Accession gi|4759012

Mean Expression Ratio 1.02 Median Expression Ratio 1.02 Credible Interval (0.627, 1.66) Associated Peptides 1 Associated Spectra 1 Coverage 0.0697

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.61 1.0 1.7 SEQ ID NO: 1654 DATNVAAAFEEAVR SEQ ID NO: 1655 1 M A G K S S L F K V I L L G D G G V G K S S L M N R Y V T N K F D T Q L F H T I G V E F L N K D L E V D G H F V T M Q I W D T A G Q E R F R S L R T P F Y R G S 81 D C C L L T F S V D D S Q S F Q N L S N W K K E F I V Y A D V K E P E S F P F V I L G N K I D I S E R Q V S T E E A Q A W C R D N G D Y P Y F E T S A K D A T N 161 V A A A F E E A V R R V L A T E D R S D H L I Q T D T V N L H R K P K P S S S C C 5.335 complement component 8, gamma polypeptide [Homo sapiens] Protein Accession gi|166197660

Mean Expression Ratio 1.02 Median Expression Ratio 1.02 Credible Interval (0.627, 1.65) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.61 1.0 1.7 SEQ ID NO: 1656 SLPVSDSVLSGFEQR 5.336 MAPK scaffold protein 1 [Homo sapiens] Protein Accession gi|11496277

Mean Expression Ratio 0.986 Median Expression Ratio 0.985 Credible Interval (0.667, 1.45) Associated Peptides 2 Associated Spectra 3 Coverage 0.210

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.64 0.97 1.5 SEQ ID NO: 1657 ELAPLFEELR 1 0.64 1 1.6 SEQ ID NO: 1658 KLPSVEGLHAIVVSDR SEQ ID NO: 1659 1 M A D D L K R F L Y K K L P S V E G L H A I V V S D R D G V P V I K V A N D N A P E H A L R P G F L S T F A L A T D Q G S K L G L S K N K S I I C Y Y N T Y Q V 81 V Q F N R L P L V V S F I A S S S A N T G L I V S L E K E L A P L F E E L R Q V V E V S 5.337 transketolase isoform 1 [Homo sapiens]; transketolase isoform 2 [Homo sapiens]; transketolase isoform 1 [Homo sapiens] Protein Accession gi|4507521 gi|205277465 gi|205277463

Mean Expression Ratio 1.01 Median Expression Ratio 1.01 Credible Interval (0.618, 1.61) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.62 1 1.7 SEQ ID NO: 1660 LDNLVAILDINR 5.338 complement factor B preproprotein [Homo sapiens] Protein Accession gi|67782358

Mean Expression Ratio 0.989 Median Expression Ratio 0.988 Credible Interval (0.646, 1.52) Associated Peptides 2 Associated Spectra 2 Coverage 0.0314

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.62 0.99 1.6 SEQ ID NO: 1661 LLQEGQALEYVCPSGFYPYPVQTR 1 0.62 1 1.6 SEQ ID NO: 1662 VCPSGFYPYPVQTR SEQ ID NO: 1663 1 M G S N L S P Q L C L M P F I L G L L S G G V T T T P W S L A R P Q G S C S L E G V E I K G G S F R L L Q E G Q A L E Y V C P S G F Y P Y P V Q T R T C R S T G 81 S W S T L K T Q D Q K T V R K A E C R A I H C P R P H D F E N G E Y W P R S P Y Y N V S D E I S F H C Y D G Y T L R G S A N R T C Q V N G R W S G Q T A I C D N 161 G A G Y C S N P G I P I G T R K V G S Q Y R L E D S V T Y H C S R G L T L R G S Q R R T C Q E G G S W S G T E P S C Q D S F M Y D T P Q E V A E A F L S S L T E 241 T I E G V D A E D G H G P G E Q Q K R K I V L D P S G S M N I Y L V L D G S D S I G A S N F T G A K K C L V N L I E K V A S Y G V K P R Y G L V T Y A T Y P K I 321 W V K V S E A D S S N A D W V T K Q L N E I N Y E D H K L K S G T N T K K A L Q A V Y S M M S W P D D V P P E G W N R T R H V I I L M T D G L H N M G G D P I T 401 V I D E I R D L L Y I G K D R K N P R E D Y L D V Y V F G V G P L V N Q V N I N A L A S K K D N E Q H V F K V K D M E N L E D V F Y Q M I D E S Q S L S L C G M 481 V W E H R K G T D Y H K Q P W Q A K I S V I R P S K G H E S C M G A V V S E Y F V L T A A H C F T V D D K E H S I K V S V G G E K R D L E I E V V L F H P N Y N 561 I N G K K E A G I P E F Y D Y D V A L I K L K N K L K Y G Q T I R P I C L P C T E G T T R A L R L P P T T T C Q Q Q K E E L L P A Q D I K A L F V S E E E K K L 641 T R K E V Y I K N G D K K G S C E R D A Q Y A P G Y D K V K D I S E V V T P R F L C T G G V S P Y A D P N T C R G D S G G P L I V H K R S R F I Q V G V I S W G 721 V V D V C K N Q K R Q K Q V P A H A R D F H I N L F Q V L P W L K E K L Q D E D L G F L 5.339 cyclin M3 isoform 1 [Homo sapiens]; cyclin M3 isoform 2 [Homo sapiens] Protein Accession gi|40068049 gi|40068047

Mean Expression Ratio 0.987 Median Expression Ratio 0.989 Credible Interval (0.601, 1.59) Associated Peptides 1 Associated Spectra 1 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.58 0.98 1.6 SEQ ID NO: AQNLPQSPENTDLQVIPGSQTR 1664 5.340 solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 [Homo sapiens] Protein Accession gi|194239733

Mean Expression Ratio 0.993 Median Expression Ratio 0.989 Credible Interval (0.608, 1.62) Associated Peptides 1 Associated Spectra 1 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.59 0.99 1.7 SEQ ID DTASDSPAGIDNPVFSPDEALDR NO: 1665 5.341 solute carrier family 12 (potassium/chloride transporters), member 9 [Homo sapiens] Protein Accession gi|31881740

Mean Expression Ratio 0.989 Median Expression Ratio 0.99 Credible Interval (0.652, 1.51) Associated Peptides 2 Associated Spectra 2 Coverage 0.0438

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.62 0.99 1.6 SEQ ID NO: 1666 AEVQEVVWGEGAGAGEPEAEEEG DFVNSGR 1 0.62 1 1.6 SEQ ID NO: 1667 YLALLETLTR SEQ ID NO: 1668 1 M A S E S S P L L A Y R L L G E E G V A L P A N G A G G P G G A S A R K L S T F L G V V V P T V L S M F S I V V F L R I G F V V G H A G L L Q A L A M L L V A Y 81 F I L A L T V L S V C A I A T N G A V Q G G G A Y F M I S R T L G P E V G G S I G L M F Y L A N V C G C A V S L L G L V E S V L D V F G A D A T G P S G L R V L 161 P Q G Y G W N L L Y G S L L L G L V G G V C T L G A G L Y A R A S F L T F L L V S G S L A S V L I S F V A V G P R D I R L T P R P G P N G S S L P P R F G H F T 241 G F N S S T L K D N L G A G Y A E D Y T T G A V M N F A S V F A V L F N G C T G I M A G A N M S G E L K D P S R A I P L G T I V A V A Y T F F V Y V L L F F L S 321 S F T C D R T L L Q E D Y G F F R A I S L W P P L V L I G I Y A T A L S A S M S S L I G A S R I L H A L A R D D L F G V I L A P A K V V S R G G N P W A A V L Y 401 S W G L V Q L V L L A G K L N T L A A V V T V F Y L V A Y A A V D L S C L S L E W A S A P N F R P T F S L F S W H T C L L G V A S C L L M M F L I S P G A A G G 481 S L L L M G L L A A L L T A R G G P S S W G Y V S Q A L L F H Q V R K Y L L R L D V R K D H V K F W R P Q L L L L V G N P R G A L P L L R L A N Q L K K G G L Y 561 V L G H V T L G D L D S L P S D P V Q P Q Y G A W L S L V D R A Q V K A F V D L T L S P S V R Q G A Q H L L R I S G L G G M K P N T L V L G F Y D D A P P Q D H 641 F L T D P A F S E P A D S T R E G S S P A L S T L F P P P R A P G S P R A L N P Q D Y V A T V A D A L K M N K N V V L A R A S G A L P P E R L S R G S G G T S Q 721 L H H V D V W P L N L L R P R G G P G Y V D V C G L F L L Q M A T I L G M V P A W H S A R L R I F L C L G P R E A P G A A E G R L R A L L S Q L R I R A E V Q E 801 V V W G E G A G A G E P E A E E E G D F V N S G R G D A E A E A L A R S A N A L V R A Q Q G R G T G G G P G G P E G G D A E G P I T A L T F L Y L P R P P A D P 881 A R Y P R Y L A L L E T L T R D L G P T L L V H G V T P V T C T D L 5.342 RAB5C, member RAS oncogene family isoform a [Homo sapiens]; RAB5C, member RAS oncogene family isoform b [Homo sapiens] Protein Accession gi|41393614 gi|41393545

Mean Expression Ratio 1.01 Median Expression Ratio 1.01 Credible Interval (0.624, 1.64) Associated Peptides 1 Associated Spectra 1 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.6 1 1.7 SEQ ID NO: 1669 FEIWDTAGQER 5.343 pyruvate kinase, liver and RBC isoform 1 [Homo sapiens] Protein Accession gi|10835121

Mean Expression Ratio 1.01 Median Expression Ratio 1.01 Credible Interval (0.63, 1.67) Associated Peptides 1 Associated Spectra 1 Coverage 0.0348

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.61 1 1.7 SEQ ID NO: 1670 GVNLPGAQVDLPGLSEQDVR SEQ ID NO: 1671 1 M S I Q E N I S S L Q L R S W V S K S Q R D L A K S I L I G A P G G P A G Y L R R A S V A Q L T Q E L G T A F F Q Q Q Q L P A A M A D T F L E H L C L L D I D S 81 E P V A A R S T S I I A T I G P A S R S V E R L K E M I K A G M N I A R L N F S H G S H E Y H A E S I A N V R E A V E S F A G S P L S Y R P V A I A L D T K G P 161 E I R T G I L Q G G P E S E V E L V K G S Q V L V T V D P A F R T R G N A N T V W V D Y P N I V R V V P V G G R I Y I D D G L I S L V V Q K I G P E G L V T Q V 241 E N G G V L G S R K G V N L P G A Q V D L P G L S E Q D V R D L R F G V E H G V D I V F A S F V R K A S D V A A V R A A L G P E G H G I K I I S K I E N H E G V 321 K R F D E I L E V S D G I M V A R G D L G I E I P A E K V F L A Q K M M I G R C N L A G K P V V C A T Q M L E S M I T K P R P T R A E T S D V A N A V L D G A D 401 C I M L S G E T A K G N F P V E A V K M Q H A I A R E A E A A V Y H R Q L F E E L R R A A P L S R D P T E V T A I G A V E A A F K C C A A A I I V L T T T G R S 481 A Q L L S R Y R P R A A V I A V T R S A Q A A R Q V H L C R G V F P L L Y R E P P E A I W A D D V D R R V Q F G I E S G K L R G F L R V G D L V I V V T G W R P 561 G S G Y T N I M R V L S I S 5.344 glutathione transferase [Homo sapiens] Protein Accession gi|4504183

Mean Expression Ratio 1.01 Median Expression Ratio 1.01 Credible Interval (0.713, 1.41) Associated Peptides 3 Associated Spectra 5 Coverage 0.205

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.71 1.0 1.4 SEQ ID NO: 1672 DQQEAALVDMVNDGVEDLR 1 0.67 1.0 1.5 SEQ ID NO: 1673 FQDGDLTLYQSNTILR 1 0.66 1 1.5 SEQ ID NO: 1674 TVVYFPVR SEQ ID NO: 1675 1 M P P Y T V V Y F P V R G R C A A L R M L L A D Q G Q S W K E E V V T V E T W Q E G S L K A S C L Y G Q L P K F Q D G D L T L Y Q S N T I L R H L G R T L G L Y 81 G K D Q Q E A A L V D M V N D G V E D L R C K Y I S L I Y T N Y E A G K D D Y V K A L P G Q L K P F E T L L S Q N Q G G K T F I V G D Q I S F A D Y N L L D L L 161 L I H E V L A P G C L D A F P L L S A Y V G R L S A R P K L K A F L A S P E Y V N L P I N G N G K Q 5.345 ATPase, H+ transporting, lysosomal 70kD, V1 subunit A, isoform 1 [Homo sapiens] Protein Accession gi|19913424

Mean Expression Ratio 1.01 Median Expression Ratio 1.01 Credible Interval (0.726, 1.41) Associated Peptides 5 Associated Spectra 5 Coverage 0.104

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.68 1.0 1.5 SEQ ID NO: 1676 FTMVQVWPVR 1 0.66 1 1.5 SEQ ID NO: 1677 HFTEFVPLR 1 0.69 1.0 1.5 SEQ ID NO: 1678 SDYAQLLEDMQNAFR 1 0.66 1 1.5 SEQ ID NO: 1679 LPANHPLLTGQR 1 0.7  1.0 1.6 SEQ ID NO: 1680 EILQEEEDLAEIVQLVGK SEQ ID NO: 1681 1 M D F S K L P K I L D E D K E S T F G Y V H G V S G P V V T A C D M A G A A M Y E L V R V G H S E L V G E I I R L E G D M A T I Q V Y E E T S G V S V G D P V L 81 R T G K P L S V E L G P G I M G A I F D G I Q R P L S D I S S Q T Q S I Y I P R G V N V S A L S R D I K W D F T P C K N L R V G S H I T G G D I Y G I V S E N S 161 L I K H K I M L P P R N R G T V T Y I A P P G N Y D T S D V V L E L E F E G V K E K F T M V Q V W P V R Q V R P V T E K L P A N H P L L T G Q R V L D A L F P C 241 V Q G G T T A I P G A F G C G K T V I S Q S L S K Y S N S D V I I Y V G C G E R G N E M S E V L R D F P E L T M E V D G K V E S I M K R T A L V A N T S N M P V 321 A A R E A S I Y T G I T L S E Y F R D M G Y H V S M M A D S T S R W A E A L R E I S G R L A E M P A D S G Y P A Y L G A R L A S F Y E R A G R V K C L G N P E R 401 E G S V S I V G A V S P P G G D F S D P V T S A T L G I V Q V F W G L D K K L A Q R K H F P S V N W L I S Y S K Y M R A L D E Y Y D K H F T E F V P L R T K A K 481 E I L Q E E E D L A E I V Q L V G K A S L A E T D K I T L E V A K L I K D D F L Q Q N G Y T P Y D R F C P F Y K T V G M L S N M I A F Y D M A R R A V E T T A Q 561 S D N K I T W S I I R E H M G D I L Y K L S S M K F K D P L K D G E A K I K S D Y A Q L L E D M Q N A F R S L E D 5.346 DnaJ (Hsp40) homolog, subfamily A, member 1 [Homo sapiens] Protein Accession gi|4504511

Mean Expression Ratio 0.986 Median Expression Ratio 0.99 Credible Interval (0.634, 1.49) Associated Peptides 1 Associated Spectra 2 Coverage 0.0479

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.63 0.98 1.5 SEQ ID NO: 1682 NVVHQLSVTLEDLYNGATR SEQ ID NO: 1683 1 M V K E T T Y Y D V L G V K P N A T Q E E L K K A Y R K L A L K Y H P D K N P N E G E K F K Q I S Q A Y E V L S D A K K R E L Y D K G G E Q A I K E G G A G G G 81 F G S P M D I F D M F F G G G G R M Q R E R R G K N V V H Q L S V T L E D L Y N G A T R K L A L Q K N V I C D K C E G R G G K K G A V E C C P N C R G T G M Q I 161 R I H Q I G P G M V Q Q I Q S V C M E C Q G H G E R I S P K D R C K S C N G R K I V R E K K I L E V H I D K G M K D G Q K I T F H G E G D Q E P G L E P G D I I 241 I V L D Q K D H A V F T R R G E D L F M C M D I Q L V E A L C G F Q K P I S T L D N R T I V I T S H P G Q I V K H G D I K C V L N E G M P I Y R R P Y E K G R L 321 I I E F K V N F P E N G F L S P D K L S L L E K L L P E R K E V E E T D E M D Q V E L V D F D P N Q E R R R H Y N G E A Y E D D E H H P R G G V Q C Q T S 5.347 aquaporin 2 [Homo sapiens] Protein Accession gi|4502179

Mean Expression Ratio 0.99 Median Expression Ratio 0.991 Credible Interval (0.645, 1.52) Associated Peptides 2 Associated Spectra 2 Coverage 0.0886

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.6  0.97 1.5 SEQ ID NO: 1684 QSVELHSPQSLPR 1 0.63 1.0 1.6 SEQ ID NO: 1685 GLEPDTDWEER SEQ ID NO: 1686 1 M W E L R S I A F S R A V F A E F L A T L L F V F F G L G S A L N W P Q A L P S V L Q I A M A F G L G I G T L V Q A L G H I S G A H I N P A V T V A C L V G C H 81 V S V L R A A F Y V A A Q L L G A V A G A A L L H E I T P A D I R G D L A V N A L S N S T T A G Q A V T V E L F L T L Q L V L C I F A S T D E R R G E N P G T P 161 A L S I G F S V A L G H L L G I H Y T G C S M N P A R S L A P A V V T G K F D D H W V F W I G P L V G A I L G S L L Y N Y V L F P P A K S L S E R L A V L K G L 241 E P D T D W E E R E V R R R Q S V E L H S P Q S L P R G T K A 5.348 serine incorporator 1 [Homo sapiens] Protein Accession gi|24308213

Mean Expression Ratio 1.01 Median Expression Ratio 1.01 Credible Interval (0.624, 1.63) Associated Peptides 1 Associated Spectra 1 Coverage 0.0375

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.61 1 1.7 SEQ ID NO: 1687 LTLTSDESTLIEDGGAR SEQ ID NO: 1688 1 M G S V L G L C S M A S W I P C L C G S A P C L L C R C C P S G N N S T V T R L I Y A L F L L V G V C V A C V M L I P G M E E Q L N K I P G F C E N E K G V V P 81 C N I L V G Y K A V Y R L C F G L A M F Y L L L S L L M I K V K S S S D P R A A V H N G F W F F K F A A A I A I I I G A F F I P E G T F T T V W F Y V G M A G A 161 F C F I L I Q L V L L I D F A H S W N E S W V E K M E E G N S R C W Y A A L L S A T A L N Y L L S L V A I V L F F V Y Y T H P A S C S E N K A F I S V N M L L C 241 V G A S V M S I L P K I Q E S Q P R S G L L Q S S V I T V Y T M Y L T W S A M T N E P E T N C N P S L L S I I G Y N T T S T V P K E G Q S V Q W W H A Q G I I G 321 L I L F L L C V F Y S S I R T S N N S Q V N K L T L T S D E S T L I E D G G A R S D G S L E D G D D V H R A V D N E R D G V T Y S Y S F F H F M L F L A S L Y I 401 M M T L T N W Y R Y E P S R E M K S Q W T A V W V K I S S S W I G I V L Y V W T L V A P L V L T N R D F D 5.349 syntaxin 7 [Homo sapiens] Protein Accession gi|170932494

Mean Expression Ratio 1.01 Median Expression Ratio 1.01 Credible Interval (0.748, 1.35) Associated Peptides 4 Associated Spectra 8 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.69 1.0 1.5 SEQ ID EFGSLPTTPSEQR NO: 1689 4 0.72 0.98 1.3 SEQ ID NLVSWESQTQPQVQVQDEEITEDDLR NO: 1690 1 0.7 1.0 1.5 SEQ ID QLEADIMDINEIFK NO: 1691 2 0.72 1.0 1.4 SEQ ID TLNQLGTPQDSPELR NO: 1692 5.350 carbonic anhydrase XII isoform 2 precursor [Homo sapiens]; carbonic anhydrase XII isoform 1 precursor [Homo sapiens] Protein Accession gi|45935383 gi|4502515

Mean Expression Ratio 0.991 Median Expression Ratio 0.993 Credible Interval (0.66, 1.49) Associated Peptides 1 Associated Spectra 3 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.67 0.99 1.5 SEQ ID NO: 1693 GQEAFVPGFNIEELLPER 5.351 major histocompatibility complex, class II, DR alpha precursor [Homo sapiens] Protein Accession gi|52426774

Mean Expression Ratio 1.00 Median Expression Ratio 1.01 Credible Interval (0.754, 1.32) Associated Peptides 5 Associated Spectra 9 Coverage 0.209

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.7 0.98 1.4 SEQ ID NO: 1694 FHYLPFLPSTEDVYDCR 3 0.76 1.1 1.5 SEQ ID NO: 1695 NGKPVTTGVSETVFLPR 2 0.73 1.0 1.4 SEQ ID NO: 1696 VEHWGLDEPLLK 1 0.69 1 1.5 SEQ ID NO: 1697 KFHYLPFLPSTEDVYDCR 1 0.66 0.95 1.4 SEQ ID NO: 1698 EDHLFR SEQ ID NO: 1699 1 M A I S G V P V L G F F I I A V L M S A Q E S W A I K E E H V I I Q A E F Y L N P D Q S G E F M F D F D G D E I F H V D M A K K E T V W R L E E F G R F A S F E 81 A Q G A L A N I A V D K A N L E I M T K R S N Y T P I T N V P P E V T V L T N S P V E L R E P N V L I C F I D K F T P P V V N V T W L R N G K P V T T G V S E T 161 V F L P R E D H L F R K F H Y L P F L P S T E D V Y D C R V E H W G L D E P L L K H W E F D A P S P L P E T T E N V V C A L G L T V G L V G I I I G T I F I I K 241 G L R K S N A A E R R G P L 5.352 cytosolic phosphoenolpyruvate carboxykinase 1 [Homo sapiens] Protein Accession gi|187281517

Mean Expression Ratio 0.996 Median Expression Ratio 0.994 Credible Interval (0.7, 1.43) Associated Peptides 3 Associated Spectra 4 Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.67 1 1.5 SEQ ID NO: 1700 IFHVNWFR 1 0.65 1 1.5 SEQ ID NO: 1701 LLGQMEEEGILR 1 0.65 1 1.5 SEQ ID NO: 1702 FLWPGFGENSR 5.353 glutathione peroxidase 3 precursor [Homo sapiens] Protein Accession gi|6006001

Mean Expression Ratio 0.996 Median Expression Ratio 0.994 Credible Interval (0.723, 1.37) Associated Peptides 4 Associated Spectra 6 Coverage 0.217

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.7 1 1.4 SEQ ID NO: 1703 FLVGPDGIPIMR 1 0.67 1 1.5 SEQ ID NO: 1704 FYTFLK 1 0.66 0.97 1.4 SEQ ID NO: 1705 QEPGENSEILPTLK 2 0.72 1.0 1.5 SEQ ID NO: 1706 YVRPGGGFVPNFQLFEK SEQ ID NO: 1707 1 M A R L L Q A S C L L S L L L A G F V S Q S R G Q E K S K M D C H G G I S G T I Y E Y G A L T I D G E E Y I P F K Q Y A G K Y V L F V N V A S Y U G L T G Q Y I 81 E L N A L Q E E L A P F G L V I L G F P C N Q F G K Q E P G E N S E I L P T L K Y V R P G G G F V P N F Q L F E K G D V N G E K E Q K F Y T F L K N S C P P T S 161 E L L G T S D R L F W E P M K V H D I R W N F E K F L V G P D G I P I M R W H H R T T V S N V K M D I L S Y M R R Q A A L G V K R K 5.354 transmembrane 7 superfamily member 3 [Homo sapiens] Protein Accession gi|7706575

Mean Expression Ratio 1.00 Median Expression Ratio 1.00 Credible Interval (0.7, 1.44) Associated Peptides 4 Associated Spectra 4 Coverage 0.0842

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.67 1 1.5 SEQ ID NO: 1708 GRPFFPPHPYK 1 0.68 1.0 1.6 SEQ ID NO: 1709 LQYDVYQYFLPENDLTEEMLLK 1 0.65 0.99 1.5 SEQ ID NO: 1710 QYFLPENDLTEEMLLK 1 0.65 1 1.5 SEQ ID NO: 1711 VTNILDPSYHIPPLR SEQ ID NO: 1712 1 M G F L Q L L V V A V L A S E H R V A G A A E V F G N S S E G L I E F S V G K F R Y F E L N R P F P E E A I L H D I S S N V T F L I F Q I H S Q Y Q N T T V S F 81 S P T L L S N S S E T G T A S G L V F I L R P E Q S T C T W Y L G T S G I Q P V Q N M A I L L S Y S E R D P V P G G C N L E F D L D I D P N I Y L E Y N F F E T 161 T I K F A P A N L G Y A R G V D P P P C D A G T D Q D S R W R L Q Y D V Y Q Y F L P E N D L T E E M L L K H L Q R M V S V P Q V K A S A L K V V T L T A N D K T 241 S V S F S S L P G Q G V I Y N V I V W D P F L N T S A A Y I P A H T Y A C S F E A G E G S C A S L G R V S S K V F F T L F A L L G F F I C F F G H R F W K T E L 321 F F I G F I I M G F F F Y I L I T R L T P I K Y D V N L I L T A V T G S V G G M F L V A V W W R F G I L S I C M L C V G L V L G F L I S S V T F F T P L G N L K 401 I F H D D G V F W V T F S C I A I L I P V V F M G C L R I L N I L T C G V I G S Y S V V L A I D S Y W S T S L S Y I T L N V L K R A L N K D F H R A F T N V P F 481 Q T N D F I I L A V W G M L A V S G I T L Q I R R E R G R P F F P P H P Y K L W K Q E R E R R V T N I L D P S Y H I P P L R E R L Y G R L T Q I K G L F Q K E Q 561 P A G E R T P L L L 5.355 cathelicidin antimicrobial peptide [Homo sapiens] Protein Accession gi|39753970

Mean Expression Ratio 0.997 Median Expression Ratio 0.996 Credible Interval (0.668, 1.49) Associated Peptides 1 Associated Spectra 3 Coverage 0.0529

A 2.5 50 97.5 Sequence ID No. Sequence 3 0.67 1 1.5 SEQ ID NO: 1713 FALLGDFFR SEQ ID NO: 1714 1 M K T Q R D G H S L G R W S L V L L L L G L V M P L A I I A Q V L S Y K E A V L R A I D G I N Q R S S D A N L Y R L L D L D P R P T M D G D P D T P K P V S F T 81 V K E T V C P R T T Q Q S P E D C D F K K D G L V K R C M G T V T L N Q A R G S F D I S C D K D N K R F A L L G D F F R K S K E K I G K E F K R I V Q R I K D F 161 L R N L V P R T E S 5.356 transmembrane protein 55B isoform 1 [Homo sapiens]; transmembrane protein 55B isoform 2 [Homo sapiens] Protein Accession gi|154816186 gi|154816184

Mean Expression Ratio 0.995 Median Expression Ratio 0.996 Credible Interval (0.652, 1.53) Associated Peptides 2 Associated Spectra 2 Coverage NaN

Sequence A 2.5 50 97.5 ID No. Sequence 1 0.63 1 1.6 SEQ ID NTFLWTEFTDR NO: 1715 1 0.61 0.98 1.6 SEQ ID IINLGPVHPGPLSPEPQPMGVR NO: 1716 5.357 aconitase 1 [Homo sapiens] Protein Accession gi|8659555

Mean Expression Ratio 0.996 Median Expression Ratio 0.997 Credible Interval (0.645, 1.56) Associated Peptides 1 Associated Spectra 2 Coverage 0.0214

A 2.5 50 97.5 Sequence ID No. Sequence 2 0.65 0.99 1.6 SEQ ID NO: 1717 VILQDFTGVPAVVDFAAMR SEQ ID NO: 1718 1 M S N P F A H L A E P L D P V Q P G K K F F N L N K L E D S R Y G R L P F S I R V L L E A A I R N C D E F L V K K Q D I E N I L H W N V T Q H K N I E V P F K P 81 A R V I L Q D F T G V P A V V D F A A M R D A V K K L G G D P E K I N P V C P A D L V I D H S I Q V D F N R R A D S L Q K N Q D L E F E R N R E R F E F L K W G 161 S Q A F H N M R I I P P G S G I I H Q V N L E Y L A R V V F D Q D G Y Y Y P D S L V G T D S H T T M I D G L G I L G W G V G G I E A E A V M L G Q P I S M V L P 241 Q V I G Y R L M G K P H P L V T S T D I V L T I T K H L R Q V G V V G K F V E F F G P G V A Q L S I A D R A T I A N M C P E Y G A T A A F F P V D E V S I T Y L 321 V Q T G R D E E K L K Y I K K Y L Q A V G M F R D F N D P S Q D P D F T Q V V E L D L K T V V P C C S G P K R P Q D K V A V S D M K K D F E S C L G A K Q G F K 401 G F Q V A P E H H N D H K T F I Y D N T E F T L A H G S V V I A A I T S C T N T S N P S V M L G A G L L A K K A V D A G L N V M P Y I K T S L S P G S G V V T Y 481 Y L Q E S G V M P Y L S Q L G F D V V G Y G C M T C I G N S G P L P E P V V E A I T Q G D L V A V G V L S G N R N F E G R V H P N T R A N Y L A S P P L V I A Y 561 A I A G T I R I D F E K E P L G V N A K G Q Q V F L K D I W P T R D E I Q A V E R Q Y V I P G M F K E V Y Q K I E T V N E S W N A L A T P S D K L F F W N S K S 641 T Y I K S P P F F E N L T L D L Q P P K S I V D A Y V L L N L G D S V T T D H I S P A G N I A R N S P A A R Y L T N R G L T P R E F N S Y G S R R G N D A V M A 721 R G T F A N I R L L N R F L N K Q A P Q T I H L P S G E I L D V F D A A E R Y Q Q A G L P L I V L A G K E Y G A G S S R D W A A K G P F L L G I K A V L A E S Y 801 E R I H R S N L V G M G V I P L E Y L P G E N A D A L G L T G Q E R Y T I I I P E N L K P Q M K V Q V K L D T G K T F Q A V M R F D T D V E L T Y F L N G G I L 881 N Y M I R K M A K 5.358 nicastrin precursor [Homo sapiens] Protein Accession gi|24638433

Mean Expression Ratio 0.997 Median Expression Ratio 0.997 Credible Interval (0.656, 1.51) Associated Peptides 2 Associated Spectra 2 Coverage 0.031

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.63 1 1.6 SEQ ID NO: 1719 GKFPVQLENVDSFVELGQVALR 1 0.63 1 1.6 SEQ ID NO: 1720 FPVQLENVDSFVELGQVALR SEQ ID NO: 1721 1 M A T A G G G S G A D P G S R G L L R L L S F C V L L A G L C R G N S V E R K I Y I P L N K T A P C V R L L N A T H Q I G C Q S S I S G D T G V I H V V E K E E 81 D L Q W V L T D G P N P P Y M V L L E S K H F T R D L M E K L K G R T S R I A G L A V S L T K P S P A S G F S P S V Q C P N D G F G V Y S N S Y G P E F A H C R 161 E I Q W N S L G N G L A Y E D F S F P I F L L E D E N E T K V I K Q C Y Q D H N L S Q N G S A P T F P L C A M Q L F S H M H A V I S T A T C M R R S S I Q S T F 241 S I N P E I V C D P L S D Y N V W S M L K P I N T T G T L K P D D R V V V A A T R L D S R S F F W N V A P G A E S A V A S F V T Q L A A A E A L Q K A P D V T T 321 L P R N V M F V F F Q G E T F D Y I G S S R M V Y D M E K G K F P V Q L E N V D S F V E L G Q V A L R T S L E L W M H T D P V S Q K N E S V R N Q V E D L L A T 401 L E K S G A G V P A V I L R R P N Q S Q P L P P S S L Q R F L R A R N I S G V V L A D H S G A F H N K Y Y Q S I Y D T A E N I N V S Y P E W L S P E E D L N F V 481 T D T A K A L A D V A T V L G R A L Y E L A G G T N F S D T V Q A D P Q T V T R L L Y G F L I K A N N S W F Q S I L R Q D L R S Y L G D G P L Q H Y I A V S S P 561 T N T T Y V V Q Y A L A N L T G T V V N L T R E Q C Q D P S K V P S E N K D L Y E Y S W V Q G P L H S N E T D R L P R C V R S T A R L A R A L S P A F E L S Q W 641 S S T E Y S T W T E S R W K D I R A R I F L I A S K E L E L I T L T V G F G I L I F S L I V T Y C I N A K A D V L F I A P R E P G A V S Y 5.359 carboxymethylenebutenolidase [Homo sapiens] Protein Accession gi|20270371

Mean Expression Ratio 0.995 Median Expression Ratio 0.997 Credible Interval (0.672, 1.45) Associated Peptides 3 Associated Spectra 3 Coverage 0.135

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.64 1 1.6 SEQ ID NO: 1722 AVIVIQDIFGWQLPNTR 1 0.63 1 1.5 SEQ ID NO: 1723 EVQVEHIK 1 0.63 0.98 1.5 SEQ ID NO: 1724 NLIEWLNK SEQ ID NO: 1725 1 M A N E A Y P C P C D I G H R L E Y G G L G R E V Q V E H I K A Y V T K S P V D A G K A V I V I Q D I F G W Q L P N T R Y I A D M I S G N G Y T T I V P D F F V 81 G Q E P W D P S G D W S I F P E W L K T R N A Q K I D R E I S A I L K Y L K Q Q C H A Q K I G I V G F C W G G T A V H H L M M K Y S E F R A G V S V Y G I V K D 161 S E D I Y N L K N P T L F I F A E N D V V I P L K D V S L L T Q K L K E H C K V E Y Q I K T F S G Q T H G F V H R K R E D C S P A D K P Y I D E A R R N L I E W 241 L N K Y M 5.360 major histocompatibility complex, class II, DR beta 3 precursor [Homo sapiens] Protein Accession gi|17986005

Mean Expression Ratio 1 Median Expression Ratio 1 Credible Interval (0.679, 1.47) Associated Peptides 2 Associated Spectra 3 Coverage 0.094

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.66 1.0 1.6 SEQ ID NO: 1726 SVSGFYPGSIEVR 2 0.66 1 1.5 SEQ ID NO: 1727 TQPLQHHNLLVCSVSGFYPGSIEVR SEQ ID NO: 1728 1 M V C L K L P G G S S L A A L T V T L M V L S S R L A F A G D T R P R F L E L R K S E C H F F N G T E R V R Y L D R Y F H N Q E E F L R F D S D V G E Y R A V T 81 E L G R P V A E S W N S Q K D L L E Q K R G R V D N Y C R H N Y G V G E S F T V Q R R V H P Q V T V Y P A K T Q P L Q H H N L L V C S V S G F Y P G S I E V R W 161 F R N G Q E E K A G V V S T G L I Q N G D W T F Q T L V M L E T V P R S G E V Y T C Q V E H P S V T S A L T V E W R A R S E S A Q S K M L S G V G G F V L G L L 241 F L G A G L F I Y F R N Q K G H S G L Q P T G F L S 5.361 hypothetical protein LOC51571 [Homo sapiens] Protein Accession gi|42734438

Mean Expression Ratio 0.997 Median Expression Ratio 1 Credible Interval (0.648, 1.52) Associated Peptides 2 Associated Spectra 2 Coverage 0.0988

A 2.5 50 97.5 Sequence ID No. Sequence 1 0.61 1 1.6 SEQ ID NO: 1729 INNVPAEGENEVNNELANR 1 0.63 1 1.6 SEQ ID NO: 1730 DAEGILEDLQSYR SEQ ID NO: 1731 1 M G N L L K V L T C T D L E Q G P N F F L D F E N A Q P T E S E K E I Y N Q V N V V L K D A E G I L E D L Q S Y R G A G H E I R E A I Q H P A D E K L Q E K A W 81 G A V V P L V G K L K K F Y E F S Q R L E A A L R G L L G A L T S T P Y S P T Q H L E R E Q A L A K Q F A E I L H F T L R F D E L K M T N P A I Q N D F S Y Y R 161 R T L S R M R I N N V P A E G E N E V N N E L A N R M S L F Y A E A T P M L K T L S D A T T K F V S E N K N L P I E N T T D C L S T M A S V C R V M L E T P E Y 241 R S R F T N E E T V S F C L R V M V G V I I L Y D H V H P V G A F A K T S K I D M K G C I K V L K D Q P P N S V E G L L N A L R Y T T K H L N D E T T S

III. Renal Status Assay Measurements

The ability of a particular renal biomarker assay measurement to distinguish between two populations can be established using ROC analysis. For example, ROC curves established from a “first” subpopulation (i.e., for example, a population predisposed to one or more future changes in renal status) and a “second” subpopulation (i.e., for example, a population not predisposed to one or more future changes in renal status). Calculation of these ROC curves and establishing the area under these ROC curves quantitate the predictive power of the specific assay measurement. In some embodiments, predictive power established by assay measurements described herein comprise an AUC ROC greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95.

A. Immunoassays

In general, immunoassays involve contacting a sample containing, or suspected of containing, a biomarker of interest with at least one antibody that specifically binds to the biomarker. A detectable signal is then generated indicative of the presence or amount of complexes formed by the binding of polypeptides in the sample to the antibody. The detectable signal is then related to the presence or amount of the biomarker in the sample. Numerous methods and devices have been reported regarding the detection and analysis of biological biomarkers. See, e.g., U.S. Pat. Nos. 6,143,576; 6,113,855; 6,019,944; 5,985,579; 5,947,124; 5,939,272; 5,922,615; 5,885,527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and 5,480,792, and The Immunoassay Handbook, David Wild, ed. Stockton Press, New York, 1994, each of which is herein incorporated by reference in its entirety, including all tables, figures and claims.

Numerous immunoassay devices and methods can utilize labeled molecules in various sandwich, competitive, or non-competitive assay formats, to generate a signal that is related to the presence or amount of the biomarker of interest. Suitable assay formats also include chromatographic, mass spectrographic, and protein “blotting” methods. Additionally, certain methods and devices, such as biosensors and optical immunoassays, may be employed to determine the presence or amount of analytes without the need for a labeled molecule. See, e.g., U.S. Pat. Nos. 5,631,171; and 5,955,377, each of which is herein incorporated by reference in its entirety, including all tables, figures and claims. Robotic instrumentation for performing these immunoassays are commercially available including, but not limited to, Beckman ACCESS®, Abbott AXSYM®, Roche ELECSYS®, Dade Behring STRATUS® systems. But any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like.

Antibodies or other polypeptides may be immobilized onto a variety of solid supports for use in immunoassays. Solid phases that may be used to immobilize specific binding members include, but are not limited to those developed and/or used as solid phases in solid phase binding assays. Examples of suitable solid phases include, but are not limited to, membrane filters, cellulose-based papers, beads (including polymeric, latex and paramagnetic particles), glass, silicon wafers, microparticles, nanoparticles, TentaGels, AgroGels, PEGA gels, SPOCC gels, and multiple-well plates. For example, an assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support. This strip could then be dipped into the test sample and then processed quickly through washes and detection steps to generate a measurable signal, such as a colored spot. Antibodies or other polypeptides may be bound to specific zones of assay devices either by conjugating directly to an assay device surface, or by indirect binding. In an example of the later case, antibodies or other polypeptides may be immobilized on particles or other solid supports, and that solid support immobilized to the device surface.

In certain embodiments, a urinary renal biomarker assay method comprises an immunoassay. For example, antibodies for use in such assays may specifically bind an epitope of a renal biomarker of interest, and may also bind one or more polypeptides that are “related” thereto, as that term is defined hereinafter. In one embodiment, the renal biomarker of interest is a fully length marker (i.e., for example, a protein). In one embodiment, the renal biomarker of interest is a protein fragment marker (i.e., for example, a peptide). Numerous immunoassay formats are available compatible with body fluid samples including, but not limited to, urine, blood, serum, saliva, tears, and plasma.

In this regard, detectable signals obtained from an immunoassay may be a direct result of complexes formed between one or more antibodies and the target biomolecule (i.e., for example, an analyte) and polypeptides containing the necessary epitope(s) to which the antibodies bind. While such assays may detect the full length biomarker and the assay result be expressed as a concentration of a biomarker of interest, the signal from the assay may actually be a result of all such “immunoreactive” polypeptides present in the sample. Expression of biomarkers may also be determined by means other than immunoassays, including protein measurements (i.e., for example, dot blots, western blots, chromatographic methods, mass spectrometry, etc.) and nucleic acid measurements (mRNA quantitation). This list is not meant to be limiting.

The foregoing method steps should not be interpreted to mean that the renal biomarker assay measurements is/are used in isolation in the methods described herein. Rather, additional variables or other clinical indicia may be included in the methods described herein. For example, risk stratification, diagnostic, classification, monitoring, etc. methods as described herein may be combined with one or more clinical indicia relevant to the patient population including, but not limited to, demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score), a glomerular filtration rate, an estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatnine ratio, a renal failure index calculated as urine sodium/(urine creatinine/plasma creatinine), a serum or plasma neutrophil gelatinase (NGAL) concentration, a urine NGAL concentration, a serum or plasma cystatin C concentration, a serum or plasma cardiac troponin concentration, a serum or plasma BNP concentration, a serum or plasma NTproBNP concentration, and a serum or plasma proBNP concentration. Other measures of renal function which may be combined with one or more renal biomarker assay measurements are described hereinafter. In: Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830; and In: Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, each of which are herein incorporated by reference in their entirety.

When more than one biomarker is measured, the individual biomarkers may be measured in samples obtained at the same time, or may be determined from samples obtained at different (e.g., an earlier or later) times. The individual biomarkers may also be measured on the same or different body fluid samples. For example, one renal biomarker may be measured in a serum or plasma sample and another renal biomarker may be measured in a urine sample. In addition, assignment of a likelihood may combine a renal biomarker assay measurement with temporal changes in one or more additional variables.

B. Detectable Labels

Generation of a detectable signal from the detectable label can be performed using various optical, acoustical, and electrochemical methods. Examples of detection modes include, but are not limited to, fluorescence, radiochemical detection, reflectance, absorbance, amperometry, conductance, impedance, interferometry, ellipsometry, etc. In certain of these methods, the solid phase antibody may be coupled to a transducer (e.g., a diffraction grating, electrochemical sensor, etc) for generation of a signal, while in others, a signal is generated by a transducer that is spatially separate from the solid phase antibody (e.g., a fluorometer that employs an excitation light source and an optical detector). This list is not meant to be limiting. Antibody-based biosensors may also be employed to determine the presence or amount of analytes that optionally eliminate the need for a labeled molecule.

Biological assays require methods for detection, and one of the most common methods for quantitation of assay measurements is to conjugate a detectable label to a protein or nucleic acid that has affinity for one of the components in the biological system being studied. Detectable labels used in the immunoassays described above may include, but are not limited to, molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, ecl (electrochemical luminescence) labels, metal chelates, colloidal metal particles, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or through the use of a specific binding molecule which itself may be detectable (e.g., a labeled antibody that binds to the second antibody, biotin, digoxigenin, maltose, oligohistidine, 2,4-dintrobenzene, phenylarsenate, ssDNA, dsDNA, etc.).

Preparation of solid phases and detectable label conjugates often comprise the use of chemical cross-linkers. Cross-linking reagents may involve at least two reactive groups, and are divided generally into homofunctional cross-linkers (containing identical reactive groups) and heterofunctional cross-linkers (containing non-identical reactive groups). Homobifunctional cross-linkers that couple through amines, sulfhydryls or react non-specifically are available from many commercial sources. Maleimides, alkyl and aryl halides, alpha-haloacyls and pyridyl disulfides are thiol reactive groups and are believed to react with sulfhydryls to form thiol ether bonds, while pyridyl disulfides react with sulfhydryls to produce mixed disulfides. The pyridyl disulfide product is cleavable. Imidoesters are also very useful for protein-protein cross-links. A variety of heterobifunctional cross-linkers, each combining different attributes for successful conjugation, are commercially available.

D. Assay Correlations

In some embodiments, the renal biomarker assay measurement is/are correlated to one or more future changes in renal function. In one embodiment, risk stratification comprises determining a subject's likelihood (i.e., for example, probability) for a future improvement in renal function.

In one embodiment, the renal biomarker assay measurement is/are correlated to a likelihood of such a future improvement in renal function. In one embodiment, the method correlates a likelihood of such a future injury to renal function. In one embodiment, the risk stratification comprises determining a subject's risk for progression to acute renal failure (ARF).

In one embodiment, the renal biomarker assay measurement is/are correlated to a likelihood of such progression to acute renal failure (ARF). In one embodiment, the risk stratification method comprises determining a subject's outcome risk.

In one embodiment, the assay measurement is/are correlated to a likelihood of the occurrence of a clinical outcome related to a renal injury suffered by the subject.

Consequently, the measured concentration value(s) may each be compared to a threshold value, wherein either a “positive going kidney injury marker”, or a “negative going kidney injury marker” is identified. In one embodiment, the risk stratification comprises determining a subject's risk for future reduced renal function. In some embodiments, the method assigns a likelihood, risk, or probability that such that an event of interest is more or less likely to occur within 180 Days of the time at which the body fluid sample is obtained from the subject. In some embodiments, the assigned likelihood, risk, or probability relates to an event of interest occurring within a time period including, but not limited to, 18 months, 120 Days, 90 Days, 60 Days, 45 Days, 30 Days, 21 Days, 14 Days, 7 Days, 5 Days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, 12 hours, or less. Alternatively, assigning a risk at 0 hours of the time at which the body fluid sample is obtained from the subject is equivalent to diagnosis of a current condition.

Selecting a diagnostic threshold involves, among other things, consideration of the probability of disease, distribution of true and false diagnoses at different test thresholds, and estimates of the consequences of treatment (or a failure to treat) based on the diagnosis. For example, when considering administering a specific therapy which is highly efficacious and has a low level of risk, few tests are needed because clinicians can accept substantial diagnostic uncertainty. On the other hand, in situations where treatment options are less effective and more risky, clinicians often need a higher degree of diagnostic certainty. Thus, a cost/benefit analysis is involved in selecting a diagnostic threshold.

1. Thresholds

Suitable thresholds may be determined in a variety of ways. For example, one recommended diagnostic threshold for the diagnosis of acute myocardial infarction uses cardiac troponin, wherein the diagnostic threshold is set at the 97.5th percentile of the cardiac troponin concentration measured in a normal population. Another method to determine a diagnostic threshold comprises measuring serial samples from the same patient, where a prior “baseline” result is used to monitor for temporal changes in a biomarker level.

Population studies may also be used to select thresholds. For example, Receiver Operating Characteristic (“ROC”) arose from the field of signal detection theory developed during World War II for the analysis of radar images, and ROC analysis is often used to select a threshold to distinguish a “diseased” subpopulation from a “nondiseased” subpopulation. Predictive power balances the occurrences of false positives (i.e., for example, when the person tests positive, but actually does not have the disease) and false negatives (i.e., for example, when the person tests negative, suggesting they are healthy, when they actually do have the disease). To draw a ROC curve, the true positive rate (TPR) and false positive rate (FPR) are determined as the decision threshold is varied continuously. Since TPR is equivalent with sensitivity and FPR is equal to (1−specificity), the ROC graph is sometimes called the sensitivity vs (1−specificity) plot. A perfect test will have an area under the ROC curve of 1.0; a random test will have an area of 0.5. A threshold value is selected to provide an acceptable level of specificity and sensitivity usually determined by summing specificity values with sensitivity values. Consequently, the larger the calculated threshold value the greater the predicative power of the specific assay measurement under analysis.

In this context, “diseased” is meant to refer to a population having one characteristic (i.e., for example, the presence of a disease or condition or the occurrence of some outcome) and “nondiseased” population lacking the same characteristic. While a single decision threshold is the simplest application of such a method, multiple decision thresholds may be used. For example, below a first threshold, the absence of disease may be assigned with relatively high confidence, and above a second threshold the presence of disease may also be assigned with relatively high confidence. Between the two thresholds may be considered indeterminate. This is meant to be exemplary in nature only.

In addition to threshold value comparisons, other methods for correlating assay measurements to a patient classification (i.e., for example, occurrence or nonoccurrence of disease, likelihood of an outcome, etc.) include, but are not limited to, decision trees, rule sets, Bayesian methods, and neural network methods. These methods can produce probability values representing the degree to which a subject or patient belongs to one classification out of a plurality of classifications.

Multiple thresholds may also be used to assess renal status in a subject and/or patient. For example, a multiple thresholding method may combine a “first” subpopulation which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc., with a “second” subpopulation which is not so predisposed into a single group. This combination group is then subdivided into three or more equal parts (i.e., for example, tertiles, quartiles, quintiles, etc., depending on the number of subdivisions). An odds ratio is assigned to subjects based on which subdivision they fall into. If one considers a tertile embodiment, the lowest or highest tertile can be used as a reference for comparison of the other subdivisions. This reference subdivision is assigned an odds ratio of 1. The second tertile is assigned an odds ratio that is relative to that first tertile. That is, someone in the second tertile might be 3 times more likely to suffer one or more future changes in renal status in comparison to someone in the first tertile. The third tertile is also assigned an odds ratio that is relative to that first tertile.

2. Specificity and Sensitivity

In some embodiments, a measured concentration of one or more renal biomarkers, or a composite of such biomarkers, may be treated as continuous variables. For example, any particular biomarker concentration can be converted into a corresponding probability of a future reduction in renal function for the subject, the occurrence of an injury, a classification, etc. Alternatively, a threshold value can provide an acceptable level of specificity and sensitivity in separating a population of subjects into “bins” such as a “first” subpopulation (e.g., which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc.) and a “second” subpopulation which is not so predisposed.

In one embodiment, a threshold value is selected to separate a first and a second population by one or more of the following measures of test accuracy:

-   -   i) an odds ratio greater than 1, preferably at least about 2 or         more or about 0.5 or less, more preferably at least about 3 or         more or about 0.33 or less, still more preferably at least about         4 or more or about 0.25 or less, even more preferably at least         about 5 or more or about 0.2 or less, and most preferably at         least about 10 or more or about 0.1 or less;     -   ii) a specificity of greater than 0.5, preferably at least about         0.6, more preferably at least about 0.7, still more preferably         at least about 0.8, even more preferably at least about 0.9 and         most preferably at least about 0.95, with a corresponding         sensitivity greater than 0.2, preferably greater than about 0.3,         more preferably greater than about 0.4, still more preferably at         least about 0.5, even more preferably about 0.6, yet more         preferably greater than about 0.7, still more preferably greater         than about 0.8, more preferably greater than about 0.9, and most         preferably greater than about 0.95;     -   iii) a sensitivity of greater than 0.5, preferably at least         about 0.6, more preferably at least about 0.7, still more         preferably at least about 0.8, even more preferably at least         about 0.9 and most preferably at least about 0.95, with a         corresponding specificity greater than 0.2, preferably greater         than about 0.3, more preferably greater than about 0.4, still         more preferably at least about 0.5, even more preferably about         0.6, yet more preferably greater than about 0.7, still more         preferably greater than about 0.8, more preferably greater than         about 0.9, and most preferably greater than about 0.95;     -   iv) at least about 75% sensitivity, combined with at least about         75% specificity; a positive likelihood ratio (calculated as         sensitivity/(1−specificity)) of greater than 1, at least about         2, more preferably at least about 3, still more preferably at         least about 5, and most preferably at least about 10; or     -   v) a negative likelihood ratio (calculated as         (1−sensitivity)/specificity) of less than 1, less than or equal         to about 0.5, more preferably less than or equal to about 0.3,         and most preferably less than or equal to about 0.1.

Various measures of test accuracy have been reported and used to determine the effectiveness of a given biomarker. Fischer et al., Intensive Care Med. 29:1043-1051 (2003). These accuracy measures include, but are not limited to, sensitivity and specificity, predictive values, likelihood ratios, diagnostic odds ratios, and AUC ROC values. For example, AUC ROC values are equal to the probability that a classifier will rank a randomly chosen positive instance higher than a randomly chosen negative one. Consequently, an AUC ROC value may be thought of as equivalent to the Mann-Whitney U test, which tests for the median difference between scores obtained in the two groups considered if the groups are of continuous data, or to the Wilcoxon test of ranks.

As discussed above, suitable tests may exhibit one or more of the following results on these various measures: a specificity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; a sensitivity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding specificity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; at least 75% sensitivity, combined with at least 75% specificity; a ROC curve area of greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95; an odds ratio different from 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less; a positive likelihood ratio (calculated as sensitivity/(1−specificity)) of greater than 1, at least 2, more preferably at least 3, still more preferably at least 5, and most preferably at least 10; and or a negative likelihood ratio (calculated as (1−sensitivity)/specificity) of less than 1, less than or equal to 0.5, more preferably less than or equal to 0.3, and most preferably less than or equal to 0.1.

G. Conventional Renal Diagnostics

As noted above, the terms “acute renal (or kidney) injury” and “acute renal (or kidney) failure” as used herein are generally defined, in part, in terms of changes in serum creatinine from a baseline value. Most conventional definitions of ARF have common elements, including but not limited to the use of serum creatinine and, often, urine output. Patients may present with renal dysfunction without an available baseline measure of renal function for use in this comparison. In such an event, one may estimate a baseline serum creatinine value by assuming the patient initially had a normal GFR.

1. Glomerular Filtration Rate And Creatinine

Glomerular filtration rate (GFR) is generally defined as the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time. Glomerular filtration rate (GFR) can be calculated by measuring any chemical that has a steady level in the blood, and is freely filtered but neither reabsorbed nor secreted by the kidneys. GFR is typically expressed in units of ml/min:

By normalizing the GFR to the body surface area, a GFR of approximately 75-100 ml/min per 1.73 m² can be assumed. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood.

There are several different techniques used to calculate or estimate the glomerular filtration rate (GFR or eGFR). In clinical practice, however, creatinine clearance is used to measure GFR. Creatinine is produced naturally by the body (creatinine is a metabolite of creatine, which is found in muscle). It is freely filtered by the glomerulus, but also actively secreted by the renal tubules in very small amounts such that creatinine clearance overestimates actual GFR by 10-20%. This margin of error is acceptable considering the ease with which creatinine clearance is measured.

Creatinine clearance (CCr) can be calculated if values for creatinine's urine concentration (UCr), urine flow rate (V), and creatinine's plasma concentration (PCr) are known. Since the product of urine concentration and urine flow rate yields creatinine's excretion rate, creatinine clearance is also said to be its excretion rate (UCr×V) divided by its plasma concentration. This is commonly represented mathematically as:

$C_{Cr} = \frac{U_{Cr}V}{P_{Cr}}$

Commonly a 24 hour urine collection is undertaken, from empty-bladder one morning to the contents of the bladder the following morning, with a comparative blood test then taken:

$C_{Cr} = \frac{{U_{Cr}24}\text{-}{hour}\mspace{14mu} {volume}}{{P_{Cr}2460}\mspace{14mu} {mins}}$

To allow comparison of results between people of different sizes, the CCr is often corrected for the body surface area (BSA) and expressed compared to the average sized man as ml/min/1.73 m². While most adults have a BSA that approaches 1.7 (1.6-1.9), extremely obese or slim patients should have their CCr corrected for their actual BSA:

$C_{{Cr}\text{-}{corrected}} = \frac{C_{Cr}1.73}{BSA}$

The accuracy of a creatinine clearance measurement (even when collection is complete) is limited because as glomerular filtration rate (GFR) falls creatinine secretion is increased, and thus the rise in serum creatinine is less. Thus, creatinine excretion is much greater than the filtered load, resulting in a potentially large overestimation of the GFR (as much as a twofold difference). However, for clinical purposes it is important to determine whether renal function is stable or getting worse or better. This is often determined by monitoring serum creatinine alone. Like creatinine clearance, the serum creatinine will not be an accurate reflection of GFR in the non-steady-state condition of ARF. Nonetheless, the degree to which serum creatinine changes from baseline will reflect the change in GFR. Serum creatinine is readily and easily measured and it is specific for renal function.

For purposes of determining urine output on a mL/kg/hr basis, hourly urine collection and measurement is adequate. In the case where, for example, only a cumulative 24-h output was available and no patient weights are provided, minor modifications of the RIFLE urine output criteria have been described. For example, some have assumed an average patient weight of 70 kg, wherein patients are assigned a RIFLE classification based on the following: <35 mL/h (Risk), <21 mL/h (Injury) or <4 mL/h (Failure). Bagshaw et al., Nephrol. Dial. Transplant. 23:1203-1210 (2008).

2. Treatment Regimen Selection

Once a renal diagnosis is obtained, the clinician can readily select a treatment regimen that is compatible with the diagnosis, such as initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, kidney transplantation, delaying or avoiding procedures that are known to be damaging to the kidney, modifying diuretic administration, initiating goal directed therapy, etc. Various appropriate treatments for numerous diseases have been previously discussed in relation to the methods of diagnosis described herein. See, e.g., Merck Manual of Diagnosis and Therapy, 17th Ed. Merck Research Laboratories, Whitehouse Station, N J, 1999. In addition, since the methods and compositions described herein provide prognostic information, the renal biomarkers of the present invention may be used to monitor a course of treatment. For example, an improved prognostic state or a worsened prognostic state may indicate that a particular treatment is or is not efficacious.

IV. Antibodies

Antibodies used in the immunoassays described herein preferably specifically bind to a kidney injury marker of the present invention. The term “specifically binds” is not intended to indicate that an antibody binds exclusively to its intended target since, as noted above, an antibody binds to any polypeptide displaying the epitope(s) to which the antibody binds. Rather, an antibody “specifically binds” if its affinity for its intended target is about 5-fold greater when compared to its affinity for a non-target molecule which does not display the appropriate epitope(s). Preferably the affinity of the antibody will be at least about 5 fold, preferably 10 fold, more preferably 25-fold, even more preferably 50-fold, and most preferably 100-fold or more, greater for a target molecule than its affinity for a non-target molecule. In some embodiments, antibodies bind with affinities of at least about 10⁷ M⁻¹, and preferably between about 10⁸ M⁻¹ to about 10⁹ M⁻¹, about 10⁹ M⁻¹ to about 10¹⁰ M⁻¹, or about 10¹⁰ M⁻¹ to about 10¹² M⁻¹.

Affinity may be calculated as K_(d)=k_(off)/k_(on) (k_(off) is the dissociation rate constant, K_(on) is the association rate constant and Kd is the equilibrium constant). Affinity can be determined at equilibrium by measuring the fraction bound (r) of labeled ligand at various concentrations (c). The data are graphed using the Scatchard equation: r/c=K(n−r): where r=moles of bound ligand/mole of receptor at equilibrium; c=free ligand concentration at equilibrium; K=equilibrium association constant; and n=number of ligand binding sites per receptor molecule. By graphical analysis, r/c is plotted on the Y-axis versus r on the X-axis, thus producing a Scatchard plot. Antibody affinity measurement by Scatchard analysis is well known in the art. See, e.g., van Erp et al., J. Immunoassay 12:425-443 (1991); and Nelson et al., Comput. Methods Programs Biomed. 27: 65-68 (1988).

Numerous publications discuss the use of phage display technology to produce and screen libraries of polypeptides for binding to a selected analyte. See, e.g, Cwirla et al., Proc. Natl. Acad. Sci. USA 87: 6378-6382 (1990); Devlin et al., Science 249:404-406 (1990); Scott et al., Science 249:386-388 (1990); and Ladner et al., U.S. Pat. No. 5,571,698 (all references herein incorporated by reference). A basic concept of phage display methods is the establishment of a physical association between DNA encoding a polypeptide to be screened and the polypeptide. This physical association is provided by the phage particle, which displays a polypeptide as part of a capsid enclosing the phage genome which encodes the polypeptide. The establishment of a physical association between polypeptides and their genetic material allows simultaneous mass screening of very large numbers of phage bearing different polypeptides. Phage displaying a polypeptide with affinity to a target bind to the target and these phage are enriched by affinity screening to the target. The identity of polypeptides displayed from these phage can be determined from their respective genomes. Using these methods a polypeptide identified as having a binding affinity for a desired target can then be synthesized in bulk by conventional means. See, e.g., U.S. Pat. No. 6,057,098, which is hereby incorporated in its entirety, including all tables, figures, and claims.

Antibodies generated by these methods may then be selected by first screening for affinity and specificity with the purified polypeptide of interest and, if required, comparing the results to the affinity and specificity of the antibodies with polypeptides that are desired to be excluded from binding. The screening procedure can involve immobilization of the purified polypeptides in separate wells of microtiter plates. The solution containing a potential antibody or groups of antibodies is then placed into the respective microtiter wells and incubated for about 30 min to 2 h. The microtiter wells are then washed and a labeled secondary antibody (for example, an anti-mouse antibody conjugated to alkaline phosphatase if the raised antibodies are mouse antibodies) is added to the wells and incubated for about 30 min and then washed. Substrate is added to the wells and a color reaction will appear where antibody to the immobilized polypeptide(s) are present.

Antibodies so identified may then be further analyzed for affinity and specificity in the assay design selected. In the development of immunoassays for a target protein, the purified target protein acts as a standard with which to judge the sensitivity and specificity of the immunoassay using the antibodies that have been selected. Because the binding affinity of various antibodies may differ; certain antibody pairs (e.g., in sandwich assays) may interfere with one another sterically, etc., assay performance of an antibody may be a more important measure than absolute affinity and specificity of an antibody.

V. Kits

In some embodiments, the present invention also contemplates devices and kits for performing the methods described herein. Suitable kits comprise reagents sufficient for performing an assay for at least one of the described kidney injury markers, together with instructions for performing the described threshold comparisons.

In certain embodiments, reagents for performing such assays are provided in an assay device, and such assay devices may be included in such a kit. Preferred reagents can comprise one or more solid phase antibodies, the solid phase antibody comprising antibody that detects the intended biomarker target(s) bound to a solid support. In the case of sandwich immunoassays, such reagents can also include one or more detectably labeled antibodies, the detectably labeled antibody comprising antibody that detects the intended biomarker target(s) bound to a detectable label. Additional optional elements that may be provided as part of an assay device are described hereinafter.

In some embodiments, the present invention provides kits for the analysis of the described kidney injury markers. The kit comprises reagents for the analysis of at least one test sample which comprise at least one antibody that a kidney injury marker. The kit can also include devices and instructions for performing one or more of the diagnostic and/or prognostic correlations described herein. Preferred kits will comprise an antibody pair for performing a sandwich assay, or a labeled species for performing a competitive assay, for the analyte. Preferably, an antibody pair comprises a first antibody conjugated to a solid phase and a second antibody conjugated to a detectable label, wherein each of the first and second antibodies that bind a kidney injury marker. Most preferably each of the antibodies are monoclonal antibodies. The instructions for use of the kit and performing the correlations can be in the form of labeling, which refers to any written or recorded material that is attached to, or otherwise accompanies a kit at any time during its manufacture, transport, sale or use. For example, the term labeling encompasses advertising leaflets and brochures, packaging materials, instructions, audio or video cassettes, computer discs, as well as writing imprinted directly on kits.

EXPERIMENTAL Example I BioMaRK Data Collection Method Patients and Study Design

BioMaRK was an observational cohort study conducted as an ancillary study to the Veterans Affairs/National Institutes of Health (VA/NIH) Acute Renal Failure Trial Network study (ATN study). The ATN study was a multicenter, prospective trial of two strategies for renal replacement therapy in critically ill patients with acute kidney injury. Coca et al., “Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review” Kidney Int, 73:1008-1016 (2008). Adult patients (18 years or older) with AKI and requiring renal-replacement therapy (RRT), as well as failure of one or more non-renal organ systems or sepsis were eligible. As a sub-study to the ATN study, 109 patients were enrolled at The University of Pittsburgh Medical Center, The VA Pittsburgh Healthcare System, The Cleveland Clinical Foundation, The University of Texas Health Science Center at Houston, and Washington University Medical Center to undergo serial blood and urine sampling. Incomplete data including unavailability of urine samples precluded inclusion of 33 subjects; consequently the remaining 76 formed the analysis cohort. Approval from the Institutional Review Boards was received from the University of Pittsburgh and all participating sites.

Data Collection/Laboratory Measurements

Medical records of study participants were prospectively reviewed to retrieve hospitalization data including baseline demographic characteristics, serial renal function, daily urine volume, and severity of illness scores. The presence of sepsis was defined by international consensus criteria. Levy et al., “2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference” Crit Care Med, 31:1250-1256 (2003). Recovery of renal function was defined by survival and dialysis independence at Day 60 post AKI. For purposes of primary analysis, partial recovery (i.e. failure to return to baseline renal function but free of dialysis) was included in the recovery group. Similarly, all deaths were included in the non-recovery group.

Fresh urine samples were obtained on Days 1, 7, and 14 post AKI. Immediately upon obtaining a well-mixed 30 ml sample, a protease inhibitor tablet (Roche Diagnostics Corporation, IN, USA) was added. After processing, the sample was frozen (at −80° C.) until analyzed. Samples were assayed in duplicate, and data were analyzed using Bio-Rad Bio-Plex Manager Software (version 4.1). Urine creatinine concentrations were measured using a non-enzymatic assay (DICT-500, BioAssay Systems, CA, USA).

Example II Proteomics Analysis

Urine collected in accordance with Example I from fourteen (14) patients with severe AKI was evaluated with an unbiased proteomics discovery platform.

Data collected from seven (7) patients that did not recover renal function after AKI was compared to data collected from seven (7) patients that did recover renal function after AKI. The two groups were matched for age (e.g., +/−5 yrs) and gender.

The data presented herein show that approximately thirty (30) proteins were differentially expressed between the Recovery Group and the Non-Recovery Group. A preliminary analysis has categorized these proteins into groups including, but not limited to:

-   -   1. Ferritin, alpha and beta globin, or catalase that may be         involved in providing protection from reactive oxygen species     -   2. Complement factor H or complement component 4 BP that may be         involved in regulation of complement activation     -   3. Olfactomedin-4, leucine rich alpha-2 glycoprotein or ring         finger protein 167 that may be involved in cell survival and         proliferation.     -   4. Inter-alpha globulin inhibitor H4, heparan sulfate         proteoglycan 2, (N-acylsphingosine aminohydrolase and saposin)         that may be involved in basement membrane, matrix proteins or         sphingolipid turnover.

Although it is not necessary to understand the mechanism of an invention, it is believed that the differential expression of proteins categorized in Group 3 and Group 4 might be directly involved in renal recovery because of their involvement with cell proliferation and/or rebuilding of the basement membrane. 

1. A composition comprising an renal injury biomarker, wherein said biomarker comprises at least a fragment of at least one protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotein, carbonic anhydrase, and uromodulin precursor.
 2. The composition of claim 1, wherein said composition further comprises a biological fluid sample.
 3. The composition of claim 2, wherein said biological fluid sample is collected from a patient between 1 day and 14 days after a kidney injury.
 4. The composition of claim 2, wherein said biological fluid sample is a human urine sample.
 5. The composition of claim 1, wherein said renal injury biomarker in said biological fluid sample is at at least one level selected from the group consisting of at least 2.5 fold higher, at least 2.0 fold higher, at least 1.5 fold higher, at least 1.25 fold higher as compared to an expected level in a renal recovery group.
 6. The composition of claim 1, wherein said renal injury biomarker in said biological fluid sample is at at least one level selected from the group consisting of at least 2.5 fold lower, at least 2.0 fold lower, at least 1.5 fold lower and at least 1.25 fold lower as compared to an expected level in a renal recovery group. 7-10. (canceled)
 11. A kit, comprising: a) a first container comprising an antibody is specifically directed to at least one of a plurality of renal injury biomarkers, wherein said biomarkers comprise at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotein, carbonic anhydrase, and uromodulin precursor; b) instructions for determining whether said biomarker is overexpressed as compared to a renal recovery group comprising individuals without an acute renal injury; c) instructions for determining whether said biomarker is underexpressed as compared to said renal recovery group; and d) instructions for determining a probability value of renal non-recovery for a patient from an acute renal injury by a combination of receiver operated characteristic area under the curve determinations for overexpression or underexpression of said biomarker as compared to a plurality of diagnostic threshold values.
 12. The kit of claim 11, wherein said antibody is a monoclonal antibody.
 13. The kit of claim 12, wherein said monoclonal antibody is specifically directed to said biomarker protein fragment.
 14. The kit of claim 11, further comprising instructions for treating said patient during the development of said renal disease with a treatment regimen selected from the group consisting of: i) said treatment regimen comprising adverse effects when said probability value of non-recovery from said acute injury is greater than 50%, and ii) said treatment regimen without adverse effects when said probability value of non-recovery from said acute renal injury is less than 50%.
 15. The kit of claim 14, wherein said instructions identify that said treatment regimen as selected from the group consisting of initiating renal replacement therapy, withdrawing kidney damaging compounds, kidney transplantation, delaying or avoiding kidney damaging procedures and modifying diuretic administration.
 16. The kit of claim 11, wherein said interactions identify that said overexpressed biomarker is between approximately 1.5 fold-1.5 fold higher in comparison to said renal recovery group.
 17. The kit of claim 11, wherein said instructions identify that said underexpressed biomarker is between approximately 1.5 fold-2.0 fold lower in comparison to said renal recovery group.
 18. The kit of claim 11, wherein said instructions identify that said probability value of non-recovery from said acute renal injury is less than 10%.
 19. The kit of claim 11, wherein said instructions identify that said probability value of non-recovery from said acute renal injury is greater than 75%.
 20. The kit of claim 11, wherein said instructions identify that said probability value of non-recovery from said acute renal injury is greater than 90%. 